US00750 l405B2 ( 12 ) Umted States Patent ( 10 ) Patent N0. : US 7 , 501 , 405 B2 Kampen et al. ( 45 ) Date 0f Patent : Mar. 10 , 2009 ( 54 ) COMBINATION THERAPY USING AN ( 51 ) Int. Cl. 118 - HYDROXYSTEROID DEHYDROGENASE A01N 43 / 00 ( 2006.01 ) TYPE 1 INHIBITOR AND AN A61 K 31 / 55 ( 2006.01 ) ANTIHYPERTENSIVE AGENT FOR THE A61 K 31 / 00 ( 2006.01 ) TREATMENT 0F METABOLIC SYNDROME AND RELATED DISEASES AND DISORDERS ( 52 ) U. S. Cl. . 55114A / / 2211220017 ; ; 55114i / 22112106l1 , ( 75 ) anent0rs : Gita Camilla Tejlgaard Kampen , ( 58 ) Field 01 ' Classiﬁcati0n Search . 514 / 259.1 , . ( 73 ) . ( * ) . ( 21 ) . ( 22 ) . ( 65 ) . ( 63 ) . ( 60 ) . Naerum ( DK ) ; Henrik Sune Andersen , Lyngby ( DK ) Assignee : High P0int Pharmaceuticals , LLC , High P0int , NC ( US ) N0tice : SubjeCt t0 any disc1aimer , the term 0f this. patent is eXtended 0r adjusted under 35 U. S. C. 154 ( b ) by 0 days. App1. N0. : 11 / 254 , 125. Fi1ed : Oct. 11 , 2005. Pri0r Publicati0n Data. US 2006 / 0111348 A1 May 25 , 2006. Related U. S. Applicati0n Data. C0ntinuati0n 0f applicati0n N0. PCT / DK2004 / 000254 , ﬁ1ed 011 Apr. 6 , 2004. Pr0Visi0na1 applicati0n N0. 60 / 537 , 099 , ﬁ1ed 0n Jan. 16 , 2004 , pr0Visi0nal app1icati0n N0. 60 / 486 , 098 , ﬁ1ed 011 Ju1. 10 , 2003 , pr0Visi0na1 app1icati0n N0. 60 / 486 , 097 , ﬁ1ed 0n Ju1. 10 , 2003 , pr0Visi0na1 app1i - cati0n N0. 60 / 486 , 095 , ﬁ1ed 0n Jul. 10 , 2003 , pr0Vi - si0nal app1icati0n N0. 60 / 486 , 094 , ﬁled 0n Jul. 10 , 2003 , pr0Visi0na1 app1icati0n N0. 60 / 486 , 078 , ﬁled 0n Ju1. 10 , 2003 , pr0Visi0na1 app1icati0n N0. 60 / 475 , 157 , ﬁ1ed 0n Jun. 2 , 2003 , pr0Visi0na1 app1icati0n N0. 60 / 474 , 421 , ﬁ1ed 0n May 30 , 2003 , pr0Visi0nal appliCati0n N0. 60 / 467 , 800 , ﬁ1ed 0n May 2 , 2003 , pr0Vi - si0nal app1icati0n N0. 60 / 467 , 453 , ﬁ1ed 0n May 2 , 2003 , pr0Visi0na1 app1icati0n N0. 60 / 467 , 437 , ﬁ1ed 0n May 2 , 2003 , pr0Visi0na1 app1icati0n N0. 60 / 467 , 363 , ﬁled 0n May 2 , 2003 , pr0Visi0na1 app1icati0n N0. 60 / 467 , 362 , ﬁled 0n May 2 , 2003 , pr0Visi0nal applicati0n N0. 60 / 467 , 284 , ﬁ1ed 0n May 2 , 2003. ( 30 ) F0reign Applicati0n Pri0rity Data Apr. 11 , 2003 ( DK ) . PA 2003 00565 Apr. 11 , 2003 ( DK ) . PA 2003 00566 Apr. 11 , 2003 ( DK ) . PA 2003 00567 Apr. 11 , 2003 ( DK ) . PA 2003 00569 Apr. 11 , 2003 ( DK ) . PA 2003 00571 Apr. 11 , 2003 ( DK ) . PA 200300570 May 22 , 2003 ( DK ) . PA 2003 00776 May 22 , 2003 ( DK ) . PA 2003 00777 Jun. 27 , 2003 ( DK ) . PA 2003 00972 Jun. 30 , 2003 ( DK ) . PA 2003 00988 Jun. 30 , 2003 ( DK ) . PA 2003 00989 Jun. 30 , 2003 ( DK ) . PA 2003 00990 Jul 2 , 2003 ( DK ) . PA 2003 00998 Dec. 20 , 2003 ( DK ) . PA 2003 01910 Jan. 6 , 2004 ( DK ) . PA 2004 00009. 514 / 212.01 , 211.01 , 212.04 , 212.07. See app1icati0n ﬁ1e f0r c0mp1ete search hist0ry. ( 56 ) References Cited. U. S. PATENT DOCUMENTS. 7 , 186 , 735 B2 * 3 / 2007 Str0be1etal. . 514 / 343 2005 / 0080087 A1 * 4 / 2005 Pendri eta1. . 514 / 25205. FORElGN PATENT DOCUMENTS. WO 97 / 07789 3 / l997 WO 01 / 90090 5 / 200l WO 01 / 9009l 5 / 200l WO 01 / 90092 5 / 200l WO 01 / 90093 5 / 200l WO 01 / 90094 5 / 200l WO 02 / 02797 1 / 2002 WO 02 / 72084 3 / 2002 WO 02 / 76435 3 / 2002 WO 03 / 086410 3 / 2003 WO 03 / 02 8730 4 / 2003 OTHER PUBLlCATlONS. Reed. P I et a1—Scand J Gastr0entre01—1980—V01. 15—pp. 51 - 56. Tannin. G M et a1—J Bi0l Chem—l99l—V01. 266—pp. 16653 - l6658. Buialska. I J et a1—End0crin010gy—l99l—V01. l40—pp. 3l88 - 3l96. ( C0ntinued ) . Primary Examiner—Sreeni Padmanabhan Assistant Examiner—Umamaheswari Ramachandran ( 74 ) Att0mey , Agent , 0r Firm—R0semarie R. Wi1k - O1 ' esCar. ( 57 ) ABSTRACT. C0mbinati0n therapy 00mprising the administrati0n 0f an 11 [ 3 - hydr0xyster0id dehydr0genase type 1 inhibit0r and an antihypertensiVe agent usefu1 f0r treating , preVenting and reducing the risk 0f deVel0ping insulin resistance , dyslipidemia , 0besity , hypertensi0n and 0ther re1ated diseases and dis0rders. 3 Claims , N0 DraWings. US 7 , 501 , 405 B2 Page 2. . OTHER PUBLlCATlONS. Wh0rW00d. C B et al—J C1in End0crin01 Metah—200l—V01. 86—pp. 2296 - 2308. C00per. M S et a1—B0ne—2000—V01. 27—pp. 375 - 38l. DaVani. B et a1—J Bi01 Chem—2000—V01. 27 5—pp. 3484 1 - 34844. Brem. A S et a17Hypertens10n719987V01. 317pp. 459 - 462. Rauz. S et a1—InVest Optha1m01Vis Sci—200 l—V01. 42—pp. 2037 - . 2042. M0isan. M - P et a1—End0crin010gy—l990—V01. l27—pp. l450 - . l455. AndreWs. R C et a17J C1in End0crin01 Metab720037V01. 887pp. 285 - 29l. Walker. B R et a1—J Clin End0crin01 Metab—l995—V01. 80—pp. 3 lS 5 - 3 159. M0rt0n. N M et a17J Bi01 Chem720017V01. 2767pp. 41293 - 413 00. K0te1etseV , Y et al—Pr0c Nat1 Acad Sci—l997—V01. 94—pp. 14924 - 14929. Masuzaki , H et al7Science7200l7V01. 2947pp. 2166 - 2170. Souness , G W et a1—Ster0ids—2002—V01. 67—pp. l95 - 201. Brind1ey , D N et a1—Pr0g Lipid Res—l99 l—V01. 30—pp. 349 - 360. Masuzaki , H et aliJ C1in InVest720037V01. 1127pp. 83 - 90. WhitW0rth. J A et a1—J Hypertens—2002—V01.20—pp. lO35 - 1043. Internati0na1 Search Rep0rt C0mp1eted Oct. 8 , 2004. * cited by examiner. US 7 , 501 , 405 B2. 1. COMBINATION THERAPY USING AN 11 [ 3 - HYDROXYSTEROID DEHYDROGENASE TYPE 1 INHIBITOR AND AN ANTIHYPERTENSIVE AGENT FOR THE TREATMENT OF METABOLIC SYNDROME AND RELATED DISEASES AND DISORDERS. CROSS - REFERENCE TO RELATED APPLlCATlONS. This application is a continuation of lnternational Application No. PCT / DK2004 / 000254 , ﬁled Apr. 6 , 2004 , which claims priority from Danish Patent Application Nos. PA 2003 00570 ﬁledApr. 11 , 2003 ; PA 2003 00566 ﬁledApr. 11 , 2003 ; PA 2003 005 65 ﬁled Apr. 11 , 2003 ; PA 2003 005 69 ﬁled Apr. 11 , 2003 ; PA 2003 005 67 ﬁled Apr. 11 , 2003 ; PA 2003 00571 ﬁled Apr. 11 , 2003 ; PA 2003 00776 ﬁled May 22 , 2003 ; PA 2003 0077 ﬁled May 22 , 2003 ; PA 2003 00972 ﬁled Jun. 27 , 2003 ; PA 2003 00990 ﬁled Jun. 30 , 2003 ; PA 2003 00989 ﬁled Jun. 30 , 2003 ; PA 2003 00988 ﬁled Jun. 30 , 2003 ; PA 2003 00998 ﬁled Jul. 2 , 2003 ; PA 2003 01910 ﬁled Dec. 22 , 2003 ; and PA 2003 00009 ﬁled Jan. 6 , 2004 ; and to U. S. Patent Application Nos. 60 / 467 , 284 ﬁ1ed May 2 , 2003 , 60 / 467 , 453 ﬁled May 2 , 2003 ; 60 / 467 , 363 ﬁled May 2 , 2003 ; 60 / 467 , 3 62 ﬁled May 2 , 2003 ; 60 / 467 , 437 ﬁled May 2 , 2003 ; 60 / 467 , 800 ﬁled May 2 , 2003 ; 60 / 474 , 421 , ﬁled May 30 , 2003 ; 60 / 475 , 157 ﬁled Jun. 2 , 2003 ; 60 / 486 , 078 ﬁled Jul. 10 , 2003 ; 60 / 486 , 098 ﬁled Jul. 10 , 2003 ; 60 / 486 , 094 ﬁled Jul. 10 , 2003 ; 60 / 486 , 095 ﬁled Jul. 10 , 2003 ; 60 / 486 , 097 ﬁled Jul. 10 , 2003 ; and 60 / 537 , 099 ﬁled Jan. 16 , 2004. FlELD OF THE lNVENTlON. The instant inVention inVolVes a combination therapy comprising the administration of an 1 1 B - hydroXysteroid dehydrogenase type 1 inhibitor and an antihypertensiVe agent for treating , preVenting and reducing the risk of deVeloping insulin resistance , dyslipidemia , obesity , hypertension and other related diseases and disorders. BACKGROUND OF THE lNVENTlON. The metabolic syndrome is a major global health problem. ln the US , the preValence of metabolic syndrome in the adult population is current1y estimated to be approXimately 25% , and it continues to increase both in the US and WorldWide. The metabolic syndrome is characterized by a combination of insulin resistance , dyslipidemia , obesity and hypertension leading to increased morbidity and mortality of cardioVascular diseases. People With the metabolic syndrome are at increased risk of deVeloping frank type 2 diabetes mellitus , the frequency of Which is equally escalating. ln type 2 diabetes the combination of insulin resistance With obesity and dyslipidemia is also highly preValent and around 70% of people With type 2 diabetes additionally haVe hypertension , once again leading to increased mortality of cardioVascular diseases. ln the clinical setting , it has long been knoWn that glucocorticoids are able to induce all of the cardinal features of the metabolic syndrome and type 2 diabetes. 11 [ 3 - HydroXysteroid dehydrogenase type 1 ( 1 1 B - HSD1 ) catalyses the local generation of actiVe glucocorticoid in seVeral tissues and organs including predominantly the liVer and adipose tissue , but also e. g. skeletal muscle , bone , pancreas , endothelium , . 5. lO. lS. 20. 25. 30. 35. 40. 45. 50. 55. 60. 2. et al. , J Bi0 / . , Chem. , 266 , l6653 ( l99l ) ; Bujalska et al. , End0Crin0 / 0gy , 140 , 3l88 ( 1999 ) ; WhorWood et al. , J. Clin. End0cdn0l. Metab. , 86 , 2296 ( 200l ) ; Cooper et al. , BOne , 27 , 375 ( 2000 ) ; DaVani et al. , J Bi0 / . Chem. , 275 , 34841 ( 2000 ) ; Brem et al. , Hypertensi0n , 3 l , 459 ( l 998 ) ; RauZ et al. , Invest. 0phthalm0 / . Ws. SCi. , 42 , 2037 ( 200l ) ; Moisan et al. , End0 - crin0l0gy , 127 , 145O ( 1990 ) ) . The role of 1 1 B - HSD1 in the metabolic syndrome and type 2 diabetes is supported by seVeral lines of eVidence. ln humans , treatment With the non - speciﬁc 1 1 B - HSD1 inhibitor carbenoxolone improVes insulin sensitiVity in lean healthy Volunteers and people With type 2 diabetes. LikeWise , 11f ) - HSD1 knock - out mice are resistant to insulin resistance induced by obesity and stress. Additionally , the knock - out mice present With an anti - atherogenic lipid proﬁle of decreased VLDL triglycerides and increased HDL - cholesterol. ConVersely , mice that oVer - eXpress 11 [ 3 - HSD1 in adipocytes deVelop insulin resistance , hyperlipidemia , Visceral obesity and hypertension , a phenotype that resembles the human metabolic syndrome ( AndreWs et al. , J. Clin. End0 - crin0 / . Metab. , 88 , 285 ( 2003 ) ; Walker et al. , J. C / in. End0— crin0 / . Metab. , 80 , 3155 ( 1995 ) ; Morton et al. , J. Bi0l. Chem. 276 , 41293 ( 2001 ) ; KotelthseV et al. , Pr0c. Natl. Acad. Sci. USA , 94 , 14924 ( 1997 ) , Masuzaki et al. , Science , 294 , 2166 ( 2001 ) , Masuzaki et al. , J. Clin anest , 112 , 83 ( 2003 ) ) . 118 - HSD1 has also been demonstrated to play a role in increasing Vessel Wall contractility ( Souness et al. , Stemids 67 , 195 ( 2002 ) . The more mechanistic aspects of 118 - HSD1 modulation and thereby modulation of intracellular leVels of actiVe glucocorticoid haVe been inVestigated in seVeral rodent models and different cellular systems. 11 [ 3 - HSD1 promotes the features of the metabolic syndrome by increasing hepatic expression of the rate - limiting enzymes in gluconeogenesis , namely phosphoenolptuate carboxykinase and glucose - 6 - phosphatase , promoting the differentiation of preadipocytes into adipocytes thus facilitating obesity , directly and indirectly stimu1ating hepatic VLDL secretion , decreasing hepatic LDL uptake and increasing Vessel contractility , presumably by decreasing the leVels of endothelial nitric oxide synthase and consequently the leVels of the Vasodialating substance nitric oXide ( KotelthseV et al. , Pmc. Natl Acad. Sci. USA , 94 , 14924 ( 1997 ) ; Morton et a1. , J. Bi0 / . Chem. 276 , 4l293 ( 200l ) ; Bujalska et al. , End0crin0 / 0gy , l40 , 3l88 ( 1999 ) ; Souness et al. , Ster0ids , 67 , 195 ( 2002 ) ; Brindley & Salter , ng. Lipid Res. , 30 , 349 ( 1991 ) ; WhitWorth et al. , J. Hypertens. 20 , 1035 ( 2002 ) ) . Hence , 118 - HSD1 inhibitors constitute a neW therapeutic principle for the treatment of insulin resistance , dyslipidemia , obesity and hypertension. ln the clinical setting , hoWeVer , monotherapeutic treatment of hypertension often lacks efﬁ - cacy due , at least in part , to the induction of compensatory mechanisms. The instant inVention addresses this problem by proViding a combination therapy comprising an 11 [ 3 - HSD1 inhibitor and an antihypertensiVe agent for the treatment of e. g. the metabolic syndrome and type 2 diabetes. When administered as a part of a combination therapy , the 118 - HSD1 inhibitor together With the antihypertensiVe agent proVide improVed control of hypertension and / or improVed treatment of the metabolic syndrome and type 2 diabetes thereby reducing the risk for late complications , e. g. cardioVascular diseases and nephropathy. Due to the greater beneﬁt of the drug combination , lesser dosage amounts of the 11 [ 3 - HSD1 inhibitor and. ocular tissue and certain parts of the central nerVous system. 65 more particularly the antihypertensiVe agent may be needed. Thus , 11 [ 3 - HSD1 serVes as a local regulator of glucocorticoid actions in the tissues and organs Where it is eXpressed ( Tannin. to achieVe the desired clinical result , thereby resulting in improVed safety. US 7 , 50l , 405 B2. 3. Examples of inhibitors and / or modulators of the human 11 [ 3 - hydroxysteroid dehydrogenase type 1 enzyme can be found in WO 01 / 90090 , WO 01 / 90091 , WO 01 / 90092 , WO 01 / 90093 , WO 01 / 90094 , WO 02 / 72084 and WO 02 / 076435 , as Well as the folloWing patent applications under common oWnership of the present application : PA 2003 00569 ﬁled 11 Apr. 2003 DK , PA 2003 00565 ﬁled 11 Apr. 2003 DK , PA 2003 00571 ﬁled 11 Apr. 2003 DK , PA 2003 00570 ﬁled 11 Apr. 2003 DK , PA 2003 00566 ﬁled 11 Apr. 2003 DK , PA 2003 00972 ﬁled 27 Jun. 2003 DK , PA 2003 00998 ﬁled 02 July 2003 DK , PA 2003 00988 ﬁled 30 Jun. 2003 DK , PA 2003 00989 ﬁled 30 Jun. 2003 DK , PA 2003 00990 ﬁled 30 Jun. 2003 DK , and PA 2003 01910 ﬁled 22 Dec. 2003 DK , the contents of Which are hereby incorporated by reference in their entirety. SUMMARY OF THE lNVENTlON. An object of the present inVention is to proVide a noVel combination therapy comprised of a therapeutically effectiVe amount of an antihypertensiVe agent in combination With an 11 [ 3 - hydroxysteroid dehydrogenase type 1 inhibitor ( 11 B - HSD1 ) for the treatment , preVention and to reduce the risk of deVeloping , metabolic syndrome , insulin resistance , dyslipidemia , obesity , hypertension and related diseases and disorders. DEFlNlTlONS. ln the folloWing structural formulas and throughout the present speciﬁcation , the folloWing terms haVe the indicated meaning : . The term “halo” inc1udes ﬂuorine , chlorine , bromine , and iodine. The term “trihalomethyl” includes triﬁuoromethyl , trichloromethyl , tribromomethyl , and triiodomethyl. The term “trihalomethoxy” includes triﬂuorometoxy , trich1orometoxy , tribromometoxy , and triiodometoxy. The term “alkyl” includes C1 ' C6 straight chain saturated and methylene aliphatic hydrocarbon groups , C3 - C6 branched saturated hydrocarbon groups haVing the speciﬁed number of carbon atoms. For example , this deﬁnition shall include but is not limited to methyl ( Me ) , ethy1 ( Et ) , propyl ( Pr ) , butyl ( Bu ) , pentyl , hexyl , isopropyl ( i - Pr ) , isobutyl ( i - Bu ) , tert - butyl ( t - Bu ) , sec - butyl ( s - Bu ) , isopentyl , neopentyl , and the like. The term “alkenyl” includes C2 - C6 straight chain unsaturated aliphatic hydrocarbon groups and branched C3 - C6 unsaturated aliphatic hydrocarbon groups haVing the speciﬁed number of carbon atoms. For example , this deﬁnition shall include but is not limited to ethenyl , propenyl , butenyl , pentenyl , hexenyl , methylpropenyl , methylbutenyl and the like. The term “a1kynyl” includes C2 - C6 straight chain unsaturated aliphatic hydrocarbon groups and C4 - C6 branched unsaturated aliphatic hydrocarbon groups haVing the speciﬁed number of carbon atoms. For example , this deﬁnition shall include but is not limited to ethynyl , propynyl , butynyl , pentynyl , hexynyl , methylbutynyl , and the like. The term “saturated or partially saturated cyclic , bicyclic or tricyc1ic ring system” represents but are not limit to aziridinyl , pyrrolinyl , pyrrolidinyl , 2 - imidazolinyl , imidazolidinyl , 2 - pyrazolinyl , morpholinyl , piperidinyl , thiomorpholinyl , piperazinyl , phthalimide , 1 , 2 , 3 , 4 - tetrahydro - quinolinyl , 1 , 2 , 3 , 4 - tetrahydro - isoquinolinyl , 1 , 2 , 3 , 4 - tetrahydro - quinoxalinyl , and indolinyl. The term “saturated or partially saturated cyclic ring system” represents but are not limited to cyclopropyl , cyclobutyl , . lO. lS. 20. 25. 30. 35. 40. 45. 50. 55. 60. 65. 4. cyclopentyl , cyclohexyl , cyclobutenyl , cyclopentenyl , cyclohexenyl , cycloheptenyl , cyclooctenyl , cyclononenyl , cyclodecenyl , tetrahydrofuranyl or tetrahydropyranyl. The term “saturated or partially saturated aromatic ring system” represents but are not limited to cyclopentyl , cyclohexyl , cyclobutenyl , cyclopentenyl , cyclohexenyl , cycloheptenyl , cyclooctenyl , cyclononenyl , cyclodecenyl , tetrahydrofuranyl , tetrahydropyranyl , phenyl , pyridyl or pyrimidinyl. The term “cycloalkyl” ( e. g. cyclopropyl , cyclobutyl , cyclopentyl , cyclohexyl , cycloheptyl , cyclooctyl , cyclononyl , cyclodecyl , bicyclo [ 3.2.1 ] octyl , spiro [ 4.5 ] decyl , norpinyl , norbornyl , norcaryl , adamantyl and the like ) represents a saturated , mono - , bi - , tri - or spirocarbocyclic group haVing the speciﬁed number of carbon atoms. The term “cycloalkylalkyl” ( e. g. cyclopropylmethyl , cyclobutylethyl , adamantylmethyl and the like ) represents a cycloalkyl group as deﬁned aboVe attached through an alkyl group haVing the indicated number of carbon atoms or substituted alkyl group as deﬁned aboVe. The term “cycloalkenyl” ( e. g. cyclobutenyl , cyclopentenyl , cyclohexenyl , cycloheptenyl , cyclooctenyl , cyclononenyl , cyclodecenyl and the like ) represents a partially saturated , mono - , bi - , tri - or spirocarbocyclic group haVing the speciﬁed number of carbon atoms. The term “hetcycloalkyl” ( tetrahydrofuranyl , tetrahydropyranyl , tertahydrothiopyranyl , and the like ) represents a saturated mono - , bi - , tri - or spirocarbocyclic group haVing the speciﬁed number of carbon atoms and one or tWo additional heteroatoms or groups selected from nitrogen , oxygen , sulphur , SO or SO2. The te1m “alkyloxy” ( e. g. methoxy , ethoxy , propyloxy , allyloxy , cyclohexyloxy ) represents an alkyl group as deﬁned aboVe haVing the indicated number of carbon atoms attached through an oxygen bridge. The term “alkyloxyalkyl” ( e. g. methyloxymethyl and the like ) represents an alkyloxy group as deﬁned aboVe attached through an “alkyl” group. The term “aryloxyhetaryl” ( e. g. 2 - phenoxy - pyridyl and the like ) represents an aryloxy group as deﬁned beloW attached through a “hetaryl” group. The term “aryloxy” ( e. g. phenoxy , naphthyloxy and the like ) represents an aryl group as deﬁned beloW attached through an oxygen bridge. The term “hetaryloxy” ( e. g. 2 - pyridyloxy and the like ) represents a hetaryl group as deﬁned beloW attached through an oxygen bridge. The term “arylalkyloxy” ( e. g. phenethyloxy , naphthylmethy1oxy and the like ) represents an ary1alkyl group as deﬁned beloW attached through an oxygen bridge. The term “hetarylalkyloxy” ( e. g. 2 - pyridy1methyloxy and the like ) represents a hetarylalkyl group as deﬁned beloW attached through an oxygen bridge. The term “alkyloxycarbonyl” ( e. g. methylformiat , ethylformiat and the like ) represents an alkyloxy group as deﬁned aboVe attached through a carbonyl group. The term “aryloxycarbonyl” ( e. g. phenylformiat , 2 - thiazolylformiat and the like ) represents an aryloxy group as deﬁned aboVe attached through a carbonyl group. The term “arylalkyloxycarbonyl” ( e. g. benzylformiat , phenyletylformiat and the like ) represents an “arylalkyloxy” group as deﬁned aboVe attached through a carbonyl group. The term “arylalkyl” ( e. g. benzyl , phenylethyl , 3 - phenylpropyl , 1 - naphtylmethyl , 2 - ( 1 - naphtyl ) ethyl and the like ) represents an aryl group as deﬁned beloW attached through an alkyl haVing the indicated number of carbon atoms or substituted alkyl group as deﬁned aboVe. US 7 , 50l , 405 B2. 5. The term “hetarylalkyl” ( e. g. ( 2 - furyl ) methyl , ( 3 - furyl ) methyl , ( 2 - thienyl ) methyl , ( 3 - thienyl ) methyl , ( 2 - pyridyl ) methyl , 1 - methyl - 1 - ( 2 - pyrimidyl ) ethyl and the like ) represents a hetaryl group as deﬁned be1oW attached through an alkyl haVing the indicated number of carbon atoms or substituted 5 alkyl group as deﬁned aboVe. The term “alkylcarbonyl” ( e. g. octylcarbonyl , pentylcarbonyl , 3 - hexenylcarbonyl ) represents an alkyl group as deﬁned aboVe haVing the indicated number of carbon atoms attached through a carbonyl group. The term “arylcarbonyl” ( e. g. benzoyl ) represents an aryl group as deﬁned beloW attached through a carbonyl group. The term “hetarylcarbonyl” ( e. g. 2 - thiophenylcarbonyl , 3 - methoxy - anthrylcarbonyl , oxazolylcarbonyl and the like ) represents a hetaryl group as deﬁned beloW attached through 15 a carbonyl group. The term “carbonylalkyl” ( e. g. acetyl and the like ) represents a carbonyl group attached through alkyl group as deﬁned aboVe haVing the indicated number of carbon atoms. The term “alkylcarbonylalkyl” ( e. g. propan - 2 - one , 4 , 4 - 20. lO. dimethyl - pentan - 2 - one and the like ) represents an alkylcarbonyl group as deﬁned aboVe attached through an alkyl group as deﬁned aboVe haVing the indicated number of carbon atoms. The term “arylcarbonylalkyl” ( e. g. 1 - phenyl - propan - 1 - 25 one , 1 - ( 3 - chloro - phenyl ) - 2 - methyl - butan - 1 - one and the like ) represents a arylcarbonyl group as deﬁned aboVe attached through an a1kyl group as deﬁned aboVe haVing the indicated number of carbon atoms. The term “hetarylcarbonylalkyl” ( e. g. 1 - pyridin - 2 - yl - pro - 30 pan - 1 - one , 1 - ( 1 - H - imidazol - 2 - yl ) - propan - 1 - one and the like ) represents a hetarylcarbonyl group as deﬁned aboVe attached through an a1kyl group as deﬁned aboVe haVing the indicated number of carbon atoms. The term “arylalkylcarbonyl” ( e. g. phenylpropylcarbonyl , 35 phenylethylcarbonyl and the like ) represents an arylalkyl group as deﬁned aboVe haVing the indicated number of carbon atoms attached through a carbonyl group. The term “hetarylalkylcarbonyl” ( e. g. imidazolylpenty1 - carbonyl and the like ) represents an hetarylalkyl group as 40 deﬁned aboVe Wherein the alkyl group is in turn attached through a carbonyl. The term “alkylcarboxy” ( e. g. hepty1carboxy , cyc1opropylcarboxy , 3 - penteny1carboxy ) represents an alky1carbonyl group as deﬁned aboVe Wherein the carbonyl is in turn 45 attached through an oxygen bridge. The term “arylcarboxy” ( e. g. benzoic acid and the like ) represents an ary1carbony1 group as deﬁned aboVe Wherein the carbonyl is in turn attached through an oxygen bridge. The term “alkylcarboxyalkyl” ( e. g. heptylcarboxymethyl , 50 propylcarboxy tert - butyl , 3 - pentylcarboxyethyl ) represents an. The term “ary1alkylcarboxy” ( e. g. benzylcarboxy , pheny1 - propylcarboxy and the like ) represents an arylalkylcarbonyl group as deﬁned aboVe Wherein the carbonyl is in turn 55 attached through an oxygen bridge. The term “arylalkylcarboxyalkyl” ( e. g. benzylcarboxymethy1 , phenylpropylcarboxypropyl and the 1ike ) represents an arylalkylcarboxy group as deﬁned aboVe Wherein the carboxy group is in turn attached through an alkyl group as deﬁned 60 aboVe haVing the indicated number of carbon atoms. The term “hetarylcarboxy” ( e. g. pyridine - 2 - carboxylic acid and the like ) represents a hetarylcarbonyl group as deﬁned aboVe Wherein the carbonyl is in turn attached through an oxygen bridge. The term “hetarylalkylcarboxy” ( e. g. ( 1 - H - imidazol - 2 - yl ) - acetic acid , 3 - pyrimidin - 2 - yl - propionic acid and the like ) rep - . 65. 6. resents a hetarylalkyl group as deﬁned aboVe Wherein the carbonyl is in turn attached through an oxygen bridge. The term “alkylthio” ( e. g. methylthio , ethylthio and the like ) represents an alkyl group as deﬁned aboVe attached through a sulphur bridge. The term “arylthio” ( e. g. benzenthiol , naphthylthiol and the like ) represents an aryl group as deﬁned beloW attached through a sulphur bridge. The term “hetarylthio” ( e. g. pyridine - 2 - thiol , thiazole - 2 - thiol and the like ) represents an hetaryl group as deﬁned beloW attached through a sulphur bridge. The term “arylthioalkyl” ( e. g. methylsulfanyl benzene , ethylsulfanyl naphthalene and the like ) represents an arylthio group as deﬁned beloW attached through an alkyl group haVing the indicated number of carbon atoms. The term “hetarylthioalkyl” ( e. g. 2 - methylsulfanyl - pyridine , 1 - ethylsulfanyl - isoquinoline and the like ) represents a hetarylthio group as deﬁned beloW attached through an alkyl group haVing the indicated number of carbon atoms. The term “hetaryloxyaryl” ( e. g. 1 - phenoxy - isoquinolyl , 2 - phenoxypyridyl and the like ) represents a hetaryloxy group as deﬁned aboVe attached through an “aryl” group as deﬁned beloW. The term “hetaryloxyhetaryl” ( e. g. 1 - ( 2 - pyridyloxy - isoquinoline ) , 2 - ( imidazol - 2 - yloxy - pyridine ) and the like ) represents a hetaryloxy group as deﬁned aboVe attached through a “hetaryl” group as deﬁned beloW. The term “aryloxyalkyl” ( e. g. phenoxymethyl , naphthyloxyethyl and the like ) represents an aryloxy group as deﬁned aboVe attached through an “alkyl” group haVing the indicated number of carbon atoms. The term “aryloxyaryl” ( e. g. 1 - phenoxy - naphthalene , phenyloxyphenyl and the like ) represents an aryloxy group as deﬁned aboVe attached through an “aryl” group as deﬁned beloW. The term “arylalkyloxyalkyl” ( e. g. ethoxymethyl - benzene , 2 - methoxymethyl - naphthalene and the like ) represents an aryla1ky1oxy group as deﬁned aboVe attached through an “alkyl” group haVing the indicated number of carbon atoms. The term “hetaryloxyalky1” ( e. g. 2 - pyridyloxymethyl , 2 - quinolyloxyethyl and the like ) represents a hetaryloxy group as deﬁned aboVe attached through an “alkyl” group haVing the indicated number of carbon atoms. The term “hetarylalkyloxyalkyl” ( e. g. 4 - methoxymethy1 - pyrimidine , 2 - methoxymethyl - quinoline and the like ) represents a hetarylalkyloxy group as deﬁned aboVe attached through an “alkyl” group haVing the indicated number of carbon atoms. The term “alkylcarbonylamino” ( e. g. methylcarbonylamino , cyclopentylcarbonyl - aminomethyl , methylcarbonylaminophenyl ) represents an “alkylcarbonyl” group as deﬁned aboVe Wherein the carbonyl is in turn attached through the nitrogen atom of an amino group. The nitrogen atom may itself be substituted With an alkyl or aryl group. The term "a1ky1carbonylaminoa1ky1” ( e. g. N - propy1 - acetamide , N - butyl - propionamide and the like ) represents an “alkylcarbonylamino” group attached through an alkyl group as deﬁned aboVe haVing the indicated number of carbon atoms. The term “arylalkylcarbonylamino” ( e. g. phenylacetamide , 3phenyl - propionamide and the like ) represents an “arylalkylcarbonyl” group as deﬁned aboVe attached through an amino group. The term “arylalkylcarbonylaminoalkyl” ( e. g. N - ethylphenylacetamide , N - butyl - 3 - phenyl - propionamide and the. US 7 , 50l , 405 B2. 7. like ) represents an “arylalkylcarbonylamino” group attached through an alkyl group as deﬁned aboVe haVing the indicated number of carbon atoms. The term “arylcarbonylamino” ( e. g. benzamide , naphthalene - 1 - carboxylic acid amide and the like ) represents an “arylcarbonyl” group as deﬁned aboVe attached through an ammo group. The term “arylcarbonylaminoalkyl” ( e. g. N - propyl - benzamide , N - Butyl - naphthalene - 1 - carboxylic acid amide and the like ) represents an “arylcarbonylamino” group attached through an alkyl group as deﬁned aboVe haVing the indicated number of carbon atoms. The term “aryl” includes but is not limited to a carbocyclic aromatic ring system being either monocyclic , bicyclic , or polycyclic , such as phenyl , biphenyl , naphthyl , anthracenyl , phenanthrenyl , ﬁuorenyl , indenyl , pentalenyl , azulenyl , biphenylenyl and the like. Aryl is also intended to include the partially hydrogenated deriVatiVes of the carbocyclic aromatic systems enumerated aboVe. Non - limiting examples of such partially hydrogenated deriVatiVes are 1 , 2 , 3 , 4 - tetrahydronaphthyl , 1 , 4 - dihydronaphthyl and the like. The term “hetaryl” includes but is not limited to pyrrolyl ( 2 - pyrrolyl ) , pyrazolyl ( 3 - pyrazoly1 ) , imidazo1yl ( 1 - imidazolyl , 2 - imidazolyl , 4 - imidazolyl , 5 - imidazolyl ) , triazolyl ( 1 , 2 , 3 - trazol - 1 - yl , 1 , 2 , 3 - triazol - 2 - yl , 1 , 2 , 3 - triazol4 - yl , 1 , 2 , 4 - triazol - 3 - yl ) , oxazolyl ( 2 - oxazolyl , oxazolyl , 5 - oxazolyl ) , isoxazolyl ( 3 - isoxazolyl , 4 - isoxazolyl , 5 - isoxazolyl ) , thiazoly1 ( 2 - thiazolyl , 4 - thiazoly1 , 5 - thiazoly1 ) , thiophenyl ( 2 - thiopheny1 , 3 - thiophenyl , 4 - thiophenyl , 5 - thiopheny1 ) , furanyl ( 2 - furanyl , 3 - ﬁ1ranyl , 4 - furanyl , 5 - furanyl ) , pyridyl ( 2 - pyridyl , 3 - pyridyl , 4 - pyridyl , 5 - pyridyl ) , 5 - tetrazolyl , pyrimidinyl ( 2 - pyrimidinyl , 4 - pyrimidinyl , 5 - pyrimidinyl , 6 - pyrimidinyl ) , pyraziny1 , pyridaziny1 ( 3 - pyridaziny1 , 4 - pyridazinyl , 5 - pyridazinyl ) , quinoly1 ( 2 - quinoly1 , 3 - quinolyl , 4 - quinolyl , 5 - quinolyl , 6 - quinolyl , 7 - quinolyl , 8 - quinolyl ) , isoquinolyl ( 1 - isoquinolyl , 3 - isoquinolyl , 4 - isoquinolyl , 5 - isoquinolyl , 6 - isoquinolyl , 7 - isoquinolyl , 8 - isoquinolyl ) , benzo [ b ] furanyl ( 2 - benzo [ b ] furanyl , 3 - benzo [ b ] furanyl , 4 - benzo [ b ] furany1 , 5 - benzo [ b ] furanyl , 6 - benzo [ b ] furanyl , 7 - benzo [ b ] furanyl ) , 2 , 3 - dihydro - benzo [ b ] furanyl ( 2 - ( 2 , 3 - dihydro - benzo [ b ] furanyl ) , 3 - ( 2 , 3 - dihydro - benzo [ b ] furanyl ) , 4 - ( 2 , 3 - dihydro - benzo [ b ] furanyl ) , 5 - ( 2 , 3 - dihydro benzo - [ b ] furany1 ) , 6 - ( 2 , 3 - dihydro - benzo - [ b ] furanyl ) , 7 - ( 2 , 3 - dihydrobenzo [ b ] furanyl ) ) , benzo [ b ] thiophenyl ( 2 - benzo [ b ] thiophenyl , 3 - benzo [ b ] thiophenyl , 4 - benzo [ b ] thiophenyl , 5 - benzo [ b ] thiophenyl , 6 - benzo [ b ] thiophenyl , 7 - benzo [ b ] thiophenyl ) , 2 , 3 - dihydro - benzo [ b ] thiophenyl ( 2 - ( 2 , 3 - dihydro - benzo [ b ] thiopheny1 ) , 3 - ( 2 , 3 - dihydro - benzo [ b ] thiophenyl ) , 4 - ( 2 , 3 - dihydro - benzo [ b ] thiophenyl ) , 5 - ( 2 , 3 - dihydro - benzo [ b ] thiophenyl ) , 6 - ( 2 , 3 - dihydro - benzo [ b ] thiophenyl ) , 7 - ( 2 , 3 - dihydro - benzo [ b ] thiophenyl ) ) , 4 , 5 , 6 , 7 - tetrahydro - benzo [ b ] thiophenyl ( 2 - ( 4 , 5 , 6 , 7 - tetrahydro - benzo [ b ] thiopheny1 ) , 3 - ( 4 , 5 , 6 , 7 - tetrahydro - benzo [ b ] thiopheny1 ) , 4 - ( 4 , 5 , 6 , 7 - tetrahydro - benzo [ b ] thiophenyl ) , 5 - ( 4 , 5 , 6 , 7 - tetrahydro - benzo [ b ] thiophenyl ) , 6 - ( 4 , 5 , 6 , 7 - tetra - hydro - benzo [ b ] thiophenyl ) , 7 - ( 4 , 5 , 6 , 7 - tetrahydro - benzo [ b ] thiophenyl ) ) , 4 , 5 , 6 , 7 - tetrahydro - thieno [ 2 , 3 - c ] pyridyl ( 4 - ( 4 , 5 , 6 , 7 - tetrahydro - thieno [ 2 , 3 - c ] pyridyl ) , 5 - 4 , 5 , 6 , 7 - tetrahydro - thieno [ 2 , 3 - c ] pyridyl ) , 6 - ( 4 , 5 , 6 , 7 - tetrahydro - thieno [ 2 , 3 - c ] pyridyl ) , 7 - ( 4 , 5 , 6 , 7 - tetrahydro - thieno [ 2 , 3 - c ] pyridyl ) ) , indolyl ( 1 - indolyl , 2 - indolyl , 3 - indolyl , 4 - indolyl , 5 - indolyl , 6 - indolyl , 7 - indolyl ) , isoindolyl ( 1 - isoindolyl , 2 - isoindolyl , 3 - isoindolyl , 4 - isoindolyl , 5 - isoindolyl , 6 - isoindolyl , 7 - isoindolyl ) , 1 , 3 - dihydro - isoindolyl ( 1 - ( 1 , 3 - dihydro - isoindolyl ) , 2 - ( 1 , 3 - dihydro - isoindolyl ) , 3 - ( l , 3 - dihydro - isoindolyl ) , 4 - ( l , 3 - dihydroisoindolyl ) , 5 - ( 1 , 3 - dihydro - isoindolyl ) , 6 - ( 1 , 3 - dihydroisoindolyl ) , 7 - ( 1 , 3 - dihydro - isoindolyl ) ) , indazole. 5. lO. lS. 20. 25. 30. 35. 40. 45. 50. 55. 60. 65. 8. ( 1 - indazolyl , 3 - indazolyl , 4 - indazolyl , 5 - indazolyl , 6 - indazolyl , 7 - indazolyl ) , benzimidazolyl ( 1 - benzimidazolyl , 2 - benzimidazolyl , 4 - benzimidazolyl , 5 - benzimidazolyl , 6 - benzimidazolyl , 7 - benzimidazolyl , 8 - benzimidazolyl ) , benzoxazolyl ( 1 - benz - oxazolyl , 2 - benzoxazolyl ) , benzothiazolyl ( 1 - benzothiazolyl , 2 - benzothiazolyl , 4 - benzothiazolyl , 5 - benzothiazolyl , 6 - benzothiazolyl , 7 - benzothiazolyl ) , carbazolyl ( 1 - carbazolyl , 2 - carbazolyl , 3 - carbazolyl , 4 - carbazolyl ) , piperidinyl ( 2 - piperidinyl , 3 - piperidinyl , 4 - piperidi - . nyl ) , pyrrolidinyl ( 1 - pyrrolidinyl , 2 - py1rolidinyl , 3 - pyrrolidinyl ) . With respect to Formula ll , the term. “NR4R5carbonylalkyl” ( e. g. N , N - dimethyl - propionamide , N - isopropyl - N - methyl - propionamide and the like ) represents NR4R5 substituted by a carbonylalkyl group as deﬁned aboVe , Wherein R4 and R5 are as deﬁned for Formula II herein. With respect to Formula ll , the term “alkle6alkyl” ( e. g. 2 - ethoxymethyl , N - ethyl - N - methy amine , methyl - propylamide , ethanesulfonic acid methylamide and the like ) represents an alkyl group as deﬁned aboVe , substituted by R6 , Which is substituted by an alkyl group as deﬁned aboVe , Wherein R6is as deﬁned for Formula II herein. With respect to Formu1a ll , the term “ary1R6a1kyl” ( e. g. ethoxy - benzene , ethyl - methyl - phenyl - amine , N - ethyl - benzamide , N - isobutyl - benzenesulfonamide and the like ) represents an aryl group as deﬁned aboVe , substituted by R6 , Which is substituted by an alkyl group as deﬁned aboVe , Wherein R6is as deﬁned for Fo1mula ll herein. With respect to Formula ll , the term “ary1alkle6alkyl” ( e. g. benzyloxymethyl , ethyl - methyl - benzyl - amine , N - ethylbenzylamide and the like ) represents an arylalkyl group as deﬁned aboVe , substituted by R6 , Which is substituted by an a1ky1 group as deﬁned aboVe , Wherein R5 is as deﬁned for Formu1a ll herein. With respect to Formula ll , the term “hetarle6alkyl” ( e. g. 2 - ethoxy - 1H - imidazol , ethyl - quinolin - 2 - yl - amine , thiazole - 2 - carboxylic acid , methyl - propyl - amide , pyridine - 3 - sulfonic acid isobutyl - amide and the like ) represents a hetaryl group as deﬁned aboVe , substituted by R6 , Which is substituted by an alkyl group as deﬁned aboVe , Wherein R5 is as deﬁned for Formula II herein. With respect to Formula ll , the term “arylcarbonleR15” ( e. g. N - benzyl - N - methy1 - benzamide and the like ) represents an ary1carbony1 group as deﬁned aboVe , substituted by NRlS , Wherein RlS is as deﬁned for Formula 11 herein. With respect to Formula ll , the term “alkylSOn” ( e. g. ethylsulfonyl , ethylsulﬁnyl and the like ) represents an alkyl group as deﬁned aboVe , Wherein the alkyl group is in turn attached through a sulphur bridge Wherein the sulphur is substituted With 11 oxygen atoms , Wherein n is as deﬁned for Formula II herein. With respect to Formula ll , the term “arylSOm” ( e. g. phenylsulﬁnyl , naphthyl - 2 - sulfony1 and the 1ike ) represents an aryl group as deﬁned aboVe , Wherein the aryl group is in turn attached through a sulphur bridge Wherein the sulphur is substituted With m oxygen atoms , Wherein m is as deﬁned for Formula II herein. With respect to Formula ll , the term “hetarylSOm” ( e. g. thiazol - 2 - sulﬁnyl , pyridine - 2 - sulfonyl and the like ) represents a hetaryl group as deﬁned aboVe , Wherein the hetaryl group is in turn attached through a sulphur bridge Wherein the sulphur is substituted With 111 oxygen atoms , Wherein is as deﬁned for Formula II herein. With respect to Formula ll , the term “arylSOmNR8” ( e. g. N - methyl - benzenesulfonamide and the like ) represents an aryl group as deﬁned aboVe , Wherein the aryl group is in turn attached through a SOmNR8 group Wherein the sulphur is. US 7 , 50l , 405 B2. 9. substituted With 111 oxygen atoms and the nitrogen atom substituted by R8 , Wherein R8 and m are as deﬁned for Formula II herein. With respect to Formula V , the term “N R4R5carbonylalkyl” ( e. g. N , N - dimethyl - propionamide , N - isopropyl - N - methyl - propionamide and the like ) represents NR4R5 substituted by a carbonylalkyl group as deﬁned aboVe , Wherein R4 and R5 are as deﬁned for Formula V herein. With respect to Formula V , the term “arle8alkyl” ( e. g. ethoxy - benzene , ethyl - methyl - phenyl - amine , N - ethyl - benzamide , N - isobutyl - benzenesulfonamide and the like ) represents an aryl group as deﬁned aboVe , substituted by R8 , Which is substituted by an alkyl group as deﬁned aboVe , Wherein R8 is as deﬁned for Formula V herein. With respect to Formula V , the term “hetarle8alkyl” ( e. g. 2 - ethoxy - 1H - imidazol , ethyl - quinolin - 2 - yl - amine , thiazole - 2 - carboxylic acid , methyl - propyl - amide , pyridine - 3 - sulfonic acid isobutyl - amide and the like ) represents a hetaryl group as deﬁned aboVe , substituted by R8 , Which is substituted by an alkyl group as deﬁned aboVe , Wherein R8 is as deﬁned for Formula V herein. With respect to Formula V , the term “arylcarbonleRl5” ( e. g. N - benzyl - N - methyl - benzamide and the like ) represents an arylcarbonyl group as deﬁned aboVe , substituted by NRlS , Wherein RlS is as deﬁned for Formu1a V herein. Certain of the aboVe deﬁned terms may occur more than once in the structural formulae , and upon such occurrence each term shall be deﬁned independently of the other. The term “optionally substituted” as used herein means that the groups in question are either unsubstituted or substituted With one or more of the sub stituents speciﬁed. When the groups in question are substituted With more than one substituent , the substituents may be the same or different. The term “treatment” is deﬁned as the management and care of a patient for the purpose of combating or a1leViating the disease , condition or disorder , and the term inc1udes the administration of the actiVe compound to preVent the onset of the symptoms or complications , or alleViating the symptoms or complications , or eliminating the disease , condition , or disorder. The term “pha1maceutica1ly acceptab1e” is deﬁned as being suitable for administration to humans Without adVerse eVents. The term “prodrug” is deﬁned as a chemically modiﬁed form of the actiVe drug , said prodrug being administered to the patient and subsequent1y being conVerted to the actiVe drug. Techniques for deVelopment of prodrugs are Well knoWn in the art. The term “combination therapy” is deﬁned as the administration of a single pharmaceutical dosage formulation Which comprises the 1 18 - HSD1 inhibitor and the anti - hypertensiVe agent , as We1l as administration of each actiVe agent in its oWn separate pharmaceutical dosage formulation. Where separate dosage formulations are used , the 11 [ 3 - HSD1 inhibitor and the anti - hypertensiVe agent can be administered to the patient at essentially the same time , i. e. concurrently , or at separate staggered times , i. e. sequentially. When giVen by different dosage formulations , the route of administration may be the same or different for each agent. Any route of administration knoWn or contemplated for the indiVidual agents is acceptable for the practice of the present inVention. The term “therapeutically effectiVe amount” is deﬁned as the amount of drug or pharmaceutical agent that Will elicit the biological or medical response of a tissue , a system or a mammal that is sought by the treating indiVidual , i. e. medical doctor or other clinician. lO. lS. 20. 25. 30. 35. 40. 45. 50. 55. 60. 65. 10. As used herein , the Various forms of the term “modulation” are intended to include stimulation ( e. g. , increasing or upregulating a particular response or actiVity ) and inhibition ( e. g. , decreasing or doWnregulating a particular response or actiVity ) . As used herein , the term “agonist” is intended to indicate a substance that actiVates the receptor ( s ) . DETAlLED DESCRlPTlON OF THE lNVENTlON. Synthetic schemes for general formula ( l ) through general formula ( V ) compounds described herein , as Well as examples , are found in the folloWing patent applications under common oWnership of the present application : PA 2003 00569 ﬁled 11 Apr. 2003 DK , PA 2003 00565 ﬁled 11 Apr. 2003 DK , PA 2003 00571 ﬁled 11 Apr. 2003 DK , PA 2003 00570 ﬁled 11 Apr. 2003 DK , PA 2003 00566 ﬁled 11 Apr. 2003 DK , PA 2003 00972 ﬁled 27 Jun. 2003 DK , PA 2003 00998 ﬁled 02 Jul. 2003 DK , PA 2003 00988 ﬁled 30 Jun. 2003 DK , PA 2003 00989 ﬁled 30 Jun. 2003 DK , PA 2003 00990 ﬁled 30 Jun. 2003 DK , and PA 2003 01910 ﬁled 22 Dec. 2003 DK , the contents of Which are hereby incorporated by reference in their entirety. ln one embodiment of the present inVention said substituted pyrazolo [ 1 , 5 - a ] pyrimidines , or a prodrug thereof , as a component of the combination therapy is of the general formula ( l ) . 5 Formula ( I ) R R4 f N / N \ \ R3 N. Wherein. R1 and R2independently are hydrogen , halo , C ( : O ) NR6R7 , CO2R15 , NR6C ( : O ) R11 , OR12 or SR” ; . R3 and R5 independently are hydrogen , NR13R14 , trihalomethyl , trihalomethoxy , C1 - C6alkyl , C2 - C6alkenyl , C2 - C6alkynyl , Cl - C6alkyloxy , Cl - C6alkylthio , aryl , arlel - C6alkyl , hetaryl or hetarlel - C6a1kyl , Wherein alkyl , alkynyl , alkenyl , aryl , hetaryl , arylalkyl or hetarylalkyl groups independently are optionally substituted With one or more of R8 ; . R4 is hydrogen , cyano , halo , CO2Rl5 , C ( : O ) NR6R7 , Cl - C6alkyl , C2 - C6alkenyl , C2 - C6alkynyl , aryl , hetaryl , arle1 - C6alkyl , hetarle1 - C6alkyl , hydroxy , C l - C6alkyloxy , arle1 - C6alkyloxy , hetarlel - C6alkyloxy , or C1 - C6alkyloxyC1 - C6alkyl , Wherein the alkyl , alkynyl , alkenyl , cycloa1kyl , ary1 , hetary1 , arylalkyl or hetarylalkyl groups independently are optionally substituted With one or more of R9 ; . R6 and R7 independently are Cl - C6alkyl , C3 - Cl0cycloalkyl , hetC3 - Cl0cycloalkyl , arlel - C6alkyl or hetarlel - C6alkyl , Wherein the alkyl , cycloalkyl , hetcycloalkyl , arylalkyl , and hetarylalkyl groups independently are optionally substituted With one or more of R“ ) ; or. R6 and R7 together With the nitrogen to Which they are attached , are forming a saturated or partially saturated cyclic , bicyclic or tricyclic ring system containing from 4 to 10 carbon atoms and from 0 to 2 additional heteroatoms selected from nitrogen , oxygen or sulphur , the ring system optionally being substituted With at least one of C1 - C6alkyl , aryl , . hetaryl , arle1 - C6alkyl , halo , hydroxy , oxo , C1 - C6alkyloxy , . US 7 , 50l , 405 B2. 11 arle1 - C6alkyloxy , hetarlel - C6alkyloxy , Cl - C6alkyloxyC1 - C6alkyl , Cl - C6alkylcarbonyl , arylcarbonyl , hetarylcarbonyl , arle1 - C6alkylcarbonyl , hetarle1 - C6alkylcarbonyl , Cl - C6alky1carboxy , arylcarboxy , hetary1 - carboxy , arle 1 - C6alkylcarboxy C6alkylcarboxy ; . R8 and R9 independently are hydrogen , halo , hydroxy , oxo , cyano , nitro , C3 - ClOcycloalkyl , C3 - C10hetocycloalkyl , Cl - C6alkyl , Cl - C6alkyloxy , trihalomethyl , trihalomethoxy , arle1 - C6alkyloxy , hetarle1 - C6alkyloxy , C1 - C6alkylcarbonyl , arylcarbonyl , hetarylcarbonyl , arle1 - C6alkylcarbonyl , hetarle1 - C6alkylcarbonyl , C l - C6alkylcarboxy , arylcarboxy , hetarylcarboxy , arle1 - C6 - . or hetarlel - . alkylcarboxy , hetarlel - C6alkylcarboxy , C1 - C6alkylcarbonylamino or arle1 - C6alkylcarbonyl - am1no ; . R10 is hydrogen , halo , cyano , nitro , hydroxy , oxo , C3 - C1Ocycloalkyl , C3 - C10hetcycloalkyl , C1 - C6 - alkyl , C1 - C6alkyloxy , trihalomethyl , triha1ometh dialky1amino oxy , arle1 - C6alkyloxy , hetarlel - C6alkyloxy , Cl - C6alkylcarbonyl , arylcarbonyl , hetarylcarbonyl , arlel - C6alkylcarbonyl , hetarlel - C6alkylcarbonyl , C1 - C6alkylcarboxy , arylcarboxy or arle1 - C6alkylcarboxy ; . R11 is Cl - C6alkyl , C2 - C6alkenyl , C2 - C6alkynyl , arlel - C6alkyl , hetarle 1 - C6alkyl , C 1 - C6alkyl - carbonle 1 - C6alkyl , C1 - C6alkyloxy , aryloxy , C1 - C6alkyloxy , arylcarbonyl , ary1Cl - C6alky1 - carbonyl , hetary1carbonlel - C6a1kyl , Wherein the alkyl , alkenyl , alkynyl , aryl and hetaryl groups independently are optionally substituted With one or more of R9 ; . R12 is C l - C6alkylcarbonylaminoC l - C6alkyl , arylcarbonylaminoC 1 - C6alkyl or arle 1 - C6alkyl - carbonylaminoC 1 - C6alkyl ; . R13 and Rl4 independent1y are hydrogen , oxo , C3 - Cl0cyc1oalkyl , C1 - C6alkyl , Cl - C6a1ky1carbonyl , ary1carbonyl , hetarylcarbonyl , arlel - C6alkylcarbonyl , hetarlel - C6alkylcarbonyl ; . RlS is hydrogen , C3 - ClOcycloalkyl , C1 - C6alkyl , aryl , hetaryl , arlel - C6a1ky1 , hetarlel - C6a1kyl , Cl - C6alkyloxyalkyl or arle l - C6a1kyloxya1ky1 ; or. a sa1t thereof With a pharmaceutically acceptable acid or base , or any optical isomer or mixture of optical isomers , including a racemic mixture , or any tautomeric forms. ln another embodiment of the present inVention said substituted pyrazolo [ 1 , 5 - a ] pyrimidines , or a prodrug thereof , as a component of the combination therapy is of the general formula ( l ) Wherein. R1 and R2 independently are hydrogen , halo , C ( : O ) NR6R7 , NC ( : O ) R11 , oR12 or SR” ; . R3 and R5 independently are hydrogen , NR13R14trihalomethy1 , trihalomethoxy , Cl - C6alkyl , C2 - C6alkenyl , C2 - C6alkynyl , Cl - C6alkyloxy , Cl - C6alkylthio , aryl , arlel - C6alkyl , hetaryl - C1 - C6alkyl , Wherein alkyl , alkynyl , alkenyl , aryl , hetaryl , arylalkyl or hetarylalkyl groups independently are optionally substituted With one or more of R8 ; . R4 is hydrogen , cyano , halo , CO2Rl5 , C ( : O ) NR6R7 , Cl - C6alkyl , C2 - C6alkenyl , C2 - C6alkynyl , aryl , hetaryl , arlel - C6alkyl , hetarlel - C6alkyl , hydroxy , C l - C6alkyloxy , arle1 - C6alkyloxy , hetarle1 - C6alkyloxy , or C1 - C6alkyloxyC1 - C6alkyl , Wherein the alkyl , alkynyl , alkenyl , cycloalkyl , aryl , hetaryl , arylalkyl or hetarylalkyl groups independently are optionally substituted With one or more of R9 ; . R6 and R7 independently are C3 - C1Ocycloalkyl , hetC3 - C1Ocycloalkyl , arle1 - C6alkyl or hetarle1 - C6alkyl , Wherein the alkyl , cycloalkyl , hetcy - . lO. lS. 20. 25. 30. 35. 40. 45. 50. 55. 60. 12. cloalkyl , arylalkyl , and hetarylalkyl groups independently are optionally substituted With one or more of Rm ; or. R6 and R7 together With the nitrogen to Which they are attached , are forming a saturated or partial1y saturated cyclic , bicyclic or tricyclic ring system containing from 4 to 10 carbon atoms and from 0 to 2 additional heteroatoms selected from nitrogen , oxygen or sulphur , the ring system optionally being substituted With at least one of C1 - C6alkyl , aryl , hetaryl , arle1 - C6alkyl , halo , hydroxy , oxo , C1 - C6alkyloxy , arle1 - C6alkyloxy , hetarlel - C6alkyloxy , Cl - C6alkyloxyC1 - C6alkyl , Cl - C6alkylcarbonyl , arylcarbonyl , hetarylcarbonyl , arle1 - C6alkylcarbonyl , hetarlel - C6alkylcarbonyl , C1 - C6alkylcarboxy , arylcarboxy , hetarylcarboxy , arlel - C6alkylcarboxy or hetarle1 - C6alkylcarboxy ; . R8 and R9 independently are hydrogen , halo , hydroxy , oxo , cyano , nitro , C3 - C1ocycloalkyl , C3 - C1Ohetocycloalkyl , C1 - C6alkyl , C1 - C6alkyloxy , trihalomethyl , trihalomethoxy , arle1 - C6alkyloxy , hetarlel - C6alkyloxy , Cl - C6alkylcarbonyl , arylcarbonyl , hetarylcarbonyl , arlel - C6alkylcarbonyl , hetarlel - C6alkylcarbonyl , C l - C6alkylcarboxy , arylcarboxy , hetarylcarboxy , arle1 - C6 - . a1ky1carboxy , hetarle 1 - C6a1ky1carboxy , C l - C6alkylcarbonylamino or arle1 - C6alkylcarbonyl - am1no ; . RlO is hydrogen , halo , cyano , nitro , hydroxy , oxo , C3 - Cl0cycloalkyl , C3 - Cl0hetcycloalkyl , Cl - C6 - alkyl , C1 - C6alkyloxy , trihalomethyl , triha1ometh dialky1amino oxy , arle1 - C6alkyloxy , hetary1Cl - C6alkyloxy , Cl - C6alkylcarbonyl , arylcarbonyl , hetarylcarbonyl , arlel - C6alkylcarbonyl , hetarlel - C6alkylcarbonyl , C l - C6alkylcarboxy , arylcarboxy or arlel - C6alkylcarboxy ; . R11 is Cl - C6a1ky1 , C2 - C6alkeny1 , C2 - C6a1kyny1 , arle1 - C6alkyl , hetarle 1 - C6alkyl , C 1 - C6alky1 - carbony1C 1 - C6alkyl , Cl - C6alkyl , arylcarbonyl , arle1 - C6alkylcarbonyl , hetarylcarbonlel - C6 - alkyl , Wherein the alkyl , alkenyl , alkynyl , aryl and hetaryl groups independently are optionally substituted With one or more of R9 ; . RlZ is C l - C6a1ky1carbony1aminoC1 - C6alkyl , arylcarbonylaminoCl - C6alkyl or arlel - C6alkyl - carbonylaminoCl - C6alkyl ; . R13 and R14 independently are hydrogen , oxo , C3 - Cl0cycloalkyl , Cl - C6a1kyl , Cl - C6a1ky1oxy , trihalomethy1 , trihalomethoxy , ary1C1 - C6alky1oxy , hetarlel - C6alkyloxy , C l - C6alkylcarbonyl , arylcarbonyl , hetarylcarbonyl , arle1 - C6alkylcarbonyl , hetarlel - C6alkylcarbonyl , Cl - C6alkyl - carboxy , arylcarboxy , hetarylcarboxy , arlel - C6alkylcarboxy ; . RlS is hydrogen , C3 - ClOcycloalkyl , C1 - C6alkyl , aryl , hetaryl , arlel - C6alkyl , hetarlel - C6alkyl , C l - C6alkyloxyalkyl or arlel - C6alkyloxyalkyl ; or. a salt thereof With a pharmaceutically acceptable acid or base , or any optical isomer or mixture of optical isomers , including a racemic mixture , or any tautomeric forms. ln another embodiment of the present inVention said substituted pyrazolo [ 1 , 5 - a ] pyrimidines , or a prodrug thereof , as a component of the combination therapy is of the general formula ( l ) Wherein R1 and R2 independently are hydrogen and / or C ( : O ) NR6R7. ln another embodiment of the present inVention said substituted pyrazolo [ 1 , 5 - a ] pyrimidines , or a prodrug thereof , as a component of the combination therapy is of the general formula ( l ) Wherein R3 and R5 independently are hydrogen , trihalomethyl , Cl - C6alkyl , Cl - C6alkyloxy , aryl , arlel - . Cl - C6alkyl , 65 C6alkyl , hetaryl or hetarle1 - C6alkyl , Wherein alkyl , aryl , . hetaryl , arylalkyl or hetarylalkyl groups independently are optionally substituted With one or more of R8. US 7 , 50l , 405 B2. 13. ln another embodiment of the present inVention said substituted pyrazolo [ 1 , 5 - a ] pyrimidines , or a prodrug thereof , as a component of the combination therapy is of the general for - mu1a ( l ) Wherein R4 is hydrogen , cyano , halo , C ( : O ) NR6R7 , C l - C6alkyl , aryl , hetaryl , arle l - C6alkyl , hetarle l - C6alkyl , 5 hydroxy , C l - C6alkyloxy , arlel - C6alkyloxy , hetarle 1 ' C6alkyloxy , Wherein the alkyl , aryl , hetaryl , arylalkyl or hetarylalkyl groups independently are optionally substituted With one or more of R9. ln another embodiment of the present inVention said sub - 10 stituted pyrazolo [ 1 , 5 - a ] pyrimidines , or a prodrug thereof , as a component of the combination therapy is of the general formula ( l ) Wherein R6 and R7 independently are C1 - C6alkyl , C3 - C1Ocycloalkyl , hetC3 - C1Ocycloalkyl , arle1 - C6alkyl or hetarlel - C6alkyl , Wherein the alkyl , cycloalkyl , hetcy - 15 cloalkyl , arylalkyl , and hetarylalkyl groups independently are optionally substituted With one or more of R10. ln another embodiment of the present inVention said substituted pyrazolo [ 1 , 5 - a ] pyrimidines , or a prodrug thereof , as a component of the combination therapy is of the general for - 20 mula ( l ) R6 and R7 together With the nitrogen to Which they are attached , are forming a saturated or partially saturated cyclic , bicyclic or tricyclic ring system containing from 4 to 10 carbon atoms and from 0 to 2 additional heteroatoms selected from nitrogen or oxygen , the ring system optionally 25 being substituted With at least one of C l - C6alkyl , aryl , hetaryl , arle1 - C6alkyl , halo , hydroxy , oxo , Cl - C6alkyloxy , ary1C1 - C6alky1oxy , hetarle1 - C6alkyloxy , Cl - C6alkyloxyC1 - C6alkyl , Cl - C6a1ky1carbony1 , arylcarbonyl , hetarylcarbonyl , arle l - C6alkylcarbonyl , hetarle1 - 30 C6alkylcarbonyl , C l - C6alkylcarboxy , arylcarboxy , hetarylcarboxy , arle 1 - C6alkylcarboxy C6alkylcarboxy. ln another embodiment of the present inVention said substitutedpyrazolo [ 1 , 5 - a ] pyrimidines , or a prodrug thereof , as a 35 component of the combination therapy is of the general formula ( l ) Wherein R6 and R7 together With the nitrogen to Which they are attached , are forming a saturated or partia1ly saturated cyclic , bicyc1ic or tricyclic ring system containing from 4 to 10 carbon atoms and from 0 to 2 additional nitrogen 40 atoms , the ring system optionally being substituted With at least one of C1 - C6alkyl , aryl , hetaryl , arlel - C6alkyl , halo , hydroxy , oxo , C l - C6a1kyloxy , arle1 - C6alky1oxy , hetarlel - C6alkyloxy , C l - C6a1kyloxyC l - C6alkyl. ln another embodiment of the present inVention said sub - 45 stituted pyrazolo [ 1 , 5 - a ] pyrimidines , or a prodrug thereof , as a component of the combination therapy is of the general for - mu1a ( l ) Wherein R8 and R9 independent1y are hydrogen , halo , hydroxy , oxo , cyanoC3 - ClOcycloalkyl , C3 - Cthetocycloalkyl , C l - C6alkyl , C l - C6alkyloxy , trihalomethyl , arle1 - C6alkyloxy , hetarle1 - C6alkyloxy. ln another embodiment of the present inVention said sub - . or hetarlel - . 50. stituted pyrazolo [ 1 , 5 - a ] pyrimidines , or a prodrug thereof , as a component of the combination therapy is of the general formula ( l ) Wherein R10 is hydrogen , halo , cyanoi nitro , hydroxy , 55 oxo , C3 - ClOcycloalkyl , C3 - Cthetcycloalkyl , C l - C6alkyl , C1 - C6alkyloxy , arle1 - C6alkyloxy , hetarle1 - C6alkyloxy , C1 - C6alkylcarbonyl , arylcarbonyl , hetarylcarbonyl , arle1 - C6alkylcarbonyl , hetarlel - C6alkyl - carbonyl , C l - C6alkylcarboxy , arylcarboxy or arlel - C6alkylcarboxy. 60 ln another embodiment of the present inVention said substituted pyrazolo [ 1 , 5 - a ] pyrimidines , or a prodnug thereof , as a component of the combination therapy is of the general formula ( l ) Wherein R11 is Cl - C6alkyl , arlel - C6alkyl , hetarlel - C6alkyl , Cl - C6alkyloxy , aryloxy , Cl - C6alkyloxy , 65 Wherein the alkyl , aryl and hetaryl groups independently are optionally substituted With one or more of R9. 14. ln another embodiment of the present inVention said sub - . stituted pyrazolo [ 1 , 5 - a ] pyrimidines , or a prodrug thereof , as a. component of the combination therapy is of the general for - . mula ( l ) Wherein RlZ is C1 - C6alkylcarbonylaminoC1 - . C6alkyl , arylcarbonylaminoCl - C6alkyl or arle 1 ' . C6alkylcarbonylaminoCl - C6alkyl. ln another embodiment of the present inVention said sub - . stituted pyrazolo [ 1 , 5 - a ] pyrimidines , or a prodrug thereof , as a. component of the combination therapy is of the general for - . mula ( l ) Wherein Rl3and Rl4 independently are hydrogen , . C3 - Cl0cycloalkyl , Cl - C6alkyl , Cl - C6alkylcarbonyl , arylcar - . bonyl , hetarylcarbonyl , arle1 - C6alkylcarbonyl. ln another embodiment of the present inVention said sub - . stituted pyrazolo [ 1 , 5 - a ] pyrimidines , or a prodrug thereof , as a. component of the combination therapy is of the general for - . mula ( l ) Wherein RlS is hydrogen , C3 - ClOcycloalkyl , . C1 - C6alkyl , aryl , hetaryl , arlel - C6alkyl , hetarle1 - C6alkyl , . C1 - C6alkyloxyalkyl or arle1 - C6alkyloxyalkyl. ln another embodiment of the present inVention said sub - . stituted pyrazolo [ 1 , 5 - a ] pyrimidines , or a prodrug thereof , as a. component of the combination therapy is selected from the. group consisting of : . ( 3 - Bromo - 5 - thiophen - 2 - yl - 7 - triﬂuoromethyl - pyrazo1o [ 1 , 5 - a ] pyrimidin - 2 - yl ) - ( 2 , 6 - dimethyl - piperidin - 1 - yl - ) methanone ; . ( 3 - Bromo - 5 - thiophen - 2 - yl - 7 - triﬁuoromethyl - pyrazolo [ 1 , 5 - a ] pyrimidin - 2 - yl ) - ( 2 - ethyl - piperidin - 1 - yl - ) methanone ; . ( 5 - Thiophen - 2 - y1 - 7 - triﬂuoromethyl - pyrazolo [ 1 , 5 - a ] pyrimidin - 2 - yl ) - ( 1 , 3 , 3 - trimethyl - 6 - aza - bicyclo [ 3.2.1 ] oct - 6 - yl ) methanone ; . ( 3 - Chloro - 5 - thiophen - 2 - yl - 7 - triﬁuoromethyl - pyrazolo [ 1 , 5 - a ] pyrimidin - 2 - yl ) - ( 2 - methyl - piperidin - 1 - yl - ) methanone ; . 5 - Methyl - 7 - phenyl - pyrazolo [ 1 , 5 - a ] pyrimidine - 2 - carboxy1ic acid cyc1ohexylamide ; . Azepan - 1 - yl - ( 3 - chloro - 5 - thiophen - 2 - yl - 7 - trifluoromethylpyrazolo [ 1 , 5 - a ] pyrimidin - 2 - yl ) - methanone ; . Azepan - 1 - yl - ( 3 - chloro - 5 - thiophen - 2 - yl - 7 - triﬁuoromethylpyrazo1o [ 1 , 5 - a ] pyrimidin - 3 - yl ) - methanone ; . ( 2 , 6 - Dimethy1 - piperidin - 1 - yl - ) - ( 3 - ch10ro - 5 - thiophen - 2 - y1 - 7 - triﬂuoromethyl - pyrazolo [ 1 , 5 - a ] pyrimidin - 3 - yl ) methanone ; . 3 - Bromo - 5 - furan - 2 - yl - 7 - triﬂuoromethyl - pyrazolo [ 1 , 5 - a ] pyrimidin - 2 - carboxylic acid cyclohexylamide ; . ( 7 - Methy1 - 5 - phenyl - pyrazolo [ 1 , 5 - a ] pyrimidin - 3 - yl ) - ( 4 - methyl - piperidin - 1 - yl ) methanone ; . 5 - ( - 4 - Methoxy - phenyl - 7 - triﬂuoromethyl - pyrazolo [ 1 , 5 - a ] pyrimidine - 3 - carboxylic acid benzyl - methyl amide ; . [ 5 - ( - 4 - Ethoxy - phenyl - 7 - methyl - pyrazolo [ 1 , 5 - a ] pyrimidine - 2 - yl ] ) - pip eridin - 1 - yl - methanone ; . Azepan - 1 - yl - ( 3 - bromo - 5 - furan - 2 - yl - 7 - triﬂuoromethylpyrazolo [ 1 , 5 - a ] pyrimidin - 2 - yl ) methanone ; . 5 - Benzo [ 1 , 3 ] dioxol - 5 - yl - 7 - triﬁuoromethyl - pyrazolo [ 1 , 5 - a ] pyrimidine - 3 - carboxylic acid cyc1ohexyl - methy1 amide ; . ( 3 , 4 - Dihydro - 1H - isoquinolin - 2 - yl ) - [ 5 - ( - 4 - Methoxy - phenyl - 7 - triﬂuoromethyl - pyrazolo [ 1 , 5 - a ] pyrimidin - 3 - yl ] methanone ; . Azepan - 1 - yl - [ 5 - ( 4 - bromo - phenyl ) - 7 - triﬁuoromethyl - pyrazolo [ 1 , 5 - a ] pyrimidin - 3 - yl ] methanone Azepan - 1 - yl - ( 5 , 7 - diphenyl ) - pyrazolo [ 1 , 5 - a ] pyrimidin - 3 - yl ) methanone ; . [ 5 - ( 4 - bromo - phenyl ) - 7 - triﬂuoromethyl - pyrazolo [ 1 , 5 - a ] pyrimidin - 3 - yl ] - ( 2 - methyl - piperidin - 1 - yl ) - methanone ; . ( 5 - Furan - 2 - yl - 7 - triﬁuoromethyl - pyrazolo [ 1 , 5 - a ] pyrimidin - 3 - yl ) - ( 2 - methyl - piperidin - 1 - yl ) - methanone ; . ( 2 , 6 - Dimethyl - piperidin - 1 - yl - ) - [ 7 - ( 4 - ethoxy - phenyl ) - 5 - methyl - pyrazolo [ l , 5 - a ] pyrimidin - 2 - yl ] methanone ; . 5 - ( 4 - Ethoxy - phenyl ) - 7 - methyl - pyrazolo [ 1 , 5 - a ] pyrimidine - 2 - carboxylic acid cyclohexyl amide ; . US 7 , 50l , 405 B2. 15. Piperidin - l - yl - ( 5 - thiophen - 2 - yl - 7 - triﬂuoromethyl - pyrazolo [ 1 , 5 - a ] pyrimidin - 3 - yl ) methanone ; . ( 5 - Furan - 2 - yl - 7 - triﬁuoromethyl - pyrazolo [ 1 , 5 - a ] pyrimidin - 3 - yl ) - ( 2 - methyl - pipe1idin - 1 - yl ) - methanone ; . ( 2 - Methyl - piperidin - 1 - yl ) - ( 5 - thiophen - 2 - yl - 7 - triﬂuoromethyl - pyrazolo [ 1 , 5 - a ] pyrimidin - 3 - yl ) - methanone ; . Azepan - 1 - yl - [ 5 - ( 4 - methoxy - phenyl ) - 7 - triﬁuoromethylpyrazolo [ 1 , 5 - a ] pyrimidin - 3 - yl ] - methanone ; . 5 - Thiophen - 2 - yl - 7 - triﬂuoromethyl - pyrazolo [ 1 , 5 - a ] pyrimidine - 3 - carboxylic acid benzyl - methyl - amide ; . 5 - p - Tolyl - 7 - triﬁuoromethyl - pyrazolo [ 1 , 5 - a ] pyrimidine - 3 - carboxylic acid ( 1 , 3 - dimethyl - 1H - pyrazol - 4 - ylmethyl ) - methyl amide ; . 5 - Methyl - 7 - phenyl - pyrazolo [ 1 , 5 - a ] pyrimidine - 2 - carboxylic acid cyclohexyl - methyl amide ; . 7 - Methyl - 5 - phenyl - pyrazolo [ 1 , 5 - a ] pyrimidine - 2 - carboxylic acid cyclohexyl - methyl amide ; . ( 5 - Phenyl - 7 - triﬁuoromethyl - pyrazolo [ 1 , 5 - a ] pyrimidin - 2 - yl ) - piperidin - 1 - yl - methanone ; . 5 - Naphthalen - 1 - yl - 7 - triﬂuoromethyl - pyrazolo [ 1 , 5 - a ] pyrimidine - 2 - carboxylic acid cyclohexyl - methyl amide ; . 5 - Naphthalen - 1 - yl - 7 - triﬁuoromethyl - pyrazolo [ 1 , 5 - a ] pyrimidine - 2 - carboxy1ic acid cyclohexyl amide ; . ( 5 - Naphthalen - 1 - yl - 7 - triﬁuoromethyl - pyrazolo [ 1 , 5 - a ] pyrimidin - 2 - yl ) - piperidin - 1 - yl - methanone. ( 2 - Methyl - piperidin - 1 - yl ) - ( 5 - naphthalen - 1 - yl - 7 - triﬁuoromethyl - pyrazolo [ 1 , 5 - a ] pyrimidin - 2 - yl ) - methanone ; . 5 , 7 - Diphenyl - pyrazolo [ 1 , 5 - a ] pyrimidine - 2 - carboxylic acid cyclohexyl amide ; . 5 , 7 - Diphenyl - pyrazolo [ 1 , 5 - a ] pyrimidine - 2 - carboxylic acid cyclohexyl - methyl amide ; . ( 5 , 7 - Dipheny1 - pyrazolo [ 1 , 5 - a ] pyrimidin - 2 - y1 ) - ( 2 - methylpiperidin - 1 - yl ) methanone ; . ( 5 , 7 - Dipheny1 - pyrazolo [ 1 , 5 - a ] pyrimidin - 2 - y1 ) - piperidin - 1 - yl - methanone ; . 5 - Methyl - 7 - triﬂuoromethyl - pyrazolo [ 1 , 5 - a ] pyrimidine - 2 - carboxy1ic acid cyclohexyl amide ; . ( 5 - Methyl - 7 - triﬁuoromethyl - pyrazolo [ 1 , 5 - a ] pyrimidin - 2 - yl ) - piperidin - 1 - y1 - methanone ; . 5 - Methyl - 7 - triﬁuoromethyl - pyrazolo [ 1 , 5 - a ] pyrimidine - 2 - carboxylic acid cyclohexyl - methyl - amide ; . ( 2 - Methyl - piperidin - 1 - yl ) - ( 5 - methyl - 7 - triﬂuoromethylpyrazolo [ 1 , 5 - a ] pyrimidin - 2 - yl ) - methanone ; . 5 - Phenyl - 7 - triﬁuoromethyl - pyrazolo [ l , 5 - a ] pyrimidine - 2 - carboxylic acid cyclohexyl amide ; . ( 5 - Pheny1 - 7 - triﬂuoromethyl - pyrazo1o [ 1 , 5 - a ] pyrimidin - 2 - yl ) - piperidin - l - yl - methanone ; . 7 - Phenyl - 5 - trifuoromethyl - pyrazolo [ 1 , 5 - a ] pyrimidine - 2 - carboxylic acid cyclohexyl - methyl - amide ; . 5 - Phenyl - 7 - triﬂuoromethyl - pyrazolo [ 1 , 5 - a ] pyrimidine - 3 - carboxy1ic acid cyclohexyl amide ; . ( 5 - Phenyl - 7 - triﬁuoromethyl - pyrazolo [ 1 , 5 - a ] pyrimidin - 3 - yl ) - piperidin - 1 - y1 - methanone ; or. a salt thereof With a pharmaceutically acceptable acid or base , or any optical isomer or mixture of optical isomers , including a racemic mixture , or any tautomeric forms. ln another embodiment of the present inVention said sub - . stituted pyrazolo [ 1 , 5 - a ] pyrimidines , or a prodrug thereof , as a. component of the combination therapy is selected from the. group of. 5 - Methyl - 7 - triﬁuoromethyl - pyrazolo [ 1 , 5 - a ] pyrimidine - 2 - carboxylic acid methyl ester ; . 5 - Methyl - 7 - phenyl - pyrazolo [ 1 , 5 - a ] pyrimidine - 2 - carboxylic acid methyl ester ; . 7 - Methyl - 5 - phenyl - pyrazolo [ 1 , 5 - a ] pyrimidine - 2 - carboxylic acid methyl ester ; . 16. ( 5 - methyl - 7 - triﬁuoromethyl - pyrazolo [ l , 5 - a ] pyrimidin - 2 - yl ) - ( pip eridin - 1 - yl ) methanone ; . ( 5 - methyl - 7 - phenyl - pyrazolo [ 1 , 5 - a ] pyrimidine - 2 - carboxylic acid cyc1ohexyl - methy1 amide ; . 5 7 - Methyl - 5 - phenyl - pyrazolo [ 1 , 5 - a ] pyrimidine - 2 - carboxylic acid cyclohexyl - methyl - amide ; . 7 - Phenyl - 5 - triﬁuoromethyl - pyrazolo [ 1 , 5 - a ] pyrimidine - 2 - carboxylic acid cyclohexyl - methyl - amide ; . ( 5 - Phenyl - 7 - triﬂuoromethyl - pyrazolo [ 1 , 5 - a ] pyrimidin - 2 - yl ) - piperidin - 1 - yl - methanone ; . ( 2 - Methyl - piperidin - l - yl ) - ( 5 - methyl - 7 - triﬁuoromethylpyrazolo [ 1 , 5 - a ] pyrimidin - 2 - yl ) - methanone ; . 5 - Methyl - 7 - triﬂuoromethyl - pyrazolo [ 1 , 5 - a ] pyrimidine - 2 - carboxylic acid cyclohexyl - methyl - amide ; . 15 ( 5 - Methyl - 7 - triﬂuoromethyl - pyrazolo [ 1 , 5 - a ] pyrimidin - 2 - yl ) - piperidin - 1 - yl - methanone ; . ( 5 , 7 - Diphenyl - pyrazolo [ 1 , 5 - a ] pyrimidin - 2 - yl ) - piperidin - 1 - yl - methanone ; . ( 5 , 7 - Diphenyl - pyrazolo [ 1 , 5 - a ] pyrimidin - 2 - yl ) - ( 2 - methylpip eri din - 1 - yl ) - methanone ; . 5 , 7 - Diphenyl - pyrazolo [ 1 , 5 - a ] pyrimidine - 2 - carboxylic acid cyclohexyl - methyl - amide ; . ( 2 - Methyl - piperidin - 1 - yl ) - ( 5 - naphthalen - 1 - yl - 7 - triﬂuoromethyl - pyrazolo [ 1 , 5 - a ] pyrimidin - 2 - yl ) - methanone ; . 25 ( 5 - Naphthalen - 1 - yl - 7 - triﬂuoromethyl - pyrazolo [ 1 , 5 - a ] pyrimidin - 2 - yl ) - piperidin - 1 - yl - methanone ; . 5 - Naphtha1en - 1 - yl - 7 - triﬂuoromethyl - pyrazolo [ 1 , 5 - a ] pyrimidine - 2 - carboxylic acid cyclohexyl - methyl - amide ; . [ 7 - ( 4 - Ethoxy - phenyl ) - 5 - methyl - pyrazolo [ 1 , 5 - a ] pyrimidin - 2 - yl ] - ( 1 , 3 , 3 - trimethyl - 6 - aza - bicyclo [ 3 .2 . 1 ] oct - 6 - yl ) - methanone ; . ( 2 - Methy1 - piperidin - 1 - yl ) - ( 7 - phenyl - 5 - tri ﬂuoromethylpyrazolo [ 1 , 5 - a ] pyrimidin - 2 - yl ) - methanone ; . ( 5 - Methy1 - 7 - triﬂuoromethy1 - pyrazo1o [ 1 , 5 - a ] pyrimidin - 2 - yl ) - ( 1. , 3 , 3 - t1imethyl - 6 - aza - bicyclo [ 3.2.1 ] oct - 6 - yl ) - methanone ; . ( 5 - Phenyl - 7 - triﬂuoromethyl - pyrazolo [ 1 , 5 - a ] pyrimidin - 2 - yl ) - ( 1 , 3 , 3 - trimethyl - 6 - aza - bicyclo [ 3 .2.1 ] oct - 6 - yl ) - methanone ; . 40 ( 6 - Bromo - 3 - ch10ro - pyrazolo [ 1 , 5 - a ] pyrimidin - 2 - yl ) - mor - . pholin - 4 - yl - methanone ; . ( 5 - Phenyl - 7 - triﬂuoromethyl - pyrazolo [ 1 , 5 - a ] pyrimidin - 2 - yl ) - piperidin - 1 - y1 - methanone ; . 5 Morpholin - 4 - yl - ( 5 - phenyl - 7 - triﬂuoromethyl - pyrazolo [ 1 , 5 - . a ] pyrimidin - 2 - yl ) - methanone ; . ( 6 - Bromo - pyrazolo [ 1 , 5 - a ] pyrimidin - 2 - yl ) - piperidin - 1 - ylmethanone ; . ( 6 - Bromo - pyrazolo [ 1 , 5 - a ] pyrimidin - 2 - yl ) - morpholin - 4 - ylmethanone ; . ( 3 , 6 - Dibromo - pyrazolo [ 1 , 5 - a ] pyrimidin - 2 - yl ) - morpholin - 4 - yl - methanone ; . ( 3 - Bromo - 5 - phenyl - 7 - triﬂuoromethyl - pyrazolo [ 1 , 5 - a ] pyrimidin - 2 - yl ) - piperidin - 1 - yl - methanone ; . 55 ( 3 - Bromo - 5 - phenyl - 7 - triﬁuoromethyl - pyrazolo [ 1 , 5 - a ] pyrimidin - 2 - yl ) - morpholin - 4 - yl - methanone ; . ( 3 - Chloro - 5 - pheny1 - 7 - triﬂuoromethyl - pyrazo1o [ 1 , 5 - a ] pyrimidin - 2 - yl ) - piperidin - 1 - yl - methanone ; . ( 3 - Chloro - 5 - phenyl - 7 - triﬁuoromethyl - pyrazolo [ 1 , 5 - a ] pyrimidin - 2 - yl ) - morpholin - 4 - yl - methanone ; . ( 3 , 6 - Dibromo - pyrazolo [ 1 , 5 - a ] py1imidin - 2 - yl ) - pipe1idin - 1 - yl - methanone ; . [ 4 - ( 4 - Fluoro - phenyl ) - piperazin - 1 - yl ] - ( 5 - thiophen - 2 - yl - 7 - triﬂuoromethyl - pyrazolo [ 1 , 5 - a ] pyrimidin - 2 - yl ) - methanone ; . 5 - Thiophen - 2 - yl - 7 - triﬂuoromethyl - pyrazolo [ 1 , 5 - a ] pyrimidine - 2 - carboxylic acid cyclohexyl - methyl - amide ; . lO. 20. 30. 35. 60. 65. US 7 , 50l , 405 B2. 17. ( 5 - Benzo [ l , 3 ] dioxol - 5 - yl - 7 - triﬁuoromethyl - pyrazolo [ 1 , 5 - a ] pyrimidin - 2 - yl ) - ( 4 - methyl - pip erazin - 1 - yl ) - methanone ; [ 5 - ( 3 , 4 - Dichloro - phenyl ) - 7 - triﬁuoromethyl - pyrazolo [ 1 , 5 - a ] pyrimidin - 2 - y1 ] - ( 2 - methyl - pip eri din - 1 - yl ) - methanone ; 3 - Chloro - 5 - ( 4 - methoxy - phenyl ) - 7 - triﬂuoromethyl - pyrazolo [ 1 , 5 - a ] pyrimidine - 2 - carboxylic acid methyl - ( 2 - pyridin - 2 - . yl - ethyl ) - amide ; . [ 3 - Chloro - 5 - ( 4 - chloro - phenyl ) - 7 - triﬁuoromethyl - pyrazolo [ 1 , 5 - a ] pyrimidin - 2 - yl ] - morpholin - 4 - yl - methanone ; . ( 3 - Chloro - 5 - thiophen - 2 - yl - 7 - triﬂuoromethyl - pyrazolo [ 1 , 5 - a ] pyrimidin - 2 - yl ) - ( 3 , 4 - dihydro - 2H - quinolin - l - yl ) - methanone ; . [ 5 - ( 3 , 4 - Dichloro - phenyl ) - 7 - triﬁuoromethyl - pyrazolo [ 1 , 5 - a ] pyrimidin - 2 - yl ] - [ 4 - ( 2 - methoxy - phenyl ) - piperazin - 1 - yl ] - methanone ; . ( 4 - Benzoyl - piperazin - 1 - yl ) - [ 3 - chloro - 5 - ( 4 - chloro - phenyl ) - 7 - triﬁuoromethyl - pyrazolo [ 1 , 5 - a ] pyrimidin - 2 - yl ] - methanone ; . 4 - ( 5 - Benzo [ 1 , 3 ] dioxol - 5 - yl - 7 - triﬂuoromethyl - pyrazolo [ 1 , 5 - a ] pyrimidine - 2 - carbonyl ) - piperazine - 1 - carboxylic acid ethyl ester ; . ( 5 - Benzo [ 1 , 3 ] dioxol - 5 - yl - 7 - triﬁuoromethyl - pyrazolo [ 1 , 5 - a ] pyrimidin - 2 - y1 ) - ( 6 , 7 - dimethoxy - 1 - methyl - 3 , 4 - dihydro - 1H - isoquinolin - 2 - yl ) - methanone ; . [ 4 - ( Furan - 2 - carbonyl ) - piperazin - 1 - yl ] - [ 5 - ( 4 - methoxy - phenyl ) - 7 - triﬁuoromethyl - pyrazolo [ 1 , 5 - a ] pyrimidin - 2 - yl ] - methanone ; . ( 3 - Chloro - 5 - thiophen - 2 - yl - 7 - triﬂuoromethy1 - pyrazo1o [ 1 , 5 - a ] pyrimidin - 2 - yl ) - [ 4 - ( 2 - methoxy - phenyl ) - piperazin - 1 - yl ] - methanone ; . [ 5 - ( 4 - Methoxy - phenyl ) - 7 - triﬁuoromethyl - pyrazolo [ 1 , 5 - a ] pyrimidin - 2 - yl ] - piperidin - 1 - yl - methanone ; . ( 3 , 4 - Dihydro - 2H - quinolin - 1 - yl ) - ( 5 - phenyl - 7 - triﬂuoromethy1 - pyrazo1o [ 1 , 5 - a ] pyrimidin - 2 - y1 ) - methanone ; . ( 3 - Bromo - 5 - thiophen - 2 - yl - 7 - triﬂuoromethyl - pyrazolo [ 1 , 5 - a ] pyrimidin - 2 - yl ) - ( 2 , 6 - dimethyl - piperidin - 1 - yl ) - methanone ; . ( 3 - Bromo - 5 - thiophen - 2 - yl - 7 - triﬂuoromethy1 - pyrazo1o [ 1 , 5 - a ] pyrimidin - 2 - yl ) - ( 2 - ethyl - piperidin - 1 - yl ) - methanone ; . 3 - Bromo - 5 - thiophen - 2 - yl - 7 - triﬂuoromethyl - pyrazolo [ 1 , 5 - a ] pyrimidine - 2 - carboxylic acid cyclohexyl - methylamide ; . [ 5 - ( 4 - Bromo - phenyl ) - 3 - chloro - 7 - triﬂuoromethy1 - pyrazolo [ 1 , 5 - a ] pyrimidin - 2 - y1 ] - pyrrolidin - 1 - yl - methanone ; . ( 3 - Chloro - 5 - furan - 2 - yl - 7 - triﬁuoromethyl - pyrazolo [ 1 , 5 - a ] pyrimidin - 2 - yl ) - [ 4 - ( 4 - ﬁuoro - phenyl ) - piperazin - 1 - yl ] - methanone ; . ( 3 - Chloro - 5 - furan - 2 - yl - 7 - t1iﬂuoromethyl - pyrazolo [ 1 , 5 - a ] pyrimidin - 2 - yl ) - ( 4 - phenyl - piperazin - 1 - yl ) - methanone ; . [ 3 - Chloro - 5 - ( 4 - chloro - phenyl ) - 7 - triﬂuoromethyl - pyrazolo [ 1 , 5 - a ] pyrimidin - 2 - yl ] - ( 4 - methyl - piperazin - 1 - yl ) - methanone ; . Azepan - 1 - y1 - [ 3 - chloro - 5 - ( 4 - chloro - phenyl ) - 7 - triﬂuoromethyl - pyrazolo [ 1 , 5 - a ] pyrimidin - 2 - yl ] - methanone ; . [ 3 - Chloro - 5 - ( 3 , 4 - dimethoxy - phenyl ) - 7 - triﬁuoromethylpyrazolo [ 1 , 5 - a ] pyrimidin - 2 - yl ] - pyrrolidin - 1 - yl - methanone ; . [ 5 - ( 4 - Chloro - phenyl ) - 7 - triﬂuoromethyl - pyrazolo [ 1 , 5 - a ] pyrimidin - 2 - yl ] - ( 2 - methyl - pip eri din - 1 - yl ) - methanone ; . ( 5 - Thiophen - 2 - yl - 7 - triﬂuoromethyl - pyrazolo [ 1 , 5 - a ] pyrimidin - 2 - yl ) - ( 1 , 3 , 3 - trimethyl - 6 - aza - bicyclo [ 3.2.1 ] oct - 6 - yl ) - methanone ; . [ 4 - ( 2 - Chloro - phenyl ) - piperazin - 1 - yl ] - ( 5 - thiophen - 2 - yl - 7 - triﬂuoromethyl - pyrazolo [ 1 , 5 - a ] pyrimidin - 2 - yl ) - methanone ; . ( 3 , 4 - Dihydro - 1H - isoquinolin - 2 - yl ) - ( 5 - thiophen - 2 - y - 7 - trifluoromethyl - pyrazolo [ 1 , 5 - a ] pyrimidin - 2 - yl ) - methanone ; . 18. ( 4 - Methyl - piperazin - l - yl ) - [ 5 - ( 4 - nitro - phenyl ) - 7 - triﬁuoromethyl - pyrazolo [ 1 , 5 - a ] pyrimidin - 2 - yl ] - methanone ; . [ 5 - ( 3 , 4 - Dichloro - phenyl ) - 7 - triﬁuoromethyl - pyrazolo [ 1 , 5 - a ] pyrimidin - 2 - y1 ] - thi omorpholin - 4 - yl - methanone ; . 5 ( 3 - Bromo - 5 - furan - 2 - yl - 7 - triﬂuoromethyl - pyrazolo [ 1 , 5 - a ] pyrimidin - 2 - yl ) - ( 3 , 4 - dihydro - 2H - quinolin - 1 - yl ) - methanone ; . ( 5 - Furan - 2 - yl - 7 - triﬁuoromethyl - pyrazolo [ 1 , 5 - a ] pyrimidin - 2 - yl ) - py1rolidin - 1 - yl - methanone ; . 10 [ 4 - ( Furan - 2 - carbonyl ) - piperazin - 1 - yl ] - [ 5 - ( 4 - methoxy - phenyl ) - 7 - triﬂuoromethyl - pyrazolo [ l , 5 - a ] pyrimidin - 2 - yl ] - methanone ; . [ 5 - ( 4 - Nitro - phenyl ) - 7 - triﬁuoromethyl - pyrazolo [ 1 , 5 - a ] pyrimidin - 2 - yl ] - piperidin - 1 - yl - methanone ; . 15 ( 5 - Furan - 2 - yl - 7 - triﬂuoromethyl - pyrazolo [ 1 , 5 - a ] pyrimidin - . 2 - yl ) - pyrrolidin - 1 - yl - methanone ; . ( 4 - Methyl - piperidin - 1 - yl ) - ( 5 - phenyl - 7 - triﬁuoromethyl - . pyrazolo [ 1 , 5 - a ] pyrimidin - 2 - yl ) - methanone ; . ( 3 - Bromo - 5 - thiophen - 2 - yl - 7 - triﬂuoromethyl - pyrazolo [ 1 , 5 - . 20 a ] pyrimidin - 2 - yl ) - [ 4 - ( 4 - ﬂuoro - phenyl ) - piperazin - 1 - yl ] - . methanone ; . [ 4 - ( 4 - Fluoro - phenyl ) - piperazin - 1 - yl ] - ( 5 - phenyl - 7 - triﬁuo - . romethyl - pyrazolo [ 1 , 5 - a ] pyrimidin - 2 - yl ) - methanone ; . [ 4 - ( 4 - Fluoro - phenyl ) - piperazin - 1 - yl ] - ( 5 - thiophen - 2 - yl - 7 - . 25 triﬂuoromethyl - pyrazolo [ 1 , 5 - a ] pyrimidin - 2 - yl ) - metha - . none ; . [ 3 - Bromo - 5 - ( 4 - methoxy - phenyl ) - 7 - triﬁuoromethyl - pyra - . zolo [ 1 , 5 - a ] pyrimidin - 2 - yl ] - morpholin - 4 - yl - methanone ; . [ 4 - ( 4 - Fluoro - phenyl ) - piperazin - 1 - yl ] - ( 7 - methyl - 5 - phenyl - . pyrazolo [ 1 , 5 - a ] pyrimidin - 2 - yl ) - methanone ; . ( 4 - Benzoyl - piperazin - 1 - yl ) - ( 5 - phenyl - 7 - triﬁuoromethyl - . pyrazolo [ 1 , 5 - a ] pyrimidin - 2 - yl ) - methanone ; . ( 3 - Chloro - 5 - thiophen - 2 - yl - 7 - triﬂuoromethyl - pyrazo1o [ 1 , 5 - . a ] pyrimidin - 2 - yl ) - ( 4 - pheny1 - piperazin - 1 - yl ) - methanone ; . 3 5 ( 2 - Ethyl - piperidin - 1 - yl ) - ( 5 - phenyl - 7 - triﬂuoromethyl - pyra - . zolo [ 1 , 5 - a ] pyrimidin - 2 - yl ) - methanone ; . ( 5 , 7 - Diphenyl - pyrazolo [ 1 , 5 - a ] pyrimidin - 2 - yl ) - ( 4 - methyl - . pip erazin - 1 - yl ) - methanone ; . ( 4 - Benzy1 - piperazin - 1 - y1 ) - ( 3 - chloro - 5 - phenyl - 7 - triﬂuorom - . ethyl - pyrazolo [ 1 , 5 - a ] pyrimidin - 2 - yl ) - methanone ; . ( 3 - Chloro - 5 - thiophen - 2 - yl - 7 - triﬁuoromethyl - pyrazolo [ 1 , 5 - . a ] pyrimidin - 2 - yl ) - ( 4 - methyl - piperazin - 1 - yl ) - methanone ; . ( 4 - Phenyl - piperazin - 1 - yl ) - ( 5 - thiophen - 2 - yl - 7 - triﬂuorom - . ethyl - pyrazo1o [ 1 , 5 - a ] pyrimidin - 2 - yl ) - methanone ; . 45 [ 5 - ( 4 - Bromo - phenyl ) - 7 - triﬁuoromethyl - pyrazolo [ 1 , 5 - a ] py - . rimidin - 2 - yl ] - pyrrolidin - 1 - yl - methanone ; . ( 5 , 7 - Diphenyl - pyrazolo [ 1 , 5 - a ] pyrimidin - 2 - yl ) - pyrrolidin - 1 - . yl - methanone ; . ( 3 - Chloro - 5 - thiophen - 2 - yl - 7 - triﬂuoromethyl - pyrazolo [ 1 , 5 - . a ] pyrimidin - 2 - yl ) - ( 2 - ethyl - piperidin - 1 - yl ) - methanone ; . ( 3 - Chloro - 5 - thiophen - 2 - yl - 7 - triﬁuoromethyl - pyrazolo [ 1 , 5 - . a ] pyrimidin - 2 - yl ) - ( 2 - methyl - piperidin - 1 - yl ) - methanone ; 5 - Methyl - 7 - phenyl - pyrazolo [ 1 , 5 - a ] py1imidine - 2 - carboxy1ic acid cyclohexyl - methyl - amide ; . 55 ( 3 - Chloro - 5 - thiophen - 2 - yl - 7 - triﬂuoromethyl - pyrazolo [ l , 5 - a ] pyrimidin - 2 - yl ) - morpholin - 4 - yl - methanone ; . ( 3 - Chloro - 5 - thiophen - 2 - yl - 7 - triﬁuoromethyl - pyrazolo [ 1 , 5 - a ] pyrimidin - 2 - yl ) - [ 4 - ( 4 - ﬂuoro - pheny1 ) - piperazin - 1 - y1 ] - methanone ; . 60 ( 3 - Bromo - 5 - thiophen - 2 - yl - 7 - triﬂuoromethyl - pyrazolo [ 1 , 5 - . a ] pyrimidin - 2 - yl ) - ( 4 - methyl - piperazin - 1 - yl ) - methanone ; . ( 7 - Methyl - 5 - phenyl - pyrazolo [ 1 , 5 - a ] pyrimidin - 2 - yl ) - piperi - . din - 1 - yl - methanone ; . Azepan - 1 - yl - ( 3 - chloro - 5 - thiophen - 2 - yl - 7 - triﬂuoromethyl - . pyrazolo [ l , 5 - a ] pyrimidin - 2 - yl ) - methanone ; . Azepan - 1 - yl - [ 3 - bromo - 5 - ( 4 - bromo - phenyl ) - 7 - triﬁuorom - . ethyl - pyrazolo [ 1 , 5 - a ] pyrimidin - 2 - yl ] - methanone ; . 30. 40. 50. 65. US 7 , 50l , 405 B2. 19. 3 - Bromo - 5 - ( 4 - bromo - phenyl ) - 7 - triﬁuoromethyl - pyrazolo [ 1 , 5 - a ] pyrimidine - 2 - carboxylic acid cyclohexyl - methylamide ; . ( 2 , 6 - Dimethyl - piperidin - 1 - y1 ) - [ 5 - ( 4 - methoxy - phenyl ) - 7 - tri - . 20. ( 3 - Bromo - 5 - furan - 2 - yl - 7 - triﬂuoromethyl - pyrazolo [ l , 5 - a ] pyrimidin - 2 - yl ) - pip eri din - 1 - yl - methanone ; . ( 3 - Chloro - 5 - phenyl - 7 - triﬁuoromethyl - pyrazolo [ 1 , 5 - a ] pyrimidin - 2 - yl ) - pyrro1idin - 1 - y1 - methanone ; . ﬁuoromethyl - pyrazolo [ 1 , 5 - a ] pyrimidin - 2 - yl ] - methanone ; 5 ( 7 - Methyl - 5 - phenyl - pyrazolo [ 1 , 5 - a ] pyrimidin - 2 - yl ) - ( 4 - me - . [ 5 - ( 4 - Bromo - phenyl ) - 7 - triﬁuoromethyl - pyrazolo [ l , 5 - a ] pyrimidin - 2 - yl ] - ( 4 - methyl - pip erazin - 1 - yl ) - methanone ; . 5 - Phenyl - 7 - triﬁuoromethyl - pyrazolo [ 1 , 5 - a ] pyrimidine - 2 - carboxylic acid benzyl - methyl - amide ; . [ 5 - ( 4 - Ethoxy - phenyl ) - 7 - methyl - pyrazolo [ 1 , 5 - a ] pyrimidin - 2 - yl ] - ( 4 - phenyl - piperazin - 1 - yl ) - methanone ; . ( 3 , 4 - Dihydro - 1H - isoquinolin - 2 - yl ) - [ 5 - ( 4 - methoxy - phenyl ) - 7 - triﬁuoromethyl - pyrazolo [ 1 , 5 - a ] pyrimidin - 2 - yl ] - methanone ; . Morpholin - 4 - yl - [ 5 - ( 4 - nitro - phenyl ) - 7 - triﬂuoromethyl - pyrazolo [ 1 , 5 - a ] pyrimidin - 2 - yl ] - methanone ; . ( Hexahydro - pyrrolo [ 1 , 2 - a ] pyrazin - 2 - yl ) - ( 5 - phenyl - 7 - trifluoromethyl - pyrazolo [ 1 , 5 - a ] pyrimidin - 2 - yl ) - methanone ; . ( Hexahydro - py1rolo [ 1 , 2 - a ] pyrazin - 2 - yl ) - ( 5 - p - tolyl - 7 - trifluoromethyl - pyrazolo [ 1 , 5 - a ] pyrimidin - 2 - yl ) - methanone ; . ( Hexahydro - pyrrolo [ 1 , 2 - a ] pyrazin - 2 - yl ) - ( 5 - thiophen - 2 - yl - 7 - triﬁuoromethyl - pyrazolo [ 1 , 5 - a ] pyrimidin - 2 - yl ) - methanone ; . ( 3 - Chloro - 5 - phenyl - 7 - triﬂuoromethyl - pyrazolo [ 1 , 5 - a ] pyrimidin - 2 - yl ) - ( hexahydro - pyrrolo [ 1 , 2 - a ] pyrazin - 2 - yl ) - methanone ; . [ 5 - ( 4 - Fluoro - phenyl ) - 7 - methyl - pyrazolo [ 1 , 5 - a ] pyrimidin - 2 - yl ] - morpholin4 - yl - methanone ; . ( 5 , 7 - Dipheny1 - pyrazolo [ 1 , 5 - a ] pyrimidin - 2 - y1 ) - ( 2 - methylpiperidin - 1 - yl ) - methanone ; . 5 - Phenyl - 7 - triﬁuoromethyl - pyrazolo [ 1 , 5 - a ] pyrimidine - 2 - carboxylic acid ( 1 , 3 - dimethyl - 1H - pyrazol - 4 - ylmethyl ) - methyl - amide ; . 5 - Thiophen - 2 - yl - 7 - triﬂuoromethy1 - pyrazolo [ 1 , 5 - a ] pyrimidine - 2 - carboxylic acid ( 1 , 5 - dimethyl - 1H - pyrazol - 4 - ylmethyl ) - methyl - amide ; . 5 - Thiophen - 2 - yl - 7 - triﬁuoromethyl - pyrazolo [ 1 , 5 - a ] pyrimidine - 2 - carboxy1ic acid methyl - ( 1 , 3 , 5 - trimethy1 - 1H - pyrazol - 4 - y1methyl ) - amide ; . 3 - Chloro - 5 - ( 4 - methoxy - phenyl ) - 7 - triﬂuoromethyl - pyrazolo [ 1 , 5 - a ] pyrimidine - 2 - carboxylic acid ( 1 , 3 - dimethyl - 1H - pyrazol - 4 - ylmethyl ) - methyl - amide ; . 5 - ( 4 - Chloro - pheny1 ) - 7 - triﬂuoromethyl - pyrazolo [ 1 , 5 - a ] pyri - midine - 2 - carboxy1ic acid ( 1 , 3 - dimethy1 - 1H - pyrazol - 4 - ylmethyl ) - methyl - amide ; . 5 - ( 3 , 4 - Dimethoxy - phenyl ) - 7 - triﬁuoromethyl - pyrazolo [ 1 , 5 - a ] pyrimidine - 2 - carboxylic acid ( 1 , 3 - dimethyl - 1H - pyrazol - 4 - y1methyl ) - methyl - amide ; . ( 2 , 5 - Dimethyl - piperidin - 1 - yl ) - ( 5 - phenyl - 7 - triﬂuoromethylpyrazolo [ 1 , 5 - a ] pyrimidin - 2 - yl ) - methanone ; . 5 - Furan - 2 - yl - 7 - triﬂuoromethyl - pyrazolo [ 1 , 5 - a ] pyrimidine - 2 - carboxylic acid methyl - ( 1 , 3 , 5 - trimethyl - 1H - pyrazol - 4 - ylmethyl ) - amide ; . 5 - ( 4 - Chloro - phenyl ) - 7 - triﬂuoromethyl - pyrazolo [ 1 , 5 - a ] pyri - midine - 2 - carboxylic acid ( 1 , 5 - dimethyl - 1H - pyrazol - 4 - ylmethyl ) - methyl - amide ; . ( 2 , 4 - Dimethyl - piperidin - 1 - yl ) - ( 5 - phenyl - 7 - triﬁuoromethylpyrazo1o [ 1 , 5 - a ] pyrimidin - 2 - yl ) - methanone ; . ( 3 - Bromo - 5 - phenyl - 7 - triﬂuoromethyl - pyrazolo [ 1 , 5 - a ] pyrimidin - 2 - yl ) - ( hexahydro - pyrrolo [ 1 , 2 - a ] pyrazin - 2 - yl ) - methanone ; . [ 5 - ( 3 , 4 - Dimethoxy - phenyl ) - 7 - triﬁuoromethyl - pyrazolo [ 1 , 5 - a ] pyrimidin - 2 - yl ] - ( hexahydro - pyrrolo [ 1 , 2 - a ] pyrazin - 2 - yl ) - methanone ; . ( 3 - Chloro - 5 - p - tolyl - 7 - triﬁuoromethyl - pyrazolo [ l , 5 - a ] pyrimidin - 2 - yl ) - ( hexahydro - pyrrolo [ 1 , 2 - a ] pyrazin - 2 - yl ) - methanone ; . lO. lS. 20. 25. 30. 35. 40. 55. 60. 65. thyl - piperidin - l - yl ) - methanone ; . ( 4 - Methyl - piperazin - 1 - yl ) - ( 5 - thiophen - 2 - yl - 7 - triﬁuoromethyl - pyrazolo [ 1 , 5 - a ] pyrimidin - 2 - yl ) - methanone ; . [ 3 - Bromo - 5 - ( 4 - methoxy - phenyl ) - 7 - triﬂuoromethyl - pyrazolo [ 1 , 5 - a ] pyrimidin - 2 - yl ] - piperidin - 1 - yl - methanone ; . ( 4 - Methyl - piperazin - l - yl ) - ( 5 - phenyl - 7 - triﬁuoromethylpyrazolo [ 1 , 5 - a ] pyrimidin - 2 - yl ) - methanone ; . [ 4 - ( 4 - Fluoro - phenyl ) - piperazin - 1 - yl ] - ( 5 - furan - 2 - yl - 7 - trifluoromethyl - pyrazolo [ 1 , 5 - a ] pyrimidin - 2 - yl ) - methanone ; . [ 5 - ( 4 - Methoxy - phenyl ) - 7 - triﬂuoromethyl - pyrazolo [ 1 , 5 - a ] pyrimidin - 2 - yl ] - morpholin - 4 - yl - methanone ; . ( 3 , 4 - Dihydro - 2H - quinolin - 1 - yl ) - ( 5 - thiophen - 2 - yl - 7 - triﬁuoromethyl - pyrazolo [ 1 , 5 - a ] pyrimidin - 2 - yl ) - methanone ; . ( 3 - Bromo - 5 - thiophen - 2 - yl - 7 - triﬂuoromethyl - pyrazolo [ 1 , 5 - a ] pyrimidin - 2 - yl ) - morpholin - 4 - yl - methanone ; . Azepan - 1 - yl - ( 3 - chloro - 5 - phenyl - 7 - triﬂuoromethyl - pyrazolo [ 1 , 5 - a ] pyrimidin - 2 - yl ) - methanone ; . ( 4 - Benzoyl - piperazin - 1 - yl ) - [ 5 - ( 4 - bromo - phenyl ) - 7 - triﬁuoromethyl - pyrazolo [ 1 , 5 - a ] pyrimidin - 2 - yl ] - methanone ; . ( 4 - Benzyl - piperazin - 1 - yl ) - [ 5 - ( 4 - bromo - phenyl ) - 3 - chloro - 7 - triﬂuoromethyl - pyrazo1o [ 1 , 5 - a ] pyrimidin - 2 - yl ] - methanone ; . [ 5 - ( 4 - Bromo - phenyl ) - 3 - chloro - 7 - triﬁuoromethyl - pyrazolo [ 1 , 5 - a ] pyrimidin - 2 - yl ] - ( 4 - methyl - piperazin - 1 - y1 ) - methanone ; . Azepan - 1 - yl - [ 5 - ( 4 - bromo - pheny1 ) - 7 - t1iﬂuoromethyl - pyrazolo [ 1 , 5 - a ] pyrimidin - 2 - yl ] - methanone ; . [ 3 - Bromo - 5 - ( 4 - bromo - phenyl ) - 7 - t1iﬁuoromethyl - pyrazolo [ 1 , 5 - a ] pyrimidin - 2 - yl ] - ( 3 , 4 - dihydro - 2H - quino1in - 1 - yl ) - methanone ; . [ 5 - ( 3 , 4 - Dimethoxy - phenyl ) - 7 - t1iﬂuoromethyl - pyrazolo [ 1 , 5 - a ] pyrimidin - 2 - yl ] - morpholin - 4 - yl - methanone ; . ( 3 - Bromo - 5 - furan - 2 - yl - 7 - triﬂuoromethyl - pyrazolo [ 1 , 5 - a ] pyrimidin - 2 - y1 ) - ( 4 - methyl - piperazin - 1 - yl ) - methanone ; . ( 4 - Benzoyl - piperazin - 1 - yl ) - ( 3 - bromo - 5 - furan - 2 - yl - 7 - trifluoromethyl - pyrazolo [ 1 , 5 - a ] pyrimindin - 2 - yl ) - methanone ; . ( 3 - Bromo - 5 - furan - 2 - yl - 7 - triﬂuoromethyl - pyrazolo [ 1 , 5 - a ] pyrimidin - 2 - yl ) - ( 3 , 4 - dihydro - 2H - quinolin - 1 - yl ) - methanone ; . [ 5 - ( 4 - Bromo - phenyl ) - 7 - triﬁuoromethyl - pyrazolo [ 1 , 5 - a ] pyrimidin - 2 - yl ] - piperidin - 1 - yl - methanone ; . [ 5 - ( 4 - Ethoxy - phenyl ) - 7 - methyl - pyrazolo [ 1 , 5 - a ] pyrimidin - 2 - yl ] - piperidin - 1 - yl - methanone ; . [ 5 - ( 4 - Ethoxy - phenyl ) - 7 - methyl - pyrazolo [ 1 , 5 - a ] pyrimidin - 2 - yl ] - morpholin - 4 - yl - methanone ; . Azepan - 1 - yl - ( 3 - bromo - 5 - furan - 2 - yl - 7 - triﬂuoromethylpyrazolo [ 1 , 5 - a ] pyrimidin - 2 - yl ) - methanone ; . ( 3 , 4 - Dihydro - 1H - isoquinolin - 2 - yl ) - ( 5 - thiophen - 2 - yl - 7 - trifluoromethyl - pyrazolo [ 1 , 5 - a ] pyrimidin - 2 - yl ) - methanone ; . ( 4 - Benzy1 - piperazin - 1 - y1 ) - ( 3 - bromo - 5 - furan - 2 - y1 - 7 - triﬂuoromethyl - pyrazolo [ 1 , 5 - a ] pyrimidin - 2 - yl ) - methanone ; . Azepan - 1 - yl - [ 5 - ( 4 - bromo - phenyl ) - 3 - chloro - 7 - triﬂuoromethyl - pyrazolo [ 1 , 5 - a ] pyrimidin - 2 - yl ] - methanone ; . ( 3 - Chloro - 5 - thiophen - 2 - yl - 7 - triﬁuoromethyl - pyrazolo [ 1 , 5 - a ] pyrimidin - 2 - yl ) - ( 3 , 4 - dihydro - 1H - isoquinolin - 2 - yl ) - methanone ; . ( 5 - Benzo [ 1 , 3 ] dioxol - 5 - yl - 7 - triﬁuoromethyl - pyrazolo [ 1 , 5 - a ] pyrimidin - 2 - yl ) - pip eri din - 1 - yl - methanone ; . Azepan - 1 - yl - ( 5 , 7 - diphenyl - pyrazolo [ 1 , 5 - a ] pyrimidin - 2 - yl ) - methanone ; . US 7 , 50l , 405 B2. 21 22 Azepan - l - yl - ( 5 - benzo [ l , 3 ] dioxol - 5 - yl - 7 - triﬂuoromethyl - [ 4 - ( 4 - Fluoro - phenyl ) - piperazin - l - yl ] - ( 5 - p - tolyl - 7 - triﬁuopyrazolo [ 1 , 5 - a ] pyrimidin - 2 - yl ) - methanone ; romethyl - pyrazolo [ 1 , 5 - a ] pyrimidin - 2 - yl ) - methanone ; [ 5 - ( 4 - Bromo - phenyl ) - 7 - triﬁuoromethyl - pyrazolo [ 1 , 5 - a ] py - ( 4 - Phenyl - piperazin - 1 - yl ) - ( 5 - p - tolyl - 7 - t1iﬂuoromethylrimidin - 2 - yl ] - morpho1in - 4 - yl - methanone ; pyrazo1o [ 1 , 5 - a ] pyrimidin - 2 - yl ) - methanone ; [ 3 - Bromo - 5 - ( 4 - bromo - phenyl ) - 7 - triﬂuoromethyl - pyrazolo 5 Morpholin - 4 - yl - ( 5 - p - tolyl - 7 - triﬂuoromethyl - pyrazolo [ 1 , 5 - [ 1 , 5 - a ] pyrimidin - 2 - yl ] - morpholin - 4 - yl - methanone ; a ] pyrimidin - 2 - yl ) - methanone ; [ 5 - ( 4 - Methoxy - phenyl ) - 7 - triﬁuoromethyl - pyrazolo [ 1 , 5 - a ] ( 4 - Benzyl - piperazin - 1 - yl ) - ( 5 - p - tolyl - 7 - triﬁuoromethylpyrimidin - 2 - yl ] - thiomorpholin - 4 - yl - methanone ; pyrazolo [ 1 , 5 - a ] pyrimidin - 2 - yl ) - methanone ; [ 5 - ( 4 - Bromo - phenyl ) - 3 - chloro - 7 - triﬁuoromethyl - pyrazolo [ 5 - ( 4 - Chloro - phenyl ) - 7 - triﬂuoromethyl - pyrazolo [ 1 , 5 - a ] py - [ 1 , 5 - a ] pyrimidin - 2 - yl ] - piperidin - 1 - yl - methanone ; 10 rimidin - 2 - yl ] - ( 4 - methyl - piperazin - 1 - yl ) - methanone ; ( 5 - Benzo [ l , 3 ] dioxol - 5 - yl - 7 - triﬁuoromethyl - pyrazolo [ 1 , 5 - a ] [ 5 - ( 4 - Chloro - phenyl ) - 7 - triﬁuoromethyl - pyrazolo [ l , 5 - a ] pypyrimidin - 2 - yl ) - ( 3 , 4 - dihydro - 2H - quinolin - 1 - yl ) - metha - rimidin - 2 - yl ] - morpholin - 4 - yl - methanone ; none ; ( 4 - Benzyl - piperazin - 1 - yl ) - [ 5 - ( 4 - chloro - phenyl ) - 7 - triﬁuo - ( 5 - Benzo [ 1 , 3 ] dioxol - 5 - yl - 7 - triﬂuoromethyl - pyrazolo [ 1 , 5 - a ] romethyl - pyrazolo [ 1 , 5 - a ] pyrimidin - 2 - yl ] - methanone ; pyrimidin - 2 - yl ) - ( 4 - benzyl - piperazin - 1 - yl ) - methanone ; 15 [ 5 - ( 4 - Fluoro - phenyl ) - 7 - triﬂuoromethyl - pyrazolo [ 1 , 5 - a ] py - ( 5 - Benzo [ 1 , 3 ] dioxol - 5 - yl - 7 - triﬁuoromethyl - pyrazolo [ 1 , 5 - a ] rimidin - 2 - yl ] - morpholin - 4 - yl - methanone ; pyrimidin - 2 - yl ) - morpholin - 4 - yl - methanone ; [ 5 - ( 4 - Fluoro - phenyl ) - 7 - triﬁuoromethyl - pyrazolo [ 1 , 5 - a ] py - [ 5 - ( 4 - Bromo - phenyl ) - 7 - triﬁuoromethyl - pyrazolo [ 1 , 5 - a ] py - rimidin - 2 - yl ] - piperidin - 1 - yl - methanone ; rimidin - 2 - yl ] - [ 4 - ( 2 - methoxy - phenyl ) - piperazin - 1 - yl ] - ( 3 , 4 - Dihydro - 2H - quinolin - 1 - yl ) - [ 5 - ( 4 - ﬂuoro - phenyl ) - 7 - trifmethanone ; 20 luoromethyl - pyrazolo [ 1 , 5 - a ] pyrimidin - 2 - yl ] - methanone ; [ 3 - Bromo - 5 - ( 4 - bromo - phenyl ) - 7 - triﬂuoromethyl - pyrazolo Azepan - 1 - yl - [ 5 - ( 3 , 4 - dimethoxy - phenyl ) - 7 - triﬂuoromethy1 - [ 1 , 5 - a ] pyrimidin - 2 - yl ] - ( 4 - methyl - piperazin - 1 - yl ) - metha - pyrazolo [ 1 , 5 - a ] pyrimidin - 2 - yl ] - methanone ; 11011€§3 ( 4 - Benzyl - piperazin - 1 - yl ) - [ 5 - ( 4 - methoxy - phenyl ) - 7 - triﬁuoAzepan - 1 - y1 - [ 5 - ( 4 - meth0Xy - pheny1 ) - 7 - triﬂu0r0methy1 - romethyl - pyrazolo [ 1 , 5 - a ] pyrimidin - 2 - yl ] - methanone ; pyrazolo [ 1 , 5 - a ] pyrimidin - 2 - yl ] - methanone ; 25 [ 5 - ( 4 - Methoxy - phenyl ) - 7 - triﬁuoromethyl - pyrazolo [ 1 , 5 - a ] ( 2 , 6 - Dimethyl - piperidin - 1 - yl ) - [ 7 - ( 4 - ethoxy - phenyl ) - 5 - me - pyrimidin - 2 - y1 ] - pyrrolidin - 1 - yl - methanone ; thyl - pyrazolo [ 1 : 5 - a ] pyrimidin - 2 ' y1l - methanone ; ( 5 - Benzo [ 1 , 3 ] dioxol - 5 - yl - 7 - triﬁuoromethyl - pyrazolo [ 1 , 5 - a ] ( 3 , 4 - D1hydro - 2H - qu1nol1n - 1 ' y1 ) ' ( 5 , 7 - d1phenyl - pyrazolo [ 1 a pyrimidin - 2 - yl ) - pyrrolidin - 1 - yl - methanone ; 5 ' 31 ] pyr1m1d1n - 2 - yl ) - methanone ; ( 3 , 4 - Dihydro - 2H - quinolin - 1 - yl ) - [ 5 - ( 4 - nitro - phenyl ) - 7 - trif - . ( 3 : 6 - Dibr 01110 ' PYr azolo [ 1 5 - a ] pyrimidin - 2 - yl ) - piperidin - 1 ' 3 0 luoromethyl - pyrazolo [ 1 , 5 - a ] pyrimidin - 2 - yl ] - methanone ; yl - methanone ; . [ 3 - Chloro - 5 - ( 4 - methoxy - phenyl ) - 7 - triﬂuoromethyl - pyra - ( 3 - Bromo - 5 - furan - 2 - yl - 7 - tr1ﬁuoromethyl - pyrazolo [ 1 , 5 - a ] zolo [ 1 , 5 - a ] pyrimidin - 2 - yl ] - ( 4 - methyl - piperidin - 1 _y1 ) _. pyrimidin - 2 - y1 ) - piperidin - 1 - yl - methanone ; methanone ' [ 5 ' ( 4 ' M?ﬂ?0XY ' Phen¥1 ) ' 7 ' triﬂW omethyl - pyr azolo [ 1 , 5 - a ] [ 3 - Chloro - 5 - ( : l - methoxy - phenyl ) - 7 - triﬁuoromethyl - pyrapyr1m1d1n - 2 ' y1 ] - th1omorphol1n - 4 - yl - methanone ; 3 5 zolo [ 1 , 5 - a ] pyrimidin - 2 - yl ] - ( 3 , 4 - dihydro - 2H - quinolin - 1 - . [ 5 - ( 3 , 4 - Dichloro - phenyl ) - 7 - t1iﬁuoromethyl - pyrazolo [ 1 , 5 - a ] pyrimidin - 2 - yl ] - thiomorpholin - 4 - yl - methanone ; . ( 3 , 4 - Dihydro - 1H - isoquinolin - 2 - y1 ) - [ 5 - ( 4 - nitro - phenyl ) - 7 - triﬂuoromethy1 - pyrazolo [ 1 , 5 - a ] pyrimidin - 2 - yl ] - methanone ; 40. Azepan - 1 - yl - [ 5 - ( 4 - methoxy - phenyl ) - 7 - triﬁuoromethylpyrazolo [ 1 , 5 - a ] pyrimidin - 2 - yl ] - methanone ; . Azepan - 1 - y1 - [ 5 - ( 4 - nitro - phenyl ) - 7 - triﬂuoromethyl - pyrazolo [ 1 , 5 - a ] pyrimidin - 2 - yl ] - methanone ; . [ 5 - ( 3 , 4 - Dichloro - phenyl ) - 7 - triﬂuoromethyl - pyrazolo [ 1 , 5 - a ] pyrimidin - 2 - yl ] - morpholin - 4 - yl - methanone ; . Azepan - 1 - yl - [ 5 - ( 3 , 4 - dichloro - phenyl ) - 7 - triﬂuoromethylpyrazo1o [ 1 , 5 - a ] pyrimidin - 2 - yl ] - methanone ; . ( 3 , 4 - Dihydro - 1H - isoquinolin - 2 - yl ) - ( 5 - phenyl - 7 - triﬁuoromethyl - pyrazolo [ 1 , 5 - a ] pyrimidin - 2 - yl ) - methanone ; . [ 5 - ( 4 - Bromo - phenyl ) - 3 - chloro - 7 - t1iﬁuoromethyl - pyrazolo [ 1 , 5 - a ] pyrimidin - 2 - yl ] - pyrrolidin - 1yl - methanone ; . 5 , 7 - Diphenyl - pyrazolo [ 1 , 5 - a ] pyrimidine - 2 - carboxy1ic acid. yl ) - methanone ; 3 - Chloro - 5 - ( 4 - methoxy - phenyl ) - 7 - triﬂuoromethyl - pyrazolo [ 1 , 5 - a ] pyrimidine - 2 - carboxylic acid cyclohexyl - methylamide ; [ 3 - Chloro - 5 - ( 4 - ﬂuoro - phenyl ) - 7 - triﬁuoromethyl - pyrazolo [ 1 , 5 - a ] pyrimidin - 2 - yl ] - ( 4 - methyl - piperazin - 1 - yl ) - methanone ; ( 3 - Chloro - 5 - p - tolyl - 7 - triﬁuoromethyl - pyrazolo [ 1 , 5 - a ] pyrimidin - 2 - yl ) - morpholin - 4 - yl - methanone ; Azepan - 1 - yl - ( 3 - chloro - 5 - p - tolyl - 7 - triﬂuoromethyl - pyrazolo [ 1 , 5 - a ] pyrimidin - 2 - yl ) - methanone ; Azepan - 1 - yl - [ 3 - chloro - 5 - ( 3 , 4 - dimethoxy - phenyl ) - 7 - triﬁuoromethyl - pyrazolo [ 1 , 5 - a ] pyrimidin - 2 - yl ] - methanone ; 50 [ 5 - ( 3 , 4 - Dichloro - phenyl ) - 7 - triﬂuoromethyl - pyrazolo [ 1 , 5 - a ] pyrimidin - 2 - yl ] - ( 4 - methyl - piperazin - 1 - yl ) - methanone ; 5 , 7 - Diphenyl - pyrazolo [ 1 , 5 - a ] pyrimidine - 2 - carboxylic acid benzyl - methyl - amide ; . 45. m. cyclohexyl - methyl - amide ; ( 5 , 7 - Dipheny1 - pyrazo1o [ 1 =5 - a ] pyrimidin - 2 - y1 ) - ( 4 - phenyl - ( 3 , 4 - Dihydro - 1H - isoquinolin - 2 - yl ) - ( 5 - furan - 2 - yl - 7 - triﬂuo - 55 p1peraz1n - 1 - yl ) - methanone ; . romethyl - pyrazolo [ 1 , 5 - a ] pyrimidin - 2 - yl ) - methanone ; Morpho_l111 - 4. - yl - ( 5 - phenyl - 7 - tr1ﬂuoromethyl - pyrazolo [ 1 , 5 ' ( 4 - Benzyl - piperazin - 1 - yl ) - ( 3 - chloro - 5 - furan - 2 - yl - 7 - triﬁuo - a ] pyr1m1d1n - 2 - yl ) - methanone ; . romethyl - pyrazolo [ 1 , 5 - a ] pyrimindin - 2 - yl ) - methanone ; Morpholin - 4 - yl - ( 5 - thiophen - 2 - yl - 7 - triluoromethyl - pyrazolo [ 3 - Chloro - 5 - ( 4 - methoxy - phenyl ) - 7 - triﬂuoromethyl - pyra - [ 1 : 5 ' 3le1‘ imidin - 2 - yl ) - methanone ; . zol0 [ 1 , 5 - a ] pyrimidin - 2 - yl ] - piperidin - 1 - yl - methanone ; 60 Piperidin - 1 - yl - ( 5 - thiophen - 2 - yl - 7 - triﬁuoromethyl - pyrazolo ( 3 - Chloro - 5 - p - tolyl - 7 - triﬁuoromethyl - pyrazolo [ 1 , 5 - a ] pyri - [ 1 aS - a ] pyrimidin - 2 - yl ) - methanone ; . midin - 2 - yl ) - ( 4 - methyl - piperazin - 1 - yl ) - methanone ; [ 3 - Bromo - 5 - ( 4 - bromo - thiophen - 2 - yl ) - 7 - triﬁuoromethyl - ( 3 - Chloro - 5 - p - tolyl - 7 - triﬁuoromethyl - pyrazolo [ 1 , 5 - a ] pyri - pyrazolo [ 1 , 5 - a ] pyrimidin - 2 - yl ] - piperidin - 1 - yl - metha - . midin - 2 - yl ) - ( 4 - phenyl - piperazin - 1 - methanone ; none ; [ 3 - Chloro - 5 - ( 3 , 4 - dimethoxy - phenyl ) - 7 - triﬁuoromethyl - 65 ( 3 - Bromo - 5 - thiophen - 2 - yl - 7 - triﬁuoromethyl - pyrazolo [ l , 5 - . pyrazolo [ 1 , 5 - a ] pyrimidin - 2 - yl ] - piperidin - 1 - yl - metha - a ] pyrimidin - 2 - yl ) - ( 3 , 4 - dihydro - 2H - quinolin - 1 - yl ) - metha - . none ; none ; . US 7 , 50l , 405 B2. 23. ( 3 - Chloro - 5 - thiophen - 2 - yl - 7 - triﬂuoromethyl - pyrazolo [ 1 , 5 - a ] py1imidin - 2 - yl ) - pipe1idin - 1 - yl - methanone ; . ( 7 - Methyl - 5 - phenyl - pyrazolo [ 1 5 - a ] pyrimidin - 2 - yl ) - morpholin - 4 - yl - methanone ; . ( 7 - Methyl - 5 - phenyl - pyrazolo [ 1 , 5 - a ] pyrimidin - 2 - yl ) - pyrrolidin - l - yl - methanone ; . 7 - Methyl - 5 - phenyl - pyrazolo [ 1 , 5 - a ] pyrimidine - 2 - carboxylic acid benzyl - methyl - amide ; . ( 2 , 6 - Dimethyl - piperidin - 1 - yl ) - [ 5 - ( 4 - ﬂuoro - phenyl ) - 7 - trifluoromethyl - pyrazolo [ 1 , 5 - a ] pyrimidin - 2 - yl ] - methanone ; . Azepan - l - yl - [ 5 - ( 4 - ﬁuoro - phenyl ) - 7 - triﬁuoromethyl - pyrazolo [ 1 , 5 - a ] pyrimidin - 2 - yl ] - methanone ; . [ 5 - ( 4 - Fluoro - phenyl ) - 7 - triﬂuoromethyl - pyrazolo [ 1 , 5 - a ] pyrimidin - 2 - yl ] - ( 4 - methyl - pip erazin - 1 - yl ) - methanone ; . [ 5 - ( 4 - Fluoro - phenyl ) - 7 - triﬂuoromethyl - pyrazolo [ 1 , 5 - a ] pyrimidin - 2 - yl ] - ( 4 - phenyl - piperazin - 1 - yl ) - methanone ; . ( 2 - Ethyl - piperidin - 1 - yl ) - [ 5 - ( 4 - ﬁuoro - phenyl ) - 7 - triﬁuoromethyl - pyrazolo [ 1 , 5 - a ] pyrimidin - 2 - yl ] - methanone ; . ( 5 - Phenyl - 7 - triﬂuoromethyl - pyrazolo [ 1 , 5 - a ] pyrimidin - 3 - yl ) - piperidin - 1 - yl - methanone ; . ( 5 - Methyl - 7 - phenyl - pyrazolo [ 1 , 5 - a ] pyrimidin - 3 - yl ) - ( 1 , 3 , 3 - trimethyl - 6 - aza - bicyclo [ 3 .2. 1 ] oct - 6 - yl ) - methanone ; . ( 5 - Thiophen - 2 - yl - 7 - triﬂuoromethyl - pyrazolo [ 1 , 5 - a ] pyrimidin - 3 - yl ) - ( 1 , 3 , 3 - trimethyl - 6 - aza - bicyclo [ 3.2.1 ] oct - 6 - yl ) - methanone ; . ( 4 - Phenyl - piperazin - 1 - yl ) - pyrazolo [ 1 , 5 - a ] pyrimidin - 3 - ylmethanone ; . Pyrazo1o [ 1 , 5 - a ] pyrimidine - 3 - carboxylic acid benzyl - ( 2 - hydroxy - ethyl ) - amide ; . [ 5 - ( 4 - Bromo - phenyl ) - 7 - triﬁuoromethyl - pyrazolo [ 1 , 5 - a ] pyrimidin - 3 - yl ] - ( 3 , 4 - dihydro - 1H - isoquinolin - 2 - yl ) - methanone ; . ( 5 , 7 - Dimethyl - pyrazo1o [ 1 , 5 - a ] pyrimidin - 3 - y ) - [ 4 - ( 4 - methoxy - phenyl ) - pip erazin - 1 - yl ] - methanone ; . ( 3 , 4 - Dihydro - 2H - quinolin - 1 - yl ) - [ 5 - ( 4 - ﬁuoro - phenyl ) - 7 - trifluoromethyl - pyrazolo [ 1 , 5 - a ] pyrimidin - 3 - yl ] - methanone ; . ( 5 - Furan - 2 - yl - 7 - triﬁuoromethyl - pyrazolo [ 1 , 5 - a ] pyrimidin - 3 - yl ) - piperidin - 1 - y1 - methanone ; . Azepan - 1 - y1 - [ 7 - triﬂuoromethyl - 5 - ( 3 , 4 , 5 - tmethoxy - phenyl ) - pyrazolo [ 1 , 5 - a ] pyrimidin - 3 - yl ] - methanone ; . ( 5 - Benzo [ 1 , 3 ] dioxol - 5 - yl - 7 - triﬁuoromethyl - pyrazolo [ 1 , 5 - a ] pyrimidin - 3 - yl ) - pyrrolidin - 1 - yl - methanone ; . Azepan - 1 - y1 - ( 5 , 7 - diphenyl - pyrazolo [ 1 , 5 - a ] pyrimidin - 3 - yl ) - methanone ; . 4 - ( 5 , 7 - Dimethyl - pyrazolo [ 1 , 5 - a ] pyrimidine - 3 - carbonyl ) - piperazine - 1 - carboxylic acid ethyl ester ; . ( 3 , 4 - Dihydro - 1H - isoquinolin - 2 - yl ) - ( 5 , 7 - dimethyl - pyrazolo [ 1 , 5 - a ] pyrimidin - 3 - y1 ) - methanone ; . [ 4 - ( 3 - Chloro - phenyl ) - piperazin - 1 - yl ] - ( 5 - p - tolyl - 7 - triﬂuoromethyl - pyrazolo [ 1 , 5 - a ] pyrimidin - 3 - yl ) - methanone ; . ( 4 - Methyl - piperidin - 1 - yl ) - pyrazolo [ 1 , 5 - a ] pyrimidin - 3 - ylmethanone ; . [ 4 - ( 2 - Methoxy - phenyl ) - piperazin - 1 - yl ] - pyrazolo [ 1 , 5 - a ] pyrimidin - 3 - yl - methanone ; . ( 3 , 4 - Dihydro - 2H - quinolin - 1 - yl ) - [ 5 - ( 4 - methoxy - phenyl ) - 7 - triﬂuoromethyl - pyrazolo [ 1 , 5 - a ] pyrimidin - 3 - yl ] - methanone ; . [ 5 - ( 4 - Methoxy - phenyl ) - 7 - triﬂuoromethy1 - pyrazolo [ 1 , 5 - a ] pyrimidin - 3 - yl ] - thiomorpholin - 4 - yl - methanone ; . ( 5 - Furan - 2 - yl - 7 - trifluoromethyl - pyrazolo [ 1 , 5 - a ] pyrimidin - 3 - yl ) - ( 2 - methyl - piperidin - 1 - yl ) - methanone ; . ( 4 - Benzyl - piperazin - 1 - yl ) - ( 5 , 7 - dimethyl - pyrazolo [ 1 , 5 - a ] pyrimidin - 3 - yl ) - methanone ; . [ 5 - ( 4 - Bromo - phenyl ) - 7 - triﬁuoromethyl - pyrazolo [ 1 , 5 - a ] pyrimidin - 3 - yl ] - morpholin - 4 - yl - methanone ; . ( 5 , 7 - Dimethyl - pyrazolo [ 1 , 5 - a ] pyrimidin - 3 - yl ) - piperidin - 1 - yl - methanone ; . 24 ( 5 - Furan - 2 - yl - 7 - triﬁuoromethyl - pyrazolo [ 1 , 5 - a ] pyrimidin - 3 - yl ) - [ 4 - ( 2 - methoxy - phenyl ) - piperazin - 1 - yl ] - methanone ; ( 5 - Phenyl - 7 - triﬁuoromethyl - pyrazolo [ 1 , 5 - a ] pyrimidin - 3 - yl ) - piperidin - 1 - y1 - methanone ; . 5 Azepan - 1 - yl - ( 5 - thiophen - 2 - yl - 7 - triﬂuoromethyl - pyrazolo [ 1 , 5 - a ] pyrimidin - 3 - yl ) - methanone ; . ( 2 , 6 - Dimethyl - piperidin - 1 - yl ) - ( 5 - thiophen - 2 - yl - 7 - triﬁuoromethyl - pyrazolo [ 1 , 5 - a ] pyrimidin - 3 - yl ) - methanone ; . [ 5 - ( 4 - Methoxy - phenyl ) - 7 - triﬂuoromethyl - pyrazolo [ 1 , 5 - a ] pyrimidin - 3 - yl ] - ( 4 - methyl - piperazin - 1 - yl ) - methanone ; . ( 4 - Methyl - piperazin - l - yl ) - ( 5 - thiophen - 2 - yl - 7 - trﬁuoromethyl - pyrazolo [ 1 , 5 - a ] pyrimidin - 3 - yl ) - methanone ; . [ 5 - ( 4 - Bromo - phenyl ) - 7 - triﬁuoromethyl - pyrazolo [ 1 , 5 - a ] pyrimidin - 3 - yl ] - ( 4 - methyl - piperazin - 1 - yl ) - methanone ; . 15 ( Hexahydro - pyrrolo [ 1 , 2 - a ] pyrazin - 2 - yl ) - ( 5 - p - tolyl - 7 - trif - . luoromethyl - pyrazolo [ 1 , 5 - a ] pyrimidin - 3 - yl ) - methanone ; . [ 5 - ( 4 - Bromo - phenyl ) - 7 - triﬁuoromethyl - pyrazolo [ 1 , 5 - a ] pyrimidin - 3 - yl ] - ( hexahydro - pyrrolo [ 1 , 2 - a ] pyrazin - 2 - yl ) - methanone ; . 20 [ 5 - ( 3 , 4 - Dimethoxy - phenyl ) - 7 - triﬁuoromethyl - pyrazolo [ 1 , 5 - a ] pyrimidin - 3 - yl ] - ( hexahydro - pyrrolo [ 1 , 2 - a ] pyrazin - 2 - yl ) - methanone ; . 1 - [ 5 - ( 3 - Methoxy - phenyl ) - 7 - triﬁuoromethyl - pyrazolo [ 1 , 5 - a ] pyrimidine - 3 - carbonyl ] - piperidine - 4 - carboxylic acid ethyl ester ; . 4 - [ 5 - ( 3 - Methoxy - phenyl ) - 7 - triﬁuoromethyl - pyrazolo [ 1 , 5 - a ] pyrimidine - 3 - carbonyl ] - piperazine - 1 - carboxy1ic acid ethyl ester ; . ( 3 , 4 - Dihydro - 2H - quino1in - 1 - yl ) - [ 5 - ( 3 - methoxy - phenyl ) - 7 - triﬂuoromethyl - pyrazo1o [ 1 , 5 - a ] pyrimidin - 3 - yl ] - methanone ; . [ 4 - ( 4 - Fluoro - phenyl ) - piperazin - 1 - yl ] - [ 5 - ( 3 - methoxy - phenyl ) - 7 - triﬂuoromethy1 - pyrazo1o [ 1 , 5 - a ] pyrimidin - 3 - y1 ] - methanone ; . 35 5 - p - Tolyl - 7 - triﬂuoromethyl - pyrazolo [ 1 , 5 - a ] pyrimidine - 3 - carboxylic acid ( 1 , 3 - dimethyl - 1H - pyrazol - 4 - ylmethyl ) - methyl - amide ; . 5 - p - Tolyl - 7 - triﬂuoromethyl - pyrazolo [ 1 , 5 - a ] pyrimidine - 3 - carboxylic acid methyl - ( 1 , 3 , 5 - trimethyl - 1H - pyrazol - 4 - ylmethyl ) - amide ; . [ 7 - Diﬂuoromethyl - 5 - ( 4 - methoxy - pheny1 ) - pyrazo1o [ 1 , 5 - a ] pyrimidin - 3 - yl ] - ( 2 - ethyl - imidazol - 1 - yl ) - methanone ; . [ 7 - Diﬂuoromethyl - 5 - ( 4 - methoxy - pheny1 ) - pyrazo1o [ 1 , 5 - a ] pyrimidin - 3 - yl ] - morpholin - 4 - yl - methanone ; . 1 - [ 7 - Diﬂuoromethyl - 5 - ( 4 - methoxy - phenyl ) - pyrazolo [ 1 , 5 - a ] pyrimidine - 3 - carbonyl ] - 1H - indole - 3 - carboxylic acid methyl ester ; . [ 4 - ( 4 - Chloro - phenyl ) - piperazin - 1 - yl ] - [ 7 - diﬂuoromethyl - 5 - ( 4 - methoxy - phenyl ) - pyrazolo [ 1 , 5 - a ] pyrimidin - 3 - yl ] - methanone ; . [ 7 - Diﬂuoromethyl - 5 - ( 4 - methoxy - pheny1 ) - pyrazo1o [ 1 , 5 - a ] pyrimidin - 3 - yl ] - ( 2 - ethyl - piperidin - 1yl ) - methanone ; . 7 - Diﬂuoromethyl - 5 - p - to1yl - pyrazolo [ 1 , 5 - a ] pyrimidine - 3 - carboxylic acid ( 1 - ethyl - 5 - methyl - 1H - pyrazol - 4 - ylmethyl ) - methyl - amide ; . 1 - ( 7 - Diﬂuoromethyl - 5 - methyl - pyrazolo [ 1 , 5 - a ] pyrimidine - 3 - carbonyl ) - piperidine - 4 - carboxylic acid amide ; . ( 7 - Diﬁuoromethyl - 5 - phenyl - pyrazolo [ 1 , 5 - a ] pyrimidin - 3 - yl ) - ( 2 - ethyl - imidazol - 1 - yl ) - methanone ; . ( 7 - Diﬁuoromethyl - 5 - phenyl - pyrazolo [ 1 , 5 - a ] pyrimidin - 3 - yl ) - thiomorpholin - 4 - yl - methanone ; . ( 7 - Diﬁuoromethyl - 5 - p - tolyl - pyrazolo [ 1 , 5 - a ] pyrimidin - 3 - yl ) - ( 4 - pyridin - 2 - yl - piperazin - 1 - yl ) - methanone ; . 65 [ 7 - Diﬁuoromethyl - 5 - ( 4 - methoxy - phenyl ) - pyrazolo [ 1 , 5 - a ] . pyrimidin - 3 - yl ] - [ 4 - ( furan - 2 - carbonyl ) - piperazin - 1 - yl ] - methanone ; . lO. 25. m. 0. 45. 50. 55. 60. US 7 , 50l , 405 B2. 25. 7 - Diﬁuoromethyl - 5 - phenyl - pyrazolo [ l , 5 - a ] pyrimidine - 3 - carboxylic acid ( 1 - ethyl - 3 - methyl - 1H - pyrazol - 4 - ylmethyl ) - methyl - amide ; . [ 7 - Diﬂuoromethyl - 5 - ( 4 - methoxy - pheny1 ) - pyrazolo [ 1 , 5 - a ] pyrimidin - 3 - yl ] - thiomorpholin - 4 - yl - methanone ; . ( 7 - Diﬁuoromethyl - 5 - phenyl - pyrazolo [ 1 , 5 - a ] pyrimidin - 3 - yl ) - ( 3 , 4 - dihydro - 1H - isoquinolin - 2 - yl ) - methanone ; . ( 7 - Diﬁuoromethyl - 5 - methyl - pyrazolo [ 1 , 5 - a ] pyrimidin - 3 - yl ) - piperidin - 1 - yl - methanone ; . Azepan - 1 - yl - ( 7 - diﬁuoromethyl - 5 - phenyl - pyrazolo [ 1 , 5 - a ] pyrimidin - 3 - yl ) - methanone ; . 7 - Diﬁuoromethyl - 5 - p - tolyl - pyrazolo [ 1 , 5 - a ] pyrimidine - 3 - carboxylic acid methyl - ( 1 - methyl - 1H - pyrazol - 4 - ylmethyl ) - amide ; . ( 7 - Diﬂuoromethyl - 5 - p - tolyl - pyrazolo [ 1 , 5 - a ] pyrimidin - 3 - yl ) - ( 3 - methyl - piperidin - 1 - yl ) - methanone ; . ( 7 - Diﬁuoromethyl - 5 - p - tolyl - pyrazolo [ 1 , 5 - a ] pyrimidin - 3 - yl ) - ( 4 - ethyl - piperazin - 1 - yl ) - methanone ; . ( 7 - Diﬂuoromethyl - 5 - p - tolyl - pyrazolo [ 1 , 5 - a ] pyrimidin - 3 - yl ) - morpholin - 4 - yl - methanone ; . 7 - Diﬂuoromethyl - 5 - phenyl - pyrazo1o [ 1 , 5 - a ] pyrimidine - 3 - carboxylic acid methyl - ( 1 , 3 , 5 - trimethyl - 1H - pyrazol - 4 - ylmethyl ) - amide ; . ( 7 - Diﬂuoromethyl - 5 - pheny1 - pyrazo1o [ 1 , 5 - a ] pyrimidin - 3 - yl ) - [ 4 - ( 2 - methyl - 2H - pyrazole - 3 - carbonyl ) - piperazin - 1 - yl ] - methanone ; . 7 - Diﬂuoromethyl - 5 - p - toly1 - pyrazo1o [ 1 , 5 - a ] pyrimidine - 3 - carboxylic acid benzyl - methyl - amide ; . 7 - Diﬂuoromethyl - 5 - ( 4 - methoxy - phenyl ) - pyrazolo [ 1 , 5 - a ] pyrimidine - 3 - carboxylic acid ( 1 - ethyl - 3 - methyl - 1H - pyrazol - 4 - ylmethyl ) - methyl - amide ; . 7 - Diﬂuoromethyl - 5 - phenyl - pyrazo1o [ 1 , 5 - a ] pyrimidine - 3 - carboxylic acid methyl - ( 4 - pyrazol - 1 - yl - benzyl ) - amide ; . Azepan - 1 - y1 - ( 5 - cyclopropy1 - 7 - diﬂuoromethyl - pyrazolo [ 1 , 5 - a ] pyrimidin - 3 - yl ) - methanone ; . ( 4 - Benzy1 - piperazin - 1 - y1 ) - [ 5 - ( 4 - methoxy - phenyl ) - 7 - triﬂuo - romethyl - pyrazolo [ 1 , 5 - a ] pyrimidin - 3 - yl ] - methanone ; . ( 3 , 4 - Dihydro - 2H - quinolin - 1 - yl ) - [ 5 - ( 4 - methoxy - phenyl ) - 7 - triﬂuoromethy1 - pyrazolo [ 1 , 5 - a ] pyrimidin - 3 - yl ] - methanone ; . 5 - ( 4 - Methoxy - phenyl ) - 7 - triﬁuoromethyl - pyrazolo [ 1 , 5 - a ] pyrimidine - 3 - carboxylic acid benzy1 - methy1 - amide ; . ( 5 - Furan - 2 - yl - 7 - triﬁuoromethyl - pyrazolo [ 1 , 5 - a ] pyrimidin - 3 - yl ) - ( 4 - methyl - piperazin - 1 - yl ) - methanone ; . ( 5 - Furan - 2 - yl - 7 - trifluoromethyl - pyrazolo [ 1 , 5 - a ] pyrimidin - 3 - yl ) - thiomorpholin - 4 - yl - methanone ; . [ 5 - ( 4 - Methoxy - phenyl ) - 7 - triﬁuoromethyl - pyrazolo [ l , 5 - a ] pyrimidin - 3 - yl ] - morpholin - 4 - yl - methanone ; . ( 4 - Benzyl - piperazin - 1 - yl ) - ( 5 - thiophen - 2 - yl - 7 - triﬂuoromethyl - pyrazolo [ 1 , 5 - a ] pyrimidin - 3 - yl ) - methanone ; . [ 5 - ( 4 - Bromo - phenyl ) - 7 - triﬂuoromethyl - pyrazolo [ 1 , 5 - a ] pyrimidin - 3 - yl ] - morpholin - 4 - yl - methanone ; . Azepan - 1 - y1 - ( 5 - benzo [ 1 , 3 ] dioxol - 5 - yl - 7 - triﬂuoromethylpyrazolo [ 1 , 5 - a ] pyrimidin - 3 - yl ) - methanone ; . ( 5 - Benzo [ 1 , 3 ] dioxol - 5 - yl - 7 - triﬁuoromethyl - pyrazolo [ 1 , 5 - a ] pyrimidin - 3 - y1 ) - ( 3 , 4 - dihydro - 2H - quinolin - 1 - yl ) - methanone ; . 5 - Benzo [ 1 , 3 ] dioxol - 5 - yl - 7 - triﬁuoromethyl - pyrazolo [ 1 , 5 - a ] pyrimidine - 3 - carboxylic acid cyclohexyl - methyl - amide ; . [ 5 - ( 4 - Bromo - phenyl ) - 7 - triﬁuoromethyl - pyrazolo [ 1 , 5 - a ] pyrimidin - 3 - yl ] - ( 3 , 4 - dihydro - 2H - quinolin - 1 - yl ) - methanone ; . [ 5 - ( 4 - Bromo - phenyl ) - 7 - triﬁuoromethyl - pyrazolo [ 1 5 - a ] pyrimidin - 3 - yl ] - piperidin - 1 - yl - methanone ; . Azepan - 1 - yl - ( 5 - furan - 2 - yl - 7 - triﬂuoromethyl - pyrazolo [ 1 , 5 - a ] pyrimidin - 3 - yl ) - methanone ; . 26. ( 5 - Benzo [ l , 3 ] dioxol - 5 - yl - 7 - triﬁuoromethyl - pyrazolo [ l , 5 - a ] pyrimidin - 3 - yl ) - pyrrolidin - 1 - yl - methanone ; . ( 5 - Benzo [ 1 , 3 ] dioxol - 5 - yl - 7 - triﬁuoromethyl - pyrazolo [ 1 , 5 - a ] pyrimidin - 3 - y1 ) - ( 4 - methyl - piperazin - 1 - yl ) - methanone ; . 5 ( 3 , 4 - Dihydro - 1H - isoquinolin - 2 - yl ) - [ 5 - ( 4 - methoxy - phenyl ) - 7 - triﬁuoromethyl - pyrazolo [ l , 5 - a ] pyrimidin - 3 - yl ] - methanone ; . Azepan - 1 - yl - [ 5 - ( 4 - bromo - phenyl ) - 7 - triﬁuoromethyl - pyrazolo [ 1 , 5 - a ] pyrimidin - 3 - yl ] - methanone ; . 10 ( 3 , 4 - Dihydro - 2H - quinolin - 1 - yl ) - ( 5 , 7 - diphenyl - pyrazolo [ 1 , 5 - a ] pyrimidin - 3 - yl ) - methanone ; . Azepan - 1 - yl - ( 5 , 7 - diphenyl - pyrazolo [ 1 , 5 - a ] pyrimidin - 3 - yl ) - methanone ; . ( 5 - Benzo [ 1 , 3 ] dioxol - 5 - yl - 7 - triﬂuoromethyl - pyrazolo [ 1 , 5 - a ] pyrimidin - 3 - yl ) - ( 4 - benzyl - piperazin - 1 - yl ) - methanone ; . ( 4 - Benzyl - piperazin - 1 - yl ) - ( 5 , 7 - diphenyl - pyrazolo [ 1 , 5 - a ] pyrimidin - 3 - yl ) - methanone ; . ( 5 , 7 - Diphenyl - pyrazolo [ 1 , 5 - a ] pyrimidin - 3 - yl ) - ( 4 - methylpip erazin - 1 - yl ) - methanone ; . 20 [ 5 - ( 4 - Bromo - phenyl ) - 7 - triﬂuoromethyl - pyrazolo [ 1 , 5 - a ] pyrimidin - 3 - yl ] - ( 2 - methyl - piperidin - 1 - yl ) - methanone ; . ( 3 , 4 - Dihydro - 2H - quinolin - 1 - yl ) - ( 5 - furan - 2 - yl - 7 - t1iﬂuoromethyl - pyrazolo [ 1 , 5 - a ] pyrimidin - 3 - yl ) - methanone ; . ( 5 - Furan - 2 - y1 - 7 - triﬂuoromethyl - pyrazolo [ 1 , 5 - a ] pyrimidin - 3 - yl ) - ( 2 - methyl - piperidin - 1 - yl ) - methanone ; . [ 5 - ( 4 - Methoxy - phenyl ) - 7 - triﬂuoromethy1 - pyrazo1o [ 1 , 5 - a ] pyrimidin - 3 - y1 ] - pip eri din - 1 - yl - methanone ; . ( 5 - Benzo [ 1 , 3 ] dioxol - 5 - yl - 7 - triﬁuoromethyl - pyrazolo [ 1 , 5 - a ] pyrimidin - 3 - y1 ) - morpho1in - 4 - yl - methanone ; . 3 0 ( 5 - Benzo [ 1 , 3 ] dioxol - 5 - yl - 7 - triﬁuoromethyl - pyrazolo [ 1 , 5 - a ] pyrimidin - 3 - y1 ) - pip eri din - 1 - yl - methanone ; . Morpholin - 4 - yl - [ 7 - triﬁuoromethyl - 5 - ( 3 , 4 , 5 - trimethoxyphenyl ) - pyrazolo [ 1 , 5 - a ] pyrimidin - 3 - yl ] - methanone ; . ( 4 - Benzyl - piperazin - 1 - yl ) - [ 7 - triﬁuoromethyl - 5 - ( 3 , 4 , 5 - trimethoxy - phenyl ) - pyrazolo [ 1 , 5 - a ] pyrimidin - 3 - yl ] - methanone ; . ( 3 , 4 - Dihydro - 2H - quinolin - 1 - yl ) - [ 7 - triﬁuoromethyl - 5 - ( 3 , 4 , . 5 - trimethoxy - phenyl ) - pyrazolo [ 1 , 5 - a ] pyrimidin - 3 - yl ] - methanone ; . 40 ( 4 - Methyl - piperazin - 1 - yl ) - [ 7 - triﬁuoromethyl - 5 - ( 3 , 4 , 5 - trimethoxy - phenyl ) - pyrazolo [ 1 , 5 - a ] pyrimidin - 3 - yl ] - methanone ; . Azepan - 1 - yl - [ 7 - triﬁuoromethyl - 5 - ( 3 , 4 , 5 - trimethoxy - phenyl ) - pyrazolo [ 1 , 5 - a ] pyrimidin - 3 - yl ] - methanone ; . [ 5 - ( 4 - Methoxy - phenyl ) - 7 - triﬂuoromethyl - pyrazolo [ 1 , 5 - a ] pyrimidin - 3 - yl ] - pip eri din - 1 - yl - methanone ; . [ 5 - ( 4 - Methoxy - phenyl ) - 7 - triﬁuoromethyl - pyrazolo [ 1 , 5 - a ] pyrimidin - 3 - yl ] - pyrrolidin - 1 - yl - methanone ; . 5 0 Piperidin - 1 - yl - ( 5 - thiophen - 2 - yl - 7 - triﬂuoromethyl - pyrazolo [ 1 , 5 - a ] pyrimidin - 3 - yl ) - methanone ; . ( 4 - Benzy1 - piperazin - 1 - y1 ) - [ 5 - ( 4 - methoxy - pheny1 ) - 7 - triﬂuoromethyl - pyrazolo [ 1 , 5 - a ] pyrimidin - yl ] - methanone ; . ( 3 , 4 - Dihydro - 2H - quino1in - 1 - yl ) - [ 5 - ( 4 - methoxy - phenyl ) - 7 - triﬂuoromethyl - pyrazolo [ 1 , 5 - a ] pyrimidin - 3 - yl ] - methanone ; . ( 5 - Furan - 2 - y1 - 7 - triﬂuoromethyl - pyrazolo [ 1 , 5 - a ] pyrimidin - 3 - yl ) - ( 2 - methyl - piperidin - 1 - yl ) - methanone ; . ( 5 - Furan - 2 - yl - 7 - triﬁuoromethyl - pyrazolo [ 1 , 5 - a ] pyrimidin - 3 - yl ) - morpholin - 4 - yl - methanone ; . ( 5 - Furan - 2 - yl - 7 - triﬁuoromethyl - pyrazolo [ 1 , 5 - a ] pyrimidin - 3 - yl ) - thiomorpholin - 4 - yl - methanone ; . [ 4 - ( 4 - Fluoro - phenyl ) - piperazin - 1 - yl ] - ( 5 - thiophen - 2 - yl - 7 - triﬂuoromethyl - pyrazolo [ 1 , 5 - a ] pyrimidin - 3 - yl ) - methanone ; . ( 4 - Methyl - piperidin - 1 - yl ) - ( 5 - thiophen - 2 - yl - 7 - triﬁuoromethyl - pyrazolo [ 1 , 5 - a ] pyrimidin - 3 - yl ) - methanone ; . lS. 25. 35. 45. 55. 60. 65. US 7 , 50l , 405 B2. 27. ( 5 - Furan - 2 - yl - 7 - trifluoromethyl - pyrazolo [ 1 , 5 - a ] pyrimidin - 3 - yl ) - ( 4 - methyl - piperazin - 1 - yl ) - methanone ; . ( 4 - Benzyl - piperazin - 1 - yl ) - ( 5 - thiophen - 2 - yl - 7 - triﬁuoromethy1 - pyrazo1o [ 1 , 5 - a ] pyrimidin - 3 - y1 ) - methanone ; . [ 5 - ( 4 - Methoxy - phenyl ) - 7 - triﬂuoromethyl - pyrazolo [ 1 , 5 - a ] pyrimidin - 3 - yl ] - morpholin - 4 - yl - methanone ; . Piperidin - 1 - yl - [ 7 - triﬁuoromethyl - 5 - ( 3 , 4 , 5 - trimethoxy - phenyl ) - pyrazolo [ 1 , 5 - a ] pyrimidin - 3 - yl ] - methanone ; . ( 2 - Methyl - piperidin - 1 - yl ) - ( 5 - thiophen - 2 - yl - 7 - triﬂuoromethyl - pyrazolo [ 1 , 5 - a ] pyrimidin - 3 - yl ) - methanone ; . Azepan - l - yl - [ 5 - ( 4 - methoxy - phenyl ) - 7 - triﬁuoromethylpyrazolo [ 1 , 5 - a ] pyrimidin - 3 - yl ] - methanone ; . 5 - Thiophen - 2 - yl - 7 - triﬁuoromethyl - pyrazolo [ 1 , 5 - a ] pyrimidine - 3 - carboxylic acid benzyl - methyl - amide ; . [ 5 - ( 4 - Methoxy - phenyl ) - 7 - triﬂuoromethyl - pyrazolo [ 1 , 5 - a ] pyrimidin - 3 - yl ] - pyrrolidin - 1 - yl - methanone ; . [ 5 - ( 4 - Chloro - phenyl ) - 2 - methyl - 7 - triﬁuoromethyl - pyrazolo [ 1 , 5 - a ] pyrimidin - 3 - yl ] - piperidin - 1 - yl - methanone ; . Azepan - 1 - yl - [ 5 - ( 4 - chloro - phenyl ) - 2 - methyl - 7 - triﬂuoromethyl - pyrazolo [ 1 , 5 - a ] pyrimidin - 3 - yl ] - methanone ; . [ 5 - ( 4 - Chloro - phenyl ) - 2 - methyl - 7 - triﬁuoromethyl - pyrazolo [ 1 , 5 - a ] pyrimidin - 3 - yl ] - ( 4 - methyl - piperazin - 1 - yl ) - methanone ; . Morpholin - 4 - yl - ( 5 - p - toly - 7 - triﬂuoromethyl - pyrazolo [ 1 , 5 - a ] pyrimidin - 3 - yl ) - methanone ; . ( 4 - Benzyl - piperazin - 1 - yl ) - ( 5 - p - tolyl - 7 - triﬁuoromethyl - pyrazolo [ 1 , 5 - a ] pyrimidin - 3 - yl ) - methanone ; . 5 - ( 4 - Methoxy - pheny1 ) - 7 - triﬂuoromethy1 - pyrazolo [ 1 , 5 - a ] pyrimidine - 3 - carboxylic acid benzy1 - methy1 - amide ; . ( 4 - Benzyl - piperazin - 1 - yl ) - ( 5 - phenyl - 7 - triﬁuoromethylpyrazolo [ 1 , 5 - a ] pyrimidin - 3 - yl ) - methanone ; . Morphol n - 4 - yl - ( 5 - phenyl - 7 - triﬁuoromethyl - pyrazolo [ 1 , 5 - a ] pyrimidin - 3 - yl ) - methanone ; or a salt thereof With a pharmaceutical1y acceptable acid or base , or any optica1 isomer. or mixture of optical isomers , including a racemic mixture , 35. or any tautomeric forms. ln another embodiment of the present inVention said substituted amides , or a prodrug thereof , as a component of the combination therapy is of the genera1 formula ( ll ) . Formula ( ll ) . Wherein. R1 is C3 - Cl0cycloalkyl , C3 - Cl0hetcycloalkyl , Cl - C8alkyl , 50. aryl , hetaryl , arle1 - C6alkyl or hetarle1 - C6alkyl , Wherein the cycloalkyl , hetcycloalkyl , alkyl , arylalkyl and hetarylalkyl groups independently are optionally substituted With one or more of R4. 28 C6alkyloxy , C l - C6alkyloxyC l - C6alkyl , C l - C6alkylcarbonyl , arylcarbonyl , hetarylcarbonyl , arlel - C6alkylcarbonyl , hetarle1 - C6alkylcarbonyl , C1 - C6alkylcarboxy , arylcarboxy or arle 1 - C6a1ky1carboxy Wherein the alky1 and aryl groups independently are optionally substituted With one ore more of Rl4 ; . R3 is C1 - C8alkyl , C1 - C6alkenyl , C3 - C10cycloalkyl , C3 - C10hetcycloalkyl , arle1 - C6alkyl , C6alkyl , aryl - R6 - Cl - C6alkyl , hetaryl - R6—C1 - C6alkyl or arle1 - C6alkyl - R6 - Cl - C6alkyl Wherein the alkyl , cycloalkyl , hetcycloalkyl , alkenyl , alkynyl , aryl and hetaryl groups independently are optionally substituted With one or more of R7 ; . R4 and R5 independently are hydrogen , hydroxy , oxo , cyano , halo , methylendioxo , NR8R9 , Cl - C8alkyl , Cl - C6alkyloxy , trihalomethyl , trihalomethyloxy , C3 - Clocycloalkyl , C3 - C1Ohetcycloalkyl , C3 - ClOcycloalkenyl , aryl , hetaryl , hetarylSOn , arlel - C6alkyloxy , hetarlel - C6alkyloxy , C1 - C6alky1 - R6—C1 - C6alky1 , arlel - C6a1ky1 - R6—Cl - C6alkyl , Cl - C6alkylcarbonyl , arylcarbonyl , arlel - C6alkylcarbonyl , hetarylcarbonyl , hetarlel - C6alkylcarbonyl , C l - C6alkylSOn , C l - C6alkyl - carboxy , arylcarboxy , hetarylcarboxy , arlel - C6alkylcarboxy or hetarlel - C6alkylcarboxy Wherein the a1ky1 , cyc1oalkyl , hetcycloalkyl , aryl and hetaryl groups independently are optionally substituted With one ore more of R15 ; . R6 is oxygen , sulphur , SOn or NRl6 ; . R7 is hydrogen , halo , hydroxy , cyano , nitro , COOR” , C1 - C8alkyl , C3 - C1Ocycloalkyl , C3 - C1Ohetcycloalkyl , methylendioxo , trihalomethy1 , triha1omethy1oxy , ary1 , arle 1 ' C6alkyl , C l - C6alkyloxy , Cl - C6alkyloxyC1 - C6alkyl , aryloxy , arle1 - C6alkyloxy , aryloxyC 1 - C6alkyl , arle 1 - C6alkyloxyC1 - C6alkyl , hetaryl , hetarle1 - C6alkyl , hetaryloxy , hetarlel - C6a1ky1oxy , hetaryloxyCl - C6alkyl , hetarlel - C6alkyl - oxyCl - C6a1kyl , NR8R9 , SO2NR8R9 , NRA ' R5 carbonle1 - C6alkyl , arylthio , hetarylthio , Rl8carbonleR8 , arylSOn , hetarylSOn , Rl9SOmNR8 , arylthioC 1 - C6alkyl , hetarylthioC 1 - C6alkyl or arle l - C6alkle6C 1 - C6alkyl ; Wherein the aryl and hetaryl groups independently are optiona1ly substituted With one or more R“ ) ; . R8 and R9 independently are hydrogen , C l - C8a1ky1 , aryl , hetaryl , arlel - C6alkyl or hetarle1 - C6alkyl Wherein the alkyl , aryl and hetaryl groups independently are optionally substituted With one or more of R1 l ; or. R8 and R9 together With the nitrogen to Which they are attached , are forming a saturated or partial1y saturated cyclic , bicyclic or tricyclic ring system containing from 4 to 10 carbon atoms and from 0 to 2 additional heteroatoms selected from nitrogen , oxygen or sulfur , the ring system optionally being substituted With at least one halo , cyano , C 1 - C8alkyl , aryl , hetaryl , arle1 - C6alkyl , hetarlel - C6alkyl , hydroxy , oxo , C1 - C6alkyloxy , arlel - C6alkyloxy , hetarlel - C6alkyloxy , Cl - C6alkyloxyCl - C6alkyl , Cl - C6alkyl - carbo - . C1 - C6alkynyl , . aryl , hetaryl , C 1 - C6alkyloxyC 1 - C6alkyl , hetarle 1 - . R2 is hydrogen , C1 - C8alkyl , aryl , hetaryl , arle1 - C6alkyl , 55 nyl , arylcarbonyl , hetarylcarbonyl , arlel - C6alkylcarbonyl , . C3 - Cl0cycloalklel - C6alkyl , C6alkyl Wherein the alkyl , aryl and cycloalkyl groups independently are optionally substituted With one or more of R5 ; or. C1 - C6alkyl - carboxyCl - . R1 and R2 together With the nitrogen to Which they are 60. attached , are forming a saturated or partially saturated cyclic , bicyclic or tricyclic ring system containing from 4 to 10 carbon atoms and from 0 to 2 additional heteroatoms selected from nitrogen , oxygen or sulphur , the ring system optionally. hetarle1 - C6alkylcarbony1 , C1 - C6alkylcarboxy , arylcarboxy , hetarylcarboxy , arlel - C6alkylcarboxy or hetarlel - C6alkylcarboxy ; . RlO and R11 independently are hydrogen , hydroxy , oxo , halo , cyano , nitro , Cl - C8alkyl , Cl - C6alkyloxy , NR12R13 , methylendioxo , trihalomethyl or trihalomethyloxy ; . Rlz and Rl3 independently are hydrogen , C1 - C8alkyl or arle1 - C6alkyl ; . Rl4 is hydrogen , halo , hydroxy , oxo , nitro , cyano , . being substituted With at least one of Cl - C8alkyl , aryl , 65 C1 - C8a1ky1 , C1 - C6a1ky10Xy 01 ' ary10Xy ; . hetaryl , arlel - C6alkyl , hetarle1 - C6alkyl , hydroxy , oxo , cyano , Cl - C6alkyloxy , arle1 - C6alkyloxy , hetarle1 - . R15 is hydrogen , halo , hydroxy , oxo , nitro , cyano , CONR8R9 or CooR” ; . US 7 , 50l , 405 B2. 29 R16 is hydrogen , Cl - C8alkyl , C3 - ClOcycloalkyl , C3 - Cthetcycloalkyl , aryl , arlel - C6alkyl , hetaryl , hetarle1 - C6alkyl , alkylcarbonyl , arylcarbonyl , arle1 - C6alkylcarbonyl , aryloxyC 1 - C6a1ky1 , hetary1oxyC1 - C6a1kyl , . arylthioCl - C6alkyl or hetarylthioCl - C6alkyl ; Wherein the 5. alkyl , cycloalkyl , hetcycloalkyl , aryl and hetaryl groups independently are optionally substituted With one or more of R“ ) ; . R17 is hydrogen , C1 - C8alkyl , aryl or arle1 - C6alkyl ; . R18 is C1 - C6alkyl , C2 - C6alkenyl , aryl , arlel - C6alkyl , hetaryl , hetarlel - C6alkyl , C3 - Cl0hetcycloalkyl , Cl - C6alkyloxy , aryloxy , arlel - C6alkyloxy , arle1 - C6alkyloxyC1 - C6alkyl , hetaryloxy , hetarle 1 - C6alkyloxy , hetarle 1 - C6alkyloxyC 1 - C6alkyl or R8R9NC1—C6alkyl Wherein the alkyl , alkenyl , cycloalkyl , . hetcycloalkyl , aryl and hetaryl groups are optionally substi - 15. tuted With RlS ; . R19 is C1 - C6alkyl , C3 - C1Ocycloalkyl , C3 - C1Ohetcycloalkyl , aryl , arle1 - C6alkyl , hetarle1 - C6alkyl ; . m is 1 or 2 ; . nis0 , 1or2 ; or. a salt thereof With a pharmaceutically acceptable acid or base , or any optical isomer or mixture of optical isomers , including a racemic mixture , or any tautomeric fo1ms. ln another embodiment of the present inVention said sub - 25. stituted amides , or a prodrug thereof , as a component of the combination therapy is of the general formula ( ll ) Wherein : R1 is C3 - C1Ocycloalkyl , C3 - Cthetcycloalkyl , Cl - C8a1kyl , ary1 , hetaryl , arlel - C6alkyl or hetaryl - Cl - C6alkyl , Wherein. the cycloalkyl , hetcycloalkyl , alkyl , arylalkyl and hetaryla - 30. lkyl groups independently are optionally substituted With one or more of R4 ; . R2 is hydrogen , C1 - C8alkyl , aryl , hetary1 , arle 1 - C6a1kyl , C3 - C 1 Ocyc1oalklel - C6a1ky1 , C 1 - C6alkyl - carboxyC 1 - . C6alkyl Wherein the alkyl , aryl and cycloalkyl groups inde - 35. pendently are optionally substituted With one or more of R5 ; or. R1 and R2 are together With the nitrogen to Which they are attached , are forming a saturated or partial1y saturated cyc1ic , . bicyclic or tricyclic ring system containing from 4 to 10 40. carbon atoms and from 0 to 2 additional heteroatoms selected from nitrogen , oxygen or sulphur , the ring system optionally being substituted With at least one of C l - C8alky1 , aryl , hetaryl , arlel - C6alkyl , hetarlel - C6a1kyl , hydroxy , oxo , . cyano , Cl - C6alkyloxy , arlel - C6alkyloxy , hetarlel - 45. C6alkyloxy , C 1 - C6alkyloxyC 1 - C6alkyl , Cl - C6alkylcarbonyl , arylcarbonyl , hetarylcarbonyl , arlel - C6alkylcarbonyl , hetarle l - C6a1ky1carbony1 , C l - C6a1ky1carboxy , arylcarboxy or arlel - 6alkylcarboxy Wherein the alkyl and aryl groups. independently are optionally substituted With one ore more of 50. R14 , R3 15 C1 - C8alkyl , C1 - C6alkenyl , C3 - Cl0cyc1oalkyl , C3 - Cl0hetcycloalkyl , . arle1 - C6alkyl , . C1 - C6alkynyl , . aryl , hetaryl , C 1 - C6alkyloxyC 1 - C6alkyl , hetarle 1 - . C6alkyl , aryl - R6—Cl - C6alkyl , hetaryl - R6—Cl - C6alkyl or 55. arle1 - C6alkyl - R6%l - C6alkyl Wherein the alkyl , cycloalkyl , hetcycloalkyl , alkenyl , alkynyl , aryl and hetaryl groups independently are optional1y substituted With one or more of R7 ; . R4 and R5 independently are hydrogen , hydroxy , oxo , 60. cyano , halo , NR8R9 , Cl - C8alkyl , C1 - C6alkyloxy , trihalomethyloxy , C3 - C1Ocycloalkyl , C3 - Cl0hetcycloalkyl , C3 - ClOcycloalkenyl , aryl , hetaryl , hetarylSOn , arlel - C6alkyloxy , hetarle 1 - C6alkyloxy , C 1 - C6alkyl - R6—C 1 - C6alkyl , arle1 - C6alkyl - R6% : 1 - C6alkyl , C1 - C6alkylcarbonyl , arylcarbonyl , arle1 - C6alkylcarbonyl , . methyl endioxo , trihalomethyl , . C3 - Cl0cycloalkyl , 10. 30. hetarylcarbonyl , hetarlel - C6alkyl - carbonyl , C l - C6alkylSOn , C l - C6alkylcarboxy , arylcarboxy , hetarylcarboxy , arle1 - C6alkylcarboxy or hetarle1 - C6alkylcarboxy Wherein the alky1 , cycloalkyl , hetcycloalkyl , ary1 and hetaryl groups independently are optionally substituted With one ore more of RlS ; . R6 is oxygen , sulphur , SOn , NRl6 ; . R7 is hydrogen , halo , hydroxyl , cyano , nitro , COOR” , C1 - C8alkyl , C3 - C1Ocycloalkyl , C3 - C1Ohetcycloalkyl , methylendioxo , trihalomethyl , trihalomethyloxy , aryl , arlel - C6alkyl , Cl - C6alkyloxy , Cl - C6alkyloxyC1 - C6alkyl , aryloxy , aryloxyC1 - C6alkyl , arlel - C6alkyloxyCl - C6alkyl , hetaryl , hetarle1 - C6alkyl , hetaryloxy , hetarle1 - C6alkyloxy , hetaryloxyC1 - C6a1ky1 , hetarle1 - C6alkyl - oxyCl - C6alkyl , NR8R9 , SO2NR8R9 , NR4R5 carbonylalkyl , arylcarbonleR8 , arylthio , hetarylthio , arylSOn , hetarylSOn , arylSOmNR8 , arylthioCl - C6alkyl , hetarylthioCl - C6alkyl or arlel - C6alkle6C1 - C6alkyl ; Wherein the aryl and hetaryl groups independently are optionally substituted With one or more RlO ; . R8 and R9 independently are hydrogen , C1 - C8alkyl , aryl , hetaryl , arlel - C6alkyl or hetarle1 - C6alkyl Wherein the alkyl , aryl and hetaryl groups independently are optionally substituted With one or more of R1 l ; or. R8 and R9 together With the nitrogen to Which they are attached , are forming a saturated or partially saturated cyclic , bicyclic or tricyclic ring system containing from 4 to 10 carbon atoms and from 0 to 2 additional heteroatoms selected from nitrogen , oxygen or sulfur , the ring system optionally being substituted With at least one C1 - C8alkyl , aryl , hetaryl , arle1 - C6alkyl , hetarle1 - C6alkyl , hydroxy , oxo , Cl - C6alkyloxy , arlel - C6alkyloxy , hetarlel - C6alkyloxy , Cl - C6alkyloxyC1 - C6alkyl , Cl - C6alkylcarbonyl , arylcarbonyl , hetarylcarbonyl , arlel - C6alkylcarbonyl , hetarlel - C6alkylcarbonyl , Cl - C6a1ky1carboxy , arylcarboxy , hetary1 - carboxy , arlel - C6alkyl - carboxy or hetarlel - C6alkylcarboxy ; . RlO and R11 independently are hydrogen , hydroxy , oxo , halo , cyano , nitro , Cl - C6alkyl , Cl - C6 - alkyloxy , NR12R13 , methylendioxo , trihalomethyl or trihalomethyloxy ; . RlZ and Rl3 independently are hydrogen , C1 - C8alkyl or arle1 - C6alkyl ; . Rl4 is hydrogen , halo , hydroxy , oxo , nitro , cyano , C l - C8alkyl , C 1 - C6alkyloxy or aryloxy ; . RlS is hydrogen , halo , hydroxy , oxo , nitro , cyano or COOR” ; . Rl6 is hydrogen , Cl - C8alkyl , C3 - Cl0cycloalkyl , C3 - Cl0hetcycloalkyl , aryl , arlel - C6alkyl , hetaryl , hetarlel - C6alkyl , alkylcarbonyl , arylcarbonyl , arlel - C6alkylcarbonyl , aryloxyCl - C6a1ky1 , hetary1oxyCl - C6alkyl , arylthioCl - C6alkyl or hetarylthioCl - C6alkyl ; Wherein the alkyl , cycloalkyl , hetcycloalkyl , aryl and hetaryl groups independently are optionally substituted With one or more of R10 ; . R17 is hydrogen , Cl - C8alkyl , aryl or arlel - C6alkyl ; . m is 1 or 2 ; . nis0 , 1 or2 ; or. a salt thereof With a pha1maceutically acceptable acid or base , or any optical isomer or mixture of optical isomers , including a racemic mixture , or any tautomeric forms. ln another embodiment of the present inVention said substituted amides , or a prodrug thereof , as a component of the. combination therapy is of the general formula ( ll ) Wherein R1 is C3 - ClOcycloalkyl or C3 - Cthetcycloalkyl Wherein the. 65 cycloalkyl and hetcycloalkyl groups independently are. optionally substituted With one or more of R4 as deﬁned aboVe. US 7 , 50l , 405 B2. 31. ln another embodiment of the present inVention said substituted amides , or a prodrug thereof , as a component of the combination therapy is of the general formula ( ll ) Wherein R1 is C3 - C10cycloa1kyl optiona1ly substituted With one or more of R4 as deﬁned aboVe. ln another embodiment of the present inVention said substituted amides , or a prodrug thereof , as a component of the combination therapy is of the general formula ( ll ) Wherein R2 is hydrogen or C1 - C8alkyl , Wherein the the alkyl group is optionally substituted With one or more of R5 as deﬁned aboVe. ln another embodiment of the present inVention said substituted amides , or a prodrug thereof , as a component of the combination therapy is of the general formula ( ll ) Wherein R2 is C1 - C8alkyl optionally substituted With one or more of R5 as deﬁned aboVe. ln another embodiment of the present inVention said substituted amides , or a prodrug thereof , as a component of the combination therapy is of the general formula ( ll ) Wherein R3 is C3 - C1Ocycloalkyl , C3 - C10hetcycloalkyl , aryl , hetaryl , arle1 - C6alkyl , hetarle1 - C6alkyl , aryl - R6% : 1 - C6alkyl , hetaryl - R6% : 1 - C6alkyl or arle1 - C6alkyl - R67C1 - C6alkyl Wherein the a1ky1 , cycloalkyl , hetcyc1oalkyl , aryl and hetaryl groups independently are optionally substituted With one or more of R7. ln another embodiment of the present inVention said substituted amides , or a prodrug thereof , as a component of the combination therapy is of the genera1 formula ( ll ) Wherein R3 is aryl or hetaryl , Wherein the ary1 and hetaryl groups are optionally substituted With one or more of R7 as deﬁned aboVe. ln another embodiment of the present inVention said substituted amides , or a prodrug thereof , as a component of the combination therapy is of the genera1 formula ( ll ) Wherein R3 is is phenyl optionally substituted With one or more of R7 as deﬁned aboVe. ln another embodiment of the present inVention said substituted amides , or a prodrug thereof , as a component of the combination therapy is of the genera1 formula ( ll ) Wherein R3 is phenyl optionally substituted independently in position 2 ( ortho ) or 4 ( para ) With one or more of R7 as deﬁned aboVe. ln another embodiment of the present inVention said substituted amides , or a prodrug thereof , as a component of the combination therapy is of the genera1 formula ( ll ) Wherein R4 and R5 independently are hydrogen , hydroxy , oxo , halo , C1 - C8alkyl , Wherein the alkyl group is optionally substituted With one ore more of R15. ln another embodiment of the present inVention said substituted amides , or a prodrug thereof , as a component of the combination therapy is of the general formula ( ll ) Wherein R6 is oxygen. ln another embodiment of the present inVention said substituted amides , or a prodrug thereof , as a component of the combination therapy is of the general formula ( ll ) Wherein R7 is hydrogen , halo , hydroxy , cyano , C1 - C8alkyl , C3 - C1Ocycloalkyl , C3 - C1Ohet - cycloalkyl , trihalomethyl , aryl , arle1 - C6alkyl , C1 - C6alkyloxy , C1 - C6alkyloxyC1 - C6alkyl , ary1oxy , arle1 - C6alkyloxy , aryloxyC1 - C6alkyl , arle1 - C6alkyloxyC1 - C6alkyl , hetaryl , hetarle1 - C6alkyl , hetaryloxy , hetarle1 - C6alkyloxy , hetaryloxyC1 - C6alkyl , hetarle1 - C6alkyl - oxyC1 - C6alkyl , NR3R9 , NR4R5carbonle1 - C6alkyl , Rl8carbonleR8 , Rl9SOmNR8 , Wherein the aryl and hetaryl groups independently are optionally substituted With one or more Rm. lO. lS. 20. 25. 30. 35. 40. 45. 50. 55. 60. 32. and R9 together With the nitrogen to Which they are attached , are forming a saturated or partially saturated cyclic , bicyclic or tricyclic ring system containing from 4 to 10 carbon atoms and from 0 to 2 additional heteroatoms selected from nitrogen , oxygen or sulfur , the ring system optionally being substituted With at least one halo , cyano , C1 - C8alkyl , aryl , hetaryl , arle1 - C6alkyl , hetarle1 - C6alkyl , hydroxy , oxo , C1 - C6alkyloxy , arle1 - C6alkyloxy , hetarle1 - C6alkyloxy , C1 - C6alkyloxyC1 - C6alkyl , C1 - C6alkyl - carbonyl , arylcarbonyl , hetarylcarbonyl , arle1 - C6alkylcarbonyl , hetarle1 - C6alkylcarbonyl , C1 - C6alkylcarboxy , arylcarboxy , hetarylcarboxy , arle1 - C6alkylcarboxy or hetarle1 - C6alkylcarboxy. ln another embodiment of the present inVention said substituted amides , or a prodrug thereof , as a component of the combination therapy is of the general formula ( ll ) Wherein R15 is CONR8R9. ln another embodiment of the present inVention said substituted amides , or a prodrug thereof , as a component of the combination therapy is of the general formula ( ll ) Wherein RlS is C1 - C6alkyl optionally substituted With R15. ln another embodiment of the present inVention said substituted amide , or a prodrug thereof , as a component of the combination therapy is selected from the group consisting of : 3 - ( 10 , 11 - Dihydro - dibenzo [ b , f ] azepin - 5 - yl ) - 1 - [ 4 - ( 1H - imidazol - 4 - yl ) - piperidin - 1 - yl ] - propan - 1 - one ; 4 - ( 10 , 11 - Dihydro - dibenzo [ b , f ] azepin - 5 - yl ) - 1 - [ 4 - ( 3H - imidazol - 4 - y1 ) - piperidin - 1 - yl ] - butan - 1 - one ; 2 , 4 - Bis - benzyloxy - benzamide ; ( 1 H - lndol - 4 - yl ) - piperidin - 1 - yl - methanone ; N - ( 1 , 4 - Dioxo - 1 , 4 - dihydro - naphthalen - 2 - yl ) - benzamide ; N - ( 2 , 3 - Dihydroxy - propyl ) - 2 - ( 2 - phenyl - adamantan - 2 - yl ) - acetamide ; ( 6 - Fluoro - 2 - methyl - 3 , 4 - dihydro - 2H - quinolin - 1 - yl ) - phenylmethanone ; ( 2 - Chloro - phenyl ) - ( 6 - ﬁuoro - 2 - methyl - 3 , 4 - dihydro - 2H - quinolin - 1 - yl ) - methanone ; 3 - Cyclopentyl - 1 - ( 6 - fluoro - 2 - methyl - 3 , 4 - dihydro - 2H - quinolin - 1 - yl ) - propan - 1 - one ; ( 3 - Chloro - thieno [ 2 , 3 - b ] thiophen - 2 - yl ) - thiomorpho1in - 4 - y1 - methanone ; 2 - [ 2 - ( 4 - Chloro - phenyl ) - adamantan - 2 - yl ] - 1 - [ 4 - ( 4 - methoxyphenyl ) - piperazin - 1 - yl ] - ethanone ; 1 - ( 4 - Benzyl - piperazin - 1 - yl ) - 2 - [ 2 - ( 4 - ch1oro - phenyl ) - adamantan - 2 - yl ] - ethanone ; 2 - [ 2 - ( 4 - Chloro - phenyl ) - adamantan - 2 - yl ] - 1 - ( 4 - methyl - pip - erazin - 1 - yl ) - ethanone ; 1 - [ 4 - ( 6 - Chloro - pyridin - 2 - yl ) - piperazin - 1 - yl ] - 2 - ( 2 - phenyladamantan - 2 - yl ) - ethanone ; 4 - Chloro - N - ( 1 , 7 , 7 - trimethyl - bicyclo [ 2.2.1 ] hept - 2 - yl ) - benzamide ; 3 - Chloro - benzo [ b ] thiophene - 2 - carboxylic acid ( 2 - cyanoethyl ) - cyclohexyl - amide ; 2 - [ 2 - ( Bicyclo [ 2.2.1 ] hept - 5 - en - 2 - ylamino ) - 4 - oxo - 4 , 5 - dihydro - thiazol - 5 - yl ] - N - ( 2 - chloro - phenyl ) - acetamide ; [ 3 - ( 4 - sec - Butyl - phenoxy ) - pheny1 ] - piperidin - 1 - yl - methanone ; 3 - ( 6 - Chloro - pyridin - 2 - yloxy ) - N - ethyl - benzamide ; N - Benzyl - 2 , 4 - dichloro - N - pyridin - 2 - yl - benzamide ; 2 - [ Benzoyl - ( 3 - chloro - 4 - ﬂuoro - phenyl ) - amino ] - propionic acid butyl ester ; 2 - [ Benzoyl - ( 3 - chloro - 4 - ﬂuoro - phenyl ) - amino ] - propionic acid pentyl ester ; . ln another embodiment of the present inVention said sub - 65 3 - ( 4 - Fluoro - phenyl ) - 1 - ( 4 - phenyl - piperidin - 1 - yl ) - but - 2 - en - . stituted amides , or a prodrug thereof , as a component of the combination therapy is of the general formula ( ll ) Wherein R8. 1 - one ; N - ( 1 , 7 , 7 - Trimethyl - bicyclo [ 2.2.1 ] hept - 2 - yl ) - benzamide ; . US 7 , 50l , 405 B2. 33. l - ( 3 - Cyclopentyl - propionyl ) - piperidine - 3 - carboxylic acid ethyl ester ; . 4 - Phenyl - 1 - phenylacetyl - piperidine - 4 - carbonitrile ; . 1 - Octanoy1 - 4 - phenyl - pipe1idine - 4 - carbonitrile ; . 2 , 2 - Dimethyl - 1 - ( 1 , 3 , 3 - trimethyl - 6 - aza - bicyclo [ 3.2.1 ] oct - 6 - yl ) - propan - l - one ; . ( 4 - Chloro - phenyl ) - ( 1 , 3 , 3 - trimethyl - 6 - aza - bicyclo [ 3 .2 . 1 ] oct - 6 - yl ) - methanone ; . N - [ 1 - ( 4 - Methanesulfonyl - phenyl ) - ethyl ] - N - ( tetrahydro - furan - 2 - ylmethyl ) - benzamide ; . 2 - ( 2 - Amino - phenylsulfanyl ) - 1 - ( 5 - ﬁuoro - 2 , 3 - dihydro - indol - 1 - yl ) - ethanone ; . N - ( 1 - Methyl - 2 , 3 - dihydro - 1H - indol - 5 - ylmethyl ) - N - ( tetrahydro - furan - 2 - ylmethyl ) - benzamide ; . 1 - Benzoyl - piperidine - 2 - carboxylic acid ethyl ester ; . N - ( 2 - Chloro - phenyl ) - 2 - ( 1 , 2 , 3 , 4 - tetrahydro - isoquinolin - 1 - yl ) - acetamide ; . ( Decahydro - naphthalen - 1 - yl ) - ( 4 - methyl - piperazin - 1 - yl ) - methanone ; . ( 4 - Methyl - piperazin - 1 - yl ) - ( 2 - p - tolylsulfanyl - phenyl ) - methanone ; . Adamantane - 1 - carboxylic acid ( 3 - benzyloxy - 2 - ethyl - 6 - methyl - pyridin - 4 - yl ) - amide ; . ( 6 - Fluoro - 2 - methyl - 3 , 4 - dihydro - 2H - quinolin - 1 - yl ) - ( 3 , 4 , 5 - trimethoxy - phenyl ) - methanone ; . N - Bicyclo [ 2.2.1 ] hept - 2 - yl - 3 - cyclopentyl - propionamide ; . ( 2 - Benzo [ 1 , 2 , 5 ] oxadiazol - 5 - yl - thiazol - 4 - yl ) - piperidin - 1 - ylmethanone ; . Thiophene - 2 - carboxylic acid droxy - butyl ] - isopropyl - amide ; . N - Cyclohexyl - 3 - ( 1 , 3 - dioxo - 1 , 3 - dihydro - isoindol - 2 - yl ) - propionamide ; . 2 - [ ( Adamantane - 1 - carbony1 ) - amino ] - 3 - ( 1H - indol - 3 - yl ) - propionic acid methy1 ester ; . Adamantane - 1 - carboxylic acid [ 3 - ( 1H - benzoimidazol - 2 - ylsulfanyl ) - 5 - nitro - phenyl ] - amide ; . N - Benzyl - N - ( 1 - cyclopropyl - ethyl ) - 4 - ﬁuoro - benzamide ; . Thiophene - 2 - carboxylic acid 2 - [ 2 - ( 2 - phenyl - adamantan - 2 - yl ) - acety1amino ] - ethy1 ester ; . N - ( 4 - Acetyl - phenyl ) - 2 - ( 2 - phenyl - adamantan - 2 - yl ) - acetamide ; . 2 - [ 2 - ( 4 - Chloro - phenyl ) - adamantan - 2 - yl ] - N - ( 2 - hydroxyethy1 ) - acetamide ; . ( 4 - Benzoy1 - piperidin - 1 - yl ) - thiophen - 2 - yl - methanone ; . N - ( 2 - Benzoyl - 4 - methyl - phenyl ) - 3 - phenyl - acrylamide ; . N - ( 2 - Benzoyl - 4 - methyl - phenyl ) - 2 - ﬁuoro - benzamide ; . Adamantane - 1 - carboxylic acid ( 4 - ethoxy - benzothiazol - 2 - yl ) - amide ; . Adamantane - 1 - carboxylic acid ( 5 - benzoyl - 4 - phenyl - thiazol - 2 - yl ) - amide ; . 3 - ( 2 - Hydroxy - phenyl ) - 1 , 3 - di - piperidin - 1 - yl - propan - 1 - one ; . N - ( 1 - Methyl - 2 - phenyl - ethyl ) - 3 - phenyl - propionamide ; . 4 - Oxo - 4 - piperidin - 1 - yl - butyric acid 4 - tert - butyl - cyclohexyl ester ; . N - tert - Butyl - N - ( 4 - methoxy - benzyl ) - 4 - nitro - benzamide ; . { 4 - [ ( Adamantane - 1 - carbonyl ) - amino ] - phenoxy } - acetic acid ; . [ 4 - ( 4 - ﬂuoro - phenyl ) - 4 - hy - . 2 - ( 4 - lsobuty1 - phenyl ) - N - ( 1 - pheny1 - ethyl ) - propionamide ; . Adamantane - 1 - carboxylic acid 4 - [ ( adamantane - 1 - carbonyl ) - amino ] - 2 , 6 - dimethyl - pyridin - 3 - yl ester ; . 2 - Phenyl - 1 - ( 3 - phenyl - pyrrolidin - 1 - yl ) - ethanone ; . Adamantane - 1 - carboxylic acid 4 - [ ( adamantane - 1 - carbonyl ) - amino ] - 2 - ethyl - 6 - methyl - pyridin - 3 - yl ester ; . N - ( 1 , 3 - Dioxo - 1 , 3 - dihydro - isoindol - 2 - ylmethyl ) - N - ( 4 - hydroxy - phenyl ) - benzamide ; . Biphenyl - 4 - yl - pip eridin - 1 - yl - methanone ; . Azepan - 1 - yl - ( 3 , 5 - dichloro - phenyl ) - methanone ; . 5. lO. lS. 20. 25. 30. 35. 40. 45. 50. 55. 60. 65. 34 Azepan - 1 - yl - biphenyl - 4 - yl - methanone ; Azepan - 1 - yl - ( 4 - chloro - phenyl ) - methanone ; 3 - Heptylcarbamoyl - bicyclo [ 2 .2 . 1 ] hept - 5 - ene - 2 - carboxylic acid ; Adamantan - 1 - yl - azep an - 1 - yl - methanone ; N , N - Dibenzyl - 3 , 4 - dimethoxy - benzamide ; N - Benzyl - N - isopropyl - 4 - nitro - benzamide ; N - [ 2 - ( 1H - lndol - 3 - yl ) - 1 - methyl - ethyl ] - 2 - ( 4 - i sobutyl - phenyl ) - propionamide ; N - tert - Butyl - 2 - ( 4 - isobutyl - phenyl ) - propionamide ; Adamantane - 1 - carboxylic acid ( 2 - acetyl - phenyl ) - amide ; N - ( 1 , 3 - Dioxo - 1 , 3 - dihydro - isoindol - 2 - ylmethyl ) - N - ( 4 - ﬁuoro - phenyl ) - benzamide ; ( Octahydro - quinolin - 1 - yl ) - phenyl - methanone ; ( 7 - Hydroxy - octahydro - quinolin - 1 - yl ) - phenyl - methanone ; N - ( 1 , 3 - Dioxo - 1 , 3 - dihydro - isoindol - 2 - ylmethyl ) - N - p - tolylbenzamide ; N , N - Dibenzyl - 4 - methyl - benzamide ; ( 2 - Chloro - phenyl ) - ( 2 - methyl - piperidin - 1 - yl ) - methanone ; [ 4 - Bromo - 3 - ( piperidine - 1 - sulfonyl ) - phenyl ] - piperidin - 1 - ylmethanone ; 2 - Chloro - N - ( 3 , 4 - dimethyl - phenyl ) - benzamide ; 1 - Azepan - 1 - yl - 2 - ( 3 , 3 - dimethyl - 3 , 4 - dihydro - 2H - isoquinolin - 1 - ylidene ) - ethanone ; N - Cyclohexyl4 - ( 2 , 4 - dichloro - phenoxy ) - butyramide ; N - Benzo [ 1 , 3 ] dioxol - 5 - yl - 2 - chloro - benzamide ; ( 4 - Benzyl - piperidin - 1 - yl ) - ( 2 - chloro - phenyl ) - methanone ; 2 - ( Benzothiazol - 2 - y1sulfanyl ) - N - cyc1ohexy1 - acetamide ; Cyclohexanecarboxy1ic acid ( 7 , 7 - dimethyl - 5 - oxo - 5 , 6 , 7 , 8 - tetrahydro - quinazolin - 2 - yl ) - amide ; 2 , 4 - Dichloro - N - ethyl - N - o - tolyl - benzamide ; ( 4 - Benzyl - piperidin - 1 - yl ) - ( 4 - ﬁuoro - phenyl ) - methanone ; N - Cyclohexyl4 - ( 2 , 4 - dichloro - phenoxy ) - N - methyl - butyramide ; 3 - [ 2 - ( 1 , 3 - Dioxo - 1 , 3 - dihydro - isoindol - 2 - yl ) - ethyl ] - adamantane - 1 - carboxylic acid ; Morpholin - 4 - yl - ( 3 - p - tolyl - adamantan - 1 - yl ) - methanone ; N - Benzyl - 2 , 4 - dich1oro - N - methyl - benzamide ; Thiophene - 2 - carboxy1ic acid dibenzy1amide ; Azepan - 1 - yl - ( 2 - bromo - phenyl ) - methanone ; ( 3 , 4 - Dichloro - phenyl ) - ( 4 - methyl - piperidin - 1 - yl ) - methanone ; N , N - Dibenzyl - 3 , 4 - dichloro - benzamide ; 4 - ( 2 , 4 - Dichloro - phenoxy ) - 1 - piperidin - 1 - y1 - butan - 1 - one ; N , N - Dibenzyl - 2 - ﬂuoro - benzamide ; ( 2 - Chl oro - phenyl ) - piperidin - 1 - yl - methanone ; 2 - Chloro - N - ( 3 - triﬂuoromethyl - phenyl ) - benzamide ; N - Benzyl - N - ethyl - 2 - phenyl - acetamide ; ( 3 , 4 - Dihydro - 2H - quinolin - 1 - yl ) - p - tolyl - methanone ; Thiophene - 2 - carboxylic acid benzyl - ethyl - amide ; N - Adamantan - 1 - yl - 2 - dib enzylamino - acetamide ; N - Cyclohexyl - 2 - ( 1 , 3 - dioxo - 1 , 3 - dihydro - isoindol - 2 - yl ) - 3 - phenyl - propionamide ; Thiophene - 2 - carboxylic acid cycloheptylamide ; N - Cyclohexyl - 3 - diethylsu1famoyl - 4 - methy1 - benzamide ; 4 - Benzoyl - N - methyl - N - phenyl - benzamide ; N - Benzyl - 2 - bromo - N - methyl - benzamide ; 2 - Chloro - N - methyl - N - pheny1 - benzamide ; 4 - Chloro - N - ethyl - N - o - tolyl - benzamide ; N - Benzyl - 4 , N - dimethyl - benzamide ; 2 - ( 4 - Ch10ro - 3 , 5 - dimethyl - phenoxy ) - N - cyclohexyl - N - methyl - acetamide ; N - Benzyl - 2 - bromo - N - isopropyl - benzamide ; 3 - ( 2 - Chloro - phenyl ) - N - cyclohexyl - N - methyl - acrylamide ; N - Phenyl - N - ( 2 , 2 , 5 - trimethyl - hex - 4 - enyl ) - acetamide ; N - m - Tolyl - N - ( 2 , 2 , 5 - trimethyl - hex - 4 - enyl ) - acetamide ; . US 7 , 50l , 405 B2. 35. ( 3 - Chloro - benzo [ b ] thiophen - 2 - yl ) - ( 4 - methyl - piperazin - 1 - yl ) - methanone ; . Adamantane - 1 - carboxylic acid ( 5 - methyl - pyridin - 2 - yl ) - amide ; . 3 - Bromo - N - [ 2 - methyl - 1 - ( 1 , 3 , 3 - trimethyl - 6 - aza - bicyclo [ 3 .2. l ] octane - 6 - carbonyl ) - butyl ] - benzamide ; . 4 - Chloro - N - [ 2 - methyl - 1 - ( 1 , 3 , 3 - trimethyl - 6 - aza - bicyclo [ 3 .2. 1 ] octane - 6 - carbonyl ) - butyl ] - benzamide ; . 4 - Methyl - N - [ 2 - methyl - 1 - ( 1 , 3 , 3 - trimethyl - 6 - aza - bicyclo [ 3 .2. 1 ] octane - 6 - carbonyl ) - butyl ] - benzamide ; Cyclohexanecarboxylic acid [ 2 - methyl - l - ( l , 3 , 3 - trim - . ethyl - 6 - aza - bicyclo [ 3.2.1 ] octane - 6 - carbonyl ) - butyl ] - amide ; . 3 - Cyclopentyl - N - [ 2 - methyl - 1 - ( 1 , 3 , 3 - trimethyl - 6 - aza - bicyclo [ 3.2.1 ] octane - 6 - carbonyl ) - butyl ] - propionamide ; . 2 - Chloro - N - [ 2 - ( 4 - ethyl - benzoylamino ) - ethyl ] - N - ( 4 - ﬂuorophenyl ) - benzamide ; . N - { 1 - Benzyl - 2 - [ 4 - ( 3 - cyclopentyl - propionyl ) - piperazin - 1 - yl ] - 2 - oxo - ethyl } - 3 - cyclopentyl - propionamide ; . N - Bicyclo [ 2.2.1 ] hept - 5 - en - 2 - ylmethyl - 3 - cyclopentyl - N - [ 2 - ( 1H - indol - 3 - yl ) - ethyl ] - propionamide ; . N - Bicyclo [ 2.2.1 ] hept - 5 - en - 2 - ylmethyl - 2 , 4 - dichloro - N - [ 2 - ( 1 H - indol - 3 - yl ) - ethyl ] - benzamide ; . Naphthalene - 2 - carboxylic acid thiophen - 3 - ylmethyl - amide ; . 3 , 4 , 5 - Trimethoxy - N - ( 4 - methyl - benzyl ) - N - [ 6 - ( pyridin - 2 - ylamino ) - hexyl ] - benzamide ; . 3 - Cyclopentyl - N - ( 4 - methyl - benzyl ) - N - [ 6 - ( pyridin - 2 - ylamino ) - hexyl ] - propionamide ; . N - ( 3 , 4 - Dimethoxy - benzy1 ) - 3 - methoxy - N - [ 6 - ( pyridin - 2 - ylamino ) - hexyl ] - benzamide ; . N , N - Dimethyl - 2 - [ 3 - ( 4 - nitro - phenyl ) - adamantan - 1 - yl ] - acetamide ; . Adamantane - 1 - carboxylic acid [ 4 - ( 1 , 3 - dioxo - 1 , 3 - dihydroisoindol - 2 - yl ) - buty1 ] - p - toly1 - amide ; . 2 - ( 1 , 3 - Dioxo - 1 , 3 - dihydro - isoindol - 2 - yl ) - 3 - methyl - N - ( 2 - tri - ﬁuoromethyl - phenyl ) - butyramide ; . 2 - ( 4 - Chloro - 2 - methyl - phenoxy ) - N - ( 2 - triﬁuoromethyl - phenyl ) - propionamide ; . 4 - ( 2 , 4 - Dichloro - phenoxy ) - 1 - [ 4 - ( 4 - ﬂuoro - phenyl ) - piperazin - 1 - yl ] - butan - 1 - one ; . ( 3 , 4 - Dihydro - 2H - quinolin - 1 - yl ) - [ 3 - ( piperidine - 1 - sulfonyl ) - phenyl ] - methanone ; . Acetic acid 4 - ( azepane - 1 - carbony1 ) - phenyl ester ; . N - Adamantan - 1 - ylmethyl - b enzamide ; . [ 3 - ( 4 - Nitro - phenyl ) - adamantan - 1 - yl ] - piperidin - 1 - yl - methanone ; . N - ( 1 , 1 - Dimethyl - hexyl ) - 2 - morpholin - 4 - yl - acetamide ; . Adamanty1 - 1 - carboxylic acid ( 2 - methoxy - ethyl ) - amide ; . N - ( 4 - Adamantan - 1 - yl - 2 - methyl - phenyl ) - ac etamide ; . 3 - p - Tolyl - adamantane - 1 - carboxylic acid ( 2 , 5 - dichloro - phenyl ) - amide ; . ( 3 - Chloro - adamantan - 1 - yl ) - pyrrolidin - 1 - yl - methanone ; . 2 - Amino - 5 - cyclohexylcarbamoyl - 4 - methy1 - thiophene - 3 - carboxylic acid ethyl ester ; . N - ( 2 - Chloro - phenyl ) - 2 - { 3 - [ ( 2 - chloro - phenylcarbamoyl ) - methyl ] - adamantan - 1 - yl } - acetamide ; . 3 - p - Tolyl - adamantane - 1 - carboxylic acid ( 2 , 4 - diﬁuoro - phenyl ) - amide ; . Adamantyl - 1 - carboxylic acid tert - butylamide ; . 2 - Adamantan - 1 - yl - N - tert - butyl - acetamide ; . N - Methyl - N - phenyl - 4 - ( pyrrolidine - 1 - sulfonyl ) - benzamide ; . N - ( 1 - Adamantan - 1 - yl - ethyl ) - 2 - ﬂuoro - benzamide ; . Adamantane - 1 - carboxylic acid [ 2 - ( 3 , 4 - dimethoxy - phenyl ) - . ( 2 - oxo - azepan - 3 - yl ) - . ethyl ] - amide ; Adamantane - l - carboxylic acid dimethylamide ; N - Benzyl - 4 - chloro - N - ( 1 - cyclopropyl - Vinyl ) - benzamide ; 3 , 5 - Dimethyl - adamantane - 1 - carboxylic acid benzylamide ; . N. 36. 2 , 4 - Dichloro - N - cyclohexyl - N - ( 2 - hydroxy - ethyl ) - benzamide ; . N - Adamantan - 1 - yl - 2 , 4 - dichloro - N - ethyl - benzamide ; . 2 - [ ( 3 - p - Toly1 - adamantane - 1 - carbonyl ) - amino ] - propionic acid methyl ester ; . N - Adamantan - l - yl - 3 - morpholin - 4 - yl - propionamide ; . 3 - p - Tolyl - adamantane - 1 - carboxylic acid isopropylamide ; . N - Adamantan - 1 - yl - 2 - b enzylamino - acetamide ; . N - Benzyl - 2 , 4 - dichloro - N - ( 1 - cyclopropyl - ethyl ) - 5 - methylbenzamide ; . 2 - [ ( Adamantane - l - carbonyl ) - amino ] - benzoic acid ethyl ester ; . N - Benzyl - N - isopropyl - 4 - methyl - 3 - nitro - benzamide ; . ( 3 , 4 - Dihydro - 2H - quinolin - 1 - yl ) - ( 2 - ﬂuoro - phenyl ) - methanone ; . N - Ethyl - 2 - ﬁuoro - N - phenyl - benzamide ; . 2 - Phenethyl - N - ( 2 - triﬁuoromethyl - phenyl ) - benzamide ; . 1 - ( 3 , 4 - Dihydro - 2H - quinolin - 1 - yl ) - 2 - o - tolyloxy - ethanone ; . 2 - ( 1 - Benzyl - 1H - imidazol - 2 - ylsulfanyl ) - N - cyclohexyl - acetamide ; . Cyclohexanecarboxylic acid ( 2 - propoxy - phenyl ) - amide ; . 2 - { 3 - [ 4 - ( 2 - Chloro - phenyl ) - piperazin - 1 - yl ] - 3 - oxo - propyl } - isoindole - 1 , 3 - dione ; . N - Cyclopentyl - 2 - ( 2 , 4 - dichloro - phenoxy ) - propionamide ; . Adamantane - 1 - carboxylic acid ( 2 - triﬂuoromethyl - phenyl ) - amide ; . ( 4 - Chloro - 3 - nitro - phenyl ) - ( 2 , 6 - dimethyl - pipe1idin - 1 - yl ) - methanone ; . 4 - ( 2 - Ethyl - phenyl ) - 4 - aza - tricyc1o [ 5 .2 .2 .026 ] undec - 8 - ene - 3 , 5 - dione ; . 2 - Phenyl - N - ( 2 - triﬂuoromethyl - phenyl ) - butyramide ; . N - Adamantan - 1 - yl - 4 - chloro - 2 - nitro - benzamide ; . 3 - p - Tolyl - adamantane - 1 - carboxylic acid ( 2 , 3 - dimethy1 - phenyl ) - amide ; . N - Benzyl - 3 - methyl4 - p - tolyl - butyramide ; . N - ( 2 - Cyclohex - 1 - enyl - ethyl ) - 2 - ( 1 , 3 - dioxo - 1 , 3 - dihydroisoindol - 2 - yl ) - propionamide ; . ( 4 - tert - Buty1 - phenyl ) - ( 3 , 4 - dihydro - 1 H - i soquinolin - 2 - yl ) - methanone ; . 2 - [ 1 - ( 4 - Chloro - benzenesulfonyl ) - 1H - benzoimidazol - 2 - ylsulfanyl ] - N - thiophen - 2 - ylmethyl - acetamide ; . 2 - Phenoxy - 1 - [ 4 - ( 2 - triﬂuoromethyl - benzyl ) - piperazin - 1 - yl ] - ethanone ; . Cyclohexanecarboxy1ic acid [ 5 - ( 2 - ﬂuoro - benzy1sulfanylmethyl ) - [ 1 , 3 , 4 ] thiadiazol - 2 - yl ] - amide ; . 4 - Methyl - 2 - phenyl - thiazole - 5 - carboxylic acid naphthalen - 1 - ylamide ; . 4 - F1uoro - N - [ 4 - ( 1 , 3 , 3 - trimethy1 - 6 - aza - bicyc1o [ 3.2.1 ] octane - 6 - carbonyl ) - phenyl ] - benzenesulfonamide ; . ( 3 - Methoxy - phenyl ) - ( 4 - o - tolyl - pip erazin - 1 - yl ) - methanone ; . N - Adamantan - 1 - yl - 3 - ( 1 , 3 - dioxo - 1 , 3 - dihydro - isoindol - 2 - yl ) - propionamide ; . N - Cycloocty1 - 2 - methoxy - 3 - methyl - benzamide ; . 2 - [ 4 - ( 2 , 3 , 3 - Trimethyl - 6 - aza - bicyclo [ 3.2.1 ] octane - 6 - carbonyl ) - phenyl ] - isoindole - 1 , 3 - dione ; . ( 2 , 3 - Diphenyl - quinoxalin - 6 - yl ) - ( 2 , 3 , 3 - trimethyl - 6 - aza - bicyclo [ 3 .2 . 1 ] oct - 6 - yl ) - methanone ; . Adamantan - 1 - y1 - ( 1 , 3 , 4 , 5 - tetrahydro - pyrido [ 4 , 3 - b ] indol - 2 - yl ) - methanone ; . N - { 4 - [ 1 - ( Naphthalene - 2 - sulfonyl ) - piperidin - 3 - yl ] - butyl } > - N ' - p - tolyl - oxalamide ; . N - Benzyl - N - ( 2 - oxo - 2 - pyrrolidin - 1 - yl - ethyl ) - benzenesulfonamide ; . ( 4 - Amino - phenyl ) - ( 1 , 3 , 3 - trimethyl - 6 - aza - bicyclo [ 3 .2 . 1 ] oct - 6 - yl ) - methanone ; . 1 - [ 4 - ( 4 - Fluoro - phenyl ) - piperazin - 1 - yl ] - 2 - ( 2 - isopropyl - 5 - methyl - phenoxy ) - ethanone ; . US 7 , 50l , 405 B2. 37. Adamantane - l - carboxylic acid benzyl - pyridin - 2 - yl - amide ; . Adamantan - 1 - yl - piperidin - 1 - yl - methanone ; . Adamantan - 1 - yl - pyrrolidin - 1 - yl - methanone ; . ( 3 , 4 - Dihydro - 2H - quinolin - 1 - yl ) - o - tolyl - methanone ; . Adamantyl - 1 - carboxylic acid benzylamide ; . Pyridine - 2 - carboxylic acid adamantan - 2 - ylamide ; . ( 3 - Chloro - adamantan - 1 - yl ) - piperidin - 1 - yl - methanone ; . Adamantan - 1 - yl - ( 4 - methyl - piperidin - 1 - yl ) - methanone ; . 2 - [ 3 - ( Azepane - 1 - carbonyl ) - phenyl ] - isoindole - 1 , 3 - dione ; . 2 - [ 3 - ( Piperidine - 1 - carbonyl ) - phenyl ] - isoindole - 1 , 3 - dione ; . 4 - ( Benzyl - methanesulfonyl - amino ) - N - furan - 2 - ylmethylbenzamide ; . ( 4 - Nitro - phenyl ) - ( 1 , 3 , 3 - trimethyl - 6 - aza - bicyclo [ 3.2.1 ] oct - 6 - yl ) - methanone ; . 1 - Cyclohexyl - 5 - oxo - pyrrolidine - 3 - carboxylic ( 4 - chloro - 3 - nitro - phenyl ) - amide ; . N - ( 2 - Chloro - phenyl ) - 2 - ( 2 - oxo - 2 - phenyl - ethylsulfanyl ) - acetamide ; . 3 - ( 4 - Hydroxy - phenyl ) - N - isochroman - 1 - ylmethyl - 3 - phenylpropionamide ; . ( 4 - Ethoxy - phenyl ) - ( 2 - methyl - pip eri din - 1 - yl ) - methanone ; . 1 - Cyclohexyl - 5 - oxo - pyrrolidine - 3 - carboxylic acid ( 3 - chloro - pheny1 ) - amide ; . N - [ 4 - ( Benzyl - isopropyl - sulfamoyl ) - phenyl ] - acetamide ; . N - ( 3 , 4 - Dimethyl - phenyl ) - N - [ 4 - ( piperidine - 1 - carbonyl ) - . acid. benzyl ] - methanesulfonamide ; . 2 - ( 5 - Phenyl - 1H - imidazol - 2 - ylsulfanyl ) - N - ( 1 , 1 , 3 , 3 - tetramethy1 - butyl ) - acetamide ; . 2 - ( Benzothiazo1 - 2 - ylsulfany1 ) - N - ( 1 , 1 , 3 , 3 - tetramethy1 - butyl ) - acetamide ; . 2 - ( Benzooxazol - 2 - ylsulfanyl ) - N - ( 1 , 1 , 3 , 3 - tetramethyl - butyl ) - acetamide ; . 2 - ( Naphtha1en - 2 - ylcarbamoylmethy1sulfanyl ) - N - ( 1 , 1 , 3 , 3 - tetramethyl - butyl ) - acetamide ; . Acetic acid 4 - ( 3 , 5 - dimethyl - pipe1idine - 1 - carbonyl ) - phenyl ester ; . ( 4 - Chloro - 3 - nitro - phenyl ) - ( 2 , 6 - dimethyl - piperidin - 1 - yl ) - methanone ; . [ 1 - ( 4 - Chloro - benzenesulfonyl ) - piperidin - 3 - yl ] - ( octahydroquinolin - 1 - yl ) - methanone ; . 2 , 4 - Dichloro - N - cyclohexyl - N - ( 2 - hydroxy - ethyl ) - benzamide ; . ( 4 - Fluoro - phenyl ) - ( 3 , 4 , 4a , 8a - tetrahydro - 2H - quinolin - 1 - yl ) - methanone ; . N - Adamantan - 1 - yl - 2 - ethoxy - acetamide ; . 2 - ( 2 - Oxo - 2 - phenothiazin - 10 - yl - ethyl ) - hexahydro - isoindole - 1 , 3 - dione ; . Adamantane - 1 - carboxylic acid ( tetrahydro - furan - 2 - ylmethy1 ) - amide ; . 2 - Bromo - N - cycloheptyl - benzamide ; . Bicyclo [ 2.2.1 ] hept - 2 - yl - [ 4 - ( 2 - ethoxy - phenyl ) - piperazin - 1 - yl ] - methanone ; . N - Furan - 2 - ylmethyl - 2 - phenyl - 2 - phenylsulfany1 - acetamide ; . Adamantane - 1 - carboxylic acid benzyl - methyl - amide ; . 1 - ( 3 , 4 - Dihydro - 2H - quinolin - 1 - yl ) - 3 - ( 4 - ﬂuoro - phenyl ) - propenone ; . Adamantan - 1 - yl - ( 2 , 6 - dimethyl - piperidin - 1 - yl ) - methanone ; . 4 - Methyl - N - homoadamantyl - 3 - yl - benzamide ; . ( 3 , 5 - Dimethyl - piperidin - 1 - yl ) - ( 3 - methyl - 4 - nitro - phenyl ) - methanone ; . Quinoline - 2 - carboxylic acid cyclooctylamide ; . Adamantane - 1 - carboxylic acid [ 2 - ( 2 , 4 - dimethoxy - phenyl ) - ethyl ] - amide ; . ( 3 , 4 - Dihydro - 1H - isoquinolin - 2 - yl ) - o - tolyl - methanone ; . ( 3 , 6 - Dichloro - benzo [ b ] thiophen - 2 - yl ) - ( 4 - methyl - piperazin - 1 - yl ) - methanone ; . 38. 3 - ( l - Benzyl - 1 H - imidazol - 2 - ylsulfanyl ) - N - cyclohexyl - propionamide ; Propionic acid 2 - amino - 4 - methyl - 5 - p - tolylcarbamoylthiophen - 3 - yl ester ; 5 2 - Cyclohexyl - N - ( 2 , 6 - dimethyl - phenyl ) - N - furan - 2 - ylmethyl - acetamide ; ( 3 - Methoxy - phenyl ) - ( 2 , 2 , 4 - trimethyl - 4 - phenyl - 3 , 4 - dihydro - 2H - quinolin - 1 - yl ) - methanone ; 1 - [ 4 - ( 2 , 3 , 3 - Trimethyl - 6 - aza - bicyclo [ 3.2.1 ] octane - 6 - carbonyl ) - phenyl ] - pyrrolidine - 2 , 5 - dione ; l - ( 3 , 4 - Dihydro - 2H - quinolin - l - yl ) - 2 - ( l - naphthalen - 1 - yl - 1H - tetrazol - 5 - ylsulfanyl ) - ethanone ; [ 4 - ( 2 , 3 - Dimethyl - phenyl ) - piperazin - 1 - yl ] - o - tolyl - methanone ; 15 ( 4 - Benzyl - piperidin - 1 - yl ) - ( 4 - methyl - 3 - nitro - phenyl ) - methanone ; N - ( 2 - Cyano - phenyl ) - 2 - ( 9 - ethyl - 9H - 1 , 3 , 4 , 9 - tetraaza - ﬁuoren - 2 - ylsulfanyl ) - acetamide ; N - ( 2 - Cyano - phenyl ) - 2 - ( 9 - methyl - 9H - 1 , 3 , 4 , 9 - tetraaza - ﬂuoren - 2 - ylsulfanyl ) - acetamide ; . lO. 20 1 - ( Thiophene - 2 - carbonyl ) - 2 , 3 - dihydro - 1H - quinolin - 4 - one ; . ( 3 - Chloro - 6 - nitro - benzo [ b ] thiophen - 2 - yl ) - piperidin - 1 - ylmethanone ; . ( 4 - Bromo - phenyl ) - ( 3 , 5 - dimethyl - piperidin - 1 - yl ) - metha - . 25 none ; . 2 - Morpholin - 4 - yl - N - ( 1 - phenyl - cyclopentylmethyl ) - acetamide ; . 9 - Oxo - 9H - ﬂuorene - 1 - carboxy1ic acid ( 3 - methy1 - buty1 ) - amide ; . 30 [ 4 - ( 2 , 5 - Dimethyl - pyrrol - 1 - yl ) - phenyl ] - ( 4 - methyl - piperidin - 1 - yl ) - methanone ; N - Cycloheptyl - 3 - diethylsulfamoyl - benzamide ; ( 4 - Methoxy - pheny1 ) - ( 3 - phenyl - piperidin - 1 - yl ) - methanone ; 3 - Amino - N - cyclohexyl - N - methy1 - benzamide ; . 35 N - Ethyl - 3 , 4 - dimethyl - N - phenyl - benzamide ; N - Benzyl - 3 , 4 , N - trimethyl - benzamide ; ( 4 - Fluoro - phenyl ) - ( 3 - phenyl - piperidin - 1 - yl ) - methanone ; . [ 4 - ( 2 , 3 - Dimethyl - phenyl ) - piperazin - 1 - yl ] - ( 3 - methoxy - phenyl ) - methanone ; . 40 Furan - 2 - carboxylic acid [ 4 - ( 4 - methyl - piperidine - 1 - sulfo - . nyl ) - phenyl ] - amide ; N - ( 2 - Cyclohex - 1 - enyl - ethyl ) - 2 - o - tolyloxy - acetamide ; 5 - ( 2 - Ch10ro - phenoxymethy1 ) - furan - 2 - carboxy1ic acid ( 1 - bicyclo [ 2.2.1 ] hept - 2 - yl - ethyl ) - amide ; . 45 3 - ( 2 - Chloro - phenyl ) - 1 - [ 4 - ( 2 , 3 - dimethyl - phenyl ) - piperazin - . 1 - yl ] - propenone ; . N - [ 3 - ( Azepane - 1 - carbonyl ) - phenyl ] - benzamide ; . [ 3 - ( Piperidine - 1 - carbonyl ) - pyrazol - 1 - yl ] - o - tolyl - methanone ; . 50 N - ( 1 - Phenyl - cyclopentylmethyl ) - 2 - piperidin - 1 - yl - propi - . onamide ; . 2 - Morpholin - 4 - yl - N - ( 1 - phenyl - cyclopentylmethyl ) - propi - . onamide ; . N - [ 4 - ( Azepane - 1 - sulfonyl ) - phenyl ] - 2 , 2 , 2 - triﬂuoro - aceta - . mide ; . 2 , 3 - Dihydro - benzo [ 1 , 4 ] dioxine - 6 - carboxylic acid ( 1 - ada - . mantan - 1 - yl - ethyl ) - amide ; . N - Adamantan - 1 - yl - 2 - ( 3 - methoxy - phenoxy ) - acetamide ; . 3 - Chloro - benzo [ b ] thiophene - 2 - carboxylic acid ( 2 - cyano - . ethyl ) - phenyl - amide ; . [ 4 - ( 4 - Nitro - benzyl ) - piperidin - 1 - yl ] - phenyl - methanone ; . [ 4 - ( 2 - Nitro - benzyl ) - piperidin - 1 - yl ] - phenyl - methanone ; . 3 - [ 5 - ( 4 - Fluoro - phenyl ) - ﬁ1ran - 2 - yl ] - 1 - ( 1 , 3 , 3 - trimethyl - 6 - . aza - bicyclo [ 3.2.1 ] oct - 6yl ) - propenone ; . 65 2 - ( 3 - Fluoro - benzoylamino ) - 4 - methyl - 5 - ( piperidine - 1 - car - . bonyl ) - thiophene - 3 - carboxylic acid methyl ester ; N - ( 2 - Ethyl - phenyl ) - 2 - ( 3 - methyl - piperidin - 1 - yl ) - acetamide ; . 55. 60. US 7 , 50l , 405 B2. 39. 2 - ( 2 - Methoxy - benzoylamino ) - 4 - methyl - 5 - ( piperidine - 1 - carbonyl ) - thiophene - 3 - carboxylic acid methyl ester ; 1 - Phenyl - cyclopentanecarboxylic acid ( 4 - phenyl - tetrahydro - pyran - 4 - y1methyl ) - amide ; 4 - ( 2 , 4 - Dichloro - phenoxy ) - 1 - ( 4 - phenyl - piperazin - 1 - yl ) - butan - l - one ; Naphthalene - 1 - carboxylic acid cycloheptylamide ; N - lndan - 5 - yl - 2 - methyl - 3 - nitro - benzamide ; N - Cyclohexyl - 3 - ( 2 2 , 2 - triﬂuoro - ethoxymethyl ) - benzamide ; 2 - Methoxy - N - ( 1 - phenyl - cyclopentylmethyl ) - benzamide ; [ 5 - ( 2 , 5 - Dichloro - phenoxymethyl ) - furan - 2 - yl ] - ( 2 , 6 - dimethyl - morpholin - 4 - yl ) - methanone ; [ 5 - ( 2 - Bromo - phenoxymethyl ) - furan - 2 - yl ] - ( 2 - methyl - piperidin - 1 - yl ) - methanone ; 5 - ( 2 - Methoxy - phenoxymethyl ) - furan - 2 - carboxylic cycloheptylamide ; ( 3 , 4 - Dihydro - 1H - isoquinolin - 2 - yl ) - [ 1 - ( 2 - nitro - benzenesulfonyl ) - piperidin - 3 - yl ] - methanone ; N - Cyclooctyl - 2 - ( 4 - methoxy - phenoxy ) - acetamide ; N - ( 2 , 3 - Dimethyl - phenyl ) - 4 - [ methyl - ( toluene - 4 - sufonyl ) - . acid. amino ] - butyramide ; . N - Phenyl - N - [ 4 - ( piperidine - 1 - carbonyl ) - benzyl ] - benzene - su1fonamide ; . N - [ 4 - ( 3 , 4 - Dihydro - 1H - isoquinoline - 2 - carbonyl ) - benzyl ] - N - ( 3 , 4 - dimethyl - phenyl ) - methanesulfonamide ; . 2 , 3 - Dihydro - benzo [ 1 , 4 ] dioxine - 2 - carboxylic acid bicyclo [ 2 .2. 1 ] hept - 2 - ylamide ; . 4 , 5 , 6 , 7 - Tetrahydro - benzo [ b ] thiophene - 3 - carboxylic cycloheptylamide ; . N - ( 2 - Azepan - 1 - yl - 2 - oxo - ethyl ) - N - benzyl - 4 - ﬂuoro - benzenesulfonamide ; . 1 - ( 2 , 6 - Dimethyl - morpholin - 4 - yl ) - 3 , 3 - diphenyl - propan - 1 - one ; . N - Bicyclo [ 2.2.1 ] hept - 2 - yl - 4 - morpho1in - 4 - ylmethy1 - benzamide ; . [ 3 - ( 2 - Chloro - 6 - nitro - phenoxy ) - phenyl ] - piperidin - 1 - ylmethanone ; . N - Adamantan - 1 - yl - 2 - ( 4 - methyl - quinolin - 2 - ylsulfanyl ) - acetamide ; . Cyclohexanecarboxylic acid ( 2 - phenylsulfanyl - phenyl ) - amide ; . ( 4 - Hydroxy - 4 - phenyl - octahydro - quinolin - 1 - yl ) - phenylmethanone ; . 3 - Cyclohexyl - N - ( 3 - phenyl - propyl ) - propionamide ; . 2 - [ 1 - ( 2 , 5 - Dimethyl - phenyl ) - 1H - tetrazol - 5 - yl sulfany1 ] - N - isopropyl - N - phenyl - acetamide ; . N - { 2 - [ 4 - ( 3 , 4 - Dihydro - 1H - isoquinoline - 2 - sulfonyl ) - phenyl ] - ethyl } - acetamide ; . N - Benzyl - N - [ 2 - oxo - 2 - ( 4 - phenyl - piperazin - 1 - yl ) - ethyl ] - benzenesu1fonamide ; . [ 4 - ( 2 - Chloro - 6 - nitro - phenoxy ) - phenyl ] - piperidin - 1 - ylmethanone ; . N - Cycloheptyl - 3 - phenyl - propionamide ; . ( 3 - Chloro - 6 - methyl - benzo [ b ] thiophen - 2 - yl ) - piperidin - 1 - ylmethanone ; . N - Cyclohepty1 - 2 , 4 - dimethoxy - benzamide ; . N - ( 3 - Chloro - phenyl ) - 2 - ( 8 , 1 1 , 1 1 - trimethyl - 3 , 4 , 6 - triaza - tricyclo [ 6.2.1.02 ' 7 ] undeca - 2 ( 7 ) , 3 , 5 - t1ien - 5 - ylsulfanyl ) - acetamide ; . N - ( 2 - Nitro - phenyl ) - 2 - ( 8 , 1 1 , 1 1 - trimethyl - 3 , 4 , 6 - triaza - tricyclo [ 6.2.1.027 ] undeca - 2 ( 7 ) , 3 , 5 - trien - 5 - ylsulfanyl ) - aceta - . acid. mide ; . N - Phenyl - 2 - ( 8 , 1 1 , 1 1 - trimethyl - 3 , 4 , 6 - triaza - tricyclo [ 6.2.1 .027 ] undeca - 2 ( 7 ) , 3 , 5 - trien - 5 - ylsulfanyl ) - acetamide ; . N - Ethyl - 3 - methyl - N - o - tolyl - b enzamide ; . 40 N - [ 5 - ( 2 , 4 - Dichloro - benzylsulfanyl ) - [ l , 3 , 4 ] thiadiazol - 2 - yl ] - 2 , 2 - dimethyl - propionamide ; 4 - Fluoro - N - [ 4 - ( 1 , 3 , 3 - trimethyl - 6 - aza - bicyclo [ 3.2.1 ] octane - 6 - carbony1 ) - pheny1 ] - benzenesulfonamide ; 5 4 - Bromo - 1 - ethyl - 1H - pyrazole - 3 - carboxylic acid ( 2 - methylsulfanyl - phenyl ) - amide ; 5 - Benzoyl - furan - 2 - carboxylic acid diisopropylamide ; 2 - [ 3 - ( Piperidine - 1 - carbonyl ) - phenyl ] - isoindole - 1 , 3 - dione ; N { 2 - [ 2 - ( 4 - Bromo - phenyl ) - 2 - oxo - ethylsulfanyl ] - benzothiazol - 6 - yl } - acetamide ; 2 - ( 6 - Amino - benzothiazol - 2 - ylsulfanyl ) - N - cyclohexyl - acetamide ; N - ( 2 - Cyclohexylcarbamoylmethylsulfanyl - benzothiazol - 6 - yl ) - 2 - methoxy - benzamide ; 15 Benzofuran - 2 - yl - ( 4 - phenyl - piperidin - 1 - yl ) - methanone ; 1 - ( 2 - Nitro - phenyl ) - piperidine - 3 - carboxylic acid diethylamide ; 1 - ( 4 - Nitro - phenyl ) - pipe1idine - 3 - carboxylic acid diethylamide ; 20 5 - Bromo - ﬁ1ran - 2 - carboxylic acid adamantan - 2 - ylamide ; 3 , 3 - Dimethyl - pentanedioic acid bis - [ ( 2 , 4 - diﬁuoro - phenyl ) - amide ] ; 2 - ( 3 - Bromo - benzylsu1fanyl ) - 1 - ( 4 - pheny1 - piperazin - 1 - y1 ) - ethanone ; 25 N - ( 2 - Azepan - 1 - yl - 2 - oxo - ethyl ) - N - benzyl - 4 - bromo - benzenesulfonamide ; 1 - ( 2 , 3 - Dihydro - indol - 1 - yl ) - 2 - p - tolylsulfanyl - ethanone ; [ 4 - ( 4 - Bromo - benzenesulfonyl ) - piperazin - 1 - yl ] - furan - 2 - yl - methanone ; 30 [ 5 - ( 2 - Bromo - phenoxymethyl ) - furan - 2 - yl ] - ( 2 , 6 - dimethylmorpholin - 4 - yl ) - methanone ; . lO. 5 - ( 2 - Ch10ro - phenoxymethy1 ) - furan - 2 - carboxy1ic acid diethylamide ; 5 - ( 2 - Bromo - phenoxymethy1 ) - furan - 2 - carboxy1ic acid 35 diethylamide ; 5 - ( 2 - Ch10ro - phenoxymethy1 ) - furan - 2 - carboxy1ic acid. methyl - phenyl - amide ; [ 5 - ( 2 - Chloro - phenoxymethyl ) - furan - 2 - yl ] - ( 4 - methyl - piperidin - 1 - yl ) - methanone ; . 40 [ 3 - ( 2 , 5 - Dichloro - phenoxymethyl ) - phenyl ] - pyrrolidin - 1 - ylmethanone ; . [ 5 - ( 4 - Ethoxy - phenoxymethyl ) - furan - 2 - yl ] - ( 4 - methyl - piperi din - 1 - yl ) - methanone ; . 3 - ( 1 , 3 - Dioxo - 1 , 3 - dihydro - isoindol - 2 - yl ) - N - ( 2 - methyl - cyclohexyl ) - propionamide ; . 3 - ( 3 , 4 - Dihydro - 2H - quinoline - 1 - carbonyl ) - N - phenyl - benzenesulfonamide ; . [ 3 - ( 2 , 3 - Dihydro - indole - 1 - sulfonyl ) - phenyl ] - ( 3 , 4 - dihydro - 2H - quinolin - 1 - yl ) - methanone ; . [ 3 - ( 2 , 5 - Dimethyl - pyrro1 - 1 - yl ) - pheny1 ] - ( 4 - methyl - piperidin - 1 - yl ) - methanone ; . N - Cyclohexyl - 3 - ( 2 - hydroxy - 4 - methyl - phenyl ) - 3 - phenylpropionamide ; . 55 2 - Diethylamino - N - ( 1 - phenyl - cyclopentylmethyl ) - propionamide ; . ( 6 - Fluoro - 2 - methyl - 3 , 4 - dihydro - 2H - quinolin - 1 - yl ) - ( 3 - trifluoromethyl - phenyl ) - methanone ; . ( 2 , 6 - Dimethyl - morpholin - 4 - yl ) - [ 4 - ( naphthalen - l - yloxymethyl ) - phenyl ] - methanone ; . N - Benzyl - 4 - bromo - N - ethyl - benzamide ; . ( 3 - Methyl - piperidin - 1 - yl ) - [ 4 - ( naphthalen - 1 - yloxymethyl ) - . 50. 60. phenyl ] - methanone ; . Azepan - 1 - yl - [ 5 - ( 2 - chloro - phenoxymethyl ) - furan - 2 - yl ] - methanone ; . ( 4 - Methyl - piperidin - 1 - yl ) - [ 4 - ( naphthalen - 1 - yloxymethyl ) - phenyl ] - methanone ; . 65. US 7 , 50l , 405 B2. 41. Azepan - l - yl - [ 5 - ( 2 , 4 - dichloro - phenoxymethyl ) - ﬁ1ran - 2 - yl ] - methanone ; . N - Cycloheptyl - 4 - ( 4 - methoxy - 2 - methyl - phenyl ) - butyramide ; . 2 - ( 4 - Benzothiazol - 2 - yl - piperazin - 1 - yl ) - N - cyclohexyl - acetamide ; . N - Cycloheptyl - 2 - ( 2 , 6 - dimethyl - phenoxy ) - acetamide ; . ( 3 , 4 - Dihydro - 2H - quinolin - 1 - yl ) - ( 3 - iodo - phenyl ) - methanone ; . N - Cycloheptyl - 3 - ( 2 , 2 , 2 - triﬂuoro - ethoxymethyl ) - benzamide ; . Azepan - 1 - yl - [ 4 - ( 2 - chloro - phenoxymethyl ) - phenyl ] - methanone ; . ( 2 , 6 - Dimethyl - morpholin - 4 - yl ) - [ 4 - ( naphthalen - 2 - yloxymethyl ) - phenyl ] - methanone ; . Azepan - 1 - yl - [ 3 - ( 4 - ethoxy - phenoxymethyl ) - phenyl ] - methanone ; . Benzo [ b ] thiophene - 3 - carboxylic acid ( 1 , 2 , 3 , 4 - tetrahydronaphthalen - 1 - yl ) - amide ; . 2 - ( 4 - Chloro - 2 - methyl - phenoxy ) - N - cycloheptyl - acetamide ; . 2 , 4 - Dichloro - N - cyclohexyl - N - methyl - benzamide ; . N - Cyclooctyl - 2 - p - tolyloxy - acetamide ; . ( 3 , 5 - Dimethyl - piperidin - 1 - y1 ) - ( 4 - methyl - 3 - nitro - phenyl ) - methanone ; . Biphenyl - 4 - yl - ( 2 , 6 - dimethyl - piperidin - 1 - yl ) - methanone ; . N - Cyclohexyl - 4 - ﬁuoro - N - methyl - benzamide ; . N - [ 4 - ( Azepane - 1 - carbonyl ) - phenyl ] - N - methyl - benzene - su1fonamide ; . N - Cyclohepty1 - 2 - ﬂuoro - benzamide ; . N - Cycloheptyl - 4 - methyl - benzamide ; . ( 3 - Methyl - piperidin - 1 - yl ) - p - tolyl - methanone ; . [ 2 - ( 3 , 4 - Dimethoxy - phenylcarbamoyl ) - piperidin - 1 - yl ] - acetic acid benzyl ester ; . N - [ 4 - ( 2 - Methyl - piperidine - 1 - sulfony1 ) - phenyl ] - acetamide ; . 2 - ( 2 , 4 - Dichloro - phenoxy ) - N - ( 2 - methyl - butyl ) - propionamide ; . [ 4 - ( 2 - Chloro - 6 - nitro - phenyl ) - piperazin - 1 - yl ] - ( 4 - methoxyphenyl ) - methanone ; . N - Cyclohexyl - 4 - ( 4 - methoxy - 3 - methyl - phenyl ) - butyramide ; . ( 3 - Chloro - 6 - methoxy - benzo [ b ] thiophen - 2 - yl ) - ( 3 , 4 - dihydro - 1H - isoquinolin - 2 - yl ) - methanone ; . 2 - ( 4 - Methy1 - benzylsulfany1 ) - 1 - piperidin - 1 - yl - ethanone ; . N - Cyclohexyl - N - [ ( 4 - phenyl - thiazol - 2 - ylcarbamoyl ) - methyl ] - benzamide ; . N - ( 2 - Azepan - 1 - yl - 2 - oxo - ethyl ) - N - ( 4 - isopropyl - phenyl ) - methanesulfonamide ; . N - Adamantan - 1 - yl - 3 - p - tolylsulfanyl - propionamide ; . 6 - ( 2 , 4 - Dichloro - phenylcarbamoyl ) - 3 , 4 - dimethyl - cyclohex - 3 - enecarboxylic acid ; . ( 4 - Buty1 - cyc1ohexyl ) - morpho1in - 4 - yl - methanone ; . ( 3 , 4 - Dichloro - phenyl ) - ( 3 , 4 - dihydro - 2H - quinolin - 1 - yl ) - methanone ; . N - ( 2 - Cyclohex - 1 - enyl - ethyl ) - 3 - methoxy - benzamide ; . N - Adamantan - 2 - yl - 3 - ( 1 , 5 - dimethyl - 1H - pyrazol - 4 - yl ) - acrylamide ; . N - Adamantan - 1 - yl - N - methy1 - 4 - ( 4 - nitro - pyrazol - 1 - ylmethyl ) - benzamide ; . 5 - ( 4 - Chloro - 3 , 5 - dimethyl - pyrazol - 1 - ylmethyl ) - furan - 2 - carboxylic acid adamantan - 2 - ylamide ; . 2 - ( 4 - Chloro - phenoxy ) - N - ( 2 - ﬁuoro - 5 - methyl - phenyl ) - 2 - methyl - propionamide ; . N - Adamantan - 1 - yl - 2 - ( 4 - chloro - 3 , 5 - dimethyl - phenoxy ) - ac - etamide ; . 2 - [ ( 3 - Carboxy - bicyclo [ 2.2. l ] heptane - 2 - carbonyl ) - amino ] - 5 , 6 - dihydro4H - cyclopenta [ b ] thiophene - 3 - carboxylic acid propyl ester ; . 42 2 - Adamantan - 1 - yl - N - [ l - ( 2 , 5 - dimethyl - phenyl ) - ethyl ] - ac - etamide ; 3 - Methyl - thiophene - 2 - carboxylic acid cyclooctylamide ; N - p - Tolyl - 2 - ( 8 , 1 1 , 1 1 - trimethyl - 3 , 4 , 6 - triaza - tricyc1o 5 [ 6 .2 .1 .027 ] undeca - 2 , 4 , 6 - trien - 5 - ylsulfanyl ) - propionamide ; Azepan - 1 - yl - [ 5 - ( 4 - chloro - 5 - methyl - 3 - nitro - pyrazol - 1 - ylmethyl ) - furan - 2 - yl ] - methanone ; N - Adamantan - 2 - yl - 3 - ( 4 - bromo - 3 - nitro - pyrazol - 1 - ylmethyl ) - benzamide ; N - Bicyclo [ 2.2. l ] hept - 2 - yl - 2 - chloro - benzamide ; [ 5 - ( 3 - Chloro - phenoxymethyl ) - furan - 2 - yl ] - piperidin - 1 - ylmethanone ; 1 - ( 4 - Ethyl - benzoyl ) - 6 - methoxy - 2 - methyl - 2 , 3 - dihydro - 1 H - quinolin - 4 - one ; 6 - Fluoro - 2 - methyl - 1 - { 3 - [ 4 - ( propane - 1 - sulfonyl ) - phenoxymethyl ] - benzoyl } - 2 , 3 - dihydro - 1H - quinolin - 4 - one ; N - Cycloheptyl - 2 - ( naphthalen - 1 - yloxy ) - acetamide ; N - Cyclohexyl - 4 - o - tolyloxy - butyramide ; 20 ( 2 - Benzylsulfanyl - phenyl ) - morpholin - 4 - yl - methanone ; ( 2 - Chloro - 5 , 6 - diﬁuoro - 3 - methyl - phenyl ) - ( 4 - methyl - piperidin - 1 - yl ) - methanone ; ( 3 - Bromo - phenyl ) - [ 4 - ( 4 - chloro - 2 - nitro - phenyl ) - piperazin - 1 - yl ] - methanone ; 25 2 - Bromo - N - ( 1 , 1 , 3 , 3 - tetramethyl - butyl ) - benzamide ; N - Adamantan - 1 - yl - 2 - ( 2 - benzoyl - 5 - methoxy - phenoxy ) - acetamide ; N - Cyclohexyl - 3 - methyl - 4 - p - tolyl - butyramide ; [ 5 - ( 4 - Methyl - 2 - nitro - phenoxymethyl ) - furan - 2 - yl ] - thiomorpholin - 4 - yl - methanone ; [ 5 - ( 2 , 5 - Dichloro - phenoxymethyl ) - furan - 2 - yl ] - thiomorpholin - 4 - yl - methanone ; 5 - ( 4 - Ch10ro - 2 - nitro - phenoxymethy1 ) - furan - 2 - carboxylic acid adamantan - 1 - ylamide ; 35 4 , 5 , 6 , 7 - Tetrahydro - benzo [ b ] thiophene - 3 - carboxylic cyclohexylamide ; 4 - Chloro - 1 , 5 - dimethyl - 1H - pyrazole - 3 - carboxylic acid adamantan - 1 - yl - methyl - amide ; 4 - ( 4 - Methoxy - 3 - methyl - phenyl ) - N - ( 2 - methyl - cyclohexyl ) - butyramide ; 3 - Benzo [ 1 , 3 ] dioxol - 5 - yl - 1 - ( 3 , 4 - dihydro - 1H - isoquinolin - 2 - yl ) - propenone ; N - Bicyclo [ 2.2.1 ] hept - 2 - yl - 3 - phenylsu1fanyl - propionamide ; Azepan - 1 - yl - [ 5 - ( 2 - nitro - phenoxymethyl ) - furan - 2 - yl ] - methanone ; N - Benzyl - 2 - ( 4 - chloro - phenylsulfanyl ) - N - methyl - acetamide ; 1 - ( 4 - Benzyl - piperidin - 1 - yl ) - 2 - benzylsulfanyl - ethanone ; 2 - ( 4 - tert - Butyl - phenoxy ) - 1 - ( 4 - ethyl - piperazin - 1 - yl ) - ethanone ; [ 4 - ( 4 - Ethoxy - phenoxymethyl ) - phenyl ] - ( 4 - methyl - piperidin - 1 - yl ) - methanone ; 5 - ( 4 - Bromo - 3 , 5 - dimethyl - pyrazol - 1 - y1methyl ) - furan - 2 - carboxylic acid adamantan - 2 - ylamide ; 55 1 - Azepan - 1 - yl - 3 - ( 4 - chloro - phenylsulfanyl ) - propan - 1 - one ; N - Bicyclo [ 2.2.1 ] hept - 2 - yl - 2 - ( 2 - chloro - benzylsulfanyl ) - acetamide ; 2 - ( 2 - Methy1 - benzy1sulfany1 ) - 1 - ( 4 - phenyl - piperazin - 1 - yl ) - ethanone ; 60 N - [ 2 - ( 1 - Benzo [ 1 , 3 ] dioxol - 5 - yl - 3 - furan - 2 - yl - 3 - oxo - propylsulfanyl ) - phenyl ] - acetamide ; ( 3 , 5 - Dimethyl - piperidin - 1 - yl ) - ( 3 - iodo - phenyl ) - methanone ; [ 5 - ( 2 - Bromo - phenoxymethyl ) - furan - 2 - yl ] - ( 6 - ﬂuoro - 2 - methyl - 3 , 4 - dihydro - 2H - quinolin - 1 - yl ) - methanone ; 65 N - Benzyl - N - cyclohex - l - enyl - isonicotinamide ; 1 - [ 4 - ( 4 - Fluoro - phenyl ) - piperazin - 1 - yl ] - 2 - ( 2 - methyl - benzylsulfanyl ) - ethanone ; . lO. lS. 30. acid. 40. 45. 50. US 7 , 50l , 405 B2. 43. 2 - ( 2 - Bromo - 4 - methyl - phenoxy ) - N - ( 2 - cyclohex - 1 - enylethyl ) - acetamide ; . 2 - [ 5 - ( 2 - Hydroxy - phenyl ) - [ 1 , 3 , 4 ] oxadiazol - 2 - ylsulfanyl ] - 1 - piperidin - 1 - yl - ethanone ; . 5 - ( 4 - Nitro - pyrazol - 1 - ylmethyl ) - furan - 2 - carboxylic acid adamantan - 2 - ylamide ; . 3 - Benzo [ 1 , 3 ] dioxol - 5 - yl - 3 - ( 2 - methoxy - phenyl ) - 1 - pyrrolidin - 1 - yl - propan - 1 - one ; . N - Adamantan - 2 - yl - 3 , 4 - dichloro - benzamide ; . Benzo [ b ] thiophen - 3 - yl - ( 6 - ﬁuoro - 2 - methyl - 3 , 4 - dihydro - 2H - quinolin - l - yl ) - methanone ; . 2 - Adamantan - 1 - yl - 1 - ( 3 , 4 - dihydro - 1H - isoquinolin - 2 - yl ) - ethanone ; . 4 , 5 , 6 , 7 - Tetrahydro - benzo [ b ] thiophene - 3 - carboxylic ( 2 - cyclohex - 1 - enyl - ethyl ) - amide ; . Benzo [ b ] thiophene - 3 - carboxylic acid ( 3 , 3 , 5 - trimethyl - cyclohexyl ) - amide ; . 2 - ( 2 , 6 - Dimethyl - phenoxy ) - N - ( 2 - isopropyl - phenyl ) - acetamide ; . 4 - Bromo - N - [ 3 - ( piperidine - 1 - carbonyl ) - phenyl ] - benzamide ; . N - Benzo [ 1 , 3 ] dioxol - 5 - ylmethyl - 2 - ( 2 - cyano - phenyl sulfanyl ) - benzamide ; . N - Adamantan - 1 - yl - 2 - ( naphthalen - 2 - yloxy ) - acetamide ; . [ 4 - ( 4 - Chloro - phenylsulfanylmethyl ) - phenyl ] - morpholin - 4 - yl - methanone ; . Thiophene - 2 - carboxylic acid ( 3 , 3 , 5 - trimethyl - cyclohexyl ) - amide ; . Benzo [ 1 , 3 ] dioxol - 5 - yl - ( 3 , 4 - dihydro - 2H - quinolin - 1 - yl ) - methanone ; . 3 - Chloro - benzo [ b ] thiophene - 2 - carboxylic acid cyclooctylamide ; . 2 - [ 2 - Morpholin - 4 - yl - 1 - ( 4 - nitro - benzyl ) - 2 - oxo - ethyl ] - isoindole - 1 , 3 - dione ; . 2 - Hydroxy - 4 , 4 - dimethyl - 6 - oxo - cyclohex - 1 - enecarboxy1ic acid phenylamide ; . ( 2 , 4 - Dichloro - pheny1 ) - ( 2 , 6 - dimethy1 - piperidin - 1 - y1 ) - methanone ; . Adamantane - 1 - carboxylic acid furan - 2 - ylmethy1 - p - tolylamide ; . Azocan - 1 - yl - ( 4 - tert - butyl - phenyl ) - methanone ; . 3 - Chloro - benzo [ b ] thiophene - 2 - carboxylic acid benzyl - methyl - amide ; . Adamantane - 1 - carboxylic acid ( 2 - ﬂuoro - phenyl ) - amide ; . 2 - ( Piperidine - 1 - carbonyl ) - 5 - piperidin - 1 - yl - oxazo1e - 4 - carbonitri1e ; . N - ( 4 , 6 - Dimethyl - 5 - nitro - pyridin - 3 - yl ) - benzamide ; . Adamantan - 1 - yl - [ 4 - ( 2 - methoxy - phenyl ) - piperazin - 1 - yl ] - methanone ; . ( 2 - Methyl - piperidin - 1 - yl ) - o - tolyl - methanone ; . N - Benzyl - 4 - chloro - N - isopropyl - 3 - nitro - benzamide ; . N - ( 3 - Hexylsulfanyl - [ 1 , 2 , 4 ] thiadiazol - 5 - yl ) - 3 - methyl - butyramide ; . 4 , N - Dimethyl - N - [ 4 - ( piperidine - 1 - carbonyl ) - phenyl ] - benzenesulfonamide ; . Azepan - 1 - yl - ( 5 - tert - butyl - 2H - pyrazol - 3 - yl ) - methanone ; . 2 - Amino - 4 - methyl - 5 - ( piperidine - 1 - carbonyl ) - thiophene - 3 - carboxylic acid ethyl ester ; . 5 - Methyl - furan - 2 - carboxylic acid ( 1 - adamantan - 1 - yl - ethyl ) - amide ; . ( 3 - Chloro - 6 - methyl - benzo [ b ] thiophen - 2 - yl ) - ( 3 , 4 - dihydro - 1H - isoquinolin - 2 - yl ) - methanone ; . N - Adamantan - 1 - yl - 2 - tri ﬁuoromethyl - b enzamide ; . ( 3 - Bromo - phenyl ) - ( 2 , 2 , 4 - trimethyl - 4 - phenyl - 3 , 4 - dihydro - 2H - quinolin - 1 - yl ) - methanone ; . Benzo [ 1 , 3 ] dioxole - 5 - carboxylic acid dipropylamide ; . N - ( 3 , 3 - Diphenyl - propyl ) - 4 - methoxy - benzamide ; . acid. 44 [ 4 - ( 2 - Chloro - 6 - nitro - phenyl ) - piperazin - 1 - yl ] - p - tolyl - methanone ; Furan - 2 - yl - [ 4 - ( toluene - 4 - sulfonyl ) - piperazin - 1 - yl ] - methanone ; 5 3 - ( 2 - Chloro - 6 - ﬂuoro - phenyl ) - 1 - ( 3 , 4 - dihydro - 2H - quinolin - l - yl ) - propenone ; 2 - Chloro - N - cycloheptyl - benzamide ; 1 - [ 4 - ( 4 - Nitro - phenyl ) - piperazin - 1 - yl ] - 3 - phenyl - propan - 1 - one ; 10 ( 3 , 4 - Dihydro - 1H - isoquinolin - 2 - yl ) - ( 3 , 4 - dimethyl - phenyl ) - methanone ; ( 1 - Adamantan - 1 - yl - 4 - bromo - 1H - pyrazol - 3 - yl ) - morpholin - 4 - yl - methanone ; 2 - Phenyl - cyclopropanecarboxylic acid cyclooctylamide ; 15 3 - [ 4 - ( 2 - Ethoxy - phenyl ) - piperazine - 1 - carbonyl ] - isochromen - 1 - one ; [ 3 - ( 4 - Bromo - pyrazol - 1 - ylmethyl ) - phenyl ] - ( 4 - methyl - piperi din - 1 - yl ) - methanone ; 2 - Azepan - 1 - yl - N - biphenyl - 2 - yl - acetamide ; 20 N - [ 5 - ( 3 , 4 - Dimethoxy - benzyl ) - [ 1 , 3 , 4 ] thiadiazol - 2 - yl ] - 3 - methyl - butyramide ; Adamantan - 1 - yl - ( 4 - phenyl - piperidin - 1 - yl ) - methanone ; N - ( 2 - Azepan - 1 - yl - 2 - oxo - ethyl ) - N - ( 4 - ethoxy - phenyl ) - 4 - methylsulfanyl - benzenesulfonamide ; 25 1 - Adamantan - 1 - yl - 4 - bromo - 1H - pyrazole - 3 - carboxylic acid diethylamide ; ( 6 - Fluoro - 2 - methyl - 3 , 4 - dihydro - 2H - quinolin - 1 - yl ) - ( 2 - ﬂuoro - phenyl ) - methanone ; 3 - [ 4 - ( 2 , 3 - Dimethy1 - phenyl ) - piperazine - 1 - carbony1 ] - isoch - 30 romen - 1 - one ; N - Cyclooctyl - 2 - ( 2 - methoxy - phenoxy ) - acetamide ; N - Cyclohexyl - N - methyl - 2 - nitro - benzamide ; Adamantane - 1 - carboxylic acid ( 1 , 1 - dioxo - tetrahydrothiophen - 3 - yl ) - amide ; 35 N - Adamantan - 2 - yl - 2 - ( 4 - chloro - phenyl ) - acetamide ; ( 2 , 4 - Dichloro - phenyl ) - ( 3 - methyl - piperidin - 1 - yl ) - methanone ; 2 - ( 4 - tert - Butyl - phenoxy ) - N - cyclooctyl - acetamide ; ( 4 - Hydroxy - 4 - phenyl - octahydro - quinolin - 1 - y1 ) - pheny1 - methanone ; ( 2 - Chloro - phenyl ) - ( 2 - methyl - piperidin - 1 - yl ) - methanone ; ( 10 , 1 1 - Dihydro - dibenzo [ b , f ] azepin - 5 - yl ) - ( 2 - methoxy - phenyl ) - methanone ; ( 3 - Chloro - phenyl ) - ( 2 - methyl - piperidin - 1 - yl ) - methanone ; 45 ( 3 - Chloro - 6 - nitro - benzo [ b ] thiophen - 2 - yl ) - ( 3 - methyl - piperidin - 1 - yl ) - methanone ; ( 2 , 5 - Dichloro - phenyl ) - ( 4 - methyl - piperidin - 1 - yl ) - methanone ; N - [ 5 - ( 3 , 4 - Dichloro - benzyl ) - [ 1 , 3 , 4 ] thiadiazol - 2 - yl ] - 2 , 2 - dimethyl - propionamide ; 4 - ( 4 - Chloro - 2 - methyl - phenoxy ) - 1 - ( 3 , 4 - dihydro - 2H - quinolin - 1 - yl ) - butan - 1 - one ; ( 3 , 4 - Dichloro - pheny1 ) - [ 4 - ( 2 , 3 - dimethyl - phenyl ) - piperazin - 1 - yl ] - methanone ; 55 Cyclooctanecarboxylic acid [ 1 - ( naphthalene - 2 - sulfonyl ) - pyrrolidin - 2 - yl ] - amide ; 1 - Butyl - pyrrolidine - 2 - carboxylic acid benzo [ 1 , 3 ] dioxol - 4 - ylamide ; 5 - Methyl - furan - 2 - carboxylic acid dibenzylamide ; 60 ( 3 , 4 - Dihydro - 2H - quinolin - 1 - yl ) - [ 3 - ( 4 - phenyl - piperazine - 1 - sulfonyl ) - phenyl ] - methanone ; Bicyclo [ 2.2.1 ] hept - 2 - yl - [ 4 - ( 2 , 3 - dimethyl - phenyl ) - piperazin - 1 - yl ] - methanone ; N - Adamantan - 1 - yl - 2 - benzoyl - benzamide ; 65 [ 5 - ( 2 - Chloro - phenoxymethyl ) - furan - 2 - yl ] - ( 3 - methyl - piperidin - 1 - yl ) - methanone ; ( 3 , 5 - Dimethyl - piperidin - 1 - yl ) - ( 2 - iodo - phenyl ) - methanone ; . 40. 50. US 7 , 50l , 405 B2. 45 46 l - Benzenesulfonyl - pyrrolidine - 2 - carboxylic acid cycloocty - 2 - [ ( Adamantane - 1 - carbonyl ) - amino ] - 3 - ( lH - indol - 3 - yl ) - lamide ; propionic acid methyl ester ; ( 3 , 4 - Dimethoxy - phenyl ) - ( 6 - ﬁuoro - 2 - methyl - 3 , 4 - dihydro - 2 - ( 5 , 6 - Dimethyl - 4 - oxo - 3 , 4 - dihydro - thieno [ 2 , 3 - d ] pyrimi - 2H - quinolin - 1 - yl ) - methanone ; din - 2 - ylsulfanyl ) - N - furan - 2 - ylmethyl - acetamide ; 3 - ( 2 , 6 - Dichloro - phenyl ) - 1 - ( 2 - ethyl - piperidin - 1 - yl ) - prope - 5 N - Allyl - 2 - ( 5 , 6 - dimethyl - 4 - oxo - 3 , 4 - dihydro - thieno [ 2 , 3 - d ] none ; pyrimidin - 2 - ylsulfanyl ) - acetamide ; N - ( 3 , 4 - Diﬁuoro - phenyl ) - 2 , 6 - diﬂuoro - benzamide ; N - Adamantan - 1 - yl - 2 - ( 5 , 6 , 7 , 8 - tetrahydro - benzo [ 4 , 5 ] thieno 2 , 6 - Diﬂuoro - N - naphthalen - 1 - yl - benzamide ; [ 2 , 3 - d ] pyrimidin - 4 - ylsulfanyl ) - acetamide ; ( 4 - Chloro - phenyl ) - ( 3 , 5 - dimethyl - piperidin - 1 - yl ) - metha - 1 - ( 3 , 4 - Dihydro - 2H - quinoline - 1 - carbonyl ) - 4 , 7 , 7 - trimethylnone ; 10 2 - oxa - bicyclo [ 2.2.1 ] heptan - 3 - one ; N - [ 4 - ( 2 , 6 - Dimethyl - piperidine - l - carbonyl ) - phenyl ] - 2 - 1 - ( 3 , 4 - Dihydro - 1H - isoquinoline - 2 - carbonyl ) - 4 , 7 , 7 - trim - ( naphthalen - 2 - yloxy ) - acetamide ; ethyl - 2 - oxa - bicyclo [ 2.2.1 ] heptan - 3 - one ; ( 2 - Chloro - phenyl ) - ( 3 - methyl - piperidin - 1 - yl ) - methanone ; Azepan - 1 - yl - ( 6 , 7 - dimethyl - 4 - oxa - tricyclo [ 4 .3 .0.03 7 ] non - 3 - N { 2 - [ 4 - ( Piperidine - 1 - sulfonyl ) - phenyl ] - ethyl } - acetamide ; yl ) - methanone ; N - Biphenyl - 2 - yl - 2 - ( pyridin - 2 - ylsulfanyl ) - acetamide ; 15 2 , 5 - Dimethyl - furan - 3 - carboxylic acid ( 1 - adamantan - 1 - ylAzepan - 1 - yl - [ 5 - ( 4 - chloro - 3 , 5 - dimethyl - pyrazol - 1 - ylm - ethyl ) - amide ; ethyl ) - furan - 2 - yl ] - methanone ; 1 - Cyclohexyl - 5 - oxo - pyrrolidine - 3 - carboxylic acid ( 3 - cyAcetic acid 4 - ( 4 - methyl - piperidine - 1 - carbonyl ) - phenyl ano - 4 , 5 , 6 , 7 - tetrahydro - benzo [ b ] thiophen - 2 - yl ) - amide ; ester ; 6 - ( 2 , 4 - Dichloro - phenylcarbamoyl ) - 3 , 4 - dimethyl - cyclohexAcetic acid 4 - ( 4 - benzyl - piperidine - 1 - carbonyl ) - phenyl ester ; 20 3 - enecarboxylic acid ; Benzo [ 1 , 3 ] dioxole - 5 - carboxylic acid cycloheptylamide ; 2 - ( 2 - Cyano - phenylsulfanyl ) - N - cyclopentyl - benzamide ; 2 - ( 2 , 4 - Dimethyl - phenoxy ) - 1 - ( 6 - ﬁuoro - 2 - methyl - 3 , 4 - dihy - [ 5 - ( 2 - Methoxy - 4 - propyl - phenoxymethyl ) - furan - 2 - yl ] - ( 3 - dro - 2H - quinolin - 1 - yl ) - ethanone ; methyl - piperidin - 1 - yl ) - methanone ; Acetic acid 4 - ( 3 , 4 - dihydro - 2H - quinoline - 1 - carbonyl ) - phe - ( 4 - tert - Butyl - phenyl ) - ( 3 , 5 - dimethyl - piperidin - 1 - yl ) - methanyl ester ; 25 none ; Azepan - 1 - yl - ( 3 , 5 - dibromo - phenyl ) - methanone ; [ 4 - ( 2 - Methoxy - naphthalen - 1 - ylmethyl ) - piperazin - 1 - yl ] - ( 4 - ( 3 , 5 - Dibromo - phenyl ) - [ 4 - ( 2 - methoxy - phenyl ) - piperazin - 1 - methoxy - phenyl ) - methanone ; yl ] - methanone ; ( 3 , 4 - Dichloro - pheny1 ) - ( 3 , 5 - dimethyl - piperidin - 1 - y1 ) - metha - N - Cycloocty1 - 4 - isopropyl - benzamide ; none ; N - Cyclooctyl - 2 - ( 4 - methoxy - phenyl ) - ac etamide ; 3 0 ( 4 - Ethoxy - phenyl ) - ( 4 - methyl - piperidin - 1 - yl ) - methanone ; ( 4 - tert - Butyl - piperidin - 1 - yl ) - phenyl - methanone ; 2 - Phenethyl - N - ( tetrahydro - furan - 2 - ylmethyl ) - b enzamide ; N - ( 4 - tert - Butyl - 3 - nitro - phenyl ) - acetamide ; N - Cycloheptyl - 2 - phenoxy - benzamide ; ( 2 , 6 - Dimethyl - piperidin - 1 - y1 ) - [ 5 - ( 2 , 3 , 5 , 6 - tetraﬂuoro - phe - Adamantane - 1 - carboxylic acid ( 2 - ethoxy - phenyl ) - amide ; n0Xymethy1 ) - ﬁJran - 2 - y1 ] - methan0ne ; N - Adamantan - 2 - yl - 2 - o - toly1oxy - acetamide ; 2 - ( 4 - Chloro - 3 5 - dimethyl - phenoxy ) - N - cyclohexyl - N - me - 35 ( 2 - Chloro - phenyl ) - ( 3 , 5 - dimethyl - piperidin - 1 - yl ) - methathyl - acetamide ; none ; N - Cyclohexyl - 3 - ( 1 , 3 - dioxo - 1 , 3 - dihydro - isoindol - 2 - yl ) - N - 1 - Morpholin - 4 - yl - 2 - [ 3 - ( 4 - nitro - phenyl ) - adamantan - 1 - yl ] - methyl - prop1onam1de ; ethanone ; 2 - ( 4 - Chloro - 3 - methyl - phenoxy ) - N - cyclohexyl - N - methyl - 2 - Dimethylamino - N - ( 2 - nitro - phenyl ) - benzamide ; acetam1de ; . . 1 40 N - Benzyl - 2 - ( 4 , 4 , 6 - trimethyl - 1 - p - tolyl - 1 , 4 - dihydro - pyrimi - N - Cyclopentyl - 3 - ( 3 , 4 - d1hydro - 2H - qu1nol1ne - 1 - carbonyl ) - din - 2 - ylsulfanyl ) - acetamide ; . benzenesulfonamide ; . . . . . ( 3 , 4 - Dihydro - lH - iS0quinolin - 2 - y1 ) ' ( 3 - dimethylamin0 - Phe - [ 4§éfﬁ3$terp - phenoxy ) - pheny1 ] - ( 2 - ethy1 - p1per1d1n - 1 _y1 ) _. n l - methanone ; . . . 3 - C ; c ) lohexylcarbamoyl - bicyclo [ 2 .2. 1 ] hept - 5 - ene - 2 - car - 45 1 - ( ( : lI ; E ; h10ro - benzoyl ) - 2 , 3 - d1hydro - 1H - benzo [ g ] qu1nol1n - 4 - . box lic acid iso ro lester ' . . . 1 - ( 3 , 4. yDihydro - 1 FT - is£guinoliﬁ - 2 - yl ) - 2 - ( 2 - methoxy - phe - 2 - [ 2 ( ; Ai1 : 11anq : 1 } 1l§n : S - t ; carbonyl ) - am1no ] - 3 - phenyl - prop1on1c N_1 ] 13yl ) - et1l1a\1I1_one ; 1 h _1_ l - b ' d . [ Benzyl - ( 4 - nitro - behzoyl ) - amino ] - acetic acid ethyl ester ; 11 ( Te1r11123 h cyc 0 ex eny. enzam1 e , . 9 - Oxo - 9H - ﬂuorene - 3 - carboxylic acid methyl - ( 4 - nitro - phe - 1 1...1.1111111111. , 1111111111_. - . - MM N - 6Ad : ilna111 ( i : ﬁ - T - yl - 2 - ( 1 - pheﬁyl - 1H - tetrazol - 5 - ylsulfanyl ) - Adamantane - 1 - carboxylic acid [ 2 - ( 4 - methoxy - phenyl ) - acetamide ; ethyl ] - am1de ; . m. 0. ( 3 , 4 - Dihydro - 2H - quinolin - 1 - yl ) - [ 4 - ( morpholine - 4 - sulfo - ( 10=1 1 - D1hydro - d1benzo [ b , f ] azep1n - 5 - yl ) - ( 4 - ﬂuoro - phenyl ) - phenyl ] - methanone ; 55 nyl ) - methanone ; ( 3 , 4 - Dihydro - 2H - quinolin - 1 - yl ) - [ 4 - ( pyrrolidine - 1 - sulfo - 2 - Benzylsulfanyl - N - [ 2 - ( 2 - methoxy - phenoxy ) - ethyl ] - acetanyl ) - phenyl ] - methanone ; m1de ; . . ( 3 , 4 - Dihydro - 2H - quinolin - 1 - yl ) - [ 1 - ( thiophene - 2 - su1fonyl ) - N - Adamantan - 1 - y1 - 2 - ( 2 - 0X0 - 4 - pheny1 - pyrr0hdm - 1 - y1 ) - aCpiperi din - 4 - yl ] - methanone ; etam1de ; ( 1 - Benzenesulfonyl - piperidin - 3 - yl ) - ( 3 , 4 - dihydro - 1H - iso - 60 2 - Bromo - N - tricyclo [ 3.2.1.024 ] oct - 6 - ylmethyl - benzamide ; quinolin - 2 - yl ) - methanone ; Adamantane - 1 - carboxylic acid ( 2 , 6 - dimethoxy - pyrimidin - 6 , 7 - Dimethyl - 4 - oxa - tricyclo [ 4.3.0.037 ] nonane - 3 - carboxylic 4 - y1 ) - amide ; acid cyclohexy1amide ; Hexanedioic acid ( 2 , 7 , 7 - trimethyl - bicyclo [ 2.2.1 ] hept - 1 - y1 ) - 6 , 7 - Dimethyl - 4 - oxa - tricyclo [ 4 .3 .0.03 7 ] nonane - 3 - carboxylic amide ( 1 , 7 , 7 - trimethyl - bicyclo [ 2.2.1 ] hept - 2 - yl ) - amide ; acid ( 2 - chloro - phenyl ) - amide ; 65 2 - Chloro - N - ( 2 - cyclohexyl - ethyl ) - benzamide ; ( 6 , 7 - Dimethyl - 4 - oxa - tricyclo [ 4 .3 .0.03 7 ] non - 3 - yl ) - piperi - 2 - [ 3 - ( 2 - Ethyl - piperidin - 1 - yl ) - 3 - oxo - propyl ] - isoindole - 1 , 3 - . din - 1 - yl - methanone ; dione ; . US 7 , 50l , 405 B2. 47. N - Adamantan - l - yl - 2 - ( 2 - oxo - 4 - phenyl - pyrrolidin - l - yl ) - acetamide ; . N - Adamantan - 1 - yl - 2 - hydroxy - 2 , 2 - diphenyl - acetamide ; . Adamantane - 1 - carboxylic acid ( naphthalen - 1 - ylmethyl ) - amide ; . Adamantane - l - carboxylic acid ( benzo [ 1 , 3 ] dioxol - 5 - ylmethyl ) - amide ; . 1 - ( Azepane - 1 - carbonyl ) - ﬁuoren - 9 - one ; . 2 - ( Quinolin - 2 - ylsulfanyl ) - N - p - tolyl - acetamide ; . 2 , 4 - Dichloro - N - [ 3 - ( piperidine - 1 - carbonyl ) - phenyl ] - benzamide ; . 2 - Chloro - 4 , 5 - diﬁuoro - N - ( 3 , 3 , 5 - trimethyl - cyclohexyl ) - benzamide ; . 2 - ( 2 - Chloro - benzylsulfanyl ) - N - p - tolyl - acetamide ; . [ 4 - ( 4 - Chloro - phenylsulfanylmethyl ) - phenyl ] - pyrrolidin - 1 - yl - methanone ; . N - Adamantan - 1 - yl - N - methyl - isonicotinamide ; . Azepan - 1 - yl - [ 4 - ( 4 - chloro - phenylsulfanylmethyl ) - phenyl ] - methanone ; . ( 2 - Chloro - phenyl ) - ( 1 , 5 , 7 - trimethyl - 3 , 7 - diaza - bicyclo [ 3 .3 . 1 ] non - 3 - yl ) - methanone ; . ( 3 - Chloro - benzo [ b ] thiophen - 2 - yl ) - ( 4 - methyl - piperidin - 1 - yl ) - methanone ; . Benzoic acid 1 - benzoyl - decahydro - quinolin - 4 - yl ester ; . 2 - ( 3 - Bromo - benzylsulfanyl ) - 1 - [ 4 - ( 2 - methoxy - phenyl ) - piperazin - 1 - yl ] - ethanone ; . 4 - Methyl - N - [ 2 - ( phenoxazine - 10 - carbonyl ) - phenyl ] - benzenesulfonamide ; . 2 - [ 1 - ( Azepane - 1 - carbonyl ) - 2 - methyl - propyl ] - isoindole - 1 , 3 - dione ; . 2 - ( 3 - Bromo - benzylsulfanyl ) - 1 - piperidin - 1 - yl - ethanone ; . 1 - [ 3 - ( 4 - Bromo - phenyl ) - 1 - furan - 2 - yl - 3 - oxo - propyl ] - pyrrolidin - 2 - one ; . 2 - Chloro - N - cyclooctyl - 4 , 5 - diﬂuoro - benzamide ; . 2 , 4 - Dich1oro - N - ( 2 - furan - 2 - ylmethy1 - cyclohexy1 ) - benzamide ; . N - ( 4 - Benzoyl - furazan - 3 - yl ) - 2 - ﬁuoro - benzamide ; . N - Adamantan - 1 - yl - 2 - ( 3 - cyano - 4 - methoxymethyl - 6 - methyl - pyridin - 2 - ylsulfanyl ) - acetamide ; . 4 - tert - Butyl - N - cyc1ooctyl - benzamide ; . N - Adamantan - 1 - yl - 2 - phenyl - butyramide ; . ( 3 - Chloro - 6 - methoxy - benzo [ b ] thiophen - 2 - yl ) - piperidin - 1 - yl - methanone ; . ( 3 , 7 - Dichloro - 6 - methoxy - benzo [ b ] thiophen - 2 - yl ) - piperidin - 1 - yl - methanone ; . Acetic acid 1 - benzoyl - decahydro - quinolin - 4 - yl ester ; . 2 - Bromo - N - methyl - N - phenyl - benzamide ; . N - Benzo [ 1 , 3 ] dioxol - 5 - yl - 2 , 4 - dichloro - benzamide ; . ( 3 - Chloro - 6 - ﬂuoro - benzo [ b ] thiophen - 2 - yl ) - piperidin - 1 - ylmethanone ; . N - ( 1 , 2 , 3 , 5 , 6 , 7 - Hexahydro - s - indacen - 1 - yl ) - 2 - piperidin - 1 - ylacetamide ; . 2 - [ ( Adamantane - 1 - carbony1 ) - amino ] - 3 - ( 1H - indol - 3 - yl ) - propionic acid methyl ester ; . 2 - [ 2 - ( 1 , 3 - Dioxo - 1 , 3 - dihydro - isoindol - 2 - yl ) - 3 - phenyl - propionylamino ] - 3 - methy1 - butyric acid methyl ester ; . 2 - ( 6 - Oxo - 6 - piperidin - 1 - yl - hexyl ) - isoindole - 1 , 3 - dione ; . 2 - [ 2 - ( l , 3 - Dioxo - l , 3 - dihydro - isoindol - 2 - yl ) - 3 - phenyl - propionylamino ] - 3 - methyl - butyric acid methyl ester ; . Adamantane - 1 - carboxylic acid ( 2 , 6 - dihydroxy - pyrimidin - 4 - yl ) - amide ; . Adamantane - 1 - carboxylic acid [ 3 - ( 1H - benzoimidazol - 2 - ylsulfanyl ) - 5 - nitro - phenyl ] - amide ; . Adamantane - 1 - carboxylic acid methyl - phenyl - amide ; . 3 - Chloro - benzo [ b ] thiophene - 2 - carboxylic acid dibenzylamide ; . 5. 48. N - Adamantan - l - y - 2 - ( 3 - cyano - 6 - methyl - 4 - triluoromethylpyridin - 2 - ylsufanyl ) - acetamide ; . 2 - ( 3 - Oxo - 3 - phenyl - propenyl ) - isoindole - 1 , 3 - dione ; . Adamantane - 1 - carboxylic acid ( 4 - ethoxy - benzothiazol - 2 - yl ) - amide ; . N - [ 5 - ( 5 - Chloro - benzooxazol - 2 - yl ) - 2 - methyl - phenyl ] - 2 - methoxy - benzamide ; . N - [ 2 - ( 2 - Bromo - phenyl ) - benzooxazol - 5 - yl ] - 2 - methoxy - benzamide ; . 10 2 - ( 4 - Chloro - phenoxy ) - N - ( 4 - chloro - 3 - triﬂuoromethyl - phe - . lS. nyl ) - acetamide ; 2 , 2 - Dimethyl - N - ( 5 - propyl - [ 1 , 3 , 4 ] thiadiazol - 2 - yl ) - propionamide ; 2 - [ 2 - ( 2 , 6 - Dimethyl - morpholin - 4 - yl ) - 1 - methyl - 2 - oxoethyl ] - isoindole - 1 , 3 - dione ; 2 - ( 2 - Cyano - phenylsulfanyl ) - N - ( 2 - triﬁuoromethyl - phenyl ) - benzamide ; Azepan - 1 - yl - ( 3 , 6 - dichloro - benzo [ b ] thiophen - 2 - yl ) - methanone ; . 20 Benzo [ 1 , 3 ] dioxol - 5 - yl - ( 4 - benzyl - piperidin - 1 - yl ) - metha - . 25. 30. 35. 40. none ; . Azepan - 1 - yl - ( 3 - chloro - 6 - methyl - benzo [ b ] thiophen - 2 - yl ) - methanone ; . N - ( 5 - Hexyl - [ 1 , 3 , 4 ] thiadiazol - 2 - yl ) - isobutyramide ; . ( 3 - Chloro - phenyl ) - ( 10 , 1 1 - dihydro - dibenzo [ b , f ] azepin - 5 - yl ) - methanone ; . ( 2 - Chloro - phenyl ) - ( 10 , 1 1 - dihydro - dibenzo [ b , f ] azepin - 5 - yl ) - methanone ; . 2 - Amino - 5 - ( azepane - 1 - carbonyl ) - 4 - methyl - thiophene - 3 - carboxylic acid ethyl ester ; . Adamantan - 1 - y1 - ( 4 - cyclopropyl - 1 , 4 , 6 , 7 - tetrahydro - imidazo [ 4 , 5 - c ] pyridin - 5 - y1 ) - methanone ; . Adamantan - 1 - yl - ( 4 - tri ﬁuoromethyl - 1 , 4 , 6 , 7 - tetrahydro - imidazo [ 4 , 5 - c ] pyridin - 5 - yl ) - methanone ; . Adamantan - 1 - yl - [ 4 - ( 1H - benzoimidazol - 2 - ylsulfanyl ) - piperi din - 1 - yl ] - methanone ; . Adamantan - 1 - yl - ( 1 , 4 , 6 , 7 - tetrahydro - imidazo [ 4 , 5 - c ] pyridin - 5 - yl ) - methanone ; . [ 4 - ( 1H - imidazol - 4 - yl ) - piperidin - 1 - yl ] - ( 4 - pentyl - phenyl ) - methanone ; . 3 - Cyclohexyl - 1 - [ 4 - ( 1H - imidazol - 4 - yl ) - piperidin - 1 - yl ] - propan - 1 - one ; . 1 - ( 4 - Propyl - piperazin - 1 - yl ) - 3 - ( 4 - triﬂuoromethyl - pheny1 ) - propan - 1 - one ; . 5 N - ( 2 - Hydroxy - benzyl ) - 3 - thiophen - 3 - yl - N - ( 2 - thiophen - 2 - . 50. 55. yl - ethyl ) - acrylamide ; . N - ( 1 , 3 - Dimethyl - pentyl ) - 2 - ( 3 - ﬂuoro - phenyl ) - N - ( 4 - hydroxy - benzy1 ) - acetamide ; . N - Cyclobutyl - 2 - ( 3 - ﬁuoro - phenyl ) - N - ( 4 - hydroxy - benzyl ) - acetamide ; . N - Cyclobutyl - N - ( 4 - hydroxy - benzyl ) - 4 - triﬂuoromethylbenzamide ; . N - ( 3 - Hydroxy - benzyl ) - 2 - methyl - 3 - nitro - N - ( 4 - sulfamoylbenzyl ) - benzamide ; . N - - ( 4 - Bromo - benzyl ) - N - ( 4 - hydroxy - benzyl ) - 2 - naphthalen - 1 - yl - acetamide ; . 6 - ( 2 - Bromo - phenylsulfanyl ) - hexanoic acid ( 3 - amino - 2 , 2 - dimethyl - propyl ) - amide ; . 60 N - ( 3 - Amino - 2 , 2 - dimethyl - propyl ) - 4 - [ 2 - ( 2 - isopropyl - phe - . 65. nylsulfanyl ) - ethyl ] - benzamide ; N - ( 3 - Amino - 2 , 2 - dimethyl - propyl ) - 4 - [ 4 - ( 4 - chloro - phenyl ) - pyrimidin - 2 - ylsulfanylmethyl ] - 3 - nitro - benzamide ; 4 - ( 4 - Bromo - phenyl ) - N - ( 2 - hydroxy - benzyl ) - 4 - oxo - N - thiophen - 2 - ylmethyl - butyramide ; N - [ 2 - ( 2 , 4 - Dichloro - phenyl ) - ethyl ] - N - ( 4 - hydroxy - benzyl ) - 2 - thiophen - 3 - yl - acetamide ; . US 7 , 50l , 405 B2. 49. N - ( 2 - Chloro - benzyl ) - N - ( 4 - hydroxy - benzyl ) - 2 - thiophen - 2 - yl - acetamide ; . Heptanoic acid benzyl - ( 4 - hydroxy - benzyl ) - amide ; . N - ( 4 - F1uoro - benzyl ) - N - ( 4 - hydroxy - benzyl ) - 2 - thiophen - 3 - yl - acetamide ; . 4 - Methyl - pentanoic acid ( 4 - ﬂuoro - benzyl ) - ( 4 - hydroxy - benzyl ) - amide ; . N - Allyl - 2 - ( 4 - chloro - phenyl ) - N - ( 4 - hydroxy - benzyl ) - acetamide ; . N - Allyl - 2 - benzo [ b ] thiophen - 3 - yl - N - ( 4 - hydroxy - benzyl ) - acetamide ; . Heptanoic acid ( 3 - ethoxy - propyl ) - ( 4 - hydroxy - benzyl ) - amide ; . Dec - 3 - enoic acid ( 4 - hydroxy - benzyl ) - ( 4 - triﬂuoromethylbenzyl ) - amide ; . 6 - Oxo - 6 - phenyl - hexanoic acid ( 4 - hydroxy - benzyl ) - ( 4 - trifluoromethyl - benzyl ) - amide ; . 2 - ( 3 , 4 - Diﬁuoro - phenyl ) - N - ( 4 - hydroxy - benzyl ) - N - thiophen - 2 - ylmethyl - acetamide ; . 2 - Methyl - pent - 4 - enoic acid ( 3 - hydroxy - benzyl ) - [ 2 - ( 2 - methoxy - phenyl ) - ethyl ] - amide ; . Heptanoic acid ( 3 - hydroxy - benzyl ) - ( 4 - isopropyl - benzyl ) - amide ; . 5 - ( 2 , 6 - Dichloro - phenylsulfanyl ) - pentanoic acid ( naphthalen - 1 - ylmethyl ) - amide ; . N - ( 6 , 6 - Dimethyl - bicyclo [ 3 . 1 .1 ] hept - 2 - ylmethyl ) - 4 - [ 2 - ( 5 - methyl - 1H - benzoimidazol - 2 - ylsulfanyl ) - ethyl ] - benzamide ; N - ( 6 , 6 - Dimethyl - bicyclo [ 3 .1 .1 ] hept - 2 - y1methyl ) - 4 - [ 2 - ( 4 - . phenoxy - pyrimidin - 2 - y1su1fanyl ) - ethy1 ] - benzamide : . N - ( 6 , 6 - Dimethyl - bicyclo [ 3 .1 .1 ] hept - 2 - ylmethyl ) - 4 - [ 2 - ( 4 - ﬁuoro - phenylsulfanyl ) - ethyl ] - benzamide ; . 4 - ( 2 , 6 - Dichloro - phenylsulfanyl ) - N - ( 6 , 6 - dimethyl - bicyclo. [ 3 . 1 . 1 ] hept - 2 - ylmethyl ) - butyramide ; N - ( 6 , 6 - Dimethyl - bicyclo [ 3 .1 .1 ] hept - 2 - y1methyl ) - 4 - [ 2 - ( 5 - . methyl - 1H - benzoimidazol - 2 - ylsulfanyl ) - ethyl ] - benza - . mide ; . N - ( 6 , 6 - Dimethyl - bicyclo [ 3 .1 .1 ] hept - 2 - ylmethyl ) - 4 - [ 2 - ( 4 - ﬂuoro - phenylsulfany1 ) - ethyl ] - benzamide ; . 5 - ( 3 - Methy1sulfanyl - [ 1 , 2 , 4 ] thiadiazo1 - 5 - ylsulfany1 ) - pentanoic acid ( 6 , 6 - dimethyl - bicyclo [ 3 .1 .1 ] hept - 2 - ylmethyl ) - amide ; . 5 - ( 2 , 6 - Dichloro - phenylsulfanyl ) - pentanoic acid [ 2 - ( 3 - trifluoromethyl - phenyl ) - ethy1 ] - amide ; . 4 - [ 2 - ( 2 , 6 - Dich10ro - pheny1sulfanyl ) - ethyl ] - N - [ 2 - ( 2 - ﬂuorophenyl ) - ethyl ] - b enzamide ; . 2 - Cyclohexylamino - thiazole - 4 - carboxylic acid ( 1 , 2 , 3 , 4 - tetrahydro - naphthalen - 1 - yl ) - amide ; . 2 - Cyclohexy1amino - thiazole - 4 - carboxylic acid ( 3 - chloro - 4 - hydroxy - phenyl ) - amide ; . 2 - Cyclohexylamino - thiazole - 4 - carboxylic acid ( 1 , 2 - dimethyl - propyl ) - amide ; . 2 - Cyclohexylamino - thiazole - 4 - carboxylic acid ( 1 - ethyl - propyl ) - amide ; . 2 - Cyclohexylamino - thiazole - 4 - carboxylic acid [ 3 - ( 1 - hydroxy - ethyl ) - phenyl ] - amide ; . 2 - Cyclohexylamino - thiazole - 4 - carboxylic acid ( 1 - ethynylcyclohexyl ) - amide ; . 2 - Cyclohexy1amino - thiazole - 4 - carboxylic acid ( 2 - methoxydibenzoﬁ1ran - 3 - yl ) - amide ; . 2 - Cyclohexylamino - thiazole - 4 - carboxylic acid [ 2 - ( 4 - hydroxy - phenyl ) - ethyl ] - amide ; . 2 - Cyclohexylamino - thiazole - 4 - carboxylic acid ( 4 - hydroxycyclohexyl ) - amide ; . 2 - ( 2 , 6 - Diﬂuoro - benzylamino ) - N - [ 2 - ( 3 - triﬂuoromethyl - phenyl ) - ethyl ] - acetamide ; . 4 - { 4 - [ 2 - ( 4 - Dimethylamino - phenyl ) - acetyl ] - piperazin - 1 - yl } - 3 - ( 2 - phenyl - propylamino ) - benzamide ; . 5. lO. lS. 20. 25. 30. 35. 40. 45. 50. 55. 60. 65. 50 2 - ( 2 - Ethyl - phenylsulfanyl ) - 3 - [ methyl - ( 2 - pyrdin - 4 - ylethyl ) - amino ] - N - prop - 2 - ynyl - propionamide ; 4 - Methyl - cyclohexanecarboxylic acid { [ 2 - ( 2 - chloro - 6 - ﬂuoro - benzylsulfanyl ) - ethylcarbamoyl ] - methy1 } - prop - 2 - ynyl - amide ; 2 - Benzylsufanyl - N { [ 2 - ( 2 - chloro - 6 - ﬁuoro - benzylsulfanyl ) - ethylcarbamoyl ] - methyl } - N - ( 2 - methoxy - ethyl ) - acetamide ; . 4 - [ 2 - ( 5 - Cyclopropylmethylsulfanyl - [ 1 , 3 , 4 ] thiadiazol - 2 - ylsulfanyl ) - ethyl ] - N - ( 6 , 6 - dimethyl - bicyclo [ 3.1.1 ] hept - 2 - ylmethyl ) - benzamide ; . N - ( 6 , 6 - Dimethyl - bicyclo [ 3 .1 .1 ] hept - 2 - ylmethyl ) - 4 - [ 2 - ( 4 - phenoxy - pyrimidin - 2 - ylsulfanyl ) - ethyl ] - benzamide ; . N - ( 6 , 6 - Dimethyl - bicyclo [ 3 .1 .1 ] hept - 2 - ylmethyl ) - 2 - p - tolyloxy - acetamide ; . Bicyclo [ 2.2.1 ] hept - 5 - ene - 2 - carboxylic acid luoro - phenoxy ) - butyl ] - amide ; . 4 - Triﬁuoromethyl - cyclohexanecarboxylic acid [ 6 - ( 2 , 6 - difluoro - phenoxy ) - hexyl ] - amide ; . N - Cyclopropyl - 3 - methoxy - N - ( 2 - piperidin - 4 - yl - ethyl ) - 5 - ( pyridine - 2 - carbonyl ) - benzamide ; . 3 - Methoxy - N - ( 2 - methoxy - ethyl ) - N - ( 2 - piperidin - 4 - ylethyl ) - 5 - ( pyridine - 2 - carbonyl ) - benzamide ; . 3 - Methoxy - N - ( 2 - piperidin - 4 - yl - ethyl ) - 5 - ( pyridine - 2 - carbonyl ) - N - ( tetrahydro - furan - 2 - ylmethyl ) - benzamide ; . 3 - Methoxy - N - ( 2 - oxo - azepan - 3 - yl ) - N - ( 2 - piperidin - 4 - ylethyl ) - 5 - ( pyridine - 2 - carbonyl ) - benzamide ; . 3 - Methoxy - N - [ 3 - ( 2 - oxo - pyrrolidin - 1 - yl ) - propyl ] - N - ( 2 - pip - eridin - 4 - yl - ethyl ) - 5 - ( pyridine - 2 - carbonyl ) - benzamide ; . 3 - Methoxy - N - methyl - N - ( 2 - piperidin - 4 - yl - ethyl ) - 5 - ( pyridine - 2 - carbonyl ) - benzamide ; . [ 2 - ( { Cyclopropyl - [ 3 - methoxy - 5 - ( pyridine - 2 - carbonyl ) - benzoyl ] - amino } methy1 ) - phenoxy ] - acetic acid ; . ( 2 - { [ [ 3 - Methoxy - 5 - ( pyridine - 2 - carbonyl ) - benzoyl ] - ( 3 - methyl - butyl ) - amino ] - methyl } - phenoxy ) - acetic acid ; . [ 2 - ( { Cyclopentyl - [ 3 - methoxy - 5 - ( pyridine - 2 - carbonyl ) - benzoyl ] - amino } methyl ) - phenoxy ] - acetic acid ; . [ 2 - ( { ( 2 - Methoxy - ethy1 ) - [ 3 - methoxy - 5 - ( pyridine - 2 - carbonyl ) - benzoyl ] - amino } - methyl ) - phenoxy ] - acetic acid ; . [ 2 - ( { Carbamoylmethyl - [ 3 - methoxy - 5 - ( pyridine - 2 - carbonyl ) - benzoyl ] - amino ] > - methyl ) - phenoxy ] - acetic acid ; . [ 2 - ( { [ 3 - Methoxy - 5 - ( pyridine - 2 - carbonyl ) - benzoyl ] - pyridin - . [ . [ . [ . [ 4 - ( 2 , 5 - dif - . 4 - yl - amino } - methyl ) - phenoxy ] - acetic acid ; . 2 - ( { Cyc1opropylmethyl - [ 3 - methoxy - 5 - ( pyridine - 2 - carbonyl ) - benzoyl ] - amino } - methyl ) - phenoxy ] - acetic acid ; . 2 - ( { [ 3 - Methoxy - 5 - ( pyridine - 2 - carbonyl ) - benzoyl ] - methylamino } - methyl ) - phenoxy ] - acetic acid ; . 4 - ( 4 - Hydroxy - benzy1 ) - piperazin - 1 - yl ] - [ 3 - methoxy - 5 - ( pyridine - 2 - carbonyl ) - phenyl ] - methanone ; . { Carbamoylmethyl - [ 3 - methoxy - 5 - ( pyridine - 2 - carbonyl ) - benzoyl ] - amino } > - acetic acid ; . { ( 3 - lmidazol - 1 - yl - propyl ) - [ 3 - methoxy - 5 - ( pyridine - 2 - carbonyl ) - benzoyl ] - amino } - acetic acid ; . { [ 3 - Methoxy - 5 - ( pyridine - 2 - carbonyl ) - benzoyl ] - pyridin - 4 - yl - amino } - acetic acid ; . [ [ 3 - Methoxy - 5 - ( pyridine - 2 - carbonyl ) - benzoyl ] - ( 2 - oxoazepan - 3 - yl ) - amino ] - acetic acid ; . 3 - Methoxy - N - ( 2 - methoxy - ethyl ) - N - piperidin - 3 - ylmethyl - 5 - ( pyridine - 2 - carbonyl ) - benzamide ; . 4 - [ 3 - Methoxy - 5 - ( pyridine - 2 - carbonyl ) - benzoylamino ] - piperidine - 1 - carboxylic acid ethyl ester ; . 3 - Methoxy - N - [ 3 - ( 2 - oxo - pyrrolidin - 1 - yl ) - propyl ] - 5 - ( pyridine - 2 - carbonyl ) - benzamide ; . 3 - ( { Carbamoylmethyl - [ 3 - methoxy - 5 - ( pyridine - 2 - carbonyl ) - benzoyl ] - amino } > - methyl ) - benzoic acid ; . 3 - ( { ( 3 - Imidazol - 1 - yl - propyl ) - [ 3 - methoxy - 5 - ( pyridine - 2 - carbonyl ) - benzoyl ] - amino } - methyl ) - benzoic acid ; . US 7 , 50l , 405 B2. 51 4 - Amino - N - ( 3 - hydroxy - benzyl ) - N - indan - 2 - yl - 2 - propionylamino - butyramide ; 5 - Amino - 2 - propionylamino - pentanoic acid ( 3 - hydroxy - benzyl ) - indan - 2 - y1 - amide ; N - Ethyl - 2 - hexylamino - N - ( 4 - hydroxy - benzyl ) - acetamide ; 2 - Hexylamino - N - ( 4 - hydroxy - benzyl ) - N - methyl - acetamide ; 1 - [ 1 - ( 6 - Phenyl - hexanoyl ) - piperidin - 4 - yl ] - 1 , 3 - dihydro - benzoimidazol - 2 - one ; 1 - [ 1 - ( 3 - Cyclohexyl - propionyl ) - piperidin - 4 - yl ] - 1 , 3 - dihydrobenzoimidazol - 2 - one ; N - ( 2 - Hydroxy - benzyl ) - N - isobutyl - benzamide ; N - ( 2 - Hydroxy - benzyl ) - 2 - ( 4 - hydroxy - phenyl ) - N - isobutylacetamide ; N - ( 2 - Hydroxy - benzyl ) - N - ( 3 - methyl - butyl ) - benzamide ; N - ( 4 - Hydroxy - benzyl ) - N - isobutyl - benzamide ; 4 - Hydroxy - N - ( 4 - hydroxy - benzyl ) - N - isobutyl - benzamide ; N - ( 4 - Hydroxy - benzyl ) - 2 - ( 4 - hydroxy - phenyl ) - N - isobutylacetamide ; N - ( 4 - Hydroxy - benzyl ) - N - ( 3 - methyl - butyl ) - benzamide ; N - ( 2 - Ethoxy - ethyl ) - 4 - hydroxy - N - ( 4 - hydroxy - benzyl ) - benzamide ; N - ( 4 - Hydroxy - benzyl ) - N - ( 3 - isopropoxy - propyl ) - benzamide ; N - ( 3 - Hydroxy - benzyl ) - N - ( 4 - methyl - pentyl ) - benzamide ; N - ( 3 - Hydroxy - benzyl ) - 2 - ( 4 - hydroxy - phenyl ) - N - ( 4 - methylpentyl ) - acetamide ; N - ( 3 - Hydroxy - benzyl ) - N - ( 3 - isopropoxy - propyl ) - benzamide ; N - ( 2 - Hydroxy - benzyl ) - N - ( 3 - methyl - butyl ) - 4 - propy1 - benzamide ; N - ( 4 - Hydroxy - benzyl ) - N - ( 6 - hydroxy - hexyl ) - 4 - propyl - benzamide ; N - ( 4 - Hydroxy - benzyl ) - N - ( 3 - methyl - butyl ) - 4 - propy1 - benzamide ; N - [ 2 - ( 4 - Fluoro - benzylamino ) - thiazol - 4 - ylmethyl ] - N - phenethyl - butyramide ; or a salt thereof With a pharmaceutically acceptable acid or base , or any optical isomer or mixture of optica1 isomers , inc1uding a racemic mixture , or any tautomeric forms. ln another embodiment of the present inVention said substituted amide , or a prodrug thereof , as a component of the combination therapy is selected from the group consisting of : : ( 4 - Tetrazol - 1 - yl - phenyl ) - ( 1 , 3 , 3 - trimethyl - 6 - aza - bicyc1o [ 3 .2. 1 ] oct - 6 - yl ) - methanone ; N - Cyclohexyl - N - methyl - 2 - phenoxymethyl - benzamide ; 4 - Amino - N - cyclohexyl - N - methyl - benzamide ; N - Cyclohepty1 - N - methyl - 2 - phenoxymethyl - benzamide ; N - Cyclohexyl - N - methyl - benzamide ; 2 - Chloro - N - cyclohexyl - 6 - ﬁuoro - N - methyl - benzamide ; N - Cyclohexyl - N - methyl - 4 - triﬁuoromethoxy - benzamide ; N - Cyclohexyl - 2 , 3 , N - trimethyl - benzamide ; 3 , 5 - Dich1oro - N - cyc10hexy1 - N - methyl - benzamide ; N - Cyclohexyl - N - methyl - 2 - phenoxy - benzamide ; 2 , 4 - Bis - benzyloxy - N - cyclohexyl - N - methyl - benzamide ; 2 - Benzyloxy - N - cyclohexyl - N - methyl - benzamide ; N - Cyclohexyl - N - methyl - 4 - phenoxy - benzamide ; 4 - Benzyloxy - N - cyclohexyl - N - methy1 - benzamide ; N - Cyclohexyl - N - methyl - 4 - phenoxymethyl - benzamide ; 2 - Chloro - N - cyclohexyl - N - ethyl - 4 - nitro - benzamide ; 4 - Chloro - N - cyclohexyl - N - ethyl - 3 - nitro - benzamide ; 6 - Fluoro4H - benzo [ 1 , 3 ] dioxine - 8 - carboxylic acid cyclohexyl - methyl - amide ; Azepan - 1 - yl - ( 2 - chloro - phenyl ) - methanone ; Azepan - l - yl - ( 3 - chloro - phenyl ) - methanone ; Azepan - 1 - yl - phenyl - methanone ; 2 - ( Biphenyl - 4 - yloxy ) - N - cyclohexyl - N - methyl - benzamide ; . 52 N - Cyclohexyl - 2 - ( 3 , 5 - dimethoxy - phenoxy ) - N - methyl - benzamide ; N - Cyclohexyl - 2 - ( 2 , 3 - dimethoxy - phenoxy ) - N - methyl - benzamide ; 5 2 , 4 - Dichloro - N - ( 3 , 3 - dimethyl - 1 , 5 - dioxa - spiro [ 5.5 ] undec - 9 - yl ) - N - methyl - benzamide ; 2 , 4 - Dichloro - N - methyl - N - ( 4 - oxo - cyclohexyl ) - benzamide ; N - Cyclohexyl - 2 - hydroxy - N - methyl - benzamide ; N - Cyclohexyl - 3 - methoxy - N - methyl - benzamide ; 10 Benzo [ 1 , 3 ] dioxole - 5 - carboxylic acid cyclohexyl - methylamide ; 3 - Benzyloxy - N - cyclohexyl - N - methyl - benzamide ; N - Cyclohexyl - 3 - hydroxy - N - methyl - benzamide ; [ 4 - ( Morpholine4 - sulfonyl ) - phenyl ] - ( 1 , 3 , 3 - trimethyl - 6 - aza - 15 bicyclo [ 3 .2. 1 ] oct - 6 - yl ) - methanone ; N - Benzyl - 3 - ( 1 , 3 , 3 - trimethyl - 6 - aza - bicyclo [ 3.2.1 ] octane - 6 - carbonyl ) - benzenesulfonamide ; [ 4 - Fluoro - 3 - ( morpholine - 4 - sulfonyl ) - phenyl ] - ( 1 , 3 , 3 - trimethyl - 6 - aza - bicyclo [ 3 .2. 1 ] oct - 6 - yl ) - methanone ; 20 Thiophene - 2 - sulfonic acid [ 4 - ( 1 , 3 , 3 - trimethyl - 6 - aza - bicyclo [ 3 .2 . 1 ] octane - 6 - carbonyl ) - phenyl ] - amide ; N - Phenyl4 - ( 1 , 3 , 3 - trimethyl - 6 - aza - bicyclo [ 3.2.1 ] octane - 6 - carbonyl ) - benzenesulfonamide ; ( 4 - Phenoxy - phenyl ) - ( 1 , 3 , 3 - trimethyl - 6 - aza - bicyclo [ 3 .2. 1 ] oct - 6 - yl ) - methanone ; N - ( 2 , 4 - Dimethyl - phenyl ) - 3 - ( 1 , 3 , 3 - trimethyl - 6 - aza - bicyclo [ 3 .2 . 1 ] octane - 6 - carbonyl ) - benzenesulfonamide ; ( 2 - Phenoxymethyl - phenyl ) - ( 1 , 3 , 3 - trimethyl - 6 - aza - bicyclo [ 3.2.1 ] oct - 6 - yl ) - methanone ; 30 4 - ( 3 - Aza - bicyclo [ 3.2.2 ] nonane - 3 - carbonyl ) - N , N - dipropylbenzenesu1fonamide ; . 25. 2 - Bromo - N - cyclohexyl - N - methyl - benzamide ; N - [ 4 - ( 1 , 3 , 3 - Trimethyl - 6 - aza - bicyclo [ 3.2.1 ] octane - 6 - carbonyl ) - phenyl ] - acetamide ; 35 ( 4 - Dimethy1amino - phenyl ) - ( 1 , 3 , 3 - trimethy1 - 6 - aza - bicyc1o [ 3.2.1 ] oct - 6 - yl ) - methanone ; ( 4 - Pyrro1 - 1 - yl - phenyl ) - ( 1 , 3 , 3 - trimethy1 - 6 - aza - bicyc1o [ 3.2.1 ] oct - 6 - yl ) - methanone ; ( 4 - lmidazol - 1 - yl - phenyl ) - ( 1 , 3 , 3 - trimethyl - 6 - aza - bicyclo [ 3.2.1 ] oct - 6 - yl ) - methanone ; ( 4 - Amino - 2 - methoxy - phenyl ) - ( trimethyl - 6 - aza - bicyclo [ 3.2.1 ] oct - 6 - yl ) - methanone ; ( 4 - Methanesulfonyl - phenyl ) - ( 1 , 3 , 3 - trimethyl - 6 - aza - bicyclo [ 3.2.1 ] oct - 6 - yl ) - methanone ; 45 ( 3 - Methanesulfonyl - phenyl ) - ( 1 , 3 , 3 - trimethyl - 6 - aza - bicyclo [ 3.2.1 ] oct - 6 - yl ) - methanone ; ( 4 - Benzenesulfonyl - phenyl ) - ( 1 , 3 , 3 - trimethyl - 6 - aza - bicyclo [ 3.2.1 ] oct - 6 - yl ) - methanone ; 5 0 Azepan - 1 - yl - [ 4 - ( 3 , 4 - dihydro - 1H - isoquinolin - 2 - ylmethyl ) - phenyl ] - methanone ; Azepan - 1 - yl - ( 4 - morpholin - 4 - ylmethyl - phenyl ) - methanone ; [ 4 - ( 3 - Triﬁuoromethyl - pyrazol - 1 - yl ) - phenyl ] - ( 1 , 3 , 3 - trimethyl - 6 - aza - bicyclo [ 3 .2. 1 ] oct - 6 - y1 ) - methanone ; 55 ( 4 - [ 1 , 2 , 4 ] Triazol - 1 - yl - phenyl ) - ( 1 , 3 , 3 - trimethyl - 6 - aza - bicyclo [ 3.2.1 ] oct - 6 - yl ) - methanone ; ( 4 - Pyrazol - 1 - yl - phenyl ) - ( 1 , 3 , 3 - trimethyl - 6 - aza - bicyclo [ 3.2.1 ] oct - 6 - yl ) - methanone ; 2 - Benzyloxymethyl - N - cyclohexyl - N - methyl - benzamide ; 60 N - Cyclohexyl - N - methyl - 4 - ( 3 - methyl - 5 - oxo - 4 , 5 - dihydropyrazol - 1 - yl ) - benzamide ; 5 - Methyl - 2 - [ 4 - ( 1 , 3 , 3 - trimethyl - 6 - aza - bicyclo [ 3.2.1 ] octane - 6 - carbonyl ) - phenyl ] - 2 , 4 - dihydro - pyrazol - 3 - one ; ( 9H - Carbazol - 3 - yl ) - ( 1 , 3 , 3 - trimethyl - 6 - aza - bicyclo [ 3.2.1 ] oct - 6 - yl ) - methanone ; [ 4 - ( 3 , 5 - Dimethyl - pyrazol - 1 - yl ) - phenyl ] - ( 1 , 3 , 3 - trimethyl - 6 - aza - bicyclo [ 3.2.1 ] oct - 6 - yl ) - methanone ; . 40. 65. US 7 , 50l , 405 B2. 53 54 Phenyl - ( l , 3 , 3 - trimethyl - 6 - aza - bicyclo [ 3.2. l ] oct - 6 - yl ) - R3 and R4 together With the nitrogen to Which they are methanone ; attached , are forming a saturated or partially saturated bicyAzepan - 1 - yl - ( 2 - bromo - phenyl ) - methanone ; clic / bridge ring system containing from 7 to 12 carbon atoms ( 3 - Aza - bicyclo [ 3.2.2 ] non - 3 - y1 ) - ( 2 - bromo - phenyl ) - metha - and from 0 to 2 additional heteroatoms selected from nitronone ; 5 gen , oxygen or sulphur , the ring system optionally being ( 4 - Benzyl - piperidin - 1 - yl ) - quinolin - 2 - yl - methanone ; substituted With at least one of C1 - C6alkyl , aryl , hetaryl , ( 2 - Methyl - piperidin - 1 - yl ) - quinolin - 2 - yl - methanone ; arle1 - C6alkyl , hetaryl - C1 - C6alkyl , hydroxy , oxo , ( 3 - Aza - bicyclo [ 3 .2.2 ] non - 3 - yl ) - quinolin - 2 - yl - methanone ; C 1 - C6alkyloxy , arle1 - C6alkyloxy or hetarle 1 - C6alkyloxy , Quinoline - 2 - carboxylic acid cyclohexyl - methyl - amide ; Wherein the alkyl and aryl groups independently are optionQuinolin - 2 - yl - ( 1 , 3 , 3 - trimethyl - 6 - aza - bicyclo [ 3.2.1 ] oct - 6 - 10 ally substituted With one ore more of R9 ; y1 ) - methan0ne ; R5 is C1 - C6alkyl , C2 - C6alkenyl , C2 - C6alkynyl , 1 - [ 4 - ( 1 , 3 , 3 - Trimethyl - 6 - aza - bicyclo [ 3.2.1 ] octane - 6 - carbo - C3 - C 1 00yC10a1ky1 , C3 - C10hetCyC10a1ky1 , C3 ' C10 ' Cy ' ny1 ) - pheny1 ] - pyrr01idine - 2 , 5 - di0ne ; cloalkle1 - C6alkyl , C3 - C1Ohetcycloalkle1 - C6alkyl , aryl , Pyridin - 3 - yl - ( 1 , 3 , 3 - trimethyl - 6 - aza - bicyclo [ 3.2.1 ] oct - 6 - yl ) - hetary ] , ary1C1 - C6a ] ky ] 0r hetary1C 1 - C6a1ky ] wherein the 11161113110113 ; 15 alkyl , alkenyl , alkynyl , aryl , hetaryl , cycloalkyl and hetcyPyridin - 4 - y1 - ( 1 , 3 , 3 - trimethy1 - 6 - aza - biCyC10 [ 3.2.1 ] 0Ct - 6 - y1 ) - cloalkyl groups independently are optionally substituted With methanone ; one or more of R9 ; Pyridin - 2 - yl - ( 1 , 3 , 3 - t1imethyl - 6 - aza - bicyclo [ 3 .2.1 ] oct - 6 - yl ) - R6 and R7 independently are hydrogen , hydroxy , oxo , halo , methanone ; nitro , cyano , C1 - C6a1kyl , C1 - C6 - alkyloxy triha1omethyl , tri - ( 6 - Pyrazol - 1 - yl - pyridin - 3 - yl ) - ( 1 , 3 , 3 - trimethyl - 6 - aza - bicy - 20 halomethoxy , NRlORl1 , arle1 - C6alkyloxy , hetarle1 - clo [ 3.2.1. ] oct - 6 - yl ) - methanone ; C6alkyloxy , C1 - C6alkylcarbonyl , arylcarbonyl , hetarylcarbo - 4 - ( 1 , 3 , 3 - Tr1methyl - 6 - aza - b1cyclo [ 3 .2. 1 ] octane - 6 - carbonyl ) - nyL arle1 - C6a1ky1Carb0ny1 , C1 - C6a1ky10xycarbonyl , benzo1c ac1d ; aryloxycarbonyl , arle1 - C6alkyloxycarbonyl , lmidazo [ 2 , 1 - b ] lh1ElZOl - 6 - yl - ( 1 , 3 , 3 - trimethyl - 6 - aza - bicyclo Cl - C6a ] ky ] Carb0ij ary ] carb0Xy 01" ary ] C1 - C6a ] ky ] carb0Xy ; [ 3.2..1 ] oct - 6 - yl ) - methanone ; . 25 R8 and R9 independently are hydrogen , C1 - C6a1ky1 , aryl , 8 - ( 4 - D1methylam1no - benzoyl ) - 8 - aza - b1cyclo [ 3.2.1 ] octan - 3 - hetaryl , arle1 - C6alkyl , hetarle1 - C6 - alkyl , hydr0xy , 0X0 , one ; cyano , NRl0Rll , C1 - C6alkyloxy , aryloxy , arle1 - ( 4 - Dimethylamino - phenyl ) - ( 3 - hydroxy - 8 - aza - bicyclo C6alkyloxy , hetaryloxy , hetarle1 - C6alkyloxy , [ 3.2.1 ] oct - 8 - yl ) - methanone ; C1 - C6alkyloxyC1 - C6alkyl , C1 - C6a1ky1carbonyl , arylcarbony ( 4 - Dimethylamino - phenyl ) - ( 3 - hydroxy - 3 - methyl - 8 - aza - bi - 30 hetarylcarbonyl , ary1C1 - C6alkylcarbonyl , hetary1C1 - CYC10 [ 3 - 2 - 1 ] oct - 8 - yl ) - methanone ; C6alkylcarbonyl , C 1 - C6alkylcarboxy , arylcarboxy or arle 1 - Triﬂuoro - acetic acid 8 - ( 4 - dimethylamino - benzoy1 ) - 8 - aza - C6alkylcarboxy ; bicyclo [ 3.2. l ] oct - 3 - yl ester ; 01‘ R10 and R11 independently are hydrogen , C1 - C8alkyl , aryl , a salt thereof With a pha1maceutica1ly acceptab1e acid or base , hetaryl , arle1 - C6a1ky11 C3 - C1O - cycloalkyl , or any optical isomer or mixture of optica1 isomers , inc1ud - 35 C3 - C10hetcycloa1ky1 , C3 - C10cyc1oa1ky1C1 - C6a1ky1 , ing a racemic mixture , or any tautomeric forms. C l. C 681ky1Carb0ny1. C 1 - C 6alkylcarboxyC 1 - C 6a1ky1 ; or ln another embodiment of the present inVention said sub - R10 and R“ together With the nitrogen m Which they are stituted amides , 01 ' a pr odrug thereof , as a component 0f the attached , are forming a saturated or partially saturated cyclic , combination therapy iS 0f the general formula ( lla ) 40 bicyclic or tricyclic ring system containing from 4 to 10. carbon atoms and from 0 to 2 additional heteroatoms se1ected from nitrogen , oxygen or sulphur , the ring system optionally ( Ha ) being substituted With at least one of C1 - C8alkyl , aryl , . R2 0 hetaryl , arle1 - C6alkyl , hetarle1 - C6alkyl , hydroxy , oxo , / R3 cyano , C1 - C6alkyloxy , arle1 - C6alkyloxy , hetarle1 - 1 \ N 45 C6alkyoxy , C1 - C6a1ky1oxyC1 - C6alkyl , C1 - C6alkylcarbonyl , R _N\ / 1|14 arylcarbonyl , hetarylcarbonyl , arle1 - C6alkylcarbonyl , N hetarle1 - C6alkylcarbonyl , C1 - C6alkylcarboxy , arylcarboxy or arle1 - 6 - alkylcarboxy ; or Wherein 50 a salt thereof With a pharmaceutically acceptable acid or R1 13 1111119 arle1 - C6a1kyl , hetaryl 01 hetarle1 - C6alkyl base , or any optical isomer or mixture of optical isomers , optionally substituted With one or more of R6 independently ; 1nclud1ng a racem1c m1xture , or any tautomer1c forms. R2 15 1151101 C1 - C6a1ky1 , C2 - C6a1keny1 , C2 - C6alkynyl , ln another embodiment of the present inVention said sub - . C3 - C10CyC10a1ky1 , C3 - C10cycloa1kle1 - C6alkyl , 11111310111 - stituted amides , or a prodrug thereof , as a component of the 11111111 1111113 aYY1C1 ' C6a1ky1a C1 ' C6a1ky10XyC1 ' C6a1ky1 : 55 comb1nat1on therapy 1s of the general formula ( lla ) Wherem : arle 1 - C 6a1ky10xyC 1 - C6a1ky11 C1. C6. a ] ky1NR5Cl - C6a1ky11 R1 is aryl or hetaryl optionally substituted With one or more arle1 - C6alkleR5C1 - C6alkyl , hetaryl or hetarle1 - C6alkyl R6 independent1y ; . Wherein the alkyl , alkenyl , alkynyl , cycloalkyl and aryl R2 is halo , C1 - C6alkyl , C2 - C6alkenyl , C2 - C6alkynyl , groups independently are optionally substituted With one or C3 - C10cycloalkyl , C3 - C10cycloalkle1 - C6alkyl , aryl , more R7 ; 60 arle1 - C6alkyl , C1 - C6alkyloxyC1 - C6alkyl , arle1 - R3 is C1 - C6alkyl optionally substituted With one or more of C5alkyloxyC1 - C6alkyl , C1 - C6alkyl , C1 - C6alkleR5C1 - ; C6alkyl , arle1 - C6alkleR5C1 - C6alkyl , hetaryl or R4 is C6 ' C1OCyC1Oa1ky13 C6 - C10hetcycloalkyl , hetarle1 - C6alkyl Wherein the alkyl , al alkynyl , cycloalkyl C6 ' C1oCyC10a1ky1C1 ' C631ky1 or C6 - C1Ohetcycloalkle1 - and aryl groups independently are optionally substituted With C6alkyl Wherein the alkyl , cycloalkyl and hetcycloalkyl 65 011€ 01‘ 1110113 R7 ; . groups independently are optionally substituted With one or R3 is C1 - C6alkyl optionally substituted With one or more of more of R8 ; or R8 ; . R8. US 7 , 50l , 405 B2. 55. R4 is C6 - C1Ocycloalkyl , C6 - C10hetcycloalkyl , C6 - C1Ocycloalkle1 - C6alkyl or C6 - C1Ohetcycloalkle1 - C6alkyl Wherein the alkyl , cycloalkyl and hetcycloalkyl groups independently are optional1y substituted With one or more of R8 ; . R5 is C1 - C6alkyl , C2 - C6alkynyl , C3 - C1Ocycloalkyl , C3 - C1Ohetcycloalkyl , C3 - C1O - cycloalkle1 - C6alkyl , C3 - C1Ohetcycloalkle1 - C6alkyl , aryl , hetaryl , arle1 - C6alkyl or hetarle1 - C6alkyl Wherein the alkyl , alkenyl , alkynyl , aryl , hetaryl , cycloalkyl and hetcycloalkyl groups independently are optionally substituted With one or more of R9 ; . R6 and R7 independently are hydrogen , hydroxy , oxo , halo , nitro , cyano , C1 - C6alkyl , C1 - C6 - alkyloxy , trihalomethyl , trihalomethoxy , NRlORll , arle1 - C6alkyloxy , hetarle1 - C6alkyloxy , C1 - C6alkylcarbonyl , arylcarbonyl , hetarylcarbonyl , arle1 - C6alkylcarbonyl , C1 - C6alkyloxycarbonyl , aryloxycarbonyl , arle1 - C6alkyloxycarbonyl , C1 - C6alkylcarboxy , ary1carboxy or arle1 - C6a1kyl - carboxy ; . R8 and R9 independently are hydrogen , C1 - C6alky1 , aryl , hetaryl , arle1 - C6alkyl , hetarle1 - C6 - alkyl , hydroxy , oxo , cyano , NRlel , C1 - C6alkyloxy , aryloxy , arle1 - C6alkyloxy , hetaryloxy , hetarle1 - C6alkyloxy , C1 - C6alkyloxyC1 - C6alkyl , C1 - C6alkyl - carbonyl , arylcarbonyl , hetarylcarbonyl , arle1 - C6a1ky1carbony1 , hetarle1 - C6alkyl - carbonyl , C1 - C6alkylcarboxy , arylcarboxy or arle1 - C6alkylcarboxy ; . R1 O and R1 1 independently are hydrogen , C1 - C8alkyl , aryl , hetaryl , arle1 - C6alkyl , C3 - C1O - cycloalkyl , C3 - C10hetcycloalky1 , C3 - C10cyc1oalkle1 - C6a1kyl , C1 - C6alkylcarboxyC1 - C6alkyl ; or. R10 and R11 together With the nitrogen to Which they are attached , are forming a saturated or partially saturated cyclic , bicyclic or tricyclic ring system containing from 4 to 10 carbon atoms and from 0 to 2 additional heteroatoms selected from nitrogen , oxygen or su1phur , the ring system optiona1ly being substituted With at least one of C1 - C8alkyl , aryl , hetaryl , arle1 - C6alkyl , hetarle1 - C6alkyl , hydroxy , oxo , cyano , C1 - C6alkyloxy , arle1 - C6alkyloxy , hetaryl C 1 - C6alkyloxy , C1 - C6alkylcarbonyl , arylcarbonyl , hetarylcarbonyl , arle1 - C6alkylcarbonyl , hetarle1 - C6alkylcarbonyl , C1 - C6alkylcarboxy , arylcarboxy or arle1 - 6 - alkylcarboxy ; or. a sa1t thereof With a pharmaceutically acceptable acid or base , or any optical isomer or mixture of optical isomers , including a racemic mixture , a prodrug thereof , or any tautomeric forms. ln another embodiment of the present inVention said substituted amides , or a prodrug thereof , as a component of the combination therapy is of the genera1 formu1a ( lla ) Wherein R1 is aryl , arle1 - C6alkyl or hetaryl optionally substituted With one or more of R6. ln another embodiment of the present inVention said substituted amides , or a prodrug thereof , as a component of the combination therapy is of the genera1 formu1a ( lla ) Wherein R1 is aryl optionally substituted With one or more of R6. ln another embodiment of the present inVention said substituted amides , or a prodrug thereof , as a component of the combination therapy is of the general formula ( lla ) Wherein R1 is arle1 - C6alkyl optionally substituted With one or more of R6. ln another embodiment of the present inVention said substituted amides , or a prodrug thereof , as a component of the combination therapy is of the general formula ( lla ) Wherein R1 is hetaryl optionally substituted With one or more of R6. C2 - C6alkenyl , . 5. lO. lS. 20. 25. 30. 56. ln another embodiment of the present inVention said substituted amides , or a prodrug thereof , as a component of the combination therapy is of the general formula ( lla ) Wherein R2 is C1 - C6alkyl , C3 - C10cycloalky1 , C3 - C1Ocycloa1kle1 - C6alkyl , trihalomethyl , arle1 - C6alkyl , or hetarle1 - C6alkyl Wherein the alkyl , cycloalkyl and aryl groups independently are optionally substituted With one or more R7. ln another embodiment of the present inVention said substituted amides , or a prodrug thereof , as a component of the combination therapy is of the general formula ( lla ) Wherein R2 is C1 - C6alkyl optionally substituted With one or more R7. ln another embodiment of the present inVention said substituted amides , or a prodrug thereof , as a component of the combination therapy is of the general formula ( lla ) Wherein R2 is trihalomethyl. ln another embodiment of the present inVention said substituted amides , or a prodrug thereof , as a component of the combination therapy is of the general formula ( lla ) Wherein R3 is C1 - C6alkyl optionally substituted With one or more of R8. ln another embodiment of the present inVention said substituted amides , or a prodrug thereof , as a component of the combination therapy is of the general formula ( lla ) Wherein R4 is C6 - C1Ocycloalkyl , or C6 - C1Ohetcycloalkyl , Wherein the cycloa1kyl and hetcycloalky1 groups independently are optionally substituted With one or more of R8. ln another embodiment of the present inVention said substituted amides , or a prodrug thereof , as a component of the combination therapy is of the general formula ( lla ) Wherein R4 is C6 - C1Ocycloalky1 optionally substituted With one or more of R8. ln another embodiment of the present inVention said substituted amides , or a prodrug thereof , as a component of the combination therapy is of the general formula ( lla ) Wherein. 5 R4 is C6 C6 - C1Ohetcycloa1kyl optional1y substituted With one. C1 - C6alky1oxyC1 - C6a1kyl , 40. 45. 50. 55. 60. 65. or more of R8. ln another embodiment of the present inVention said substituted amides , or a prodrug thereof , as a component of the combination therapy is of the general formula ( lla ) Wherein R3 and R4 together With the nitrogen to Which they are attached , are forming a saturated or partial1y saturated bicyclic / bridge ring system containing from 7 to l2 carbon atoms and from 0 to 2 additional heteroatoms selected from nitrogen , oxygen or sulphur , the ring system optionally being substituted With at least one of C1 - C6alkyl , aryl , hetaryl , arle1 - C6alkyl , hetaryl - C1 - C6alkyl , hydroxy , oxo , C1 - C6alkyloxy , arle1 - C6alkyloxy or hetarle_C6alkyloxy , Wherein the alkyl and aryl groups independently are optionally substituted With one ore more of R9. ln another embodiment of the present inVention said substituted amides , or a prodrug thereof , as a component of the combination therapy is of the general formula ( lla ) Wherein the saturated or partially saturated bicyclic / bridge ring system is 6 - aza - bicyclo [ 3 .2.1 ] octane. ln another embodiment of the present inVention said substituted amides , or a prodrug thereof , as a component of the combination therapy is of the general formula ( lla ) Wherein R6 and R7 independently are hydrogen , hydroxy , oxo , halo , cyano , C1 - C6alkyl , C1 - C6alkyloxy , trihalomethyl , NRlORll , arle1 - C5alkyloxy , hetarle1 - C6alkyloxy , C1 - C6alkylcarbonyl , arylcarbonyl , hetarylcarbonyl , arle1 - C6alkylcarbonyl , C1 - C6alkyloxycarbonyl , aryloxycarbonyl or arle1 - C6alkyloxycarbonyl. ln another embodiment of the present inVention said substituted amides , or a prodrug thereof , as a component of the combination therapy is of the general formula ( lla ) Wherein. US 7 , 50l , 405 B2. 57. R8 and R9 independently are hydrogen , C1 - C6alkyl , hydroxy , oxo , C1 - C6alkyloxy or arle1 - C6alkyloxy. ln another embodiment of the present inVention said substituted amides , or a prodrug thereof , as a component of the. 58 C1 - C6alkyloxy , C1 - C6alkylthio , aryl , arle1 - C6alkyl , hetaryl or hetaralkyl , Wherein the alkyl , aryl and hetaryl groups independently are optionally substituted With one or more of R8 ; or. combination therapy is of the general formula ( lla ) Wherein 5 R2 together With R3 are fo1ming a saturated or partially satu - . RlO and R” independently are hydrogen or C1 - C8alkyl. ln another embodiment of the present inVention said sub - . stituted amides , or a prodrug thereof , as a component of the. combination therapy is selected from the group consisting of : . 1 - ( 4 - Chloro - phenyl ) - 5 - propyl - 1H - pyrazole - 4 - carboxylic acid cyclohexyl - methyl - amide ; l - ( 4 - Chloro - phenyl ) - 5 - triﬂuoromethyl - 1H - pyrazole - 4 - carboxylic acid cyclohexyl - methyl - amide ; . [ 1 - ( 4 - Methoxy - phenyl ) - 5 - methyl - 1H - pyrazol - 4 - yl ] - ( 1 , 3 , 3 - trimethyl - 6 - aza - bicyclo [ 3 .2. 1 ] oct - 6 - yl ) - methanone ; 1 [ 1 - ( 4 - Chloro - phenyl ) - 5 - propyl - 1 H - pyrazol - 4 - yl ] - ( 1 , 3 , 3 - trimethyl - 6 - aza - bicyclo [ 3 .2 . 1 ] oct - 6 - yl ) - methanone ; . [ 1 - ( 3 , 5 - Dichloro - phenyl ) - 5 - propyl - 1 H - pyrazol - 4 - yl ] - ( 1 , 3 , 3 - trimethyl - 6 - aza - bicyclo [ 3.2.1 ] oct - 6 - yl ) - methanone ; or. a salt thereof With a pha1maceutically acceptable acid or base , or any optical isomer or mixture of optical isomers , including a racemic mixture , or any tautomeric forms. ln another embodiment of the present inVention said sub - . stituted amides , or a prodrug thereof , as a component of the. combination therapy is selected from the group consisting of : 1 - ( Phenyl ) - 5 - methyl - 1H - pyrazole - 4 - carboxylic acid cyclohexyl - methyl - amide ; . 1 - ( 4 - Fluoro - phenyl ) - 5 - methyl - 1H - pyrazo1e - 4 - carboxy1ic acid cyclohexyl - methyl - amide ; . 1 - ( 4 - Methoxy - phenyl ) - 5 - methyl - 1H - pyrazole - 4 - carboxylic acid cyclohexyl - methyl - amide ; . 1 - ( 4 - Chloro - phenyl ) - 5 - methyl - 1H - pyrazole - 4 - carboxylic acid cyclohexyl - methyl - amide ; . 1 - ( 2 - Methy1 - phenyl ) - 5 - methy1 - 1H - pyrazo1e - 4 - carboxylic acid cyclohexyl - methyl - amide ; . 1 - ( 4 - Amino - phenyl ) - 5 - methyl - 1H - pyrazole - 4 - carboxylic acid cyclohexyl - methyl - amide ; . 1 - ( 2 - Pyridyl ) - 5 - methyl - 1H - pyrazole - 4 - carboxylic acid cyclohexyl - methy1 - amide ; 1 - ( 2 - Pyridyl ) - 5 - propyl - 1H - pyrazole - 4 - carboxylic acid. cyclohexyl - methyl - amide ; or a salt thereof With a pharmaceutically acceptable acid or base , or any optical isomer or mixture of optica1 isomers , inc1uding a racemic mixture , or any tautomeric forms. ln another embodiment of the present inVention said substituted amides , or a prodrug thereof , as a component of the combination therapy is of the general formula ( llb ) . ( Hb ) . . Wherein. R1 is hydrogen , trihalomethyl , C1 - C6alkyl , C1 - C6alkyloxy , C1 - C6alkylthio , aryl , arle1 - C6alkyl , hetaryl or hetaralkyl , Wherein the alkyl , aryl and hetaryl groups independently are optionally substituted With one or more of R8 ; . R2 , R3 , R4 and R5 independently are hydrogen , halo , nitro , cyano , hydroxy , NR9R1O , trihalomethyl , C1 - C6alkyl , . lO. lS. 20. 30. 35. 40. 45. 55. 60. 65. rated cyclic ring system containing from 3 to 6 carbon atoms and from 0 to 2 additional heteroatoms selected from nitrogen , oxygen or sulphur , the ring system optionally being substituted With at least one of C1 - C6alkyl , aryl , hetaryl , arle1 - C6alkyl , hetarle1 - C6alkyl , hydroxy , oxo , C1 - C6alkyloxy , aryloxy , arle1 - C6alkyloxy or hetarle1 - C6alkyloxy ; or. R3 together With R4 are forming a saturated or partially saturated cyclic ring system containing from 3 to 6 carbon atoms and from 0 to 2 additional heteroatoms selected from nitrogen , oxygen or sulphur , the ring system optionally being substituted With at least one of C1 - C6alkyl , aryl , hetaryl , arle1 - C6alkyl , hetarle1 - C6alkyl , hydroxy , oxo , C1 - C6alkyloxy , aryloxy , arle1 - C6alkyloxy or hetarle1 - C6alkyloxy ; or. R4 together With R5 are forming a saturated or partially saturated cyclic ring system containing from 3 to 6 carbon atoms and from 0 to 2 additional heteroatoms selected from nitrogen , oxygen or sulphur , the ring system optionally being substituted With at least one of C1 - C6alkyl , aryl , hetaryl , arle1 - C6alkyl , hetarle1 - C6alkyl , hydroxy , oxo , C1 - C6alkyloxy , aryloxy , arle1 - C6alkyloxy or hetarle1 - C6alky1oxy ; . R6 is ary1 , hetary1 , ary1C1 - C6alkyl , C3 - C1Ocycloalkyl , C3 - C10hetcycloalkyl , C3 - C10cycloalkle1 - C6alkyl , C1 - C6alkylcarboxyC1 - C6alkyl , Wherein the alkyl , aryl and cycloalkyl groups independently are optionally substituted With one or more of R” ; . R7 is C1 - C8a1kyl , ary1 , C3 - C1ocycloalkyl , C3 - C10hetcycloalkyl , C3 - C1Ocycloalkle1 - C6alkyl , C1 - C3alkylcarboxyC1 - C6alkyl , Wherein the alkyl , aryl and cycloalkyl groups independently are optiona1ly substituted With one or more of R” ; or. R6 and R7 , together With the nitrogen to Which they are attached , are forming a saturated or partially saturated cyclic , bicyclic or tricyclic ring system containing from 6 to 10 carbon atoms and from 0 to 2 additiona1 heteroatoms selected from nitrogen , oxygen or sulphur , the ring system optionally being substituted With at least one of C1 - C8alkyl , aryl , hetaryl , arle1 - C6alkyl , hetarle1 - C6alkyl , hydroxy , oxo , cyano , C1 - C6alkyloxy , arle1 - C6alky1oxy , hetarle1 - C6a1kyloxy , C1 - C6a1kyloxyC1 - C6alkyl , C1 - C6alkylcarbonyl , arylcarbonyl , hetarylcarbonyl , arle1 - C6alkylcarbonyl , hetarle1 - C6alkylcarbonyl , C1 - C6alkylcarboxy , arylcarboxy or arle1 - C6 - alkylcarboxy Wherein the alkyl and aryl groups independently are optiona1ly substituted With one ore more of R8 ; . R9 and RlO independently are hydrogen , C1 - C8alkyl , aryl , hetaryl , arle1 - C6alkyl , C3 - C1O - cycloalkyl , C3 - C1Ohetcycloalkyl , C3 - C1Ocycloalkle1 - C6alkyl , C1 - C6alky1carboxyC1 - C6a1ky1 , Wherein the a1ky1 , ary1 and cycloalkyl groups independently are optionally substituted With one or more of R” ; or. R9 and R” ) , together With the nitrogen to Which they are attached , are fo1ming a saturated or partially saturated. hetary1 , ary1C1 - C6alkyl , . cyclic , bicyclic or tricyclic ring system containing from 4 to 10 carbon atoms and from 0 to 2 additional heteroatoms selected from nitrogen , oxygen or sulphur , the ring system optionally being substituted With at least one of C1 - C8alkyl , aryl , hetaryl , arle1 - C6alkyl , hetarle1 - . US 7 , 50l , 405 B2. 59. C6alkyl , hydroxy , oxo , cyano , C1 - C6alkyloxy , arle1 - C6alkyloxy , hetarle1 - C6alkyloxy , C1 - C6alkyloxyC1 - C6alkyl , C1 - C6alkylcarbonyl , arylcarbonyl , hetarylcarbony1 , arle1 - C6alkylcarbonyl , hetarle1 - C6alkylcarbonyl , C1 - C6alkylcarboxy , arylcarboxy or arle1 - C6 - alkylcarboxy Wherein the alkyl and aryl groups independently are optionally substituted With one ore more of R8 ; . R8 and R” independently are hydrogen , halo , hydroxy , oxo , nitro , cyano , C1 - C8alkyl , C1 - C6 - alkyloxy or aryloxy ; or a salt thereof With a pharmaceutically acceptable acid or base , or any optical isomer or mixture of optical isomers , including a racemic mixture , or any tautomeric forms. ln another embodiment of the present inVention said sub - . stituted amides , or a prodrug thereof , as a component of the. combination therapy is of the general formula ( llb ) Wherein. R1 is hydrogen or C1 - C6alkyl , Wherein the alkyl group is. optionally substituted With one or more of R8. ln another embodiment of the present inVention said sub - . stituted amides , or a prodrug thereof , as a component of the combination therapy is of the general formula ( llb ) Wherein. R1 is hydrogen. ln another embodiment of the present inVention said sub - . stituted amides , or a prodrug thereof , as a component of the. combination therapy is of the general formula ( llb ) Wherein. R2 , R3 , R4 and R5 are hydrogen. ln another embodiment of the present inVention said sub - . stituted amides , or a prodrug thereof , as a component of the. combination therapy is of the general formu1a ( llb ) Wherein. R3 together With R4 are forming a saturated or partially satu - . rated cyclic ring system containing from 3 to 6 carbon atoms. and from 0 to 2 additional heteroatoms selected from nitrogen or oxygen , the ring system optiona1ly being substituted With at least one of C1 - C6a1kyl , aryl , hetary1 , arle1 - C6a1kyl , hetarle1 - C6alkyl , hydroxy , oxo , C1 - C6alkyloxy , aryloxy , arle1 - C6alkyloxy or hetarle1 - C6alkyloxy. ln another embodiment of the present inVention said substituted amides , or a prodrug thereof , as a component of the combination therapy is of the general formu1a ( llb ) Wherein. R4 together With R5 are forming a saturated or partially satu - . rated cyclic ring system containing from 3 to 6 carbon atoms. and from 0 to 2 additional heteroatoms selected from nitrogen or oxygen , the ring system optiona1ly being substituted With at least one of C1 - C6a1kyl , aryl , hetary1 , arle1 - C6a1kyl , hetarle1 - C6alkyl , hydroxy , oxo , C1 - C6alkyloxy , aryloxy , arle1 - C6alkyloxy or hetarle1 - C6alkyloxy. ln another embodiment of the present inVention said substituted amides , or a prodrug thereof , as a component of the combination therapy is of the general formula ( llb ) Wherein. R6 and R7 , together With the nitrogen to Which they are. attached , are forming a saturated or partially saturated cyclic , . bicyclic or tricyclic ring system containing from 6 to 10. carbon atoms and from 0 to 2 additional heteroatoms selected. from nitrogen or oxygen , the ring system optionally being substituted With at least one of C1 - C8alkyl , aryl , hetaryl , arle1 - C6alkyl , hetarle1 - C6alkyl , hydroxy , oxo , cyano , . C1 - C6alkyloxy , arle1 - C6alkyloxy , hetarle1 - C6alkyloxy , . C1 - C6alkyloxyC1 - C6alkyl , C1 - C6a1ky1carbony1 , arylcarbo - . nyl , hetarylcarbonyl , arle 1 - C6alkylcarbonyl , hetarle1 - . C6alkylcarbonyl , C1 - C6alkylcarboxy , arylcarboxy or arle1 - . C6 - alkylcarboxy Wherein the alkyl and aryl groups. independently are optionally substituted With one ore more of. R8 ; ln another embodiment of the present inVention said sub - . stituted amides , or a prodrug thereof , as a component of the. combination therapy is of the general formula ( llb ) Wherein. R6 and R7 ; together With the nitrogen to Which they are. 5. lO. lS. 20. 25. 30. 35. 40. 45. 50. 55. 60. 65. 60. attached , are forming a saturated or partially saturated bicyclic or tricyclic ring system containing from 6 to 10 carbon atoms and from 0 to 2 additional heteroatoms selected from nitrogen or oxygen , the ring system optionally being substituted With at least one of C1 - C8alkyl , aryl , hetaryl , arle1 - C6alkyl , hetarle1 - C6alkyl , hydroxy , oxo , cyano , C1 - C6alkyloxy , arle1 - C6alkyloxy , hetarle1 - C6alkyloxy , C1 - C6alkyloxyC1 - C6alkyl , C1 - C6alkylcarbonyl , arylcarbonyl , hetarylcarbonyl , arle1 - C6alkylcarbonyl , hetarle1 - C6alkylcarbonyl , C1 - C6alkylcarboxy , arylcarboxy or arle1 - C6alkylcarboxy Wherein the alkyl and aryl groups independently are optionally substituted With one ore more of R8. ln another embodiment of the present inVention said substituted amides , or a prodrug thereof , as a component of the combination therapy is of the general formula ( llb ) Wherein R9 and Rm , together With the nitrogen to Which they are attached , are forming a saturated or partially saturated cyclic , bicyclic or tricyclic ring system containing from 4 to 10 carbon atoms and from 0 to 2 additional heteroatoms selected from nitrogen or oxygen , the ring system optionally being substituted With at least one of C1 - C8alkyl , aryl , hetaryl , arle1 - C6alkyl , hetarle1 - C6alkyl , hydroxy , oxo , cyano , C1 - C6alkyloxy , arle1 - C6alkyloxy , hetarle1 - C6alkyloxy , C1 - C6alkyloxyC1 - C6alkyl , C1 - C6alkylcarbonyl , arylcarbonyl , hetarylcarbonyl , arle1 - C6alkylcarbonyl , hetarle1 - C6alkylcarbonyl , C1 - C6alkylcarboxy , arylcarboxy or arle1 - C6 - alkylcarboxy Wherein the alkyl and aryl groups independently are optionally substituted With one ore more of R8. ln another embodiment of the present inVention said substituted amides , or a prodrug thereof , as a component of the combination therapy is se1ected from the group consisting of : pyrazolo [ 1 , 5 - a ] pyridin - 3 - yl - ( 1 , 3 , 3 - trimethyl - 6 - aza - bicyc1o [ 3 .2. 1 ] oct - 6 - yl ) - methanone ; ( 2 - Methyl - pyrazolo [ 1 , 5 - a ] pyridin - 3 - yl ) - ( 1 , 3 , 3 - trimethyl - 6 - aza - bicyclo [ 3 .2. 1 ] oct - 6 - yl ) - methanone ; Pyrazolo [ 1 , 5 - a ] pyridine - 3 - carboxylic acid cyclohexy1 - methyl - amide ; or a salt thereof With a pharmaceutica1ly acceptable acid or base , or any optical isomer or mixture of optical isomers , including a racemic mixture , or any tautomeric forms. ln another embodiment of the present inVention said substituted amides , or a prodrug thereof , as a component of the combination therapy is of the genera1 formula ( llc ) : . ( 11C ) . R5 N R4 R6 —< / / N R3 R1 R , . Wherein. R1 is hydrogen , C1 - C8alkyl , C1 - C6alkyloxyC1 - C6alkyl , aryl , hetaryl , arle1 - C6alkyl , hetarle1 - C6alkyl , C1 - C6SO2 , arylSO2 , hetarylSO2 , arle1 - C6alkylSO2 or hetarle1 - C6alkylSO2 all of Which is optionally substituted With one or more R8 ; . R2 and R5 independently are hydrogen , halo , nitro , cyano , trihalomethyl , C1 - C6alkyl , aryl , arle1 - C6alkyl , hetaryl or hetarle1 - C6alkyl Wherein the alkyl , aryl , arylalkyl , hetaryl and hetarylalkyl groups independently are substituted With one or more R9 ; and. US 7 , 50l , 405 B2. 61. either R3 is hydrogen ; and R4 is C ( O ) NR7R8 ; or R3 is C ( O ) NR7R8 ; and R4 is hydrogen ; and. R6 is hydrogen , halo , cyano , trihalomethyl , NR”R” , C1 - C6alkyl , aryl , arle1 - C6alkyl , hetaryl or hetarle1 - C6alkyl Wherein the alkyl , aryl , arylalkyl , hetaryl and hetarylalkyl groups independently are substituted With one. or more R9 ; and. R7 and R8 independently are C1 - C8alkyl , C3 - C1Ocycloalkyl , C3 - C1Ohetcycloalkyl , C3 - C10cycloalkle1 - C6alkyl , 10 Wherein the alkyl , cycloalkyl and hetcycloalkyl groups independently are optionally substituted With one or more. of R” ) ; or. R7 and R8 together With the nitrogen to Which they are 15 attached , are forming a saturated or partially saturated bicyclic or tricyclic ring system containing from 6 to 10 carbon atoms and from 0 to 2 additional heteroatoms selected from nitrogen or oxygen , the ring system optionally being substituted With at least one of C1 - C8alkyl , arle1 - C6alkyl , hetarle1 - C6alkyl , hydroxy , cyano , . C1 - C6alkyloxy , arle 1 - C6alkyloxy , hetarle 1 - C6alkyloxy , C1 - C6alkyloxyC1 - C6alkyl , C1 - C6alkylcarbonyl , arylcar - 25 bonyl , arle1 - C6alkylcarbonyl , hetarle1 - C6alkylcarbonyl , C1 - C6alkylcarboxy , ary1carboxy or arle1 - C6alkylcarboxy Wherein the alkyl and aryl groups independently are optionally substituted With one. 20. hetarylcarbonyl , . ore more of R” ; 30. R9 is hydrogen , hydroxy , oxo , ha1o , nitro , cyano , C1 - C6a1kyl , C1 - C6a1ky1oxy , trihalomethyl , triha1omethoxy , NR”Rl3 , C ( O ) NR”Rl3 , arle1 - C6alkyloxy , C1 - C6alkylcarbonyl , . arylcarbonyl , arle1 - C6alkylcarbonyl , 35 C1 - C6alkylcarboxy , arylcarboxy or arle1 - C6alkylcarboxy ; . R10 and R1 1 independently are hydrogen , halo , oxo , hydroxy , C1 - C6alkyl , aryl , arle 1 - C6alkyl , hetaryl or hetarylalkyl ; R” and R” independently are hydrogen , C1 - C8alkyl , aryl , hetaryl , arle1 - C6alkyl , C3 - C10 - cycloalkyl , C3 - C10hetcycloalky1 , C3 - C10cyc1oalkle1 - C6a1kyl , C 1 - C6a1ky1carbonyl , ary1carbonyl , arle1 - C8alkylcarbonyl , hetarylcarbonyl , hetarle1 - 45 C6alkylcarbonyl , C1 - C6alkylcarboxyC1 - C6alkyl ; or. R” and Rl3 together With the nitrogen to Which they are attached , are forming a saturated or partially saturated cyclic , bicyclic or tricyclic ring system containing from 4 50 to 10 carbon atoms and from 0 to 2 additiona1heteroatoms selected from nitrogen , oxygen or sulphur , the ring system optionally being substituted With at least one of C1 - C8a1ky1 , ary1 , hetary1 , arle1 - C6alkyl , hetarle1 - C6alkyl , hydroxy , oxo , cyano , C1 - C6alkyloxy , arle1 - C6alkyloxy , hetarle1 - C6alkyloxy , C1 - C6alkyl - oxyC1 - C6alkyl , C1 - C6alkylcarbonyl , arylcarbonyl , hetarylcarbonyl , arle1 - C6alkyl - carbonyl , hetarle1 - C6alkylcarbonyl , C1 - C6alkylcarboxy , arylcarboxy or arle 1 - C6alkylcarboxy ; or a salt thereof With a pharmaceu - 60 tically acceptable acid or base , or any optical isomer or mixture of optical isomers , including a racemic mixture , a prodrug thereof , or any tautomeric fo1ms. 40. 55. ln another embodiment of the present inVention said sub - 65 stituted amides , or a prodrug thereof , as a component of the combination therapy is of the general formula ( lld ) . 62 R5 ( Hd ) N R4 < / / N R3 R1 R , . Wherein. R1 is hydrogen , C1 - C8alkyl , aryl , hetaryl , arle1 - C6alkyl or hetarle1 - C6alkyl optionally substituted With one or more R8 ; . R2 and R5 independently are hydrogen , halo , nitro , cyano , trihalomethyl , C1 - C6alkyl , aryl , arle1 - C6alkyl , hetaryl or hetarle1 - C6alkyl Wherein the alkyl , aryl , arylalkyl , hetaryl and hetarylalkyl groups independently are substituted With one or more R8 ; and. either R3is hydrogen ; and R4is C ( O ) NR6R7 ; or R3 is C ( O ) NR6R7 ; and R4is hydrogen ; . R6 and R7 independently are C1 - C8alkyl , C3 - C1Ocycloalkyl , C3 - C10hetcycloalkyl , C3 - C10cycloalkle1 - C6alkyl , Wherein the alkyl , cycloalkyl and hetcycloalkyl groups independently are optiona1ly substituted With one or more of R9 ; or. R6 and R7 together With the nitrogen to Which they are attached , are forming a saturated or partially saturated bicyclic or tricyclic ring system containing from 6 to 10 carbon atoms and from 0 to 2 additional heteroatoms selected from nitrogen or oxygen , the ring system option - al1y being substituted With at least one of C1 - C8alkyl , ary1C1 - C6alkyl , hetary1C1 - C6alky1 , hydroxy , cyano , C 1 - C6alkyloxy , arle1 - C6alkyloxy , hetarle 1 - C6alkyloxy , C1 - C6alkyloxyC1 - C6alkyl , C1 - C6alkylcarbonyl , arylcarbonyl , hetarylcarbonyl , arle1 - C6alkylcarbonyl , hetarle1 - C6a1kylcarbony1 , C1 - C6alkylcarboxy , arylcarboxy or arle 1 - C6alkylcarboxy Wherein the alkyl and aryl groups independently are optionally substituted With one ore more of R” ; . R8 is hydrogen , hydroxy , oxo , halo , nitro , cyano , C1 - C6alkyl , C1 - C6alkyloxy , trihalomethyl , trihalomethoxy , NR”R” , arle1 - C6alkyloxy , C1 - C6alkylcarbonyl , arylcarbonyl , arle1 - C6alkylcarbonyl , C1 - C6alkylcarboxy , arylcarboxy or arle1 - C6alkylcarboxy ; . R9 and RlO independently are hydrogen , halo , oxo , hydroxy , C1 - C6alkyl , aryl , arle1 - C6alkyl , hetaryl or hetarylalkyl ; . R” and R” independently are hydrogen , C1 - C8alkyl , aryl , hetaryl , arle1 - C6alkyl , C3 - C10 - cycloalkyl , C3 - C1Ohetcycloalkyl , C3 - C10cycloalkle1 - C6alkyl , C1 - C6alkyl - carboxyC1 - C6alkyl ; or. R” and R” together With the nitrogen to Which they are attached , are forming a saturated or partially saturated cyclic , bicyclic or tricyclic ring system containing from 4 to 10 carbon atoms and from 0 to 2 additiona1 heteroatoms selected from nitrogen , oxygen or sulphur , the ring system optionally being substituted With at least one of C1 - C8alkyl , aryl , hetaryl , arle1 - C6alkyl , hetarle1 - C6alkyl , hydroxy , oxo , cyano , C1 - C6alkyloxy , arle1 - C6alkyloxy , hetarle1 - C6alkyloxy , C1 - C6alkyl - oxyC1 - C6alkyl , C1 - C6alkylcarbonyl , arylcarbonyl , hetarylcarbonyl , arle1 - C6alkyl - carbonyl , hetarle1 - C6alkylcarbonyl , C1 - C6alkylcarboxy , arylcarboxy or arle1 - C6alkylcarboxy ; or. US 7 , 50l , 405 B2. 63. a salt thereof With a pharmaceutically acceptable acid or base , or any optical isomer or mixture of optical isomers , including a racemic mixture , or any tautomeric forms. ln another embodiment of the present inVention said sub - . stituted amides , or a prodrug thereof , as a component of the 5. combination therapy is of the general formula ( llc ) and ( lld ) Wherein R1 is hydrogen , C1 - C8alkyl , arle1 - C6alkyl , hetarle1 - C6alkyl , arylSO2 , hetarylSO2 , arle1 - C6alkylSO2 or hetarle1 - C6alkylSO2 all of Which is optionally substituted With one or more R8. ln another embodiment of the present inVention said substituted amides , or a prodrug thereof , as a component of the combination therapy is of the general formula ( llC ) and ( lld ) Wherein R1 is hydrogen , C1 - C8alkyl , arle1 - C6alkyl , . hetarle1 - C6alkyl all of Which is optionally substituted With 15. one or more R8. ln another embodiment of the present inVention said substituted amides , or a prodrug thereof , as a component of the combination therapy is of the general formula ( llC ) and ( lld ) . Wherein R1 is arylSO2 , hetarylSO2 , arle1 - C6alkylSO2 or 20. hetarle1 - C6alkylSO2 all of Which is optionally substituted With one or more R8. ln another embodiment of the present inVention said substituted amides , or a prodrug thereof , as a component of the. combination therapy is of the general formula ( llC ) and ( lld ) 25. Wherein R2 is hydrogen. ln another embodiment of the present inVention said substituted amides , or a prodrug thereof , as a component of the combination therapy is of the genera1 formu1a ( llC ) and ( lld ) Wherein R3 is hydrogen and R4 is C ( O ) NR7R8. ln another embodiment of the present inVention said substituted amides , or a prodrug thereof , as a component of the combination therapy is of the genera1 formu1a ( llC ) and ( lld ) Wherein R3 is C ( O ) NR7R8 and R4 is hydrogen. ln another embodiment of the present inVention said sub - 35. stituted amides , or a prodrug thereof , as a component of the combination therapy is of the general formula ( llc ) and ( lld ) Wherein R5 is hydrogen. ln another embodiment of the present inVention said sub - . stituted amides , or a prodrug thereof , as a component of the 40. combination therapy is of the general formula ( llC ) Wherein R6 is hydrogen , NR”R13 , C1 - C6alkyl , aryl or hetaryl Wherein the a1ky1 , aryl and hetaryl independently are substituted With one or more R9. ln another embodiment of the present inVention said sub - 45. stituted amides , or a prodrug thereof , as a component of the combination therapy is of the general formula ( llC ) and ( lld ) Wherein R7 and R8 independent1y are C1 - C8alkyl or C3 - C10cycloalkyl , Wherein the alkyl and cycloalkyl groups. 64. ln another embodiment of the present inVention said substituted amides , or a prodrug thereof , as a component of the combination therapy is of the general formula ( llC ) and ( lld ) Wherein R9 is hydrogen , hydroxy , oxo , halo , nitro , cyano , C1 - C6alkyl , C1 - C6alkyloxy , trihalomethyl , trihalomethoxy , NR”R” , C ( O ) NR”R” , arle1 - C6alkyloxy , C1 - C6alkylcarbonyl , arylcarbonyl , arle1 - C6alkylcarbonyl. ln another embodiment of the present inVention said substituted amides , or a prodrug thereof , as a component of the combination therapy is of the general formula ( llc ) and ( lld ) Wherein RlO and R” independently are hydrogen , halo , oxo , hydroxy , C1 - C6alkyl , aryl , arle1 - C6alkyl , hetaryl or hetarylalkyl. ln another embodiment of the present inVention said substituted amides , or a prodrug thereof , as a component of the combination therapy is of the general formula ( llC ) and ( lld ) Wherein R11 and R12 together With the nitrogen to Which they are attached , are forming a saturated or partially saturated cyclic , bicyclic or tricyclic ring system containing from 4 to 10 carbon atoms and from 0 to 2 additional heteroatoms selected from nitrogen or oxygen , the ring system optionally being substituted With at least one of C1 - C8alkyl , aryl , hetaryl , arle1 - C6alkyl , hetarle1 - C6a1kyl , hydroxy , oxo , cyano , C1 - C6alkyloxy , arle1 - C6alkyloxy , hetarle1 - C6alkyloxy , C1 - C6alkyl - oxyC1 - C6alkyl , C1 - C6alkylcarbonyl , arylcarbonyl , hetarylcarbonyl , arle1 - C6alkyl - carbonyl , hetarle1 - C6alkylarbonyl , C1 - C6alkylcarboxy , ary1carboxy or arle1 - C6a1kylcarboxy. ln another embodiment of the present inVention said substituted amides , or a prodrug thereof , as a component of the combination therapy is selected from the gropu consisting of : 1H - Benzoimidazole - 5 - carboxylic acid cyclohexyl - methylamide ; 1 - Benzy1 - 1H - benzoimidazo1e - 5 - carboxylic acid cyc1ohexy1 - methyl - amide ; ( 1 H - Benzoimidazol - 5 - yl ) - ( 1 , 3 , 3 - trimethyl - 6 - aza - bicyclo [ 3 .2 . 1 ] oct - 6 - yl ) - methanone ; or a salt thereof With a pharmaceutica1ly acceptab1e acid or base , or any optical isomer or mixture of optica1 isomers , including a racemic mixture , or any tautomeric forms. ln another embodiment of the present inVention said substituted amides , or a prodrug thereof , as a component of the combination therapy is se1ected from the group consisting of : lsopropyl - 2 - triﬂuoromethyl - 1H - benzoimidazole - 5 - carboxylic acid cyclohexyl - methyl - amide ; 1 - Benzyl - 1H - benzoimidazole - 5 - carboxylic acid cyclohexylmethyl - amide ; 2 - Methyl - 1H - benzoimidazo1e - 5 - carboxylic acid cyc1ohexy1 - methyl - amide ; . independently are optionally substituted With one or more of 50 2 - Hydroxymethyl - 1H - benzoimidazole - 5 - carboxylic acid. R10. ln another embodiment of the present inVention said substituted amides , or a prodrug thereof , as a component of the combination therapy is of the general formula ( llc ) and ( lld ) . Wherein R7 and R8 together With the nitrogen to Which they 55. are attached , are forming a saturated or partially saturated bicyclic or tricyclic ring system containing from 6 to 10 carbon atoms and from 0 to 2 additional heteroatoms selected from nitrogen or oxygen , the ring system optionally being. cyclohexyl - methyl - amide ; 2 - ( 4 - Amino - phenyl ) - 1H - benzoimidazole - 5 - carboxylic acid cyclohexyl - methyl - amide ; ( 1 H - Benzoimidazol - 5 - yl ) - ( 1 , 3 , 3 - trimethyl - 6 - aza - bicyclo [ 3 .2 . 1 ] oct - 6 - yl ) - methanone ; ( 2 - Methyl - 1H - benzoimidazol - 5 - yl ) - ( 1 , 3 , 3 - trimethyl - 6 - azabicyclo [ 3 .2. 1 ] oct - 6 - yl ) - methanone ; ( 2 - Amino - 1H - benzoimidazol - 5 - yl ) - ( 1 , 3 , 3 - trimethyl - 6 - azabicyclo [ 3 .2. 1 ] oct - 6 - yl ) - methanone ; . substituted With at least one of C1 - C8alkyl , arle1 - C6alkyl , 60 ( 2 - Benzo [ 1 , 3 ] dioxol - 5 - yl - 1H - benzoimidazol - 5 - yl ) - ( 1 , 3 , 3 - . hetarle1 - C6alkyl , hydroxy , cyano , C1 - C6alkyloxy , arle1 - C6alkyloxy , hetarle 1 - C6alkyloxy , C 1 - C6alkyloxyC1 - C6alkyl , C1 - C6alkylcarbonyl , arylcarbonyl , hetarylcarbonyl , arle1 - C6alkylcarbonyl , hetarle1 - C6alkylcarbonyl , . C1 - C6alkylcarboxy , arylcarboxy or arle1 - C6alkylcarboxy 65. Wherein the alkyl and aryl groups independently are optionally substituted With one ore more of R”. trimethyl - 6 - aza - bicyclo [ 3 .2. 1 ] oct - 6 - yl ) - methanone ; 3 - [ 5 - ( 1 , 3 , 3 - Trimethyl - 6 - aza - bicyclo [ 3.2.1 ] octane - 6 - carbonyl ) - 1H - benzoimidazol - 2 - yl ] - benzoic acid methyl ester ; ( 2 - Thiophen - 2 - yl - 1H - benzoimidazol - 5 - yl ) - ( 1 , 3 , 3 - trimethyl - 6 - aza - bicyclo [ 3.2. l ] oct - 6 - yl ) - methanone ; [ 2 - ( 2 - Nitro - phenyl ) - 1H - benzoimidazol - 5 - yl ] - ( 1 , 3 , 3 - trimethyl - 6 - aza - bicyclo [ 3 .2. 1 ] oct - 6 - yl ) - methanon ; or. US 7 , 50l , 405 B2. 65. a salt thereof With a pharmaceutically acceptable acid or base , or any optical isomer or mixture of optical isomers , including a racemic mixture , a prodrug thereof , or any tautomeric forms. ln another embodiment of the present inVention said sub - . stituted amides , or a prodrug thereof , as a component of the. combination therapy is of the general formula ( lle ) . ( lle ) . Wherein. X is oxygen or ( CRlR2 ) , 1 ; . R1 , R2 , R3 , and R4 independently are hydrogen , C1 - C6alkyl , aryl , arle1 - C6alkyl , hetaryl or hetarle1 - C6alkyl optionally substituted With one or more R8 independently ; or. R1 and either R3 or R4 together are fo1ming a saturated or partially saturated ring system containing from 4 to 8 carbon atoms , the ring system optionally being substituted With at least one of C1 - C6alkyl , hydroxy , oxo , aryl , hetaryl , arle1 - C6alkyl or hetarle1 - C6alkyl ; or. R1 and either R3 or R4 together With the single bond are forming a carbon - carbon double bond ; . R5 ii C1 - C8alkyl optionally substituted With one or more of R ; . R6 is C3 - C1Ocycloalkyl , C3 - C10hetcycloalkyl , C3 - C10cycloalkle1 - C6alkyl , Wherein the alkyl , cycloalkyl and hetcycloalkyl groups independent1y are optionally substituted With one or more of R9 ; or. R5 and R6 together With the nitrogen to Which they are attached , are forming a saturated or partially saturated cyclic , bicyc1ic or tricyclic ring system containing from 6 to 10 carbon atoms and from 0 to 2 additional heteroatoms selected from nitrogen , oxygen or sulphur , the ring system optionally being substituted With at least one of C1 - C6a1ky1 , ary1 , hetary1 , arle1 - C6alkyl , hetarle1 - C6alkyl , hydroxy , oxo , cyano , C1 - C6alkyloxy , arle1 - C6alkyloxy , hetarle1 - C6alkyloxy , C1 - C6alkyloxyC1 - C6alkyl , C1 - C6alkylcarbonyl , arylcarbonyl , hetarylcarbonyl , arle1 - C6alkylcarbonyl , hetarle1 - C6alkylcarbonyl , C1 - C6alkylcarboxy , arylcarboxy or arle 1 - C6alkylcarboxy Wherein the a1ky1 and aryl groups indepCendently are optionally substituted With one ore more of R ; . R7 is hydrogen , halo , nitro , NR”R” , cyano , trihalomethyl , C1 - C6alkyl , aryl , arle1 - C6alkyl , C1 - C6alkyloxy , aryloxy , arle1 - C6alkyloxy , hetaryl , hetarle1 - C6alkyl , hetaryloxy or hetarle1 - C6 - alkyloxy optionally substituted With one or more R” independent1y ; . R8 and R9 independently are hydrogen , hydroxy , oxo , halo , nitro , cyano , C1 - C6alkyl , C1 - C6 - alkyloxy , trihalomethyl , trihalomethoxy , NR”R” , C1 - C6alkylcarbonyl , arylcarbonyl , arle1 - C6alkylcarbonyl , C1 - C6alkylcarboxy , arylcarboxy or arle1 - C6alkylcarboxy ; RlO is hydrogen , C1 - C8alkyl , arle1 - C6alkyl , hetarle1 - C6alkyl , C1 - C6alkyloxy , arle 1 - C6alkyloxy , hetarle1 - C6alkyloxy ; . R” is hydrogen , halo , hydroxy , oxo , nitro , cyano , C1 - C8alkyl , C1 - C6alkyloxy , aryloxy or hetaryloxy ; . 5. lO. lS. 20. 66. R” and R” independently are hydrogen , C1 - C8alkyl , aryl , hetaryl , arle1 - C6alkyl , C3 - C10cycloalkyl , C3 - C1Ohetcycloalkyl , C1 - C6alkylcarbonyl , arle1 - C6alky1carbonyl , C3 - C10cycloalkle1 - C6 - alkyl , Cl - C6alkyloxycarbonyl ; or. R” and R13 are together With the nitrogen to Which they are attached , are forming a saturated or partially saturated cyclic , bicyclic or tricyclic ring system containing from 4 to 10 carbon atoms and from 0 to 2 additional heteroatoms selected from nitrogen , oxygen or sulphur , the ring system optionally being substituted With at least one of C1 - C6alkyl , aryl , hetaryl , arle1 - C6 - alkyl , hetarle1 - C6alkyl , hydroxy , oxo , cyano , C1 - C6alkyloxy , arle1 - C6alkyloxy , hetarle1 - C6alkyloxy , C1 - C6alkyloxyC1 - C6alkyl , C1 - C6alkylcarbonyl , arylcarbonyl , hetarylcarbonyl , arle1 - C6alkylcarbonyl , hetarle1 - C6alkylcarbonyl , C1 - C6alkylcarboxy , arylcarboxy or arle1 - 6alkylcarboxy ; . n is 1 or 2 ; or. a salt thereof With a pharmaceutically acceptable acid or base , or any optical isomer or mixture of optical isomers , including a racemic mixture , a prodrug thereof , or any tautomeric forms. ln another embodiment of the present inVention said sub - . 25 stituted amides , or a prodrug thereof , as a component of the. 30. 35. 40. 45. 50. 55. 65. combination therapy is of the general formula ( lle ) Wherein X is ( CR1R2 ) , 1 , Wherein R1 , R2 and n are as deﬁned aboVe. ln another embodiment of the present inVention said substituted amides , or a prodrug thereof , as a component of the combination therapy is of the general formula ( lle ) Wherein n is 1. ln another embodiment of the present inVention said substituted amides , or a prodrug thereof , as a component of the combination therapy is of the general fo1mula ( lle ) Wherein X is oxygen. ln another embodiment of the present inVention said substituted amides , or a prodrug thereof , as a component of the combination therapy is of the general formu1a ( lle ) Wherein Rl , R2 , R3 , and R4 independently are hydrogen , Cl - C6alkyl or arle1 - C6alkyl , optionally substituted With one or more R8. ln another embodiment of the present inVention said substituted amides , or a prodrug thereof , as a component of the combination therapy is of the general formu1a ( lle ) Wherein R1 and either R3 or R4 together With the single bond are forming a carbon - carbon double bond. ln another embodiment of the present inVention said substituted amides , or a prodrug thereof , as a component of the combination therapy is of the general formu1a ( lle ) Wherein R5 is C1 - C8alkyl optionally substituted With one or more of R9. ln another embodiment of the present inVention said substituted amides , or a prodrug thereof , as a component of the combination therapy is of the general formu1a ( lle ) Wherein R6 is C3 - C1Ocycloalkyl or C3 - C1Ohetcycloalkyl each of Which is optionally substituted With one or more of R9. ln another embodiment of the present inVention said substituted amides , or a prodrug thereof , as a component of the combination therapy is of the general formu1a ( lle ) Wherein R6 is C3 - C1Ocycloalkyl optionally substituted With one or. arle1 - C6alkyloXy , 60 more of R9. ln another embodiment of the present inVention said substituted amides , or a prodrug thereof , as a component of the combination therapy is of the general formula ( lle ) Wherein R5 and R6 together With the nitrogen to Which they are attached , are forming a saturated or partially saturated cyclic , bicyclic or tricyclic ring system containing from 6 to 10 carbon atoms and from 0 to 2 additional heteroatoms selected. US 7 , 50l , 405 B2. 67. from nitrogen , oxygen or sulphur , the ring system optionally being substituted With at least one of C1 - C6alkyl , aryl , hetaryl , arle1 - C6alkyl , hetarle1 - C6alkyl , hydroxy , oxo , cyano , C1 - C6alky1oxy , arle 1 - C6alkyloxy , hetarle1 - C6alkyloxy , C1 - C6alkyloxyC1 - C6alkyl , C1 - C6alkylcarbonyl , 5 arylcarbonyl , hetarylcarbonyl , arle1 - C6alkylcarbonyl , hetarle1 - C6alkylcarbonyl , C1 - C6alkylcarboxy , arylcarboxy or arle1 - C6alkylcarboxy Wherein the alkyl and aryl groups independently are optionally substituted With one ore more of R”. ln another embodiment of the present inVention said substituted amides , or a prodrug thereof , as a component of the combination therapy is of the general formula ( lle ) Wherein R7 is hydrogen , halo , NR”R” , trihalomethyl , C1 - C6alkyloxy , aryloxy , arle1 - C6alkyloxy or hetaryloxy 15 optionally substituted With one or more R” independently. ln another embodiment of the present inVention said sub - . lO. stituted amides , or a prodrug thereof , as a component of the combination therapy is of the general formula ( lle ) Wherein R8 and R9 independently are hydrogen , hydroxy , oxo , halo , 20 nitro , cyano , C1 - C6alkyl , C1 - C6 - alkyloxy , trihalomethyl , or NRl2Rl3. ln another embodiment of the present inVention said substituted amides , or a prodrug thereof , as a component of the combination therapy is of the general formula ( lle ) Wherein 25 R” is hydrogen or C1 - C8alkyl. ln another embodiment of the present inVention said substituted amides , or a prodrug thereof , as a component of the combination therapy is of the genera1 formu1a ( lle ) Wherein the bicyclic ring system is 6 - aza - bicyclo [ 3 .2.1 ] octane option - 30 ally substituted With one or more of C1 - C6alkyl. ln another embodiment of the present inVention said substituted amides , or a prodrug thereof , as a component of the combination therapy is of the genera1 formu1a ( lle ) Wherein the bicyclic ring system is 1 , 3 , 3 - trimethyl - 6 - aza - bicyclo 35 [ 3.2.1 ] octane. ln another embodiment of the present inVention said substituted amides , or a prodrug thereof , as a component of the combination therapy is se1ected from the group consisting of : 2 , 3 - Dimethyl - 2 , 3 - dihydro - benzofuran - 7 - carboxylic acid 40 cyclohexyl - methyl - amide ; 2 , 5 - Dimethyl - 3 - phenyl - benzofuran - 7 - carboxylic acid cyclohexyl - methy1 - amide ; 2 , 2 - Dimethyl - 2 , 3 - dihydro - benzofuran - 7 - carboxylic cyclohexyl - methyl - amide ; 2 - Methyl - 2 , 3 - dihydro - benzoﬁ1ran - 7 - carboxylic acid cyclohexyl - methyl - amide ; 2 , 3 - Dimethyl - 2 , 3 - dihydro - benzofuran - 7 - yl ) - ( 2 , 4 , 4 - trimethyl - 6 - aza - bicyclo [ 3.2.1 ] oct - 6 - yl ) - methanone ; 4 - Methoxy - 2 - methyl - 2 , 3 - dihydro - benzofuran - 7 - carboxylic 50 acid cyclohexyl - methyl - amide ; 2 - Methyl - benzofuran - 7 - carboxylic acid cyclohexyl - methylamide ; ( 2 - Methyl - 2 , 3 - dihydro - benzofuran - 7 - yl ) - ( 1 , 3 , 3 - trimethyl - 6 - aza - bicyclo [ 3.2.1 ] oct - 6 - yl ) - methanone ; Benzofuran - 7 - carboxylic acid cyclohexyl - methyl - amide ; 2 , 3 - dihydro - benzofuran - 7 - carboxylic acid cyclohexylmethyl - amide ; 3 , 3 - Dimethyl - 2 , 3 - dihydro - benzofuran - 7 - carboxylic cyclohexyl - methyl - amide ; Chroman - 8 - carboxylic acid cyclohexyl - methyl - amide ; or a salt thereof With a pharmaceutically acceptable acid or base , . acid 45. 55. acid 60. or any optical isomer or mixture of optical isomers , includ - . ing a racemic mixture , or any tautomeric forms. ln another embodiment of the present inVention said sub - 65 stituted amides , or a prodrug thereof , as a component of the combination therapy is selected from the group consisting of : . 68. 2 , 3 - dihydro - benzofuran - 7 - carboxylic acid cyclohexyl - methyl - amide ; Benzofuran - 7 - carboxylic acid cyclohexyl - methyl - amide ; 2 - Methyl - 2 , 3 - dihydro - benzofuran - 7 - carboxylic acid cyclohexyl - methyl - amide ; 2 - Methyl - benzofuran - 7 - carboxylic acid cyclohexyl - methylamide ; 3 , 3 - Dimethyl - 2 , 3 - dihydro - benzofuran - 7 - carboxylic cyclohexyl - methyl - amide ; ( 2 , 3 - Dimethyl - 2 , 3 - dihydro - benzoﬁ1ran - 7 - yl ) - ( 2 , 4 , 4 - trimethyl - 6 - aza - bicyclo [ 3 .2. l ] oct - 6 - yl ) - methanone ; 4 - Methoxy - 2 - methyl - 2 , 3 - dihydro - benzofuran - 7 - carboxylic acid cyclohexyl - methyl - amide ; 2 , 2 - Dimethyl - 2 , 3 - dihydro - benzofuran - 7 - carboxylic cyclohexyl - methyl - amide ; ( 2 - Methyl - 2 , 3 - dihydro - benzofuran - 7 - yl ) - ( 1 , 3 , 3 - trimethyl - 6 - aza - bicyclo [ 3.2.1 ] oct - 6 - yl ) - methanone ; Chroman - 8 - carboxylic acid cyclohexyl - methyl - amide ; or a salt thereof With a pharmaceutically acceptable acid or base , or any optical isomer or mixture of optical isomers , including a racemic mixture , a prodrug thereof , or any tautomeric forms. ln another embodiment of the present inVention said substituted amides , or a prodrug thereof , as a component of the combination therapy is of the general formula ( llf ) . acid. acid. mm. . Wherein. R1 is hydrogen , C1 - C8alkyl , hetaryl , arle 1 - C6alkyl or. hetarle1 - C6alkyl optionally substituted With one or more. R9 ; . R2 , R3 , R4 , R5 and R6 independently are hydro gen , halo , nitro , cyano , trihalomethyl , carboxy , N ( R”R” ) , C ( O ) NR7R8 , C1 - C8alkyl , C3 - C10cycloalkyl , C3 - C10hetcycloalkyl , N ( R”R” ) C1 - C6alkyl , C1 - C6alkyloxy , C1 - C6a1kyloxyC1 - C6alkyl , aryl , arle1 - C6alkyl , aryloxy , aryloxyC1 - C6alkyl , arle1 - C6alkyloxy , arle1 - C6alkyloxyC1 - C6alkyl , C1 - C6alkylcarboxy , arylcarboxy , arle1 - C6alkyl - carboxy , hetaryl , hetarle1 - C6alkyl , hetarle1 - C6alkyloxy , hetaryloxyC1 - C6alkyl or hetary1C1 - C6alkyloxyC1 - C6a1kyl Wherein Wherein the alkyl , aryl , arylalkyl , hetaryl and hetarylalkyl groups independently are substituted With one or more R9 ; . R7 is hydrogen or C1 - C8alkyl optionally substituted With one or more of R” ; . R8 is C3 - C1Ocycloalkyl , C3 - C10cycloalkle1 - C6alkyl , Wherein the cycloalkyl and hetcycloalkyl groups independently are optionally substituted With one or more of R” ; or. R7 and R8 together With the nitrogen to Which they are attached , are forming a saturated or partially saturated cyclic , bicyclic or tricyclic ring system containing from 4 to 10 carbon atoms and from 0 to 2 additional heteroatoms selected from nitrogen or oxygen , the ring system optionally being substituted With at least one of C1 - C8alkyl , aryl , hetaryl , arle1 - C6alkyl , hetarle1 - C6alkyl , hydroxy , oxo , cyano , C1 - C6alkyloxy , arle1 - C6alkyloxy , hetarle1 - . C3 - C10hetcycloalkyl , . US 7 , 50l , 405 B2. 69 C6alkyl - oxy , C1 - C6alkyloxyC1 - C6alkyl , C1 - C6alkylcarbonyl , arylcarbonyl , hetarylcarbonyl , arle1 - C6 - alkylcarbonyl , hetarle1 - C6alkylcarbonyl , C1 - C6a1ky1carboxy , arylcarboxy or arle1 - C6alkyl - car - . boxy Wherein the alkyl and aryl groups independently are 5. optionally substituted With one ore more of R1 l ; . R9 is hydrogen , hydroxy , oxo , halo , nitro , cyano , C1 - C6alkyl , C1 - C6alkyloxy , trihalomethyl , trihalomethoxy , NR”Rl3 , arle1 - C6alkyloxy , C1 - C6alkylcarbonyl , arylcarbonyl , . arle1 - C6alkylcarbonyl , C1 - C6alkylcarboxy , arylcarboxy 10. or arle1 - C6alkylcarboxy ; . R” and R1 1 independently are hydrogen , halo , oxo , hydroxy , C1 - C6alkyl , aryl , arle1 - C6alkyl , hetaryl or hetarylalkyl ; . R” and R” independently are hydrogen , C1 - C8alkyl , aryl , hetaryl , arle1 - C6alkyl , C3 - C1Ohetcycloalkyl , C3 - C10cycloalkle1 - C6alkyl , C1 - C6alkylcarbonyl , arylcarbonyl , arle1 - C6alkylcarbonyl , C3 - C1Ocycloalkylcarbonyl , C3 - C1Ohetcycloalkylcarbonyl or C3 - C10cycloalkle1 - . C6alkylcarbonyl Wherein the alkyl and aryl groups inde - 20. pendently are optionally substituted With one or more of R” , Wherein R” is as deﬁned aboVe ; or. R” and R” together With the nitrogen to Which they are attached , are forming a saturated or partially saturated. cyclic , bicyclic or tricyclic ring system containing from 4 25. to 10 carbon atoms and from 0 to 2 additional heteroatoms selected from nitrogen , oxygen or sulphur , the ring system optionally being substituted With at 1east one of C1 - C8a1ky1 , ary1 , hetary1 , arle1 - C6alkyl , hetarle1 - . C6alkyl , hydroxy , oxo , cyano , C1 - C6alkyloxy , arle1 - 30. C6alkyloxy , hetarle1 - C6alkyloxy , C1 - C6alkyl - oxyC1 - C6alkyl , C1 - C6alkylcarbonyl , arylcarbonyl , hetarylcarbony1 , arle1 - C6alkylcarbonyl , hetarle1 - C6alkylcarbonyl , C1 - C6alkylcarboxy , arylcarboxy or arle1 - C6alkylcarboxy ; or. a salt thereof With a pharmaceutically acceptable acid or base , or any optical isomer or mixture of optical isomers , including a racemic mixture , or any tautomeric forms. ln another embodiment of the present inVention said sub - . stituted amides , or a prodrug thereof , as a component of the 40. combination therapy is of the general formula ( llf ) Wherein R1 is hydrogen , C1 - C8alkyl , hetaryl , arle1 - C6alkyl or he ; tarle1 - C6alkyl optionally substituted With one or more R . R2 and R5 independently are hydrogen , halo , nitro , cyano , 45. trihalomethyl , C1 - C6alkyl , C1 - C6 - alkyloxy , C1 - C6alkyloxyC1 - C6alkyl , aryl , arle1 - C6alkyl , aryloxy , . aryloxyC1 - C6alkyl , ary1C1 - C6 - a1ky1oxy , arle1 - C6alkyloxyC1 - C6alkyl , hetaryl or hetarle1 - C6alkyl. Wherein the alkyl , aryl , arylalkyl , hetaryl and hetarylalkyl 50. groups independently are substituted With one or more R9 ; and. either R3 is C ( O ) NR7R8 , and R4 is hydrogen ; or R3 is hydrogen , and R4 is C ( O ) NR7R8 ; . R6 is C1 - C8alkyl , C3 - C10cycloalkyl , C3 - C10hetcycloalkyl , 55. N ( R”R” ) C1 - C6alkyl , C1 - C6alkyloxyC1 - C6alkyl , aryloxyC 1 - C6alkyl , arle1 - C6alkyloxy or arle1 - C6alkyloxyC1 - C6alkyl ; . R7 isOC1 - C8alkyl optionally substituted With one or more of R ; . R8 is C3 - C10cycloalkyl , C3 - C1Ohetcycloalkyl , C3 - C1Ocycloalkle1 - C6alkyl , Wherein the cycloalkyl and hetcycloalkyl groups independently are optionally substituted With one or more of R” ; or. C3 - C10 - cycloalkyl , 15. 70. to lO carbon atoms and from 0 to 2 additional heteroatoms selected from nitrogen or oxygen , the ring system optionally being substituted With at least one of C1 - C8alkyl , aryl , hetaryl , arle1 - C6alkyl , hetarle1 - C6a1kyl , hydroxy , oxo , cyano , C1 - C6alkyloxy , arle1 - C6alkyloxy , hetarle1 - C6alkyloxy , C1 - C6alkyloxyC1 - C6alkyl , . C1 - C6alkylcarbonyl , arylcarbonyl , hetarylcarbonyl , arle1 - C6 - alkylcarbonyl , hetarle1 - C6alkylcarbonyl , C1 - C6alkylcarboxy , arylcarboxy or arle1 - . C6alkylcarb oxy Wherein the alkyl and aryl groups independently are optionally substituted With one ore more of R1 l ; R9 is hydrogen , hydroxy , oxo , halo , nitro , cyano , C1 - C6alkyl , C1 - C6alkyloxy , trihalomethyl , trihalomethoxy , NR”Rl3 , arle1 - C6alkyloxy , C1 - C6alkylcarbonyl , arylcarbonyl , arle1 - C6alkylcarbonyl , C1 - C6alkylcarboxy , arylcarboxy or arle 1 - C6alkylcarboxy ; R” and R1 1 independently are hydrogen , halo , oxo , hydroxy , C1 - C6alkyl , aryl , arle 1 - C6alkyl , hetaryl or hetarylalkyl ; R” and R” independently are hydrogen , C1 - C8alkyl , aryl , hetaryl , arle1 - C6alkyl , C3 - C10 - cycloalkyl , C3 - C1Ohetcycloalkyl , C3 - C1Ocycloalkle1 - C6alkyl , C1 - C6alkylcarbonyl , arylcarbonyl , arle1 - C6alky1carbonyl , C3 - C1Ocycloalkylcarbonyl , C3 - C1Ohetcycloalkylcarbonyl or C3 - C1Ocycloalkle1 - C6alkylcarbonyl ; or R” and R” together With the nitrogen to Which they are attached , are forming a saturated or partially saturated cyclic , bicyc1ic or tricyclic ring system containing from 4 to 10 carbon atoms and from 0 to 2 additiona1 heteroatoms selected from nitrogen , oxygen or sulphur , the ring system optionally being substituted With at least one of C1 - C8alkyl , aryl , hetaryl , arle1 - C6alkyl , hetarle1 - C6alky1 , hydroxy , oxo , cyano , C1 - C6alkyloxy , arle 1 - C6alky1oxy , hetarle1 - C6alkyloxy , C1 - C6a1ky1 - oxyC1 - C6alkyl , C1 - C6alkylcarbonyl , arylcarbonyl , hetarylcarbonyl , arle1 - C6alkylcarbonyl , hetarle1 - C6alkylcarbonyl , C1 - C6alkylcarboxy , arylcarboxy or ary1C1 - C6alkylcarboxy ; or a salt thereof With a pharmaceutica1ly acceptab1e acid or base , or any optical isomer or mixture of optical isomers , including a racemic mixture , or any tautomeric forms. ln another embodiment of the present inVention said substituted amides , or a prodrug thereof , as a component of the combination therapy is of the genera1 formula ( llf ) Wherein R2 is C ( O ) NR7R8 and R3 R4 and R5 are hydrogen , Wherein R7 and R8 are as deﬁned aboVe. ln another embodiment of the present inVention said substituted amides , or a prodrug thereof , as a component of the combination therapy is of the general formula ( llf ) Wherein R3 is C ( O ) NR7R8 and R2 R4 and R5 are hydrogen , Wherein R7 and R8 are as deﬁned aboVe. ln another embodiment of the present inVention said substituted amides , or a prodrug thereof , as a component of the combination therapy is of the general formula ( llf ) Wherein R4 is C ( O ) NR7R8 and R2 R3 and R5 are hydrogen , Wherein R7 and R8 are as deﬁned aboVe. ln another embodiment of the present inVention said substituted amides , or a prodrug thereof , as a component of the combination therapy is of the general formula ( llf ) Wherein R5 is C ( O ) NR7R8 and R2 R3 and R4 are hydrogen , Wherein R7 and R8 are as deﬁned aboVe. ln another embodiment of the present inVention said substituted amides , or a prodrug thereof , as a component of the combination therapy is of the general formula ( llf ) Wherein. R7 and R8 together With the nitrogen to Which they are 65 R6 is C ( O ) NR7R8 , Wherein R7 and R8 are as deﬁned aboVe. attached , are forming a saturated or partially saturated cyclic , bicyclic or tricyclic ring system containing from 6. ln another embodiment of the present inVention said substituted amides , or a prodrug thereof , as a component of the. US 7 , 50l , 405 B2 71 72. combination therapy is of the general formula ( llf ) Wherein 1 - Methyl - 1H - indole - 3 - carboxylic acid cycloheptylamide ; R3 is C ( O ) NR7R8 and R4 is hydrogen , Wherein R7 and R8 are 1 - Methyl - 1H - indole - 3 - carboxylic acid adamantan - 1 - yla - as deﬁned aboVe. mide ; . ln another embodiment of the present inVention said sub - ( 3 - Aza - bicyclo [ 3.2.2 ] non - 3 - yl ) - ( 1 - methyl - 1H - indol - 3 - yl ) - stituted amides , or a prodrug thereof , as a component of the 5 methanone ; combination therapy is of the general formula ( llf ) Wherein ( 1 - Methyl - 1H - indol - 3 - yl ) - ( 4 - methyl - piperazin - 1 - yl ) - metha - . R3 is hydrogen and R4 is C ( O ) NR7R8 , Wherein R7 and R8 are none ; as deﬁned aboVe. 1 - Methyl - 1H - indole - 3 - carboxylic acid ( 3 - hydroxy - adaman - ln another embodiment of the present inVention said sub - tan - 1 - yl ) - amide ; . stituted amides , or a prodrug thereof , as a component of the 10 1 - Methyl - 1H - indole - 3 - carboxylic acid azepan - 1 - ylamide ; combination therapy is of the general formula ( llf ) Wherein 1 - Methyl - 1H - indole - 3 - carboxylic acid ( 2 - oxo - azepan - 3 - yl ) - R8 is C3 - C1Ocycloalkyl or C3 - C10hetcycloalkyl , each of amide ; . Which is optionally substituted With one or more of R” , ( 4 - Benzyl - piperidine - 1 - yl ) - ( 1 - methyl - 1H - indol - 3 - yl ) - . Wherein R” is as deﬁned aboVe. methanone ; . ln another embodiment of the present inVention said sub - 15 1 - Methyl - 1H - indole - 3 - carboxylic acid ( 2 , 6 - dimethyl - piperistituted amides , or a prodrug thereof , as a component of the din - 1 - yl ) - amide ; combination therapy is of the general formula ( llf ) Wherein 1 - Methyl - 1H - indole - 3 - carboxylic acid ( 2 - methyl - piperidin - R7 and R8 together With the nitrogen to Which they are 1 - yl ) - amide ; . attached , are forming a saturated or partially saturated bicy - ( 1 - cyclopropylmethyl - 6 - ﬂuoro - 1H - indol - 3 - yl ) - ( 1 , 3 , 3 - trimclic or tricyclic ring system containing from 6 to 10 carbon 20 ethyl - 6 - aza - bicyclo [ 3.2.1 ] oct - 6 - yl ) - methanone ; . atoms and from 0 to 2 additional heteroatoms selected from Azepan - 1 - yl - ( 1 - methyl - 1H - indol - 3 - yl ) - methanone ; nitrogen or oxygen , the ring system optionally being substi - ( 5 - Benzyloxy - 1H - indol - 3 - yl ) - ( 1 , 3 , 3 - trimethyl - 6 - aza - bicytuted With at 1east one of C1 - C8alkyl , aryl , hetary1 , arle1 - clo [ 3.2.1 ] oct - 6 - y1 ) - methanone ; . C6alkyl , hetarle1 - C6alkyl , hydroxy , oxo , cyano , ( 5H - [ 1 , 3 ] Dioxolo [ 4 , 5 ] indol - 7 - yl ) - ( 1 , 3 , 3 - trimethyl - 6 - aza - bi - C1 - C6alkyloxy , arle 1 - C6alkyloxy , hetarle1 - C6alkyloxy , 25 cyclo [ 3.2.1 ] oct - 6 - yl ) - methanone ; C1 - C6alkyloxyC1 - C6alkyl , C1 - C6alkylcarbonyl , arylcarbo - ( 5 - Chloro - 1H - indol - 3 - yl ) - ( 1 , 3 , 3 - trimethyl - 6 - aza - bicyclo. nyl , hetarylcarbonyl , arle 1 - C6alkylcarbonyl , hetarle1 - [ 3.2.1 ] oct - 6 - yl ) - methanone ; C6alkylcarbonyl , C 1 - C6alkylcarboxy , arylcarboxy or arle1 - ( 6 - Triﬂuoromethyl - 1 H - indo1 - 3 - yl ) - ( 1 , 3 , 3 - trimethy1 - 6 - aza - C6alkylcarboxy Wherein the alkyl and ary1 groups bicyc1o [ 3.2.1 ] oct - 6 - yl ) - methanone ; independently are optionally substituted With one ore more of 30 ( 6 - Methyl - 1H - indol - 3 - yl ) - ( 1 , 3 , 3 - trimethyl - 6 - aza - bicyclo R” , Wherein R1 l is as deﬁned aboVe. [ 3.2.1 ] oct - 6 - yl ) - methanone ; . ln another embodiment of the present inVention said sub - ( 6 - Nitro - 1H - indol - 3 - yl ) - ( 1 , 3 , 3 - t1imethyl - 6 - aza - bicyclo stituted amides , or a prodrug thereof , as a component of the [ 3.2.1 ] oct - 6 - yl ) - methanone ; . combination therapy is of the genera1 formula ( llf ) Wherein ( 5 - Methoxy - 1H - indol - 3 - yl ) - ( 1 , 3 , 3 - trimethy1 - 6 - aza - bicyc1o. the bicyclic ring system is 6 - aza - bicyclo [ 3 .2.1 ] octane option - 35 [ 3 .2.1 ] oct - 6 - yl ) - methanone ; . ally substituted With one or more C1 - C6alkyl. ( 6 - Fluoro - 1H - indol - 3 - yl ) - ( 1 , 3 , 3 - t1imethyl - 6 - aza - bicyclo ln another embodiment of the present inVention said sub - [ 3.2.1 ] oct - 6 - yl ) - methanone ; . stituted amides , or a prodrug thereof , as a component of the ( 6 - Methoxy - 1H - indol - 3 - yl ) - ( 1 , 3 , 3 - trimethy1 - 6 - aza - bicyc1o combination therapy is of the genera1 formula ( llf ) Wherein [ 3.2.1 ] oct - 6 - yl ) - methanone ; . the bicyclic ring system is 1 , 3 , 3 - trimethyl - 6 - aza - bicyclo 40 ( 7 - Nitro - 1H - indol - 3 - yl ) - ( 1 , 3 , 3 - trimethyl - 6 - aza - bicyclo [ 3.2.1 ] octane. [ 3.2.1 ] oct - 6 - yl ) - methanone ; . ln another embodiment of the present inVention said sub - ( 1H - lndol - 4 - yl ) - ( 1 , 3 , 3 - trimethyl - 6 - aza - bicyclo [ 3.2.1 ] oct - 6 - stituted amides , or a prodrug thereof , as a component of the yl ) - methanone ; combination therapy is se1ected from the group consisting of : 2 - ( 1H - lndol - 3 - yl ) - 1 - ( 1 , 3 , 3 - trimethyl - 6 - aza - bicyclo [ 3 .2. 1 ] ( 1H - lndol - 5 - yl ) - ( 1 , 3 , 3 - trimethyl - 6 - aza - bicyclo [ 3 .2. 1 ] oct - 6 - 45 oct - 6 - yl ) - ethanone ; . yl ) - methanone ; 1 - ( 3 - Aza - bicyclo [ 3.2.2 ] non - 3 - yl ) - 2 - ( 1H - indol - 3 - yl ) - etha - 1H - lndole - 6 - carboxylic acid cyclohexyl - methyl - amide ; none ; ( 1H - lndo1 - 7 - y1 ) - ( 1 , 3 , 3 - trimethyl - 6 - aza - bicyc1o [ 3.2.1 ] oct - 6 - 1 - ( 3 - Aza - bicyc1o [ 3.2.2 ] non - 3 - yl ) - 2 - ( 1 - methyl - 1H - indo1 - 3 - yl ) - methanone ; yl ) - ethanone ; ( 1H - lndol - 6 - yl ) - ( 1 , 3 , 3 - trimethyl - 6 - aza - bicyclo [ 3.2.1 ] oct - 6 - 50 2 - ( 1 - Methyl - 1H - indol - 3 - yl ) - 1 - ( 1 , 3 , 3 - trimethyl - 6 - aza - bicy - yl ) - methanone ; clo [ 3.2.1 ] oct - 6 - yl ) - ethanone ; 1H - lndole - 6 - carboxylic acid adamantan - 2 - ylamide ; [ 3 - ( 1 , 3 , 3 - Trimethyl - 6 - aza - bicyclo [ 3.2.1 ] octane - 6 - carbo - ( 6 - Aza - bicyclo [ 3.2.1 ] oct - 6 - yl ) - ( 1H - indo1 - 6 - yl ) - methanone ; nyl ) - 1H - indol - 6 - yloxy ] - acetic acid tertbutyl ester ; 1H - lndole - 6 - carboxylic acid ( 8 - methyl - 8 - aza - bicyclo [ 3 .2. 1 ] 6 - ( 1 , 3 , 3 - Trimethyl - 6 - aza - bicyclo [ 3 .2 . 1 ] octane - 6 - carbonyl ) - oct - 3 - yl ) - amide ; 55 1H - indole - 3 - carboxylic acid ; 1H - lndole - 5 - carboxylic acid adamantan - 2 - ylamide ; 6 - ( 1 , 3 , 3 - Trimethyl - 6 - aza - bicyclo [ 3.2.1 ] octane - 6 - carbonyl ) - ( 6 - Aza - bicyclo [ 3.2.1 ] oct - 6 - yl ) - ( 1H - indol - 5 - yl ) - methanone ; 1H - indole - 3 - carboxylic acid ethyl ester ; ( 1H - lndo1 - 4 - y1 ) - ( 1 , 3 , 3 - trimethyl - 6 - aza - bicyc1o [ 3 .2. 1 ] oct - 6 - 5 - ( 1 , 3 , 3 - Trimethyl - 6 - aza - bicyc1o [ 3 .2 . 1 ] octane - 6 - carbony1 ) - yl ) - methanone ; 1H - indole - 3 - carboxylic acid ; ( 1H - lndol - 3 - yl ) - ( 1 , 3 , 3 - trimethyl - 6 - aza - bicyclo [ 3.2.1 ] oct - 6 - 60 5 - ( 1 , 3 , 3 - Trimethyl - 6 - aza - bicyclo [ 3.2.1 ] octane - 6 - carbonyl ) - yl ) - methanone ; 1H - indole - 3 - carboxylic acid ethyl ester ; ( 1H - Indol - 2 - yl ) - ( 1 , 3 , 3 - trimethyl - 6 - aza - bicyclo [ 3 .2. 1 ] oct - 6 - 4 - ( 1 , 3 , 3 - Trimethyl - 6 - aza - bicyclo [ 3 .2 . 1 ] octane - 6 - carbonyl ) - yl ) - methanone ; 1H - indole - 3 - carboxylic acid ; ( 1 - Methyl - 1H - indol - 3 - yl ) - ( 1 , 3 , 3 - trimethyl - 6 - aza - bicyclo 4 - ( 1 , 3 , 3 - Trimethyl - 6 - aza - bicyclo [ 3 .2 . 1 ] octane - 6 - carbonyl ) - [ 3.2. l ] oct - 6 - yl ) - methanone ; 65 lH - indole - 3 - carboxylic acid ethyl ester ; ( 3 - Aza - bicyclo [ 3 .2.2 ] non - 3 - yl ) - ( 1 H - indol - 3 - yl ) - metha - 5 - ( 1 , 3 , 3 - Trimethyl - 6 - aza - bicyclo [ 3 .2 . 1 ] octane - 6 - carbonyl ) - . none ; 1H - indole - 3 - carboxylic acid ; . US 7 , 50l , 405 B2. 73. 5 - ( l , 3 , 3 - Trimethyl - 6 - aza - bicyclo [ 3 .2. l ] octane - 6 - carbonyl ) - 1H - indole - 3 - carboxylic acid ethyl ester ; . 4 - ( 1 , 3 , 3 - Trimethyl - 6 - aza - bicyclo [ 3 .2. 1 ] octane - 6 - carbonyl ) - 1H - indole - 3 - carboxylic acid ; . 4 - ( 1 , 3 , 3 - Trimethyl - 6 - aza - bicyclo [ 3 .2. 1 ] octane - 6 - carbonyl ) - 1H - indole - 3 - carboxylic acid ethyl ester ; . [ 3 - ( Piperidine - 1 - carbonyl ) - 1H - indol - 5 - yl ] - ( 1 , 3 , 3 - trimethyl - 6 - aza - bicyclo [ 3.2.1 ] oct - 6 - yl ) - methanone ; . 5 - ( 1 , 3 , 3 - Trimethyl - 6 - aza - bicyclo [ 3 .2. 1 ] octane - 6 - carbonyl ) - 1H - indole - 3 - carboxylic acid cyanomethyl - amide ; . 5 - ( l , 3 , 3 - Trimethyl - 6 - aza - bicyclo [ 3 .2. l ] octane - 6 - carbonyl ) - 1H - indole - 3 - carboxylic acid benzylamide ; . 5 - ( 1 , 3 , 3 - Trimethyl - 6 - aza - bicyclo [ 3 .2. 1 ] octane - 6 - carbonyl ) - 1H - indole - 3 - carboxylic acid dimethylamide ; . 5 - ( 1 , 3 , 3 - Trimethyl - 6 - aza - bicyclo [ 3 .2. 1 ] octane - 6 - carbonyl ) - 1H - indole - 3 - carboxylic acid allylamide ; . 5 - ( 1 , 3 , 3 - Trimethyl - 6 - aza - bicyclo [ 3 .2. 1 ] octane - 6 - carbonyl ) - 1H - indole - 3 - carboxylic acid ( 2 - dimethylamino - ethyl ) - methyl - amide ; . 5 - ( 1 , 3 , 3 - Trimethyl - 6 - aza - bicyclo [ 3 .2. 1 ] octane - 6 - carbonyl ) - 1H - indole - 3 - carboxylic acid ( 2 - methoxy - ethy1 ) - amide ; . 5 - ( 1 , 3 , 3 - Trimethyl - 6 - aza - bicyclo [ 3 .2. 1 ] octane - 6 - carbonyl ) - 1H - indole - 3 - carboxylic acid 4 - methoxy - benzylamide ; . 5 - ( 1 , 3 , 3 - Trimethyl - 6 - aza - bicyclo [ 3 .2. 1 ] octane - 6 - carbonyl ) - 1H - indole - 3 - carboxylic acid ( tetrahydro - furan - 2 - ylmethy1 ) - amide ; . [ 3 - ( 2 - Methoxymethyl - pyrrolidine - 1 - carbonyl ) - 1H - indol - 5 - yl ] - ( 1 , 3 , 3 - trimethyl - 6 - aza - bicyclo - [ 3.2.1 ] oct - 6 - yl ) - methanone ; . [ 3 - ( 2 , 6 - Dimethyl - morpholine - 4 - carbonyl ) - 1H - indol - 5 - yl ] - ( 1 , 3 , 3 - t1imethyl - 6 - aza - bicyclo [ 3 .2. 1 ] oct - 6 - yl ) - methanone ; . 5 - ( 1 , 3 , 3 - Trimethyl - 6 - aza - bicyclo [ 3 .2. 1 ] octane - 6 - carbonyl ) - 1H - indole - 3 - carboxylic acid ( 1 , 1 - dioxo - tetrahydrothiophen - 3 - y1 ) - amide ; . 5 - ( 1 , 3 , 3 - Trimethyl - 6 - aza - bicyclo [ 3 .2. 1 ] octane - 6 - carbonyl ) - 1H - indole - 3 - carboxylic acid [ 3 - ( 4 - methyl - piperazin - 1 - yl ) - propyl ] - amide ; . 5 - ( 1 , 3 , 3 - Trimethyl - 6 - aza - bicyclo [ 3 .2. 1 ] octane - 6 - carbonyl ) - 1H - indole - 3 - carboxylic acid 4 - triﬂuoromethyl - benzy1a - mide ; . 5 - ( 1 , 3 , 3 - Trimethyl - 6 - aza - bicyclo [ 3 .2. 1 ] octane - 6 - carbonyl ) - 1H - indole - 3 - carboxylic acid ( furan - 2 - ylmethyl ) - amide ; [ 3 - ( 2 , 3 , 5 , 6 - Tetrahydro - [ 1 , 2 ' ] bipyrazinyl - 4 - carbonyl ) - 1 H - indol - 5 - yl ] - ( 1 , 3 , 3 - trimethy1 - 6 - aza - bicyc1o [ 3.2.1 ] oct - 6 - yl ) - . methanone ; . 5 - ( 1 , 3 , 3 - Trimethyl - 6 - aza - bicyclo [ 3 .2. 1 ] octane - 6 - carbonyl ) - 1H - indole - 3 - carboxylic acid ( 2H - tetrazol - 5 - ylmethyl ) - amide ; . [ 3 - ( 1 , 3 , 3 - Trimethyl - 6 - aza - bicyclo [ 3.2.1 ] octane - 6 - carbonyl ) - 1H - indol - 5 - yl ] - ( 1 , 3 , 3 - trimethyl - 6 - aza - bicyclo [ 3 .2. 1 ] oct - 6 - yl ) - methanone ; . 3 - { [ 5 - ( 1 , 3 , 3 - Trimethyl - 6 - aza - bicyclo [ 3.2.1 ] octane - 6 - carbonyl ) - 1H - indole - 3 - carbonyl ] - amino } - propionic acid ethyl ester ; . 5 - ( 1 , 3 , 3 - Trimethyl - 6 - aza - bicyclo [ 3 .2. 1 ] octane - 6 - carbonyl ) - 1H - indole - 3 - carboxylic acid ( 4 - methoxy - phenyl ) - amide ; . 3 - { [ 5 - ( 1 , 3 , 3 - Trimethyl - 6 - aza - bicyclo [ 3.2.1 ] octane - 6 - carbonyl ) - 1H - indole - 3 - carbonyl ] - amino } - propionic acid ; . Azepan - 1 - yl - ( 1H - indol - 5 - yl ) - methanone ; . 1H - lndole - 5 - carboxylic acid dibenzylamide ; . ( 3 - Aza - bicyclo [ 3.2.2 ] non - 3 - yl ) - ( 1H - indol - 5 - yl ) - methanone ; . ( 4 - Benzyl - piperidin - 1 - yl ) - ( 1H - indol - 5 - yl ) - methanone ; . 8 - ( 1H - lndole - 5 - carbonyl ) - 1 - phenyl - 1 , 3 , 8 - triaza - spiro [ 4. 5 ] decan - 4 - one ; . 74 [ 4 - ( 4 - Chloro - phenyl ) - 4 - hydroxy - piperidin - l - yl ] - ( l H - indol - 5 - yl ) - methanone ; 1 - [ 1 - ( 1H - lndole - 5 - carbonyl ) - piperidin - 4 - yl ] - 1 , 3 - dihydrobenzoimidazo1 - 2 - one ; 5 ( 4 - tert - Butyl - piperidin - 1 - yl ) - ( 1H - indol - 5 - yl ) - methanone ; 1 - ( lH - lndole - 5 - carbonyl ) - 4 - phenyl - piperidine - 4 - carbonitrile ; ( 1 H - lndol - 5 - yl ) - ( 4 - phenyl - piperidin - 1 - yl ) - methanone ; ( 5 - Benzyl - 2 , 5 - diaza - bicyclo [ 2.2.1 ] hept - 2 - yl ) - ( 1H - indol - 5 - 10 yl ) - methanone ; ( l H - lndol - 5 - yl ) - ( 4 - pyrrolidin - 1 - yl - piperidin - l - yl ) - methanone ; 1H - lndole - 5 - carboxylic acid ( 5 - hydroxy - 1 , 3 , 3 - trimethyl - cyclohexylmethyl ) - amide ; 15 1H - lndole - 5carboxylic acid ( 3 , 4 - dihydrospiro ( 1H - indene - 1 , 4 - piperidine ) - amide ; ( 3 - Methanesulfonylmethyl - 1H - indol - 5 - yl ) - ( 1 , 3 , 3 - trimethyl - 6 - aza - bicyclo [ 3 .2. 1 ] oct - 6 - yl ) - methanone ; ( 3 - Dimethylaminomethyl - 1H - indol - 6 - yl ) - ( 1 , 3 , 3 - trimethyl - 6 - aza - bicyclo [ 3.2.1 ] oct - 6 - yl ) - methanone ; 1 - { 3 - Acetyl - 2 - [ 5 - ( 1 , 3 , 3 - trimethyl - 6 - aza - bicyclo [ 3.2.1 ] octane - 6 - carbonyl ) - 1H - indol - 3 - yl ] - 2 , 3 - dihydro - imidazol - 1 - yl } - ethanone ; 1 - Ethyl - 3 - [ 5 - ( 1 , 3 , 3 - trimethyl - 6 - aza - bicyclo [ 3 .2 . 1 ] octane - 6 - carbonyl ) - 1H - indol - 3 - yl ] - pyrrolidine - 2 , 5 - dione ; ( 3 - Thiazol - 2 - yl - 1 H - indol - 5 - yl ) - ( 1 , 3 , 3 - trimethyl - 6 - aza - bicyclo [ 3.2.1 ] oct - 6 - yl ) - methanone ; ( 3 - lodo - 1H - indo1 - 5 - y1 ) - ( 1 , 3 , 3 - trimethy1 - 6 - aza - bicyc1o [ 3.2.1 ] oct - 6 - yl ) - methanone ; 30 6 - ( 1 , 3 , 3 - Trimethyl - 6 - aza - bicyclo [ 3.2.1 ] octane - 6 - carbonyl ) - 1H - indole - 3 - carbonitrile ; 5 - ( 1 , 3 , 3 - Trimethyl - 6 - aza - bicyclo [ 3.2.1 ] octane - 6 - carbonyl ) - 1H - indole - 3 - carbonitri1e ; 6 - ( 1 , 3 , 3 - Trimethyl - 6 - aza - bicyc1o [ 3.2.1 ] octane - 6 - carbony1 ) - 1H - indole - 3 - carboxylic acid amide ; [ 3 - ( 2H - Tetrazol - 5 - yl ) - 1H - indol - 6 - yl ] - ( 1 , 3 , 3 - trimethyl - 6 - aza - bicyclo [ 3.2.1 ] oct - 6 - yl ) - methanone ; N - [ 3 - ( 1 , 3 , 3 - Trimethyl - 6 - aza - bicyclo [ 3.2.1 ] octane - 6 - carbonyl ) - 1H - indol - 7 - yl ] - acetamide ; 40 ( 1 - Benzenesulfonyl - 1 H - indol - 5 - yl ) - ( 1 , 3 , 3 - trimethyl - 6 - azabicyclo [ 3 .2. 1 ] oct - 6 - yl ) - methanone ; ( 1 - Benzenesufonyl - 2 - methyl - 1H - indol - 5 - yl ) - ( 1 , 3 , 3 - trimethyl - 6 - aza - bicyclo [ 3 .2. 1 ] oct - 6 - y1 ) - methanone ; ( 1 - methyl - 1 H - indol - 5 - y1 ) - ( 1 , 3 , 3 - trimethyl - 6 - aza - bicyclo [ 3.2.1 ] oct - 6 - yl ) - methanone ; ( 1 - Benzyl - 1 H - indol - 5 - yl ) - ( 1 , 3 , 3 - trimethyl - 6 - aza - bicyclo [ 3.2.1 ] oct - 6 - yl ) - methanone ; [ 6 - ( 1 , 3 , 3 - Trimethyl - 6 - aza - bicyclo [ 3.2.1 ] octane - 6 - carbonyl ) - indol - 1 - yl ] - acetic acid ethyl ester ; 50 [ 1 - ( 2 - Ethoxy - ethyl ) - 1H - indol - 6 - yl ] - ( 1 , 3 , 3 - trimethyl - 6 - azabicyclo [ 3 .2. 1 ] oct - 6 - yl ) - methanone ; { 1 - [ 2 - ( 2 - Methoxy - ethoxy ) - ethyl ] - 1 H - indol - 6 - yl } - ( 1 , 3 , 3 - trimethyl - 6 - aza - bicyclo [ 3 .2.1 ] oct - 6 - yl ) - methanone ; 3 - [ 5 - ( 1 , 3 , 3 - Trimethyl - 6 - aza - bicyclo [ 3.2.1 ] octane - 6 - carbonyl ) - indol - 1 - yl ] - propionic acid ethyl ester ; ( 1 - Phenethyl - 1H - indol - 5 - yl ) - ( 1 , 3 , 3 - trimethyl - 6 - aza - bicyclo [ 3.2.1 ] oct - 6 - yl ) - methanone ; [ 1 - ( Tetrahydro - furan - 2 - ylmethyl ) - 1H - indol - 5 - yl ] - ( 1 , 3 , 3 - trimethyl - 6 - aza - bicyclo [ 3 .2.1 ] oct - 6 - yl ) - methanone ; 60 2 - [ 5 - ( 1 , 3 , 3 - Trimethyl - 6 - aza - bicyclo [ 3.2.1 ] octane - 6 - carbonyl ) - indol - 1 - yl ] - acetamide ; [ 1 - ( 4 - Triﬁuoromethoxy - benzyl ) - 1 H - indol - 5 - yl ] - ( 1 , 3 , 3 - trimethyl - 6 - aza - bicyclo [ 3 .2.1 ] oct - 6 - yl ) - methanone ; 3 - [ 5 - ( 1 , 3 , 3 - Trimethyl - 6 - aza - bicyclo [ 3.2.1 ] octane - 6 - carbonyl ) - indol - l - ylmethyl ] - benzoic acid methyl ester ; 4 - [ 5 - ( 1 , 3 , 3 - Trimethyl - 6 - aza - bicyclo [ 3.2.1 ] octane - 6 - carbonyl ) - indol - 1 - ylmethyl ] - benzonitrile ; or. 20. 25. 35. 45. 55. 65. US 7 , 50l , 405 B2. 75 76 a salt thereof With a pharmaceutically acceptable acid or base , cycloalkyl and hetcycloalkyl groups independently are or any optical isomer or mixture of optical isomers , includ - optionally substituted With one or more of R7 ; or ing a racemic mixture , or any tautomeric forms. R9 and R” together With the nitrogen to Which they are ln another embodiment of the present inVention said sub - attached , are forming a saturated or partially saturated. stituted amides , or a prodrug thereof , as a component of the 5 bicyclic or tricyclic ring system containing from 4 to 10 combination therapy is of the general formula ( llg ) carbon atoms and from 0 to 2 additional heteroatoms selected from nitrogen or oxygen , the ring system option - . ally being substituted With at least one of C1 - C8alkyl , . ( Hg ) arle1 - C6alkyl , hetarle1 - C6alkyl , hydroxy , cyano , . O 10 C1 - C6alkyloxy , arle1 - C5alkyloxy , hetarle 1 - C6alkyloxy , . C1 - C6alkyloxyC1 - C6alkyl , C1 - C6alkylcarbonyl , arylcar - X Rl 5 X / R5 bonyl , hetarylcarbonyl , arle 1 - C6alkylcarbonyl , R3 I 1 ] R3 I T hetarle1 - C6alkylcarbonyl , C1 - C6alkylcarboxy , arylcar - \ N m \ R6 boxy or arle 1 - C6alkylcarboxy Wherein the alkyl and aryl N \R5 N R2 15 groups independently are optionally substituted With one ore more of R” ; . R1 l is hydrogen , halo , oxo , hydroxy , C1 - C6alkyl , aryl , arle1 - C6alkyl , hetaryl or hetarylalkyl ; . O. Wherein a salt thereof With a pharmaceutically acceptable acid or base , X iS NR4 , S 01‘ O ; 20 or any optical isomer or mixture of optical isomers , includ - Rl and R2 independently are hydrogen , halo , Cyah0a trihalom - ing a racemic mixture , or any tautomeric forms. ethyl , C1 - C6alkyl 01 ' C1 ' C6 ' a1ky10Xya Wherein the alkyl ln the deﬁnitions of R4 , in the aboVe formula ( llg ) , hetcygroups independently are optionally substituted With one cloalkyl cannot be 7 - aza [ 2 , 2 , 1 ] bicycle - heptane. 3or more 0f R73 ln another embodiment of the present inVention said sub - R 15 hydrogen , C1 - C6alkyl , C3 - C10cycloalkyl , 25 stituted amides , or a prodrug thereof , as a component of the C1 - C6alkyloxy , C1 - C6alkylth1o , aryl , arle1 - C6alkyl , combination therapy is of the general formula ( llg ) Wherein. hetaryl or hetarylalkyl , Wherein the alkyl , cycloalkyl , aryl , X is NR4 S or O ' hetaryl and hetary1alkyl groups independently are option - . ally substituted With one or more of R7 ; . R4 is hydrogen , C1 - C8alkyl , C1 - C6alkyloxyC1 - C6alkyl , aryl , 30 hetaryl , hetarle1 - C6alkyl , arle1 - C6alkyl , arle1 - C al lox C - C al 1 C - C c cloal l C : - Ck13 : , hetZyclloaTky1T , yj C3 - C1Ocyc1odlk3il% : ] ] - C6a1kkyyl : R3 ” hydrogen , C1 ' C6“1ky1 C3 - C1Ocycloalkyl , C1 - C6a1ky1carboxyC1 - C6a1ky1 Wherein the alkyl , aryl , C1 - C6alkyloxy , C1 - C6alkylth1o , aryl , arle1 - C6alkyl , hetaryl , cycloalkyl and hetcycloalkyl groups indepen - 35 hetary 1 or hetary lalkyl , Where1n the alkyl , cycloalkyl , aryl , dently are optionally substituted With one or more of R7 ; hetaryl and hetarylalkyl groups 1ndependently are opt1on - . R5 is hydrogen , and R6 is adamantyl optionally substituted 4”” substituted With one or more 0f R7 ; mm hydroxy , C1 - C6alkyloxy , 1111111 ary1C1 - C6a1ky1 , ary - R 1s hydrogen , C1 - C8alkyl , C1 - C6a1kyloxyC1 - C6alky1 , aryl , loxy , arle1 - C6alkyloxy , hetary1 , hetary1oxy or hetarle1 - hetaryl , arle1 - C6alkyl , arle1 - C6alkyloxyC1 - C6alkyl , C6alkyloxy Whereinthe alkyl , aryl andhetaryl groups inde - 40 C3 - C1Ocycloalkyl , C3 - C10hetcycloalkyl , pendently are optionally substituted With one or more of C3 - C10cycloalkle1 - C6alkyl , C1 - C6alkylcarboxyC1 - R7 ; 01 C6alky1 Where1n the alky1 , aryl , hetaryl , cyc1oalkyl and R5 and R6 are together 11111111 the nitrogen 111 Which they are hetcycloalkyl groups independently are optionally substi - . attached , forming a saturated or partially saturated cyc1ic , tuted With 01” or more 0f R7§ bicyclic or tricyclic ring system containing from 6 to 10 45 R5 E hydrogen , and R6 iS adamantyl optionally substituted carbon atoms and from 0 to 2 additional heteroatoms W1th hydroxy , C1_C6a1ky10XyJ aryl , ary1C1 ' C6a1ky1 : 313“. R1 and R2 independently are hydrogen , halo , cyano , trihalomethyl , C1 - C6alkyl or C1 - C6 - alkyloxy , Wherein the alkyl groups independently are optionally substituted With one or more of R7 ; . selected from nitrogen , oxygen or sulphur , the ring system loxy , W 1C1 ' C6a1hy10Xy : hetaryl , hetary 10XY or hetary 1C1 ' optionally being substituted With at 1east one of C6a1ky10Xy Where1nthe alkyl , WW and hetary1 groups 1nde - C1 - C6alkyl , aryl , hetaryl , ary1C1 - C6a1ky1 , hetarylalkyl , pendently are optionally substituted With one or more of hydroxy , oxo , cyano , C1 - C6alkyloxy , arle1 - C6alkyloxy , 50 R7 ; or hetary1C1 - C6a1ky10xy , C1. C6g11ky10xyC1. C6g11ky1a R5 and R6 are together With the nitrogen to Which they are C1 - C6a1ky1carb0ny1 ; arylcarbonyl , hetarylcarbonyl , attached , forming a saturated or partially saturated cyclic , arle1 - C6a1ky1carb0ny1 , hetary1C1 - C6alkylcarbonyl , bicyc1ic or tricyclic ring system containing from 5 to 10 C1 - C6alkylcarb0xy ; arylcarboxy or arle1 - carbon atoms and from 0 to 2 additional heteroatoms C6a1ky1carb0xy wherein the alkyl and aryl groups indepen - 55 selected from nitrogen , oxygen or sulphur , the ring system dently are optionally substituted With one ore more of R7 ; optionally being substituted With at least one 0f R7 are independently hydrogen , halo , hydroxy , oxo , nitro , C1 - C6alkyl , ary1 , hetaryl , arle1 - C6alkyl , hetarylalkyl , NR9R” , cyano , COORF1 CONR9R1O1 C1 - C8a1kyl , hydroxy , oxo , cyano , C1 - C6alkyloxy , arle1 - C6alkyloxy , C1 - C6alkyloxy , aryloxy , arle 1 - C6alkyloxy , hetaryloxy or hetarle l - C6a1ky10Xy , C1 - C6a1ky10XyC1 - C6a1ky1 , hetary1C1—C6a1ky1oxy ; 60 C1 - C6alkylcarbonyl , arylcarbonyl , hetarylcarbonyl , R8 is hydrogen ; C1 - C6a1ky11 ary1a ary1C1—C6a1ky11 hetaryla - arle1 - C6alkylcarbonyl , hetarle1 - C6alkylcarbonyl , lkyl , Wherein the alkyl , aryl and hetarylalkyl groups inde - C1 - C6alkylcarboxy , arylcarboxy 0r arle1 - pendently are optionally substituted With one or more of C6alkylcarboxy Wherein the alkyl and ary1 gr0upS indepen - R7 ; dently are optionally substituted With one ore more of R7 ; R9 and R” independently are hydrogen , C1 - C8alkyl , 65 R7 are independently hydrogen , halo , hydroxy , oxo , nitro , C3 - C1Ocycloalkyl , C3 - C1Ohetcycloalkyl , NR5R5 , cyano , COOR8 , CONR5R6 , C1 - C8alkyl , . C3 - C1Ocycloalkle1 - C6alkyl , Wherein the alkyl , C1 - C6alkyloxy , aryloxy or hetaryloxy ; . US 7 , 50l , 405 B2. 77. R8 is hydrogen , C1 - C6alkyl , aryl , arle1 - C6alkyl , hetaryla - . lkyl , Wherein the alkyl , aryl and hetarylalkyl groups inde - . pendently are optionally substituted With one or more of. R7 ; or a salt thereof With a phannaceutically acceptable acid or base , . or any optical isomer or mixture of optical isomers , includ - . ing a racemic mixture , or any tautomeric forms. ln another embodiment of the present inVention said substituted amides , or a prodrug thereof , as a component of the combination therapy is of the general formula ( H g ) Wherein X is NR4 or S Wherein R4 is deﬁned as aboVe. ln another embodiment of the present inVention said substituted amides , or a prodrug thereof , as a component of the combination therapy is of the general formula ( H g ) Wherein X is O. ln another embodiment of the present inVention said substituted amides , or a prodrug thereof , as a component of the combination therapy is of the general formula ( H g ) Wherein X is S. ln another embodiment of the present inVention said substituted amides , or a prodrug thereof , as a component of the combination therapy is of the general formula ( H g ) Wherein is NR4 Wherein R4 is deﬁned as aboVe. ln another embodiment of the present inVention said substituted amides , or a prodrug thereof , as a component of the combination therapy is of the general formu1a ( llg ) Wherein R1 and R2 independently are hydrogen , halo , trihalomethyl or C1 - C6alkyl , Wherein the alkyl groups independently are optionally substituted With one or more of R7. ln another embodiment of the present inVention said substituted amides , or a prodrug thereof , as a component of the combination therapy is of the general formula ( llg ) Wherein R3 is hydrogen , C1 - C6alkyl , aryl , arle1 - C6alkyl , hetaryl or hetarylalkyl , Wherein the alkyl , cycloalkyl , aryl , hetaryl and hetarylalkyl groups independently are optionally substituted With one or more of R7. ln another embodiment of the present inVention said substituted amides , or a prodrug thereof , as a component of the combination therapy is of the general formula ( llg ) Wherein R4 is hydrogen , C1 - C8alkyl , aryl , hetaryl , hetarle1 - C6alkyl , ary1C1 - C6alky1 , Wherein the alkyl , aryl , hetaryl , groups independently are optional1y substituted With one or more of R7. ln another embodiment of the present inVention said substituted amides , or a prodrug thereof , as a component of the combination therapy is of the general formula ( llg ) Wherein R5 and R6 are together With the nitrogen to Which they are attached , forming a saturated or partia1ly saturated cyc1ic , bicyclic or tricyclic ring system containing from 6 to 10 carbon atoms and from 0 to 2 additional heteroatoms selected from nitrogen , oxygen or sulphur , the ring system optionally being substituted With at least one of C1 - C6alkyl , aryl , hetaryl , arle1 - C6alky1 , hetarylalkyl , hydroxy , oxo , cyano , C1 - C6alkyloxy , arle1 - C6alkyloxy , hetarle1 - C6alkyloxy , C1 - C6alkyloxyC1 - C6alkyl , C1 - C6alkylcarbonyl , arylcarbonyl , hetarylcarbonyl , arle1 - C6alkylcarbonyl , hetarle1 - C6alkylcarbonyl , C1 - C6alkylcarboxy , arylcarboxy or arle1 - C6alkylcarboxy Wherein the alkyl and aryl groups independently are optionally substituted With one ore more of R . ln another embodiment of the present inVention said substituted amides , or a prodrug thereof , as a component of the combination therapy is of the general formula ( llg ) Wherein R5 and R6 , together With the nitrogen to Which they are. 5. lO. lS. 20. 25. 30. 35. 40. 45. 50. 55. 60. 78. tane , 6 - aza - bicyclo [ 3.2.2 ] nonane , 3 - aza - bicyclo [ 3.2.2 ] nonane , 4 - aza - tricyclo [ 4.3.1.13 ' 8 ] undecane. ln another embodiment of the present inVention said substituted amides , or a prodrug thereof , as a component of the combination therapy is selected from the group consisting of : ( 4 - Methyl - 2 - phenyl - thiazol - 5 - yl ) - ( 1 , 3 , 3 - trimethyl - 6 - aza - bicyclo [ 3 .2 . 1 ] oct - 6 - yl ) - methanone ; ( 2 , 4 - Dimethyl - thiazol - 5 - yl ) - ( 1 , 3 , 3 - trimethyl - 6 - aza - bicyclo [ 3.2.1 ] oct - 6 - yl ) - methanone ; ( 4 - Methyl - 2 - pyrazin - 2 - yl - thiazol - 5 - yl ) - ( 1 , 3 , 3 - trimethyl - 6 - aza - bicyclo [ 3.2.1 ] oct - 6 - yl ) - methanone ; [ 4 - Methyl - 2 - ( 4 - triﬁuoromethyl - phenyl ) - thiazol - 5 - yl ] - ( 1 , 3 , 3 - trimethyl - 6 - aza - bicyclo [ 3.2.1 ] oct - 6 - yl ) - methanone ; ( 3 - Aza - bicyclo [ 3.2.2 ] non - 3 - yl ) - ( 2 , 4 - dimethyl - thiazol - 5 - yl ) - methanone ; ( 1H - lmidazol - 4 - yl ) - ( 1 , 3 , 3 - trimethyl - 6 - aza - bicyclo [ 3.2.1 ] oct - 6 - yl ) - methanone ; ( 3 - Aza - bicyclo [ 3.2.2 ] non - 3 - yl ) - ( 4 - methyl - 2 - phenyl - thiazol - 5 - yl ) - methanone ; 2 , 4 - Dimethyl - thiazole - 5 - carboxylic acid cycloheptylamide ; Azepan - 1 - yl - ( 2 , 4 - dimethyl - thiazol - 5 - yl ) - methanone ; 2 , 4 - Dimethyl - thiazole - 5 - carboxylic acid adamantan - 1 - ylamide ; ( 3 - Aza - bicyclo [ 3.2.2 ] non - 3 - yl ) - ( 1H - imidazol - 4 - yl ) - methanone ; 2 , 4 - Dimethyl - thiazole - 5 - carboxy1ic acid ( 3 - hydroxy - adamantan - 1 - yl ) - amide ; or a salt thereof With a pharmaceutically acceptable acid or base , or any optical isomer or mixture of optical isomers , including a racemic mixture , or any tautomeric forms. ln another embodiment of the present inVention said substituted amides , or a prodrug thereof , as a component of the combination therapy is selected from the group consisting of : ( 1 - Methyl - 1 H - imidazol - 4 - yl ) - ( 1 , 3 , 3 - trimethyl - 6 - aza - bicyclo [ 3.2.1 ] oct - 6 - yl ) - methanone ; [ 1 - ( 6 - Methyl - pyridin - 2 - yl ) - 1 H - imidazol - 4 - yl ] - ( 1 , 3 , 3 - trimethyl - 6 - aza - bicyclo [ 3 .2. 1 ] oct - 6 - y1 ) - methanone ; [ 1 - ( 4 - Chloro - benzyl ) - 5 - methy1 - 1H - imidazol - 4 - y1 ] - ( 1 , 3 , 3 - trimethyl - 6 - aza - bicyclo [ 3 .2. 1 ] oct - 6 - yl ) - methanone ; or a salt thereof With a pharmaceutically acceptable acid or base , or any optical isomer or mixture of optical isomers , including a racemic mixture , or any tautomeric forms. ln another embodiment of the present inVention said fused 1 , 2 , 4 - triazo1e , or a prodrug thereof , as a component of the combination therapy is of the general formula ( lll ) . Fonnula ( lll ) . Wherein. R1 is C5 - C1Ocycloalkyl , C5 - C10hetcycloalkyl , aryl , hetaryl , arle1 - C6alkyl or hetarle1 - C6alkyl , Wherein the cycloalkyl , hetcycloalkyl , aryl , hetaryl and arylalkyl groups independently are optionally substituted With one or more of R7 ; . attached , are azepane , azocane , 6 - aza - bicyclo [ 3.2. l ] octane , 65 R2 and R3 independently are hydrogen , C1 - C6alkyl , aryl , . 8 - aza - bicyclo [ 3.2.1 ] octane , 3 - aza - bicyclo [ 3 .2. 1 ] octane , 2 - aza - bicyclo [ 3.2.1 ] octane , 3 - oxa - 6 - aza - bicyclo [ 3.2.1 ] oc - . hetaryl , arle1 - C6alkyl , hetarle1 - C6 - alkyl , aryloxy , hetaryloxy , arle1 - C6alkyloxy or hetarle1 - C6alkyloxy. US 7 , 50l , 405 B2. 79. Wherein the alkyl , aryl , hetaryl , arylalkyl and hetarylalkyl groups independently are optionally substituted With one or more of R8 ; or. R2 and R3 together With the carbon atom to Which they are attached , are forming a saturated or partially saturated cyclic ring system containing from 3 to 6 carbon atoms and from 0 to 2 additional heteroatoms selected from nitrogen , oxygen or sulphur , the ring system optionally being substituted With at least one of C1 - C6alkyl , aryl , hetaryl , arle1 - C6alkyl , hetarle1 - C6alkyl , hydroxy , oxo , C1 - C6alkyloxy , aryloxy , arle1 - C6alkyloxy or hetarle1 - C6alkyloxy ; . R4 and R5 independently are hydrogen , halo , hydroxy , C1 - C6alkyl , C2 - C6alkenyl , C1 - C6alkynyl , C1 - C6alkyloxy , aryl , hetaryl , aryloxyC1 - C6alkyl , aryloxyaryl , hetaryloxyaryl , aryloxyhetaryl , hetaryloxyhetaryl or arle1 - C6alkyloxyC1 - C6alkyl Wherein the alkyl , alkenyl , alkynyl , aryl and hetaryl groups independently are optionally substituted With one or more of R9 ; or. R4 and R5 together With the carbon atoms to Which they are attached , are forming a saturated , partially saturated or aromatic ring system containing from 5 to 8 carbon atoms and from 0 to 2 additional heteroatoms selected from nitrogen , oxygen or sulphur , the ring system optionally being substituted With at least one of C1 - C6alkyl , aryl , arle1 - C6alkyl , NR”R” , halo , trihalomethyl , trihalomethoxy , hydroxy , oxo , C1 - C6alkyloxy , arle1 - C6alkyloxy , C1 - C6a1ky1oxy - C1 - C6alkyl , C1 - C6alkylcarbonyl , ary1carbonyl , arle1 - C6alkylcarbonyl , C1 - C6a1kylcarboxy , ary1 - carboxy or arle1 - C6alkylcarboxy ; or. R4 and either R2 or R3 together are forming a saturated or partially saturated bridge containing from 1 to 4 carbon atoms , the bridge can optionally be substituted With at least one of C1 - C6alkyl , aryl , hetaryl , ary1C1 - C6alkyl or hetarle1 - C6alkyl ; . R6 is hydrogen , C1 - C6alkyl , aryl , hetaryl , arle1 - C6alkyl or hetarle1 - C6alkyl ; or. R6 and either R4 or R5 together With the carbon atoms to Which they are attached , are forming a saturated , partia1ly saturated or aromatic ring system containing from 5 to 8 carbon atoms and from 0 to 2 additional heteroatoms selected from nitrogen , oxygen or sulphur , the ring system optionally being substituted With at 1east one of C1 - C6a1ky1 , aryl , ary1C1 - C6alkyl , NR”R” , halo , trihalomethyl , trihalomethoxy , hydroxy , oxo , C1 - C6alkyloxy , arle1 - C6alkyloxy , C1 - C6alkyloxyC1 - C6alkyl , C1 - C6alkylcarbonyl , arylcarbonyl , arle1 - C6alkylcarbonyl , C1 - C6alkylcarboxy , arylcarboxy or arle1 - C6alkylcarboxy ; . R7 and R8 independently are hydrogen , halo , hydroxy , cyano , nitro , C1 - C6alkyl , C1 - C6alkyloxy , trihalomethyl , trihalomethoxy , aryloxy , hetarle1 - C6alkyloxy , loxyC1 - C6alkyl , . C 1 - C6alkylcarbonyl , arle1 - C6alkylcarbonyl , C1 - C6alkylcarboxy , arylcarboxy , hetarylcarboxy , arle1 - C6alkylcarboxy or hetarle1 - C6alkylcarboxy ; . R9 is hydrogen , halo , hydroxy , cyano , C1 - C6alkyl , methylendioxo , trihalomethyl , trihalomethoxy , aryl , arle1 - C6alkyl , aryloxy , NR”R1 1 or aryloxyC1 - C6alkyl , Wherein the aryl group is optionally substituted With one or more of R12 ; . R” and R” independently are hydrogen , C1 - C6alkyl , aryl or arle1 - C6alkyl Wherein the alkyl and aryl groups independently are optionally substituted With one or more of R” ; or. hetaryloxy , arle1 - C6alkyloxy , C1 - C6a1ky1oxyC1 - C6alkyl , aryarle1 - C6alkyloxyC1 - C6alkyl , arylcarbonyl , hetarylcarbonyl , hetarle1 - C6alkylcarbonyl , . lO. lS. 20. 25. 30. 35. 40. 45. 50. 55. 60. 65. 80. R” and R” together With the nitrogen to Which they are attached , are forming a saturated or partially saturated cyclic , bicyclic or tricyclic ring system containing from 4 to 10 carbon atoms and from 0 to 2 additiona1 heteroatoms selected from nitrogen , oxygen or sulfur , the ring system optionally being substituted With at least one of C1 - C6alkyl , aryl , hetaryl , arle1 - C6alkyl , hydroxy , oxo , C1 - C6alkyloxy , arle1 - C6alkyloxy , C1 - C6alkyloxyC1 - C6alkyl , C1 - C6alkylcarbonyl , arylcarbonyl , arle1 - C6alkylcarbonyl , C1 - C6alkylcarboxy , arylcarboxy or arle1 - C6alkyl - carboxy ; . R” is oxo or halo ; . R” is halo , hydroxy , cyano , C1 - C6alkyl , C1 - C6alkyloxy , NR”R” , methylendioxo , trihalomethyl , or trihalomethoxy ; . Rl4 and R” independently are hydrogen , C1 - C6alkyl , aryl , hetaryl , arle1 - C6alkyl or hetarle1 - C6alkyl ; . A is a single , double or triple bond ; . X is a chemical bond , ( CR”R” ) , , or NR” , Wherein Rl6 and Rl7 independently are hydrogen , oxo or C1 - C6alkyl , or. X , together With either R2 or R3 , is a double bond ; . Y is CR” or nitrogen , Wherein R” is hydrogen , C1 - C6alkyl , ary1 , hetaryl , arle 1 - C6alkyl or hetarle1 - C6alkyl ; or. R” and either R2 or R3 together are forming a saturated or partially saturated cyclic ring system containg from 1 to 4 carbon atoms , the ring system can optionally be substituted With at least one of C1 - C6alkyl , aryl , hetaryl , arle1 - C6alky1 or hetarle1 - C6a1ky1 ; or. R” With either R2 or R3 and either R4 or R5 together are forming a saturated or partially saturated cyclic ring system haVing one common carbon atom containing from 8 to 12 carbon atoms , the ring system can optionally be substituted With at least one of C1 - C6a1ky1 , aryl , hetary1 , arle1 - C6alky1 or hetarle1 - C6a1ky1 ; . nis0 , 1 or2 ; or. a salt thereof With a pharmaceutically acceptable acid or base , or any optical isomer or mixture of optical isomers , including a racemic mixture , or any tautomeric forms. In another embodiment of the present inVention said fused 1 , 2 , 4 - triazole , or a prodrug thereof , as a component of the combination therapy is of the general formula ( Ill ) Wherein R1 is C5 - C1Ocycloalkyl , C5 - C10hetcycloalkyl , aryl , hetaryl , or arle1 - C6alkyl , Wherein the cycloalkyl , hetcyc1oalkyl , aryl , hetaryl and arylalkyl groups independently are optionally substituted With one or more of R7. In another embodiment of the present inVention said fused 1 , 2 , 4 - triazole , or a prodrug thereof , as a component of the combination therapy is of the genera1 formula ( Ill ) Wherein R1 is C5 - C1Ocycloalkyl , C5 - C10hetcycloalkyl , aryl , Wherein the cycloalkyl , hetcycloalkyl and aryl groups independently are optionally substituted With one or more of R7. In another embodiment of the present inVention said fused 1 , 2 , 4 - triazo1e , or a prodrug thereof , as a component of the combination therapy is of the general formula ( Ill ) Wherein R1 is C5 - C10cycloalkyl optionally substituted With one or more of R7. In another embodiment of the present inVention said fused 1 , 2 , 4 - triazo1e , or a prodrug thereof , as a component of the combination therapy is of the general formula ( Ill ) Wherein R1 is C5 - C10hetcycloalkyl optionally substituted With one or more of R7. In another embodiment of the present inVention said fused 1 , 2 , 4 - triazole , or a prodrug thereof , as a component of the combination therapy is of the general formula ( Ill ) Wherein R1 is aryl , optionally substituted With one or more of R7. In another embodiment of the present inVention said fused 1 , 2 , 4 - triazole , or a prodrug thereof , as a component of the. US 7 , 50l , 405 B2. 81. combination therapy is of the general formula ( lII ) Wherein R1 is hetaryl optionally substituted With one or more of R7. In another embodiment of the present inVention said fused 1 , 2 , 4 - triazole , or a prodrug thereof , as a component of the combination therapy is of the general formula ( Ill ) Wherein R1 is arle1 - C6alkyl optionally substituted With one or more of R7. In another embodiment of the present inVention said fused 1 , 2 , 4 - triazole , or a prodrug thereof , as a component of the combination therapy is of the general formula ( Ill ) Wherein R2 and R3 independently are hydrogen or C1 - C6alkyl. In another embodiment of the present inVention said fused 1 , 2 , 4 - triazole , or a prodrug thereof , as a component of the combination therapy is of the general formula ( Ill ) Wherein R2 and R3 together With the carbon atom to Which they are attached , are forming a saturated or partially saturated cyclic ring system containing from 3 to 6 carbon atoms and from 0 to 2 additional heteroatoms selected from nitrogen or oxygen , the ring system optionally being substituted With at least one of C1 - C6alkyl , aryl , hetaryl , arle1 - C6alkyl , hetarle1 - C6alkyl , hydroxy , oxo , C1 - C6alkyloxy , aryloxy , arle1 - C6alkyloxy or hetarle1 - C6alkyloxy. In another embodiment of the present inVention said fused 1 , 2 , 4 - triazole , or a prodrug thereof , as a component of the combination therapy is of the general formula ( Ill ) Wherein R4 and R5 independently are hydrogen , C1 - C6alkyl , C1 - C6alkyloxy , aryloxyC1 - C6alkyl , Wherein the alkyl and ary1 groups independently are optionally substituted With one or more of R9. In another embodiment of the present inVention said fused 1 , 2 , 4 - triazole , or a prodrug thereof , as a component of the combination therapy is of the general formula ( Ill ) Wherein R4 and R5 together With the carbon atoms to Which they are attached , are fo1ming a saturated or partial1y saturated ring system containing from 5 to 8 carbon atoms and from 0 to 2 additional heteroatoms selected from nitrogen or oxygen , the ring system optionally being substituted With at least one of C1 - C6alkyl. In another embodiment of the present inVention said fused 1 , 2 , 4 - triazole , or a prodrug thereof , as a component of the combination therapy is of the general formula ( Ill ) Wherein R4 and either R2 or R3 together are forming a saturated or partially saturated bridge containing from 1 to 4 carbon atoms , the bridge can optiona1ly be substituted With at least one of C1 - C6alkyl or arle 1 - C6alkyl. In another embodiment of the present inVention said fused 1 , 2 , 4 - triazole , or a prodrug thereof , as a component of the combination therapy is of the genera1 formula ( Ill ) Wherein R6 is hydrogen or C1 - C6alkyl. In another embodiment of the present inVention said fused 1 , 2 , 4 - triazole , or a prodrug thereof , as a component of the combination therapy is of the general formula ( Ill ) Wherein R6 and either R4 or R5 together With the carbon atoms to Which they are attached , are forming a saturated , partially saturated or aromatic ring system containing from 5 to 8 carbon atoms and from 0 to 2 additional heteroatoms selected from nitrogen or oxygen or sulphur , the ring system option - al1y being substituted With at 1east one of C1 - C6a1kyl , halo , trihalomethyl , C1 - C6alkyloxy or arle1 - C6alkyloxy. lO. lS. 20. 25. 30. 35. 40. 45. 50. 55. 82. ln another embodiment of the present inVention said fused 1 , 2 , 4 - triazole , or a prodrug thereof , as a component of the combination therapy is of the general formula ( III ) Wherein R9 is hydrogen. In another embodiment of the present inVention said fused l , 2 , 4 - triazole , or a prodrug thereof , as a component of the combination therapy is of the general formula ( III ) WhereinA is a double or aromatic bond ; X is ( CR”R” ) , , , Wherein R” and R” independently are hydrogen or C1 - C6alkyl and n is 1 ; Y is CR1 8 Wherein R” is hydrogen , C1 - C6alkyl , aryl , hetaryl , arle1 - C6alkyl or hetarle1 - C6alkyl ; R6 and either R4 or R5 together With the carbon atoms to Which they are attached , are forming an aromatic ring system containing 6 carbon atoms , the ring system optionally being substituted With at least one of C1 - C6alkyl , aryl , arle1 - C6alkyl , NR” R” , halo , trihalomethyl , trihalomethoxy , hydroxy , oxo , C1 - C6alkyloxy , arle1 - C5alkyloxy , C1 - C6alkyloxyC 1 - C6alkyl , C1 - C6alkylcarbonyl , arylcarbonyl , arle1 - C6alkylcarbonyl , C1 - C6alkylcarboxy , arylcarboxy or arle1 - C6alkylcarboxy. In another embodiment of the present inVenbon said fused 1 , 2 , 4 - triazole , or a prodrug thereof , as a component of the combination therapy is of the general formula ( III ) WhereinA is a double or aromatic bond. In another embodiment of the present inVention said fused 1 , 2 , 4 - triazole , or a prodrug thereof , as a component of the combination therapy is of the general formula ( III ) Wherein X is ( CR”R” ) , , 1 , Wherein Rl6 and R” independently are hydrogen or C1 - C6alkyl and n is 1. In another embodiment of the present inVention said fused 1 , 2 , 4 - triazole , or a prodrug thereof , as a component of the combination therapy is of the general formula ( III ) WhereinY is CR” Wherein R” is hydrogen , C1 - C6alkyl , aryl , hetaryl , arle1 - C6alkyl or hetarle1 - C6a1ky1. In another embodiment of the present inVention said fused 1 , 2 , 4 - triazole , or a prodrug thereof , as a component of the combination therapy is selected from the group consisting : 3 - ( 2 - Bromo - phenyl ) - 6 , 7 , 8 , 9 - tetrahydro - 5H - [ 1 , 2 , 4 ] triazolo. [ 4 , 3 - a ] azepine ; 3 - Phenyl - [ 1 , 2 , 4 ] triazolo [ 3 , 4 - a ] isoquino1ine ; ( 2 - Methoxy - benzyl ) - ( 3 - phenyl - [ 1 , 2 , 4 ] triazolo [ 4 , 3 - b ] py - . ridazin - 6 - yl ) - amine ; 3 - ( 2 - Fluoro - phenyl ) - 5 - ( 4 - methoxy - phenoxy ) - [ 1 , 2 , 4 ] tria - . zolo [ 4 , 3 - c ] quinazoline ; 3 - Phenyl - 6 , 7 , 8 , 9 - tetrahydro - 5H - [ 1 , 2 , 4 ] triazolo [ 4 , 3 - a ] . azepine ; 3 - ( 4 - Chloro - phenyl ) - 6 , 7 , 8 , 9 - tetrahydro - 5H - [ 1 , 2 , 4 ] triazolo. [ 4 , 3 - a ] azepine ; 3 - ( 3 - Chioro - pheny1 ) - 6 , 7 , 8 , 9 - tetrahydro - 5H - [ 1 , 2 , 4 ] triazo1o. [ 4 , 3 - a ] azepine ; 3 - ( 3 , 4 - Dichloro - phenyl ) - 6 , 7 , 8 , 9 - tetrahydro - 5H - [ 1 , 2 , 4 ] tria - . zolo [ 4 , 3 - a ] azepine ; . 5 , 5 - Dimethyl - 3 - thiophen - 2 - yl - 5 , 6 - dihydro - [ 1 , 2 , 4 ] triazolo. [ 3 , 4 - a ] isoquinoline ; 3 - ( 2 - Chioro - phenyl ) - 6 , 7 , 8 , 9 - tetrahydro - 5H - [ 1 , 2 , 4 ] triazolo. [ 4 , 3 - a ] azepine ; 5 , 5 - Dimethyl - 3 - ( 3 , 4 , 5 - trimethoxy - phenyl ) - 5 , 6 - dihydro - [ 1 , . 2 , 4 ] triazolo [ 3 , 4 - a ] isoquinoline ; 3 - Furan - 2 - y1 - 5 , 5 - dimethy1 - 5 , 6 - dihydro - [ 1 , 2 , 4 ] triazo1o [ 3 , 4 - . a ] isoquinoline ; . In another embodiment of the present inVention said fused 60 3 - ( 3 - Bromo - phenyl ) - 6 , 7 , 8 , 9 - tetrahydro - 5H - [ 1 , 2 , 4 ] triazolo. 1 , 2 , 4 - triazole , or a prodrug thereof , as a component of the combination therapy is of the general formula ( III ) Wherein R7 and R8 independently are hydrogen , halo , hydroxy , cyano , C1 - C6alkyl , C1 - C6alkyloxy , trihalomethyl , trihalomethoxy , aryloxy , hetaryloxy , arle1 - C6alkyloxy , hetarle1 - C6alkyloxy , C1 - C6alkyloxyC1 - C6alkyl , aryloxyC1 - C6alkyl or arle1 - C6alkyloxyC1 - C6alkyl. 65. [ 4 , 3 - a ] azepine ; . 3 - ( 4 - Bromo - phenyl ) - 5 , 5 - dimethyl - 5 , 6 - dihydro - [ 1 , 2 , 4 ] triazolo [ 3 , 4 - a ] isoquinoline ; . 4 - ( 5 , 5 - Dimethyl - 5 , 6 - dihydro - [ 1 , 2 , 4 ] triazolo [ 3 , 4 - a ] isoquinolin - 3 - yl ) - phenol ; . 3 - ( 4 - Methoxy - phenyl ) - 5 , 5 , 8 , 9 - tetramethyl - 5 , 6 - dihydro - [ 1 , 2 , 4 ] triazolo [ 3 , 4 - a ] isoquinoline ; . US 7 , 50l , 405 B2. 83. 5 , 5 - Dimethyl - 3 - phenyl - 5 , 6 - dihydro - [ l , 2 , 4 ] triazolo [ 3 , 4 - a ] isoquinoline ; . 3 - ( 5 , 5 - Dimethyl - 5 , 6 - dihydro - [ 1 , 2 , 4 ] triazolo [ 3 , 4 - a ] isoquinolin - 3 - yl ) - phenol ; . 5 , 5 - Dimethyl - 3 - p - tolyl - 5 , 6 - dihydro - [ 1 , 2 , 4 ] triazolo [ 3 , 4 - a ] isoquinoline ; . 5 , 5 - Dimethyl - 3 - thiophen - 2 - yl - 5 , 6 - dihydro - [ 1 , 2 , 4 ] triazolo [ 3 , 4 - a ] isoquinoline ; . 7 , 1 0 - Dimethoxy - 5 , 5 - dimethyl - 3 - phenyl - 5 , 6 - dihydro - [ 1 , 2 , 4 ] triazolo [ 3 , 4 - a ] isoquinoline ; . 3 - ( 2 , 4 - Dichloro - phenyl ) - 6 , 6 - dimethyl - 5 , 6 , 7 , 8 - tetrahydro - [ 1 , 2 , 4 ] triazolo [ 4 , 3 - a ] pyrimidine ; . 2 - ( 6 , 6 - Dimethyl - 5 , 6 , 7 , 8 - tetrahydro - [ 1 , 2 , 4 ] triazolo [ 4 , 3 - a ] pyrimidin - 3 - yl ) - phenol ; . 3 - ( 2 - Chloro - phenyl ) - 6 , 6 - dimethyl - 5 , 6 , 7 , 8 - tetrahydro - [ 1 , 2 , 4 ] triazolo [ 4 , 3 - a ] pyrimidine ; . 4 - Benzyl - 3 , 5 - di - p - tolyl - 4H - [ 1 , 2 , 4 ] triazole ; . 3 - p - Toly1 - 6 , 7 , 8 , 9 - tetrahydro - 5H - [ 1 , 2 , 4 ] triazolo [ 4 , 3 - a ] azepine ; . 3 - ( 4 - Methoxy - phenyl ) - 6 , 7 , 8 , 9 - tetrahydro - 5H - [ 1 , 2 , 4 ] triazolo [ 4 , 3 - a ] azepine ; . 3 - Pyridin - 4 - yl - 6 , 7 , 8 , 9 - tetrahydro - 5H - [ 1 , 2 , 4 ] triazolo [ 4 , 3 - a ] azepine ; . 3 - ( 4 - Bromo - phenyl ) - 6 , 7 , 8 , 9 - tetrahydro - 5H - [ 1 , 2 , 4 ] triazolo [ 4 , 3 - a ] azepine ; . 3 - Furan - 2 - yl - 5 , 5 , 8 , 9 - tetramethyl - 5 , 6 - dihydro - [ 1 , 2 , 4 ] triazolo [ 3 , 4 - a ] isoquinoline ; . 6 , 6 - Dimethyl - 3 - ( 2 - nitro - phenyl ) - 5 , 6 , 7 , 8 - tetrahydro - [ 1 , 2 , 4 ] triazo1o [ 4 , 3 - a ] pyrimidine ; . 3 - ( 2 , 4 - Dichloro - phenyl ) - 5 , 5 - dimethyl - 5 , 6 - dihydro - [ 1 , 2 , 4 ] triazo1o [ 3 , 4 - a ] isoquino1ine ; or. a salt thereof With a pharmaceutically acceptable acid or base , or any optical isomer or mixture of optical isomers , including a racemic mixture , or any tautomeric forms. In another embodiment of the present inVention said fused. 1 , 2 , 4 - triazole , or a prodrug thereof , as a component of the combination therapy is of the genera1 formula ( IIIa ) . ( IIIa ) . Wherein. R1 is aryl or hetary1 , Wherein the aryl and hetaryl groups independently are optionally substituted With one or more of R7 ; . R2 and R3 together With the atoms to Which they are connected forms a C5 - C10cycloalkyl or C5 - C10hetcycloalkyl , Wherein the cycloalkyl and hetcycloalkyl rings independently are optionally substituted With one or more of R8 ; or. R2 and R3 are connected to one of the folloWing ring systems at the carbon atoms marked With an asterix ( * ) . 44 44 >3 X $ $ $. 5. 10. lS. 20. 25. 40. 50. m. 5. 60. 84. - continued. bQﬁ / Q QQQ. Wherein the ring systems independently are optionally substituted With one or more R8 ; . R7is hydrogen , halo , hydroxy , cyano , nitro , C1 - C6alkyl , C1 - C6alkyloxy , trihalomethyl , trihalomethoxy , aryloxy , hetaryloxy , NR9R” , arle1 - C6alkyloxy , hetarle1 - C6alkyloxy , C1 - C6alkyloxyC 1 - C6alkyl , aryloxyC 1 - C6alkyl , arle1 - C5alkyloxyC1 - C6alkyl , C1 - C6alky1carbonyl , arylcarbonyl , hetarylcarbonyl , arle1 - C6alkylcarbonyl , hetarle1 - C6alkylcarbonyl , C1 - C6alkylcarboxy , arylcarboxy , hetarylcarboxy , arle1 - C6alkylcarboxy or hetarle1 - C6alkylcarboxy ; . R8 is hydrogen , C1 - C6alkyl , halo , aryl , hetaryl , arle1 - C6alkyl , NR9R” , trihalomethyl , trihalomethoxy , hydroxy , oxo , C1 - C6alkyloxy , aryloxy , arle1 - C6alkyloxy , hetarle 1 - C6alkyloxy , C1 - C6alkyloxyC 1 - C6alkyl , C1 - C6alky1carbonyl , ary1carbony1 , arle1 - C6alkylcarbonyl , C1 - C6alkylcarboxy , arylcarboxy or arle1 - C6alkylcarboxy ; . R9 and R” independently are hydrogen , C1 - C6alkyl , ary1 or arle1 - C6alkyl Wherein the alkyl and aryl groups independently are optionally substituted With one or more of R” ; or. R9 and R” together With the nitrogen to Which they are attached , are forming a saturated or partially saturated cyclic , bicyclic or tricyclic ring system containing from 4 to 10 carbon atoms and from 0 to 2 additiona1 heteroatoms selected from nitrogen , oxygen or sulfur , the ring system optional1y being substituted With at 1east one of C1 - C6alkyl , aryl , hetaryl , arle1 - C6alkyl , hydroxy , oxo , C1 - C6alkyloxy , arle 1 - C6alkyloxy , C1 - C6alkyloxyC1 - C6alkyl , C1 - C6alkylcarbonyl , arylcarbonyl , arle1 - C6alky1carbonyl , C1 - C6a1ky1carboxy , arylcarboxy or arle1 - C6alkylcarboxy ; . R” is C1 - C6alkyl , oxo or halo ; . X is ( CR”R” ) , , , Wherein R” and R” independently are hydrogen , oxo , hydroxy or C1 - C6alkyl ; and. n is 1 or 2 ; or. a salt thereof With a pharmaceutically acceptable acid or base , or any optical isomer or mixture of optica1 isomers , including a racemic mixture , or any tautomeric forms. In another embodiment of the present inVention said fused 1 , 2 , 4 - triazo1e , or a prodrug thereof , as a component of the combination therapy is of the general formula ( IIIa ) Wherein R1 is aryl optionally substituted With R7 as deﬁned aboVe. ln another embodiment of the present inVention said fused 1 , 2 , 4 - triazole , or a prodrug thereof , as a component of the combination therapy is of the general formula ( IIIa ) Wherein R1 is pheny1 optionally substituted With R7 as deﬁned aboVe. In another embodiment of the present inVention said fused 1 , 2 , 4 - triazole , or a prodrug thereof , as a component of the combination therapy is of the general formula ( llIa ) Wherein R2 and R3 are connected to one of the folloWing ring systems at the carbon atoms marked With an asterix ( * ) . US 7 , 50l , 405 B2. 85. CtoQQQ. Wherein the ring systems independently are optionally substituted With one or more R8 as deﬁned aboVe. In another embodiment of the present inVention said fused 1 , 2 , 4 - triazole , or a prodrug thereof , as a component of the combination therapy is of the general formula ( IIIa ) Wherein R7 is hydrogen , halo , hydroxy , cyano , C1 - C6alkyl , C1 - C6alkyloxy , trihalomethyl , aryloxy , arle1 - C6alkyloxy , hetarle1 - C6alkyloxy , C1 - C6alkyloxyC1 - C6alkyl , aryloxyC1 - C6alkyl or arle1 - C6alkyloxyC1 - C6alkyl. In another embodiment of the present inVention said fused 1 , 2 , 4 - triazole , or a prodrug thereof , as a component of the combination therapy is of the general formula ( IIIa ) Wherein R8 is hydrogen , C1 - C6alkyl or halo. In another embodiment of the present inVention said fused 1 , 2 , 4 - triazole , or a prodrug thereof , as a component of the combination therapy is of the general formula ( IIIb ) . ( 11lb ) . Wherein. R1 is aryl or hetary1 , Wherein the aryl and hetaryl groups independently are optiona1ly substituted With one or more of R7 ; . R7 is hydrogen , halo , hydroxy , cyano , nitro , C1 - C6a1kyl , C1 - C6alkyloxy , trihalomethyl , trihalomethoxy , aryloxy , hetaryloxy , NR9R” , arle1 - C6alkyloxy , hetarle1 - C6alkyloxy , C 1 - C6alkyloxyC 1 - C6alkyl , aryloxyC1 - C6alkyl , ary1C1 - C6alky1oxyC1 - C6a1kyl , C1 - C6a1ky1carbonyl , arylcarbonyl , hetarylcarbonyl , arle 1 - C6alkylcarbonyl , hetarle1 - C6alkylcarbonyl , C1 - C6alkylcarboxy , arylcarboxy , hetarylcarboxy , arle1 - C6alkylcarboxy or hetarle1 - C6alkylcarboxy ; . R9 and R” independently are hydrogen , C1 - C6alkyl , aryl or arle1 - C6alkyl Wherein the alkyl and aryl groups independently are optionally substituted With one or more of R” ; or. R9 and R” together With the nitrogen to Which they are attached , are forming a saturated or partially saturated cyclic , bicyc1ic or tricyclic ring system containing from 4 to 10 carbon atoms and from 0 to 2 additional heteroatoms selected from nitrogen , oxygen or sulfur , the ring system optionally being substituted With at least one of C1 - C6alkyl , aryl , hetaryl , arle1 - C6alkyl , hydroxy , oxo , C1 - C6alkyloxy , arle 1 - C6alkyloxy , C 1 - C6alkyloxyC1 - C6alkyl , C1 - C6alkylcarbonyl , arylcarbonyl , arle1 - C6alkylcarbonyl , C1 - C6alkylcarboxy , arylcarboxy or arle1 - C6a - alkylcarboxy ; . R” is C1 - C6alkyl , oxo or halo ; . a salt thereof With a pharmaceutically acceptable acid or base , or any optical isomer or mixture of optical isomers , including a racemic mixture , or any tautomeric forms. 5. lO. lS. 20. 25. 30. 35. 40. 45. 50. 55. 60. 65. 86. ln another embodiment of the present inVention said fused 1 , 2 , 4 - triazole , or a prodrug thereof , as a component of the combination therapy is of the general formula ( IIIb ) Wherein R1 is aryl optionally substituted With R7 as deﬁned aboVe. In another embodiment of the present inVention said fused 1 , 2 , 4 - triazole , or a prodrug thereof , as a component of the combination therapy is of the general formula ( IIIb ) Wherein R1 is phenyl optionally substituted With R7 as deﬁned aboVe. In another embodiment of the present inVention said fused 1 , 2 , 4 - triazole , or a prodrug thereof , as a component of the combination therapy is of the general formula ( IIIb ) Wherein R1 is phenyl substituted in the ortho position. In another embodiment of the present inVention said fused 1 , 2 , 4 - triazole , or a prodrug thereof , as a component of the combination therapy is of the general formula ( IIIb ) Wherein R1 is phenyl substituted in both the ortho and para position. In another embodiment of the present inVention said fused 1 , 2 , 4 - triazole , or a prodrug thereof , as a component of the combination therapy is of the general formula ( IIIb ) Wherein R7 is halo , hydroxy , cyano , C1 - C6alkyl , C1 - C6alkyloxy , trihalomethy1 , triha1omethoxy , aryloxy , hetary1oxy , NR9R” , arle1 - C6alkyloxy , hetarle1 - C6alkyloxy , C1 - C6alkyloxyC1 - C6alkyl , aryloxyC1 - C6alkyl , arle1 - C6alkyloxyC1 - C6alkyl , C1 - C6alkylcarbonyl , arylcarbonyl , hetarylcarbonyl , arle1 - C6alkylcarbonyl or hetarle1 - C6alkylcarbonyl ; Wherein R9 and R” are deﬁned as aboVe. In another embodiment of the present inVention said fused 1 , 2 , 4 - triazole , or a prodrug thereof , as a component of the combination therapy is of the general formula ( IIIb ) Wherein R7 is C1 - C6alkyloxy , trihalomethoxy , aryloxy , hetaryloxy , arle1 - C6alkyloxy , hetarle1 - C6alkyloxy , C1 - C6alkyloxyC1 - C6alkyl , aryloxyC1 - C6alkyl or arle1 - C6alkyloxyC1 - C6alkyl. In another embodiment of the present inVention said fused 1 , 2 , 4 - triazo1e , or a prodrug thereof , as a component of the combination therapy is selected from the group consisting of : 3 - ( 2 - Bromo - pheny1 ) - 6 , 7 , 8 , 9 - tetrahydro - 5H - [ 1 , 2 , 4 ] triazo1o. [ 4 , 3 - a ] azepine ; 3 - ( 2 - Phenoxymethyl - phenyl ) - 5 , 6 , 7 , 8 - tetrahydro - [ 1 , 2 , 4 ] tria - . zolo [ 4 , 3 - a ] azepin - 9 - one ; 3 - ( 2 - Phenoxymethyl - phenyl ) - 6 , 7 , 8 , 9 , 10 , 1 1 - hexahydro - 5H - . 5 , 9 : 7 , 11 - dimethano [ 1 , 2 , 4 ] triazolo [ 4.3 - a ] azonine ; 3 - ( 5 - Bromo - pyridin - 3 - yl ) - 6 , 7 , 8 , 9 - tetrahydro - 5H - [ 1 , 2 , 4 ] triazolo [ 4 , 3 - a ] azepine ; 3 - ( 5 - Hex - 1 - ynyl - pyridin - 3 - yl ) - 6 , 7 , 8 , 9 - tetrahydro - 5H - [ 1 , 2 , 4 ] triazolo [ 4 , 3 - a ] azepine ; 3 - ( 6 - Chioro - pyridin - 3 - yl ) - 6 , 7 , 8 , 9 - tetrahydro - 5H - [ 1 , 2 , 4 ] triazolo [ 4 , 3 - a ] azepine ; 3 - ( 6 - Morpholin - 4 - yl - pyridin - 3 - yl ) - 6 , 7 , 8 , 9 - tetrahydro - 5H - . [ 1 , 2 , 4 ] triazolo [ 4 , 3 - a ] azepine ; 3 - Pyridin - 3 - yl - 6 , 7 , 8 , 9 - tetrahydro - 5H - [ 1 , 2 , 4 ] triazolo [ 4 , 3 - a ] . azep1ne ; 3 - ( 2 - Benzyloxymethyl - phenyl ) - 6 , 7 , 8 , 9 - tetrahydro - 5H - 5 , 9 - . methano [ 1 , 2 , 4 ] triazolo [ 4.3 - a ] azepine ; 3 - Phenyl - [ 1 , 2 , 4 ] triazolo [ 3 , 4 - a ] isoquinoline ; or sa1t thereof With a pharmaceutica1ly acceptable acid or base , or any optical isomer or mixture of optical isomers , including a racemic mixture , or any tautomeric forms. ln another embodiment of the present inVention said alpha - . amino ketones , or a prodrug thereof , as a component of the combination therapy is of the general formula ( IV ) . US 7 , 50l , 405 B2. Formula ( IV ) . Wherein. R1 and R2 independently are hydrogen , C1 - C6alkyl , C3 - C1Ocycloalkyl , C3 - C1OHetcycloalkyl , aryl , hetaryl , arle1 - C6alkyl or hetarle1 - C6alkyl , Wherein the alkyl , cycloalkyl , hetcycloalkyl , aryl and hetaryl groups independently are optionally substituted With one or more of R6 ; or. R1 and R2 together With the nitrogen to Which they are attached , are forming a saturated or partially saturated cyclic or bicyclic ring system containing from 4 to 8 carbon atoms and from 0 to 2 additional heteroatoms selected from nitrogen , oxygen or sulphur , the ring system optionally being substituted With at least one of C1 - C6alkyl , aryl , hetaryl , arle1 - C6alkyl , hetaryl - C1 - C6alkyl , hydroxy , oxo , C 1 - C6a1ky1 - oxy , arle 1 - C6a1kyloxy , hetarle1 - C6alkyloxy , C1 - C6alkyloxyC1 - C6alkyl , C1 - C6alkyl - carbonyl , arylcarbonyl , hetarylcarbonyl , arlel - C6alkylcarbonyl , C1 - C6alkylcarboxy , arylcarboxy , hetarylcarboxy or arle1 - C6alkylcarboxy ; . R3 and R4 independently are hydrogen , C1 - C6a1kyl , C1 - C6alkenyl , C1 - C6alkynyl , aryl , hetaryl , arle1 - C6alkyl or hetarle1 - C6alkyl , Wherein the alkyl , alkenyl , alkynyl , aryl , and hetaryl groups independently are optionally substituted With one or more of R7 ; . R5 is C3 - C1Ocycloalkyl , C3 - C10hetcycloa1kyl , aryl or hetaryl , Wherein the aryl , hetaryl , cycloalkyl and hetcycloalkyl groups independently are optionally substituted With one or more of R8 ; or. R3 and R5 together With the carbon atoms to Which they are attached , are forming a saturated or partially saturated cyclic , bicyc1ic or tricyclic ring system containing from 4 to 10 carbon atoms and from 0 to 2 additiona1heteroatoms se1ected from nitrogen , oxygen or sulphur , the ring system optionally being substituted With at least one of C1 - C6alkyl , aryl , hetaryl , arle1 - C6alkyl , hetarle1 - C6alkyl , hydroxy , oxo , C1 - C6alkyloxy , arle1 - C6alkyloxy , C1 - C6a1ky1oxyC1 - C6alkyl , C1 - C6alkylcarbonyl , arylcarbonyl , hetarylcarbonyl , arle1 - C6alkylcarbonyl , C1 - C6alkylcarboxy , aryl - carboxy , hetarylcarboxy or arle1 - C6alkylcarboxy ; or. R2 , R3 and R5 together With the atoms to Which they are attached , are forming a saturated or partially saturated bicyclic or tricyclic ring system containing from 6 to 10 carbon atoms and from 0 to 2 additional heteroatoms se1ected from nitrogen , oxygen or sulphur , the ring system optionally being substituted With at least one of C1 - C6alkyl , aryl , hetaryl , arle1 - C6alkyl , hetaryl - C1 - C6alkyl , hydroxy , oxo , C1 - C6alkyl - oxy , arle1 - C6alkyloxy , C1 - C6alkyloxyC1 - C6alkyl , C1 - C6alkylcarbonyl , arylcarbonyl , hetarylcarbonyl , arle 1 - C6alkylcarbonyl , C1 - C6alkylcarboxy , arylcarboxy , hetaryl - carboxy or arle1 - C6alkylcarboxy ; . R6 is hydrogen , hydroxy , oxo , halo , adamantyl , C1 - C6alkyl , C1 - C6alkyloxy , trihalomethyl , trihalomethoxy , NR9R” , arle1 - C6alkyloxy , C1 - C6alkylcarbonyl , arylcarbonyl , arle1 - C6alkylcarbonyl , C1 - C6alkylcarboxy , arylcarboxy or arle1 - C6alkylcarboxy ; . R7 and R8 independently are hydrogen , hydroxy , oxo , halo , cyano , nitro , NR9R” , C1 - C6alkyl , C1 - C6alkyloxy , aryl , . lO. lS. 20. 25. 30. 35. 40. 45. 50. 55. 60. 65. 88. hetaryl , arle 1 - C6alkyloxy , hetarle1 - C6alkyloxy , . C1 - C6alkylcarbonyl , arylcarbonyl , hetarylcarbonyl , . arle1 - C6alkylcarbonyl , C1 - C6alkyl - carboxy , arylcarboxy. or ary1C1 - C6alkylcarboxy , Wherein the aryl and hetaryl groups independently are optionally substituted With. C3 - C1Ocycloalkyl or C3 - C10hetcycloalkyl ; . R9 and R” independently are hydrogen , C1 - C6alkyl , C3 - C1Ocycloalkyl , C3 - C1Ohetcycloalkyl , aryl , hetaryl , arle1 - C6alkyl or hetarle1 - C6alkyl ; or. R9 and R” together With the nitrogen to Which they are attached , are forming a saturated or partially saturated cyclic , bicyclic or tricyclic ring system containing from 5 to 10 carbon atoms and from 0 to 2 additional heteroatoms selected from nitrogen , oxygen or sulfur , the ring system optionally being substituted With at least one C1 - C6alkyl , aryl , hetaryl , arle1 - C6alkyl , hetarle1 - C6alkyl , hydroxy , oxo , C1 - C6alkyloxy , arle1 - C6alkyloxy , C1 - C6alkyloxyC1 - C6alkyl , C1 - C6alkylcarbonyl , arylcarbonyl , hetarylcarbonyl , arle1 - C6alkylcarbonyl , C1 - C6alkylcarboxy , arylcarboxy , hetarylcarboxy or arle1 - C6alkylcarboxy ; or. a salt thereof With a pharmaceutically acceptable acid or base , or any optical isomer or mixture of optica1 isomers , including a racemic mixture , or any tautomeric forms. In another embodiment of the present inVention said alphaamino ketones , or a prodrug thereof , as a component of the combination therapy is selected from the group consisting of : 1 - Adamantan - 1 - yl - 2 - morpholin - 4 - yl - ethanone ; . 1 - Adamantan - 1 - yl - 2 - benzylamino - propan - 1 - one ; . 1 - Adamantan - 1 - yl - 2 - benzylamino - ethanone ; . 2 - Pyrrolidin - 1 - yl - 1 - ( 3 - p - tolyl - adamantan - 1 - yl ) ethanone ; . 1 - Adamantan - 1 - yl - 2 - morpholin - 4 - yl - propan - 1 - one ; . 1 - [ 4 - ( 5 - Adamantan - 1 - yl - [ 1 , 2 , 3 ] triazo1 - 1 - yl ) - pheny1 ] - 2 - phenylamino - ethanone ; . 6 - Benzo [ 1 , 3 ] dioxol - 5 - yl - 8 - benzyl - 8 - aza - bicyclo [ 3.2.1 ] octan - 2 - one ; . 2 - tert - Butylamino - 1 - ( 3 - p - tolyl - adamantan - 1 - yl ) ethanone ; . 2 - Morpholin - 4 - y1 - 1 - ( 3 - p - to1y1 - adamantan - 1 - yl ) ethanone ; . 1 - Adamantan - 1 - yl - 2 - [ 4 - ( 4 - nitro - phenyl ) - piperazin - 1 - yl ] ethanone ; or. a salt thereof With a pharmaceutically acceptable acid or base , or any optical isomer or mixture of optical isomers , including a racemic mixture , or any tautomeric forms. In another embodiment of the present inVention said substituted 1 , 2 , 4 - triazole , or a prodrug thereof , as a component of the combination therapy is of the general formula ( V ) . N N Formula ( V ) A k R1 R3 N x / | R2. Wherein. X is O or S ; . R1 is hydrogen , C1 - C6alkyl , C2 - C6alkenyl , C2 - C6alkynyl , C3 - C10cycloalkyl , arle1 - C6alkyl , hetarle1 - C6alkyl , R4R5Ncarbonle1 - C6alkyl , arylcarbonle1 - C6alkyl , hetarylcarbonle1 - C6alkyl ; Wherein the alkyl , alkenyl , alkynyl , aryl and hetaryl groups independently are optionally substituted With one or more of R6 ; . R2 is C1 - C6alkyl , C1 - C6alkenyl , arle1 - C6alkyl , C3 - C1Ocycloalkyl or hetarle1 - C6alkyl ; Wherein the alkyl , alkenyl , cycloalkyl , aryl and hetaryl groups independently are optionally substituted With one or more of R7 ; . US 7 , 50l , 405 B2. 89. R3 is C3 - C1ocycloalkyl , C3 - C10hetcycloalkyl , aryl , hetaryl , arle1 - C6alkyl , hetarle1 - C6alkyl , arle8C1 - C6alkyl or hetarle8C1 - C6alkyl ; Wherein the alkyl , cycloalkyl , hetcycloalkyl , aryl and hetaryl groups independently are optionally substituted With one or more of R9 ; 5. R4 and R5 independently are hydrogen , C1 - C6alkyl , C3 - C1Ocycloalkyl , C5 - C8hetcycloalkyl , aryl , hetaryl , arle1 - C6alkyl or hetarle1 - C6alkyl ; Wherein the alkyl , cycloalkyl , hetcycloalkyl , aryl , hetaryl ; arylalkyl or hetary - 10 lalkyl groups independently are optionally substituted With one or more of R” ; or. R4 and R5 together With the nitrogen to Which they are attached , are forming a saturated or partially saturated cyclic , bicyclic or tricyclic ring system containing from 4 15 to 10 carbon atoms and from 0 to 2 additional heteroatoms selected from nitrogen , oxygen or sulphur , the ring system optionally being substituted With at least one of C1 - C6a1ky1 , aryl , arle1 - C6a1kyl , hydroxy , oxo , C1 - C6alkyloxy , arle1 - C6alkyloxy , C1 - C6alkyloxyC1 - 20 C6alkyl , C1 - C6alkylcarbonyl , arylcarbonyl , arle1 - C6alkyl - carbonyl , C1 - C6alkylcarboxy , arylcarboxy or arle1 - C6alkylcarboxy ; . R6 , R7 , R9 and R” independently are hydrogen , halo , NO2 , NH2 , cyano , NR4R5 , CONR4R5 , triha1omethyl , trihalom - 25 ethoxy , hydroxy , oxo , C1 - C6alkyl , C3 - C10cycloalkyl , C3 - C1Ohetcycloalkyl , aryl , hetaryl , arle1 - C6alkyl , hetarle1 - C6alkyl , C1 - C6alkylSO2 , R”R”NSO2 , C1 - C6alkyloxy , aryloxy , hetaryloxy , arle1 - C6alkyloxy , C1 - C6a1ky1carbonyl , ary1carbonyl , arle1 - 30 C6alkylcarbonyl , arylcarbonleR” , carboxyC1 - C6alkyl or carboxyarle1 - C6alkyl ; . R8 is oxygen , NR” , C ( : O ) NR” or SONNR” ; Wherein n is 1 or 2 ; . R10 is hydrogen , C1 - C6alkyl , aryl , hetaryl , arle1 - C6alkyl or hetarle1 - C6alkyl ; . R” and R” independently are hydrogen , C1 - C6a1kyl , C3 - C1Ocycloalkyl , C5 - C8hetcycloalkyl , aryl or hetaryl ; Wherein the alkyl , cycloalkyl , hetcycloalkyl , aryl or hetaryl 40 groups independently are optionally substituted With one or more of R” ; or. 35. R” and R” together With the nitrogen to Which they are attached , are forming a saturated or partially saturated cyclic , bicyclic or tricyclic ring system containing from 4 45 to 8 carbon atoms and from 0 to 2 additional heteroatoms selected from nitrogen , oxygen or sulphur , the ring system optionally being substituted With at least one of C1 - C6a1ky1 , aryl , arle1 - C6a1kyl , hydroxy , oxo , C1 - C6alkyloxy , arle 1 - C6alkyloxy , C1 - C6alkyloxyC1 - 50 C6alkyl , C1 - C6alkylcarbonyl , arylcarbonyl , arle1 - C6alkylcarbonyl , C1 - C6alkylcarboxy , arylcarboxy or arle1 - C6alkyl - carboxy ; or. a salt thereof With a pharmaceutically acceptable acid or base , or any optical isomer or mixture of optical isomers , includ - 5 5 ing a racemic mixture , or any tautomeric forms. In another embodiment of the present inVention said substituted 1 , 2 , 4 - triazole , or a prodrug thereof , as a component of. 90. R2 is C1 - C6alkyl , C1 - C6alkenyl , arle 1 - C6alkyl or hetarle1 - C6alkyl ; Wherein the alkyl , alkenyl , aryl and hetaryl groups independently are optionally substituted With one or more of R7 ; . R3 is C5 - C8cycloalkyl , C5 - C8hetcycloalkyl , aryl , hetaryl , arle1 - C6alkyl , hetarle1 - C6alkyl , arle8C1 - C6alkyl or hetarle8C1 - C6alkyl ; Wherein the alkyl , cycloalkyl , hetcycloalkyl , aryl and hetaryl groups independently are optionally substituted With one or more of R9 ; . R4 and R5 independently are hydrogen , C1 - C6alkyl , C5 - C1Ocycloalkyl , C5 - C8hetcycloalkyl , aryl , hetaryl , arle1 - C6alkyl or hetarle1 - C6alkyl ; Wherein the alkyl , cycloalkyl , hetcycloalkyl , aryl , hetaryl , arylalkyl or hetarylalkyl groups independently are optionally substituted With one or more of R” ; or. R4 and R5 together With the nitrogen to Which they are attached , are forming a saturated or partially saturated cyclic , bicyclic or tricyclic ring system containing from 4 to 10 carbon atoms and from 0 to 2 additional heteroatoms selected from nitrogen , oxygen or sulphur , the ring system optionally being substituted With at least one of C1 - C6alkyl , aryl , arle1 - C6alkyl , hydroxy , oxo , C1 - C6alky1oxy , arle 1 - C6alkyloxy , C1 - C6a1kyloxyC1 - C6alkyl , C1 - C6alkylcarbonyl , arylcarbonyl , arle1 - C6alkylcarbonyl , C1 - C6alkylcarboxy , arylcarboxy or arle1 - C6alkyl - carboxy ; . R6 , R7 , R9 and R” independently are hydrogen , halo , NO2 , NH1 , cyano , trihalomethyl , trihalomethoxy , hydroxy , oxo , C1 - C6alky1 , ary1 , hetaryl , ary1C1 - C6alkyl , hetarle1 - C6alkyl , SO2NR” R” , C1 - C6alkyloxy , aryloxy , hetaryloxy , arle1 - C6alkyloxy , C1 - C6alkylcarbonyl , arylcarbonyl , arle 1 - C6alkylcarbonyl , arylcarbonleR” , carboxyC1 - C6alkyl or carboxyary1C1 - C6alkyl ; . R8 is oxygen , NR” , C ( : O ) NR” or SO , NR” ; Wherein n is 1 or 2 ; . R” is hydrogen , C1 - C6alkyl , aryl , hetaryl , arle 1 - C6alkyl or hetarle1 - C6alkyl ; . R” and R” independently are hydrogen , C1 - C6alkyl , C5 - C10cyc1oa1kyl , C5 - C8hetcycloa1ky1 , ary1 or hetary1 ; Wherein the alkyl , cycloalkyl , hetcycloalkyl , aryl or hetaryl groups independently are optionally substituted With one or more of R” ; or. R” and R” together With the nitrogen to Which they are attached , are forming a saturated or partially saturated cyclic , bicyclic or tricyclic ring system containing from 4 to 8 carbon atoms and from 0 to 2 additional heteroatoms selected from nitrogen , oxygen or sulphur , the ring system optional1y being substituted With at 1east one of C1 - C6alkyl , aryl , arle1 - C6alkyl , hydroxy , oxo , C1 - C6alkyloxy , arle 1 - C6alkyloxy , C1 - C6alkyloxyC1 - C6alkyl , C1 - C6alkylcarbonyl , arylcarbonyl , arle1 - C6alkylcarbonyl , C1 - C6alkylcarboxy , arylcarboxy or ary1C1 - C6alkyl - carboxy ; or. a salt thereof With a pharmaceutically acceptable acid or base , or any optical isomer or mixture of optical isomers , including a racemic mixture , or any tautomeric forms. In another embodiment of the present inVention said substituted 1 , 2 , 4 - triazole , or a prodrug thereof , as a component of. the combination therapy is of the general formula ( V ) Wherein. the combinationtherapy is of the general formula ( V ) Wherein 60 X is O. X is O or S ; . R1 is hydrogen , C1 - C6alkyl , C2 - C6alkenyl , C2 - C6alkynyl , arle1 - C6alkyl , hetarle1 - C6alkyl , NR4R5carbonle1 - C6alkyl , arylcarbonle1 - C6alkyl , hetarylcarbonle1 - C6alkyl ; Wherein the alkyl , alkenyl , alkynyl , aryl and 65 hetaryl groups independently are optionally substituted With one or more of R6 ; . In another embodiment of the present inVention said substituted 1 , 2 , 4 - triazole , or a prodrug thereof , as a component of. the combination therapy is of the general formula ( V ) Wherein X is S. ln another embodiment of the present inVention said substituted 1 , 2 , 4 - triazole , or a prodrug thereof , as a component of. the combination therapy is of the general formula ( V ) Wherein. US 7 , 50l , 405 B2. 91 92. R1 is arle1 - C6alkyl , hetarle1 - C6alkyl , R4R5Ncarbonle1 - ln another embodiment of the present inVention said sub - C6alkyl , arylcarbonle1 - C6alkyl , hetarylcarbonle1 - stituted 1 , 2 , 4 - triazole , or a prodrug thereof , as a component of C 6a1ky1 ; Wherein aryl and hetaryl groups independently are the combination therapy is selected from the group consisting optionally substituted With one or more of R6. 0h. In another embodiment of the present inVention said sub - 5 3 - ( 4 - Al1y1 - 5 - mercapto - 4H - [ 11214 ] tr1az101 - 3 - y1 ) - 1 - ( 214 - stituted1 , 2 , 4 - triazole , oraprodrug thereof , asacomponent of 4 EEClﬂ01 / ( g - be1nzy 1 ) 1 - 111Hépy£1d1n1211one , 1 5 1 5 2 the combinationtherapy is ofthe general formula ( V ) Wherein _ et1y1 - ( 1 - : 1n§t T 2 1111 1eny1 - t1 1azo ' - y ) ' - prop - ' R2 iS C1 ' C6a1ky1 : ary1C1 - C6a1ky1. C3 - C1Ocycloalky1 0r yny Su any _ _ [ 3 3 ] r1azo e , . hetarle1 - C6alky1 ; all of Which is optionally substituted With 111 Ntﬁ a£ : l ( 3iiiiiiiiiZ? : : 1lle ( irS ( 1 ) l - 1h : h } ; 2n : s : ] 1th : nT1d : : 2j4 ] one or more of R . 4 - Methyl - 3 - methylsulfanyl - 5 - [ 3 - ( 3 - trluoromethyl - benzy - . In another embodiment of the present inVention said sub - loxy ) - thiophen - 2 - yl ] - 4H - [ 1 , 2 , 4 ] triazole ; stituted 1 , 2 , 4 - triazole , or a prodrug thereof , as a component of N - ( 4 - Chloro - phenyl ) - 2 - ( 4 - methyl - 5 - thiophen - 3 - ylmethylthe combinationtherapy is of the general formula ( V ) Wherein 4H - [ 1 1 2141111 azol - 3 _y1 sulfanyl ) - acetamide ; . R3 is C3 - C1ocyC10a1kyL C3 - C1ohetcyc10a1k1g , ary1 , hetary1 , 15 2 - [ 4 - Methyl - 5 - ( 2 - oxo - 2 - phenyl - ethylsulfanyl ) - 4H - [ 1 , 2 , 4 ] ary 1C1 ' C6a1ky1a hetarle1 - C6alkyl , ary 1R Cl ' C6a1ky1 01 ' triazol - 3 - ylmethyl ] - 4H - benzo [ 1 , 4 ] thiazin - 3 - one ; hetarle8C1 - C6alkyl , Wherein all groups indenpendently are 3 - ( 4 - Fluoro - benzylsulfanyl ) - 5 - ( 2 - ﬁuoro - phenyl ) - 4 - methylopt1onally subst1tuted W1th one or more of R9. 4H - [ 1 , 2 , 4 ] triazole ; . In another embodiment of the present inVention said sub - 3 - ( 2 - Fluoro - phenyl ) - 4 - methyl - 5 - ( 4 - methyl - benzylsulfanyl ) - stituted 1 , 2 , 4 - triazole , oraprodrug thereof , as a component of 20 4H - [ 1 , 2 , 4 ] triazole ; the combinationtherapy is of the general formula ( V ) Wherein 4 - Methyl - 3 - ( 4 - methyl - benzylsulfanyl ) - 5 - ( 3 - triﬁuorom - . R3 is C3 - C1Ohetcycloalkyl , aryl , hetaryl , arle1 - C6alkyl , ethyl - phenyl ) - 4H - [ 1 , 2 , 4 ] triazole ; . hetarle1 - C6a1ky1 , arle8C1 - C6alky1 or hetarle8C1 - 3 - ( 2 , 4 - Dichloro - phenyl ) - 4 - furan - 2 - y1methyl - 5 - methylsu1fa - . C6alkyl , Wherein all groups indenpendently are optionally nyl - 4H - [ 1 , 2 , 4 ] triazole ; . substituted With one or more of R9. 25 3 - ( 4 - tert - Butyl - phenyl ) - 5 - ( 2 , 6 - dichloro - benzylsulfanyl ) - 4 - In another embodiment of the present inVention said sub - furan - 2 - ylmethyl - 4H - [ 1 aza4 ] triaZO1ei~. stituted 1 , 2 , 4 - triazole , or a prodrug thereof , as a component of 4 - Methyl - 3 - ( 4 - methyl - benzylsulfanyl ) - 5 - ( 5 - methyl - isox - . the combinationtherapy is of the general formula ( V ) Wherein azol - 3 ' Y1 ) ' 4H ' [ 1 , 2 , 4 ] tr1azole ; . R4 and R5 independently are aryl or hetaryl Wherein both 3 - ( 3 - Methoxy - benzylsulfanyl ) - 4 - methy1 - 5 - thiophen - 2 - ylgroups indenpendently are optionally substituted With one or 30 4H ' [ 1 aZ : 4 ] tnaZ01e ; 1 1110113 0f Rl 11 3 - ( 4 - Fluoro - benzylsulfanyl ) - 4 - methyl - 5 - th1ophen - 2 - yl - 4H - [ 1 , 2 , 4 ] triazole ; 3 - ( 4 - tert - Butyl - benzy1su1fanyl ) - 4 - methyl - 5 - thiophen - 2 - y1 - 4H - [ 1 , 2 , 4 ] triazole ; 35 4 - Methyl - 3 - ( 2 - methyl - benzylsulfanyl ) - 5 - thiophen - 2 - yl - 4H - [ 1 , 2 , 4 ] triazole ; 2 - ( 5 - Benzylsulfanyl - 4 - methyl - 4H - [ 1 , 2 , 4 ] triazol - 3 - ylm - . In another embodiment of the present inVention said substituted 1 , 2 , 4 - triazole , or a prodrug thereof , as a component of the combinationtherapy is of the genera1 formu1a ( V ) Wherein R4 and R5 together With the nitrogen to Which they are attached , are forming a saturated or partially saturated cyclic , bicyclic or tricyclic ring system containing from 4 to 10. carbon atoms and from 0 to 2 additional nitrogen atoms , the ethyl ) - 4H - benzo [ l , 4 ] thiazin - 3 - one ; _ ring system optiona1ly being substituted With at 1east one of 2 - [ 5 - ( 4 - Chloro - benzy1sulfanyl ) - 4 - methyl - 4H - [ 1 , 2 , 4 ] tr1azo1 - . 40 3 - lmeth l - 4H - benzo 1 , 4 thiazin - 3 - one ; a : g : : igibe , aryl11ry1Ca féE ; 1_1 : : y61 : 111§1 : 15 C111§f ( ( : 1 : ( z ) 1l ( lzylox ; C ( 1 ) : 5 - [ 5 - 3 ( 2 , 6 - Dichloro - benzyilsuRIfanyl ) - 4 - methyl - 4H - [ 1 , 2 , 4 ] . triazol - 3 - l - benzo 1 , 2 , 5 oxadiazole ; g6 : 1g11 : arb&1 - ( 1 : 6 ( alky : lca1rbo1nyl13 arylc1a rb ( 1 ) nyl , ary1C1 : 1 - ( 4 - Chloro ) - [ p ] heny1 ) - T - [ 4 - niethy1 - 5 - ( 4 - triﬂuoromethyl - pyri - 6 y , l 68ky car oxy , 31 ' ) car oxy or ary Cl din - 3 - l ) - 4H - [ 1 2 4 ] triazol - 3 - lsu1fan l ] - ethanone° C6alkylcarboxy. y 5 y y . In another embodiment of the present inVention said sub - 45 3 - [ 5 - ( : l - Chlor ( 1 ) 1 - blenzy ( llsulfanyl ) - 4 - me ( t1hyl - 4H - [ 1 , 2 , 4 ] triazolstituted 1 , 2 , 4 - triazo1e , or a prodrug thereof , as a component of 3_ [ 35__3E2 ] 1 : BI ] : ] 1131 ; 1 : I11 ) ; 11 : Z11O1 [ 1111112fai ] ypgr111 - ii11 : ihyl - 4H - 11 1214 ] 1. the combinationtherapy is of the general formula ( V ) Wherein 11112013 _y1 ] _218 - dimethyl - imidaZ0 [ 1 , 2 ' all3y1 ' idine ; . R6 R7 R9 and R141 i511depende111tly are hydrogen , halo , NO2 4 - Allyl - 5 - ( 2 , 4 - dichloro - phenyl ) - 4H - [ 1 , 2 , 4 ] triazole - 3 - thiol ; NH2 cyano , NR R CONR R tr1halomethyl , tr1halom - 50 3 - ( 5 - Allylsulfanyl - 4 - methyl - 4H - [ 1 , 2 , 4 ] triazol - 3 - yl ) - 1 - benethoxy , hydroxy , oxo , C1 - C6alkyl , C3 - C10cycloa1kyl , zyl - 1H - pyri din - 2 - 1111111. C3 ' C1ohetCyC10a1kyL WW hetarYL arY11§r1Cg6a1kYL 3 - ( 4 - Allyl - 5 - methylsulfanyl - 4H - [ 1 , 2 , 4 ] triazol - 3 - yl ) - 1 - ( 2 , 4 - hetarle1 - C6alkyl , C1 - C6alkylSO2 , R R NSO2 dichloro - benzyl ) - 1H - pyridin - 2 - one ; C1 - C6alkyloxy , aryloxy , hetaryloxy , arle1 - C6alkyloxy , 3 - ( 4 - Allyl - 5 - mercapto - 4H - [ 1 , 2 , 4 ] triazol - 3 - yl ) - 1 - ( 4 - chioro - . C1 - C6alkylcarbonyl , arylcarbonyl , arle1 - C6alkylcarbonyl , 55 benzyl ) - lH - pyridin - 2 - one ; . ary1carbonleR” , carboxyC1 - C6alkyl or carboxyary 1C1 ' 3 - ( 4 - Allyl - 5 - prop - 2 - ynylsulfanyl - 4H - [ 1 , 2 , 4 ] triazol - 3 - yl ) - 1 - . C6alkyl. ( 4 - chloro - benzyl ) - 1H - pyridin - 2 - one ; . In another embodiment of the present inVention said sub - 3 - ( 5 - Ally1sulfany1 - 4 - ethyl - 4H - [ 1 2 4 ] triazo1 - 3 - y1 ) - l _ ( 2 4_ stituted 1 , 2 , 4 - triazole , or a prodrug thereof , as a component of dichloro - benzyl ) - 1 H - pyridin - 2 : 6113 ; j the combinationtherapy is of the general formula ( V ) Wherein 60 1 - ( 2 , 4 - Dichloro - benzyl ) - 3 - [ 4 - ethyl - 5 - ( 2 - oxo - 2 - pheny1 - eth - R8 15 oxygen , NR” : C ( : O ) NRlO 01 ' SO11NR” ; Where1n 1115 ylsulfanyl ) - 4H - [ 1 , 2 , 4 ] triazol - 3 - yl ] - 1H - pyridin - 2 - one ; 1 0F 2 - 3 - ( 4 - Allyl - 5 - prop - 2 - ynylsulfanyl - 4H - [ 1 , 2 , 4 ] triazol - 3 - yl ) - 1 - . In another embodiment of the present inVention said sub - ( 3 , 4 - dichioro - benzyl ) - 1H - pyridin - 2 - one ; stituted 1 , 2 , 4 - triazole , or a prodrug thereof , as a component of 4 - Allyl - 5 - ( 4 - methyl - 2 - phenyl - thiazol - 5 - yl ) - 4H - [ 1 , 2 , 4 ] triazthe combinationtherapy is of the general formula ( V ) Wherein 65 ole - 3 - thiol ; R” is hydrogen , C1 - C6alkyl , aryl , hetaryl , arle1 - C6alkyl or 3 - Allylsulfanyl - 4 - methyl - 5 - ( 4 - methyl - 2 - phenyl - thiazol - 5 - hetarle1 - C6alkyl. yl ) - 4H - [ 1 , 2 , 4 ] triazole ; . US 7 , 50l , 405 B2. 93 4 - Allyl - 5 - [ 2 - ( 3 , 4 - dimethoxy - phenyl ) - thiazol - 4 - yl ] - 4H - [ l , 2 , 4 ] triazole - 3 - thiol ; . N - [ 5 - ( 4 - tert - Butyl - benzylsulfanyl ) - 4 - methyl - 4H - [ 1 , 2 , 4 ] tria - . zol - 3 - y1methyl ] - 4 - methy1 - benzenesulfonamide ; 4 - Methyl - 3 - [ 3 - ( 4 - methyl - benzyloxy ) - thiophen - 2 - y ] - 5 - methylsulfanyl - 4H - [ l , 2 , 4 ] triazole ; 5 - [ 3 - ( 2 , 4 - Dichloro - benzyloxy ) - thiophen - 2 - yl ] - 4 - methyl - 4H - [ 1 , 2 , 4 ] triazole - 3 - thiol ; 3 - [ 3 - ( 2 , 4 - Dichioro - benzyloxy ) - thiophen - 2 - yl ] - 4 - methyl - 5 - methylsulfanyl - 4H - [ 1 , 2 , 4 ] triazole ; 4 - Methyl - 5 - [ 3 - ( 3 - triﬁuoromethyl - benzyloxy ) - thiophen - 2 - yl ] - 4H - [ 1 , 2 , 4 ] triazole - 3 - thiol ; . 2 - ( 5 - Benzyl - 4 - methyl - 4H - [ 1 , 2 , 4 ] triazol - 3 - ylsulfanyl ) - N - ( 4 - . iodo - phenyl ) - acetamide ; 3 - ( 5 - Allylsulfanyl - 4 - methyl - 4H - [ 1 , 2 , 4 ] triazol - 3 - yl ) - 2 , 7 - dimethyl - imidazo [ 1 , 2 - a ] pyridine ; 3 - ( 5 - Benzylsulfanyl - 4 - methyl - 4H - [ 1 , 2 , 4 ] t1iazol - 3 - yl ) - 2 , 7 - dimethyl - imidazo [ 1 , 2 - a ] pyridine ; 3 - ( 5 - Benzylsulfanyl - 4 - methyl - 4H - [ 1 , 2 , 4 ] triazol - 3 - yl ) - 2 - methyl - imidazo [ 1 , 2 - a ] pyridine ; 4 - Buty1 - 5 - ( 3 - chloro - phenyl ) - 4H - [ 1 , 2 , 4 ] triazole - 3 - thiol ; 4 - Allyl - 5 - ( 3 - chloro - phenyl ) - 4H - [ 1 , 2 , 4 ] triazole - 3 - thiol ; N - ( 5 - { 2 - [ 5 - ( 4 - Methoxy - phenyl ) - 3 - thiophen - 2 - yl - 4 , 5 - dihydro - pyrazol - 1 - yl ] - 2 - oxo - ethylsulfanyl } - 4 - methyl - 4H - [ 1 , 2 , 4 ] triazol - 3 - ylmethyl ) - benzamide ; N - ( 5 - { 2 - [ 3 , 5 - Bis - ( 4 - methoxy - phenyl ) - 4 , 5 - dihydro - pyrazol - 1 - yl ] - 2 - oxo - ethylsulfanyl } - 4 - methyl - 4H - [ 1 , 2 , 4 ] triazol - 3 - ylmethyl ) - 3 - methoxy - benzamide ; N - ( 5 - { 2 - [ 5 - ( 4 - Methoxy - phenyl ) - 3 - thiophen - 2 - yl - 4 , 5 - dihydro - pyrazol - 1 - yl ] - 2 - oxo - ethylsulfanyl } - 4 - methyl - 4H - [ 1 , . 2 , 4 ] triazol - 3 - ylmethyl ) - 4 - ( pyrrolidine - 1 - sulfonyl ) - benza - . mide ; . N - ( 5 - { 2 - [ 5 - ( 4 - Methoxy - phenyl ) - 3 - thiophen - 2 - yl - 4 , 5 - dihydro - pyrazol - 1 - yl ] - 2 - oxo - ethylsulfanyl } - 4 - methy1 - 4H - [ 1 , 2 , 4 ] triazol - 3 - ylmethyl ) - 4 - ( piperidine - 1 - sulfony1 ) - benzamide ; . N - ( 5 - { 2 - [ 5 - ( 4 - Methoxy - pheny1 ) - 3 - thiophen - 2 - y1 - 4 , 5 - dihydro - pyrazol - 1 - yl ] - 2 - oxo - ethylsulfanyl } - 4 - methy1 - 4H - [ 1 , 2 , 4 ] triazol - 3 - ylmethyl ) - 4 - ( morpholine - 4 - sulfonyl ) - benzamide ; . 4 - Benzyl - 3 - ( 4 - ﬁuoro - naphthalen - l - ylmethylsulfanyl ) - 5 - phenyl - 4H - [ 1 , 2 , 4 ] triazole ; . 2 - [ 4 - A1lyl - 5 - ( 4 - methoxy - phenyl ) - 4H - [ 1 , 2 , 4 ] triazol - 3 - ylsu1 - . fanyl ] - 1 - naphthalen - 1 - yl - ethanone ; 1 - ( 4 - Fluoro - phenyl ) - 4 - ( 4 - methyl - 5 - phenyl - 4H - [ 1 , 2 , 4 ] triazol - 3 - ylsulfanyl ) - butan - 1 - one 2 - ( 4 - Methyl - 5 - phenyl - 4H - [ 1 , 2 , 4 ] triazol - 3 - ylsulfanyl ) - 1 - ( 5 , 6 , 7 , 8 - tetrahydro - naphtha1en - 2 - yl ) - ethanone ; . 5 - ( 2 - Carbazol - 9 - yl - ethyl ) - 4 - ( 2 - methyl - allyl ) - 4H - [ 1 , 2 , 4 ] tria - . zole - 3 - thiol ; 1 - ( 4 - Methoxy - phenyl ) - 2 - [ 4 - ( 2 - methyl - allyl ) - 5 - phenyl - 4H - [ 1 , 2 , 4 ] triazol - 3 - ylsulfanyl ] - ethanone ; . 2 - { 2 - [ 4 - Allyl - 5 - ( 3 - methoxy - phenyl ) - 4H - [ 1 , 2 , 4 ] triazol - 3 - yl - . sulfanyl ] - acetylamino } - benzoic acid methyl ester ; . 5 - ( 2 , 4 - Dichloro - phenyl ) - 4 - ( 2 - methyl - allyl ) - 4H - [ 1 , 2 , 4 ] triaz - . ole - 3 - thiol ; 4 - Allyl - 3 - ( 4 - methoxy - benzylsulfanyl ) - 5 - ( 3 - methoxy - phenyl ) - 4H - [ l , 2 , 4 ] triazole ; . 2 - [ 4 - Allyl - 5 - ( 3 - methoxy - phenyl ) - 4H - [ 1 , 2 , 4 ] triazol - 3 - ylsul - . fanyl ] - 1 - ( 9H - ﬂuoren - 2 - yl ) - ethanone ; 3 - ( 4 - Methoxy - benzylsulfanyl ) - 4 - methyl - 5 - phenyl - 4H - [ 1 , 2 , 4 ] triazole ; . 2 - [ 4 - Allyl - 5 - ( 3 - methoxy - phenyl ) - 4H - [ 1 , 2 , 4 ] triazol - 3 - ylsul - . fanyl ] - 1 - ( 4 - ethyl - phenyl ) - ethanone ; 2 - ( 4 - Allyl - 5 - phenyl - 4H - [ 1 , 2 , 4 ] triazol - 3 - ylsufanyl ) - N - ( 4 - chloro - phenyl ) - acetamide ; . lO. lS. 20. 25. 30. 35. 40. 45. 50. 55. 60. 65. 94. 2 - [ 4 - Allyl - 5 - ( 4 - tert - butyl - phenyl ) - 4H - [ l , 2 , 4 ] triazol - 3 - ylsulfanyl ] - 1 - ( 4 - chloro - phenyl ) - ethanone ; . 2 - ( 4 - Allyl - 5 - phenylaminomethyl - 4H - [ 1 , 2 , 4 ] triazol - 3 - ylsulfanyl ) - N - ( 2 , 4 - difluoro - phenyl ) - acetamide ; . 2 - ( 4 - Allyl - 5 - phenoxymethyl - 4H - [ 1 , 2 , 4 ] triazol - 3 - ylsulfanyl ) - 1 - ( 4 - methoxy - phenyl ) - ethanone ; . 2 - ( 4 - Allyl - 5 - phenoxymethyl - 4H - [ 1 , 2 , 4 ] triazol - 3 - ylsulfanyl ) - 1 - ( 4 - bromo - phenyl ) - ethanone ; . ( 4 - Allyl - 5 - benzylsulfanyl - 4H - [ 1 , 2 , 4 ] triazol - 3 - ylmethyl ) - phenyl - amine ; . 2 - ( 4 - Allyl - 5 - benzotriazol - 1 - ylmethyl - 4H - [ 1 , 2 , 4 ] triazol - 3 - ylsulfanyl ) - 1 - ( 4 - methoxy - phenyl ) - ethanone ; . 2 - ( 4 - Allyl - 5 - phenylaminomethyl - 4H - [ 1 , 2 , 4 ] triazol - 3 - ylsulfanyl ) - N - ( 2 - chloro - phenyl ) - acetamide ; . 1 - ( 4 - Methoxy - phenyl ) - 2 - [ 4 - ( 2 - methyl - allyl ) - 5 - phenyl - 4H - [ 1 , 2 , 4 ] triazol - 3 - ylsulfanyl ] - ethanone ; . 2 - [ 4 - Ethyl - 5 - ( 2 - methoxy - phenyl ) - 4H - [ 1 , 2 , 4 ] triazol - 3 - ylsulfanyl ] - N - ( 4 - methyl - 3 - nitro - phenyl ) - acetamide ; . [ 5 - ( 2 - Methoxy - phenyl ) - 4 - methyl - 4H - [ 1 , 2 , 4 ] triazol - 3 - ylsulfanyl ] - acetic acid isopropyl ester ; . N - ( 4 - Chloro - phenyl ) - 2 - [ 4 - ethyl - 5 - ( 2 - methoxy - phenyl ) - 4H - [ 1 , 2 , 4 ] triazol - 3 - ylsulfanyl ] - acetamide ; . 2 - [ 4 - Ethyl - 5 - ( 2 - methoxy - phenyl ) - 4H - [ 1 , 2 , 4 ] triazol - 3 - y1sulfanyl ] - N - ( 4 - methoxy - phenyl ) - acetamide ; . N - ( 3 - Cyano - 4 , 5 , 6 , 7 - tetrahydro - benzo [ b ] thiophen - 2 - yl ) - 2 - [ 4 - ethyl - 5 - ( 2 - methoxy - phenyl ) - 4H - [ 1 , 2 , 4 ] triazol - 3 - y1sulfanyl ] - acetamide ; . N - ( 4 - Acety1 - phenyl ) - 2 - [ 4 - ethyl - 5 - ( 2 - methoxy - pheny1 ) - 4H - [ 1 , 2 , 4 ] triazol - 3 - ylsulfanyl ] - acetamide ; . 4 - [ 5 - ( 2 , 6 - Dichloro - benzylsulfanyl ) - 4 - furan - 2 - ylmethyl - 4H - [ 1 , 2 , 4 ] triazol - 3 - yl ] - pyridine ; . N - ( 4 - Methyl - 3 - nitro - phenyl ) - 2 - [ 4 - methyl - 5 - ( 3 , 4 , 5 - trimethoxy - phenyl ) - 4H - [ 1 , 2 , 4 ] triazol - 3 - ylsulfanyl ] - acetamide ; . N - ( 3 - Cyano - 4 , 5 , 6 , 7 - tetrahydro - benzo [ b ] thiophen - 2 - yl ) - 2 - ( 4 - furan - 2 - ylmethyl - 5 - pyridin - 4 - yl - 4H - [ 1 , 2 , 4 ] triazol - 3 - ylsulfanyl ) - acetamide ; . 2 - [ 2 - ( 4 - Ethyl - 5 - m - toly1 - 4H - [ 1 , 2 , 4 ] triazol - 3 - ylsu1fanyl ) - acetylamino ] - benzoic acid methyl ester ; . 2 - ( 4 - Methyl - 5 - phenyl - 4H - [ 1 , 2 , 4 ] triazol - 3 - ylsulfanyl ) - N - thiazol - 2 - y1 - acetamide ; . N - ( 4 - Chloro - phenyl ) - 2 - ( 4 - ethyl - 5 - m - tolyl - 4H - [ 1 , 2 , 4 ] triazol - 3 - ylsulfanyl ) - acetamide ; . N - ( 4 - Ethoxy - phenyl ) - 2 - ( 4 - ethyl - 5 - m - tolyl - 4H - [ 1 , 2 , 4 ] triazol - 3 - ylsulfanyl ) - acetamide ; . 2 - ( 4 - Ethyl - 5 - m - tolyl - 4H - [ 1 , 2 , 4 ] triazol - 3 - ylsulfanyl ) - N - ( 2 - nitro - phenyl ) - acetamide ; . 2 - ( 5 - Benzyl - 4 - methyl - 4H - [ 1 , 2 , 4 ] triazo1 - 3 - ylsulfanyl ) - N - ( 4 - bromo - phenyl ) - acetamide ; . 2 - { 5 - [ ( 2 , 6 - Dimethyl - phenylamino ) - methyl ] - 4 - methyl - 4H - [ 1 , 2 , 4 ] triazol - 3 - ylsulfanyl } > - 1 - phenyl - ethanone ; . 2 - [ 5 - ( 2 - Bromo - phenyl ) - 4 - ethyl - 4H - [ 1 , 2 , 4 ] triazol - 3 - ylsulfanyl ] - N - ( 4 - ﬂuoro - phenyl ) - acetamide ; . 2 - [ 4 - Ethyl - 5 - ( 4 - methoxy - phenyl ) - 4H - [ 1 , 2 , 4 ] triazol - 3 - y1sulfanyl ] - 1 - ( 4 - methoxy - phenyl ) - ethanone ; . N - ( 4 - lodo - 2 - methyl - phenyl ) - 2 - [ 5 - ( 2 - methoxy - phenyl ) - 4 - methyl - 4H - [ 1 , 2 , 4 ] triazol - 3 - ylsulfanyl ] - acetamide ; . 2 - ( 5 - Benzyl - 4 - methyl - 4H - [ 1 , 2 , 4 ] triazol - 3 - ylsulfanyl ) - 1 - ( 3 , 4 - dihydro - 2H - quinolin - 1 - yl ) - ethanone ; . N - ( 2 - Bromo - 4 - methy1 - phenyl ) - 2 - ( 4 - furan - 2 - ylmethy1 - 5 - pyridin - 4 - yl - 4H - [ 1 , 2 , 4 ] triazol - 3 - yl sulfanyl ) - acetamide ; . N - ( 4 - Chloro - phenyl ) - 2 - ( 4 - phenethyl - 5 - pyridin - 4 - yl - 4H - [ 1 , 2 , 4 ] triazol - 3 - ylsulfanyl ) - acetamide ; . 2 - [ 4 - Ethyl - 5 - ( 2 - methoxy - phenyl ) - 4H - [ 1 , 2 , 4 ] triazol - 3 - ylsulfanyl ] - N - ( 3 - triﬁuoromethyl - phenyl ) - acetamide ; . US 7 , 50l , 405 B2. 95 2 - [ 5 - [ ( 4 - Fluoro - phenylamino ) - methyl ] - 4 - ( tetrahydro - furan - 2 - ylmethyl ) - 4H - [ 1 , 2 , 4 ] triazol - 3 - ylsulfanyl ] - 1 - p - tolyl - . ethanone ; . 2 - ( 5 - Methy1 - 4 - phenethyl - 4H - [ 1 , 2 , 4 ] triazo1 - 3 - y1su1fanyl ) - N - naphthalen - 1 - yl - acetamide ; . N - ( 5 - Ethyl - [ l , 3 , 4 ] thiadiazol - 2 - yl ) - 2 - ( 5 - methyl - 4 - phenethyl - 4H - [ 1 , 2 , 4 ] triazol - 3 - ylsulfanyl ) - acetamide ; . 2 - ( 5 - Methyl - 4 - phenethyl - 4H - [ 1 , 2 , 4 ] triazol - 3 - ylsulfanyl ) - N - phenyl - acetamide ; . [ 5 - ( 4 - Bromo - phenyl ) - 4 - methyl - 4H - [ 1 , 2 , 4 ] triazol - 3 - ylsulfanyl ] - acetic acid cyclohexyl ester ; . 2 - [ 5 - ( 2 - Bromo - phenyl ) - 4 - ethyl - 4H - [ 1 , 2 , 4 ] triazol - 3 - ylsulfanyl ] - N - ( 3 - chloro - phenyl ) - acetamide ; . 2 - [ 5 - ( 2 - Bromo - phenyl ) - 4 - ethyl - 4H - [ 1 , 2 , 4 ] triazol - 3 - ylsulfanyl ] - N - ( 4 - chloro - phenyl ) - acetamide ; . 2 - [ 5 - ( 2 - Bromo - phenyl ) - 4 - ethyl - 4H - [ 1 , 2 , 4 ] triazol - 3 - ylsulfanyl ] - N - m - tolyl - acetamide ; . N - ( 3 - Cyano - 4 , 5 , 6 , 7 - tetrahydro - benzo [ b ] thiophen - 2 - yl ) - 2 - [ 5 - ( 4 - hydroxy - phenyl ) - 4 - methyl - 4H - [ 1 , 2 , 4 ] triazol - 3 - ylsulfanyl ] - acetamide ; . 2 - ( 5 - Benzyl - 4 - ethyl - 4H - [ 1 , 2 , 4 ] triazol - 3 - ylsulfanyl ) - N - ( 2 - methyl - 4 - nitro - phenyl ) - acetamide ; . 3 - Benzylsulfany1 - 4 - methyl - 5 - phenyl - 4H - [ 1 , 2 , 4 ] triazo1e ; . 3 - Butylsulfanyl - 5 - ( 4 - methoxy - phenyl ) - 4 - methyl - 4H - [ 1 , 2 , 4 ] triazole ; . 2 - [ 5 - ( 2 - Bromo - phenyl ) - 4 - ethyl - 4H - [ 1 , 2 , 4 ] triazol - 3 - ylsulfanyl ] - N - ( 4 - ethoxy - phenyl ) - acetamide ; . N - ( 4 - Acetyl - phenyl ) - 2 - ( 4 - benzy1 - 5 - pyridin - 3 - yl - 4H - [ 1 , 2 , 4 ] triazo1 - 3 - ylsulfany1 ) - acetamide ; . 2 - ( 4 - Benzyl - 5 - pyridin - 3 - yl - 4H - [ 1 , 2 , 4 ] triazol - 3 - ylsulfanyl ) - N - ( 2 , 4 - dimethyl - phenyl ) - acetamide ; . N - ( 3 - Nitro - phenyl ) - 2 - ( 4 - phenethyl - 5 - pyridin - 3 - yl - 4H - [ 1 , 2 , 4 ] triazol - 3 - ylsulfanyl ) - acetamide ; . 2 - ( 4 - Phenethy1 - 5 - pyridin - 3 - yl - 4H - [ 1 , 2 , 4 ] triazo1 - 3 - y1sulfanyl ) - N - phenyl - acetamide ; . N - Naphthalen - 1 - yl - 2 - ( 4 - phenethyl - 5 - pyridin - 3 - yl - 4H - [ 1 , 2 , 4 ] triazol - 3 - ylsulfanyl ) - acetamide ; . ( 4 - Benzy1 - 5 - pyridin - 3 - yl - 4H - [ 1 , 2 , 4 ] triazo1 - 3 - y1su1fanyl ) - acetic acid cyclohexyl ester ; . 1 - ( 3 , 4 - dihydro - 2H - quinolin - 1 - yl ) - 2 - ( 4 - ethyl - 5 - phenyl - 4H - [ 1 , 2 , 4 ] triazol - 3 - ylsulfanyl ) - ethanone ; . N - ( 3 - Cyano - 4 , 5 , 6 , 7 - tetrahydro - benzo [ b ] thiophen - 2 - yl ) - 2 - ( 4 - ethyl - 5 - phenyl - 4H - [ 1 , 2 , 4 ] triazol - 3 - y1sulfanyl ) - acetamide ; . 2 - [ 5 - ( 4 - Methoxy - phenyl ) - 4 - methyl - 4H - [ 1 , 2 , 4 ] triazol - 3 - ylsulfanyl ] - 1 - phenyl - ethanone ; . 3 - Benzylsulfanyl - 5 - ( 4 - methoxy - phenyl ) - 4 - methyl - 4H - [ 1 , 2 , 4 ] triazole ; . 2 - ( 4 , 5 - Dibenzyl - 4H - [ 1 , 2 , 4 ] triazol - 3 - ylsulfanyl ) - N - thiazol - 2 - yl - acetamide ; . 2 - ( 4 - Phenethyl - 5 - pyridin - 3 - yl - 4H - [ 1 , 2 , 4 ] triazol - 3 - yfsulfanyl ) - N - m - tolyl - acetamide ; . 2 - ( 4 - Phenethy1 - 5 - pyridin - 3 - yl - 4H - [ 1 , 2 , 4 ] triazo1 - 3 - y1sulfanyl ) - N - phenyl - propionamide ; . 3 - ( 5 - Benzylsulfanyl - 4 - phenethyl - 4H - [ 1 , 2 , 4 ] triazol - 3 - yl ) - pyridine ; . ( 4 - Phenethyl - 5 - pyridin - 3 - yl - 4H - [ 1 , 2 , 4 ] triazol - 3 - ylsulfanyl ) - acetic acid ethyl ester ; . 2 - ( 4 - Phenethyl - 5 - pyridin - 3 - yl - 4H - [ 1 , 2 , 4 ] triazol - 3 - ylsulfanyl ) - 1 - phenyl - ethanone ; . 2 - ( 4 - Phenethyl - 5 - pyridin - 3 - yl - 4H - [ 1 , 2 , 4 ] triazol - 3 - ylsulfanyl ) - N - p - tolyl - propionamide ; . 1 - ( 3 , 4 - dihydro - 2H - quinolin - 1 - yl ) - 2 - { 4 - ethyl - 5 - [ ( 4 - ﬂuorophenylamino ) - methyl ] - 4H - [ 1 , 2 , 4 ] triazol - 3 - ylsulfanyl } - ethanone ; . 2 - [ 5 - ( 3 , 4 - Dimethoxy - phenyl ) - 4 - methyl - 4H - [ 1 , 2 , 4 ] triazol - 3 - ylsulfanyl ] - 1 - p - tolyl - ethanone ; . 5. lO. lS. 20. 25. 30. 35. 40. 45. 50. 55. 60. 65. 96. N - ( 3 - Chloro - 2 - methyl - phenyl ) - 2 - ( 4 - methyl - 5 - o - tolyl - 4H - [ 1 , 2 , 4 ] triazol - 3 - ylsulfanyl ) - acetamide ; . 2 - ( 4 - Ethyl - 5 - pyridin - 3 - yl - 4H - [ 1 , 2 , 4 ] t1iazol - 3 - ylsulfanyl ) - N , N - dipheny1 - propionamide ; . 2 - ( 5 - cyclohexyl - 4 - ethyl - 4H - [ 1 , 2 , 4 ] triazol - 3 - ylsulfanyl ) - N - ( 2 - nitro - phenyl ) - acetamide ; . 2 - ( 5 - cyclohexyl - 4 - ethyl - 4H - [ 1 , 2 , 4 ] t1iazol - 3 - ylsulfanyl ) - N - ( 4 - methyl - 3 - nitro - phenyl ) - acetamide ; . N - ( 2 - Bromo - 4 - methyl - phenyl ) - 2 - ( 4 - ethyl - 5 - pyridin4 - yl - 4H - [ 1 , 2 , 4 ] triazol - 3 - ylsulfanyl ) - acetamide ; . l - ( 3 , 4 - dihydro - 2H - quinolin - 1 - yl ) - 2 - ( 4 - phenethyl - 5 - pyridin4 - yl - 4H - [ 1 , 2 , 4 ] triazol - 3 - ylsulfanyl ) - ethanone ; . N - ( 4 - Fluoro - phenyl ) - 2 - ( 4 - phenethyl - 5 - pyridin - 4 - yl - 4H - [ 1 , 2 , 4 ] triazol - 3 - ylsulfanyl ) - acetamide ; . N - ( 4 - Acetyl - phenyl ) - 2 - ( 5 - benzyl - 4 - ethyl - 4H - [ 1 , 2 , 4 ] triazol - 3 - ylsulfanyl ) - acetamide ; . 2 - ( 5 - Benzyl - 4 - ethyl - 4H - [ 1 , 2 , 4 ] triazol - 3 - ylsulfanyl ) - N - ( 2 - chloro - phenyl ) - acetamide ; . N - ( 3 - Chloro - 2 - methyl - phenyl ) - 2 - [ 4 - ethyl - 5 - ( 2 - methoxyphenyl ) - 4H - [ 1 , 2 , 4 ] triazol - 3 - ylsulfanyl ] - acetamide ; . 2 - [ 5 - ( 2 - Bromo - phenyl ) - 4 - ethyl - 4H - [ 1 , 2 , 4 ] triazol - 3 - ylsulfanyl ] - N - ( 2 - methyl - 4 - nitro - phenyl ) - acetamide ; . 2 - [ 5 - ( 2 - Methoxy - pheny1 ) - 4 - methyl - 4H - [ 1 , 2 , 4 ] triazol - 3 - ylsufanyl ] - N - p - tolyl - propionamide ; . [ 4 - Ethyl - 5 - ( 2 - methoxy - phenyl ) - 4H - [ 1 , 2 , 4 ] triazol - 3 - ylsulfanyl ] - acetic acid ethyl ester ; . 2 - ( 4 - Methyl - 5 - o - tolyl - 4H - [ 1 , 2 , 4 ] triazol - 3 - ylsulfanyl ) - N - ( 3 - nitro - phenyl ) - acetamide ; . 2 - [ 4 - Ethyl - 5 - ( 2 - methoxy - phenyl ) - 4H - [ 1 , 2 , 4 ] triazol - 3 - y1sulfanyl ] - N - naphthalen - 1 - yl - propionamide ; . 2 - [ 4 - Ethyl - 5 - ( 2 - methoxy - phenyl ) - 4H - [ 1 , 2 , 4 ] triazol - 3 - ylsulfanyl ] - N - p - tolyl - propionamide ; . 2 - [ 4 - Ethyl - 5 - ( 2 - methoxy - phenyl ) - 4H - [ 1 , 2 , 4 ] triazol - 3 - y1sulfanyl ] - N - phenyl - propionamide ; . 2 - [ 4 - Ethyl - 5 - ( 2 - methoxy - phenyl ) - 4H - [ 1 , 2 , 4 ] triazol - 3 - ylsulfanyl ] - N - ( 4 - phenyl - thiazol - 2 - yl ) - acetamide ; . 2 - [ 4 - Ethyl - 5 - ( 2 - methoxy - phenyl ) - 4H - [ 1 , 2 , 4 ] triazol - 3 - ylsulfanyl ] - N - p - tolyl - acetamide ; . N - ( 3 - Ch1oro - 4 - methy1 - phenyl ) - 2 - [ 4 - ethyl - 5 - ( 2 - methoxyphenyl ) - 4H - [ 1 , 2 , 4 ] triazol - 3 - ylsulfanyl ] - acetamide ; . 2 - [ 5 - ( 4 - Hydroxy - phenyl ) - 4 - methyl - 4H - [ 1 , 2 , 4 ] triazol - 3 - ylsulfanyl ] - N - ( 4 - nitro - phenyl ) - acetamide ; . 4 - { 2 - [ 5 - ( 2 - Bromo - phenyl ) - 4 - methy1 - 4H - [ 1 , 2 , 4 ] triazol - 3 - ylsufanyl ] - acetylamino } - benzoic acid ethyl ester ; . 2 - [ 5 - ( 2 - Bromo - phenyl ) - 4 - methyl - 4H - [ 1 , 2 , 4 ] triazol - 3 - ylsulfanyl ] - N - o - tolyl - acetamide ; . 2 - [ 5 - ( 2 - Bromo - phenyl ) - 4 - methyl - 4H - [ 1 , 2 , 4 ] triazol - 3 - ylsulfanyl ] - N - ( 4 - chloro - pheny1 ) - acetamide ; . 2 - [ 5 - ( 2 - Bromo - phenyl ) - 4 - methyl - 4H - [ 1 , 2 , 4 ] triazol - 3 - ylsulfanyl ] - N - ( 4 - methoxy - 2 - nitro - phenyl ) - acetamide ; . 2 - [ 5 - ( 2 - Bromo - phenyl ) - 4 - methyl - 4H - [ 1 , 2 , 4 ] triazol - 3 - ylsulfanyl ] - N - ( 2 - methyl - 4 - nitro - phenyl ) - acetamide ; . 1 - ( 3 , 4 - dihydro - 2H - quinolin - 1 - yl ) - 2 - { 5 - [ ( 2 , 4 - dimethyl - phenylamino ) - methyl ] - 4 - ethyl - 4H - [ 1 , 2 , 4 ] triazol - 3 - ylsulfanyl } - ethanone ; . N - ( 4 - Chloro - 3 - nitro - phenyl ) - 2 - [ 5 - ( 4 - chloro - phenyl ) - 4 - ethyl - 4H - [ 1 , 2 , 4 ] triazol - 3 - ylsulfanyl ] - acetamide ; . 2 - [ 5 - ( 2 - Bromo - phenyl ) - 4 - ethyl - 4H - [ 1 , 2 , 4 ] triazol - 3 - y1sulfanyl ] - 1 - ( 3 , 4 - dihydro - 2H - quinolin - 1 - yl ) - ethanone ; . 2 - ( 5 - Benzyl - 4 - methyl - 4H - [ 1 , 2 , 4 ] triazol - 3 - ylsulfanyl ) - 1 - p - tolyl - ethanone ; . 2 - ( 4 - Benzyl - 5 - pyridin - 3 - yl - 4H - [ 1 , 2 , 4 ] t1iazol - 3 - ylsulfanyl ) - N - ( 4 - methoxy - phenyl ) - acetamide ; . 2 - ( 4 - Benzyl - 5 - pyridin - 3 - yl - 4H - [ 1 , 2 , 4 ] triazol - 3 - ylsulfanyl ) - N - ( 2 - chloro - phenyl ) - acetamide ; . 2 - ( 4 - Benzyl - 5 - pyridin - 3 - yl - 4H - [ 1 , 2 , 4 ] t1iazol - 3 - ylsulfanyl ) - N - ( 5 - ethyl - [ 1 , 3 , 4 ] thiadiazol - 2 - yl ) - acetamide ; . US 7 , 50l , 405 B2. 97 4 - { 2 - [ 5 - ( 2 - Bromo - phenyl ) - 4 - ethyl - 4H - [ 1 , 2 , 4 ] triazol - 3 - ylsulfanyl ] - acetylamino } benzoic acid methyl ester ; 2 - ( 5 - Benzyl - 4 - methyl - 4H - [ 1 , 2 , 4 ] triazol - 3 - ylsulfanyl ) - N - ( 2 - nitro - pheny1 ) - acetamide ; 2 - ( 5 - Benzyl - 4 - methyl - 4H - [ 1 , 2 , 4 ] triazol - 3 - ylsulfanyl ) - N - ( 3 - cyano - 4 , 5 , 6 , 7 - tetrahydrobenzo [ b ] thiophen - 2 - yl ) - acetamide ; 2 - [ 5 - ( 4 - Chloro - phenyl ) - 4 - ethyl - 4H - [ 1 , 2 , 4 ] triazol - 3 - ylsulfanyl ] - N - ( 2 - nitro - phenyl ) - acetamide ; ( 5 - Benzylsulfanyl - 4 - ethyl - 4H - [ 1 , 2 , 4 ] triazol - 3 - ylmethyl ) - ( 4 - chloro - phenyl ) - amine ; N - ( 2 - Methoxy - phenyl ) - 2 - [ 5 - ( 2 - methoxy - phenyl ) - 4 - methyl - 4H - [ 1 , 2 , 4 ] triazol - 3 - ylsulfanyl ] - acetamide ; 2 - ( 4 - Allyl - 5 - pyridin - 4 - yl - 4H - [ 1 , 2 , 4 ] triazol - 3 - ylsulfanyl ) - N - ( 3 , 4 - dichloro - phenyl ) - acetamide ; 2 - ( 5 - Benzyl - 4 - ethyl - 4H - [ 1 , 2 , 4 ] triazol - 3 - ylsulfanyl ) - N - p - tolyl - acetamide ; 2 - ( 5 - Benzyl - 4 - methyl - 4H - [ 1 , 2 , 4 ] triazol - 3 - ylsulfanyl ) - N - ( 4 - chloro - phenyl ) - acetamide ; 2 - ( 5 - Benzyl - 4 - ethyl - 4H - [ 1 , 2 , 4 ] triazol - 3 - ylsulfanyl ) - N - ( 4 - methoxy - phenyl ) - acetamide ; N - ( 5 - Chloro - 2 - methyl - phenyl ) - 2 - ( 4 - methyl - 5 - o - tolyl - 4H - [ 1 , 2 , 4 ] triazol - 3 - ylsulfanyl ) - acetamide ; N - ( 4 - Methoxy - phenyl ) - 2 - ( 4 - methyl - 5 - o - tolyl - 4H - [ 1 , 2 , 4 ] triazol - 3 - ylsulfanyl ) - acetamide ; N - ( 2 , 4 - Dimethyl - phenyl ) - 2 - ( 4 - methyl - 5 - o - tolyl - 4H - [ 1 , 2 , 4 ] triazol - 3 - ylsulfanyl ) - acetamide ; N - ( 4 - Ethoxy - phenyl ) - 2 - ( 4 - methy1 - 5 - o - tolyl - 4H - [ 1 , 2 , 4 ] triazol - 3 - y1sulfanyl ) - acetamide ; 4 - [ 2 - ( 4 - Methyl - 5 - o - tolyl - 4H - [ 1 , 2 , 4 ] triazol - 3 - ylsulfanyl ) - acetylamino ] - benzoic acid methyl ester ; N - ( 4 - Chloro - phenyl ) - 2 - ( 4 - methyl - 5 - o - tolyl - 4H - [ 1 , 2 , 4 ] triazol - 3 - y1sulfanyl ) - acetamide ; 2 - [ 5 - ( 4 - Hydroxy - pheny1 ) - 4 - methyl - 4H - [ 1 , 2 , 4 ] triazol - 3 - ylsulfanyl ] - N - ( 4 - phenyl - thiazol - 2 - yl ) - acetamide ; 2 - ( 5 - Benzyl - 4 - methyl - 4H - [ 1 , 2 , 4 ] triazol - 3 - ylsulfanyl ) - N - ( 2 - bromo - 4 - methyl - phenyl ) - acetamide ; 2 - ( 5 - Benzy1 - 4 - methyl - 4H - [ 1 , 2 , 4 ] triazol - 3 - y1sulfanyl ) - 1 - phenyl - ethanone ; 2 - ( 5 - Benzyl - 4 - ethyl - 4H - [ 1 , 2 , 4 ] triazol - 3 - ylsulfanyl ) - N - ( 4 - nitro - phenyl ) - acetamide ; 2 - ( 5 - cyclohexyl - 4 - ethyl - 4H - [ i , 2 , 4 ] triazol - 3 - ylsulfanyl ) - N - p - tolyl - acetamide ; 2 - [ 5 - ( 2 - Bromo - phenyl ) - 4 - methy1 - 4H - [ 1 , 2 , 4 ] triazol - 3 - y1su1 - fanyl ] - N - ( 4 - ethoxy - phenyl ) - acetamide ; 2 - ( 5 - cyclohexyl - 4 - ethyl - 4H - [ 1 , 2 , 4 ] triazol - 3 - ylsulfanyl ) - N - naphthalen - 1 - yl - acetamide ; 4 - [ 5 - ( 4 - tert - Buty1 - benzylsulfanyl ) - 4 - ethyl - 4H - [ 1 , 2 , 4 ] triazol - 3 - yl ] - pyridine ; 4 - [ 5 - ( 2 , 4 - Dichloro - benzylsulfanyl ) - 4 - ethyl - 4H - [ 1 , 2 , 4 ] triazol - 3 - yl ] - pyridine ; 2 - ( 5 - cyclohexyl - 4 - ethyl - 4H - [ 1 , 2 , 4 ] triazol - 3 - ylsulfanyl ) - N - ( 2 - methyl - 4 - nitro - phenyl ) - acetamide ; 2 - ( 5 - cyclohexyl - 4 - ethyl - 4H - [ 1 , 2 , 4 ] triazol - 3 - ylsulfanyl ) - N - ( 3 - triﬂuoromethyl - phenyl ) - acetamide ; 2 - [ 5 - ( 2 - Bromo - phenyl ) - 4 - methyl - 4H - [ 1 , 2 , 4 ] triazol - 3 - ylsulfanyl ] - N - ( 4 - ﬁuoro - phenyl ) - acetamide ; 4 - { 2 - [ 5 - ( 2 - Bromo - phenyl ) - 4 - methyl - 4H - [ 1 , 2 , 4 ] triazol - 3 - ylsulfanyl ] - acetylamino } - benzoic acid methyl ester ; N - ( 3 - Chloro - phenyl ) - 2 - ( 5 - cyclohexyl - 4 - ethyl - 4H - [ 1 , 2 , 4 ] triazol - 3 - ylsulfanyl ) - acetamide ; 2 - ( 5 - cyclohexyl - 4 - ethyl - 4H - [ 1 , 2 , 4 ] triazol - 3 - ylsulfanyl ) - N - ( 4 - ethoxy - phenyl ) - acetamide ; 2 - { 5 - [ ( 4 - Chloro - phenylamino ) - methyl ] - 4 - ethyl - 4H - [ 1 , 2 , 4 ] triazol - 3 - ylsulfanyl } - N - ( 2 - nitro - phenyl ) - acetamide ; 2 - ( 5 - Benzyl - 4 - ethyl - 4H - [ 1 , 2 , 4 ] triazol - 3 - ylsulfanyl ) - N - ( 3 - chloro - 2 - methyl - phenyl ) - acetamide ; . 98 2 - [ 5 - ( 2 - Bromo - phenyl ) - 4 - ethyl - 4H - [ l , 2 , 4 ] triazol - 3 - ylsulfanyl ] - N - phenyl - acetamide ; 3 - Benzyl - 5 - ( 2 - chloro - 6 - ﬁuoro - benzylsulfanyl ) - 4 - methyl - 4H - [ 1 , 2 , 4 ] triazole ; 5 2 - ( 5 - cyclohexyl - 4 - ethyl - 4H - [ 1 , 2 , 4 ] triazol - 3 - ylsulfanyl ) - N - ( 4 - nitro - phenyl ) - acetamide ; 2 - [ 5 - ( 4 - Hydroxy - phenyl ) - 4 - methyl - 4H - [ 1 , 2 , 4 ] triazol - 3 - ylsulfanyl ] - 1 - phenyl - ethanone ; 4 - [ 5 - ( 4 - Chloro - benzylsulfanyl ) - 4 - methyl - 4H - [ 1 , 2 , 4 ] triazol - 3 - yl ] - phenol ; 2 - ( 5 - Benzyl - 4 - ethyl - 4H - [ l , 2 , 4 ] triazol - 3 - ylsulfanyl ) - N - ( 4 - ﬁuoro - phenyl ) - acetamide ; 2 - ( 5 - cyclohexyl - 4 - ethyl - 4H - [ 1 , 2 , 4 ] triazol - 3 - ylsulfanyl ) - 1 - ( 4 - methoxy - phenyl ) - ethanone ; 15 2 - ( 5 - Benzyl - 4 - ethyl - 4H - [ 1 , 2 , 4 ] triazol - 3 - ylsulfanyl ) - N - ( 4 - bromo - phenyl ) - acetamide ; 2 - ( 5 - Benzyl - 4 - ethyl - 4H - [ 1 , 2 , 4 ] triazol - 3 - ylsulfanyl ) - N - phenyl - acetamide ; 2 - ( 5 - cyclohexyl - 4 - ethyl - 4H - [ 1 , 2 , 4 ] triazol - 3 - ylsulfanyl ) - N - ( 4 - nitro - phenyl ) - propionamide ; 2 - ( 5 - Benzyl - 4 - ethyl - 4H - [ 1 , 2 , 4 ] triazol - 3 - ylsulfanyl ) - N - ( 2 - triﬂuoromethyl - phenyl ) - acetamide ; { 5 - [ ( 3 - Chloro - 4 - methyl - pheny1amino ) - methyl ] - 4 - ethyl - 4H - [ 1 , 2 , 4 ] triazol - 3 - ylsulfanyl } - acetic acid cyclohexyl ester ; 3 - [ 5 - ( 2 , 4 - Dichloro - benzylsulfanyl ) - 4 - methyl - 4H - [ 1 , 2 , 4 ] triazol - 3 - yl ] - pyridine ; 2 - [ 5 - ( 2 - Bromo - phenyl ) - 4 - methyl - 4H - [ 1 , 2 , 4 ] triazol - 3 - ylsulfanyl ] - N - phenyl - acetamide ; N - ( 3 - Ch1oro - 4 - methy1 - phenyl ) - 2 - [ 5 - ( 4 - hydroxy - pheny1 ) - 4 - methyl - 4H - [ 1 , 2 , 4 ] triazol - 3 - ylsulfanyl ] - acetamide ; N - ( 4 - Ch1oro - phenyl ) - 2 - [ 5 - ( 4 - hydroxy - phenyl ) - 4 - methyl - 4H - [ 1 , 2 , 4 ] triazol - 3 - ylsu1fanyl ] - acetamide ; 3 - Benzyl - 5 - ( 4 - chloro - benzylsulfanyl ) - 4 - methyl - 4H - [ 1 , 2 , 4 ] triazole ; 2 - [ 5 - ( 2 - Bromo - phenyl ) - 4 - methyl - 4H - [ 1 , 2 , 4 ] triazol - 3 - ylsulfanyl ] - N - ( 4 - nitro - phenyl ) - ac etamide ; N - ( 4 - Ethoxy - phenyl ) - 2 - [ 5 - ( 4 - hydroxy - phenyl ) - 4 - methyl - 4H - [ 1 , 2 , 4 ] triazol - 3 - ylsulfanyl ] - acetamide ; 2 - [ 5 - ( 2 - Bromo - phenyl ) - 4 - methyl - 4H - [ 1 , 2 , 4 ] triazol - 3 - ylsulfanyl ] - N - ( 4 - methoxy - phenyl ) - acetamide ; { 5 - [ ( 4 - Chloro - phenylamino ) - methyl ] - 4 - ethyl - 4H - [ l , 2 , 4 ] triazol - 3 - ylsulfanyl } - acetic acid cyclohexyl ester ; 3 - Benzy1sulfanyl - 5 - ( 2 - methoxy - phenyl ) - 4 - methyl - 4H - [ 1 , 2 , 4 ] triazole ; N - ( 2 - Ch1oro - phenyl ) - 2 - ( 4 - methyl - 5 - m - tolyl - 4H - [ 1 , 2 , 4 ] triazol - 3 - ylsulfanyl ) - acetamide ; N - ( 2 - Methoxy - phenyl ) - 2 - ( 4 - methyl - 5 - o - tolyl - 4H - [ 1 , 2 , 4 ] triazol - 3 - y1sulfany1 ) - acetamide ; 2 - ( 5 - cyclohexyl - 4 - ethyl - 4H - [ 1 , 2 , 4 ] t1iazol - 3 - ylsulfanyl ) - N - phenyl - acetamide ; 2 - [ 5 - ( 2 - Bromo - phenyl ) - 4 - ethyl - 4H - [ 1 , 2 , 4 ] triazol - 3 - ylsulfanyl ] - N - ( 3 - nitro - phenyl ) - acetamide ; 127 2 - [ 5 - ( 2 - Bromo - phenyl ) - 4 - methyl - 4H - [ 1 , 2 , 4 ] triazol - 3 - ylsulfanyl ] - 1 - ( 3 , 4 - dihydro - 2H - quinolin - 1 - yl ) - ethanone ; 2 - ( 5 - Benzyl - 4 - ethyl - 4H - [ 1 , 2 , 4 ] triazol - 3 - ylsulfanyl ) - N - ( 2 - bromo - 4 - methyl - phenyl ) - acetamide ; N - ( 2 - Chloro - phenyl ) - 2 - [ 5 - ( 2 - methoxy - phenyl ) - 4 - methyl - 4H - [ l , 2 , 4 ] triazol - 3 - ylsulfanyl ] - acetamide ; 60 ( 5 - Benzylsulfanyl - 4 - ethyl - 4H - [ 1 , 2 , 4 ] triazol - 3 - ylmethyl ) - ( 3 - triﬂuoromethyl - phenyl ) - amine ; 2 - [ 5 - ( 2 - Bromo - phenyl ) - 4 - methyl - 4H - [ 1 , 2 , 4 ] triazol - 3 - ylsulfanyl ] - 1 - ( 4 - methoxy - phenyl ) - ethanone ; . lO. 20. 25. 30. 35. 40. 45. 55. [ 4 - Allyl - 5 - ( 3 - bromo - benzylsulfanyl ) - 4H - [ 1 , 2 , 4 ] triazol - 3 - 65 ylmethyl ] - phenyl - amine ; 2 - ( 4 - Furan - 2 - ylmethyl - 5 - pyridin - 4 - yl - 4H - [ 1 , 2 , 4 ] triazol - 3 - ylsulfanyl ) - 1 - ( 3 - nitro - phenyl ) - ethanone ; . US 7 , 50l , 405 B2. 99. l - ( 4 - Bromo - phenyl ) - 2 - ( 4 - furan - 2 - ylmethyl - 5 - pyridin - 4 - yl - 4H - [ 1 , 2 , 4 ] triazol - 3 - ylsulfanyl ) - ethanone ; . 4 - { 5 - [ 2 - ( 2 - Methoxy - phenoxy ) - ethylsulfanyl ] - 4 - methyl - 4H - [ 1 , 2 , 4 ] triazol - 3 - yl } - phenylamine ; . 4 - [ 5 - ( 4 - Chloro - benzylsulfanyl ) - 4 - methyl - 4H - [ 1 , 2 , 4 ] triazol - 3 - yl ] - phenylamine ; . [ 4 - Allyl - 5 - ( 1 , 3 - dioxo - 1H , 3H - benzo [ de ] isoquinolin - 2 - ylmethyl ) - 4H - [ 1 , 2 , 4 ] triazol - 3 - ylsulfanyl ] - acetic acid ethyl ester ; . 2 - { 4 - Allyl - 5 - [ ( 4 - chloro - phenylamino ) - methyl ] - 4H - [ 1 , 2 , 4 ] triazol - 3 - yl sulfanyl } - l - phenyl - ethanone ; . 5 - ( 3 - Bromo - phenyl ) - 4 - ( 2 - methyl - allyl ) - 4H - [ 1 , 2 , 4 ] triazole - 3 - thiol ; . 2 - ( 4 - Allyl - 5 - benzotriazol - 1 - ylmethyl - 4H - [ 1 , 2 , 4 ] triazol - 3 - ylsulfanyl ) - N - ( 4 - chloro - phenyl ) - acetamide ; . 1 - ( 4 - Fluoro - phenyl ) - 2 - ( 4 - methyl - 5 - phenyl - 4H - [ 1 , 2 , 4 ] triazol - 3 - ylsulfanyl ) - ethanone ; . 8 - ( 4 - Methyl - 5 - phenyl - 4H - [ 1 , 2 , 4 ] triazol - 3 - ylsulfanyl ) - 5 - nitro - quinoline ; . 3 - ( 2 - Bromo - benzylsulfanyl ) - 4 - methyl - 5 - ( 4 - nitro - phenyl ) - 4H - [ 1 , 2 , 4 ] triazole ; . 2 - [ 4 - Allyl - 5 - ( 3 - methoxy - phenyl ) - 4H - [ 1 , 2 , 4 ] triazol - 3 - ylsulfanyl ] - 1 - ( 2 , 4 - dimethy1 - pheny1 ) - ethanone ; . 1 - ( 4 - Bromo - phenyl ) - 2 - ( 5 - furan - 2 - yl - 4 - methyl - 4H - [ 1 , 2 , 4 ] triazol - 3 - ylsulfanyl ) - ethanone ; . 2 - [ 5 - ( 2 - Bromo - phenyl ) - 4 - ethyl - 4H - [ 1 , 2 , 4 ] triazol - 3 - ylsulfanyl ] - N - ( 5 - methyl - thiazol - 2 - yl ) - acetamide ; . 2 - [ 4 - Ethyl - 5 - ( p - toly1amino - methyl ) - 4H - [ 1 , 2 , 4 ] triazol - 3 - yl - su1fanyl ] - 1 - p - tolyl - ethanone ; . 2 - ( 5 - Benzyl - 4 - ethyl - 4H - [ 1 , 2 , 4 ] triazol - 3 - ylsulfanyl ) - N - ( 4 - ethyl - phenyl ) - acetamide ; . 2 - ( 5 - Benzyl - 4 - ethyl - 4H - [ 1 , 2 , 4 ] triazol - 3 - ylsulfanyl ) - 1 - ( 4 - methoxy - phenyl ) - ethanone ; . 2 - ( 5 - Benzy1 - 4 - ethy1 - 4H - [ 1 , 2 , 4 ] triazol - 3 - ylsu1fanyl ) - N - ( 5 - ethyl - [ 1 , 3 , 4 ] thiadiazol - 2 - yl ) - acetamide ; . 2 - [ 5 - ( 2 - Bromo - phenyl ) - 4 - methyl - 4H - [ 1 , 2 , 4 ] triazol - 3 - ylsulfanyl ] - 1 - p - tolyl - ethanone ; . 3 - ( 2 - Bromo - pheny1 ) - 4 - methyl - 5 - ( 4 - nitro - benzylsu1fanyl ) - 4H - [ 1 , 2 , 4 ] triazole ; . 2 - [ 5 - ( 2 - Bromo - phenyl ) - 4 - methyl - 4H - [ 1 , 2 , 4 ] triazol - 3 - ylsulfanyl ] - N - ( 4 - phenyl - thiazol - 2 - yl ) - acetamide ; . 2 - [ 5 - ( 2 - Bromo - phenyl ) - 4 - methyl - 4H - [ 1 , 2 , 4 ] triazol - 3 - ylsulfanyl ] - N - ( 2 , 4 - dimethyl - pheny1 ) - acetamide ; . N - ( 4 - Bromo - phenyl ) - 2 - [ 5 - ( 2 - bromo - phenyl ) - 4 - ethyl - 4H - [ 1 , 2 , 4 ] triazol - 3 - ylsulfanyl ] - acetamide ; . 2 - { 5 - [ ( 2 , 4 - Dimethyl - phenylamino ) - methyl ] - 4 - ethyl - 4H - [ 1 , 2 , 4 ] triazol - 3 - ylsulfany } - 1 - ( 4 - methoxy - phenyl ) - ethanone ; . 2 - { 5 - [ ( 2 , 4 - Dimethyl - pheny1amino ) - methyl ] - 4 - ethyl - 4H - [ 1 , 2 , 4 ] triazol - 3 - ylsulfanyl } - 1 - p - tolyl - ethanone ; . { 5 - [ ( 2 , 4 - Dimethyl - phenylamino ) - methyl ] - 4 - ethyl - 4H - [ 1 , 2 , 4 ] triazol - 3 - ylsulfanyl } - acetic acid cyclohexyl ester ; . 2 - { 5 - [ ( 4 - Fluoro - phenylamino ) - methyl ] - 4 - methyl - 4H - [ 1 , 2 , 4 ] triazol - 3 - ylsulfanyl } - 1 - phenyl - ethanone ; . 2 - { 4 - Ethyl - 5 - [ ( 4 - ﬂuoro - phenylamino ) - methyl ] - 4H - [ 1 , 2 , 4 ] triazol - 3 - yl sulfanyl } - 1 - ( 4 - methoxy - phenyl ) - ethanone ; . [ 4 - Ethyl - 5 - ( 4 - methyl - benzylsulfanyl ) - 4H - [ 1 , 2 , 4 ] triazol - 3 - ylmethyl ] - ( 4 - ﬁuoro - phenyl ) - amine ; . ( 5 - Benzy1sulfany1 - 4 - ethyl - 4H - [ 1 , 2 , 4 ] triazo1 - 3 - y1methyl ) - ( 4 - ﬂuoro - phenyl ) - amine ; . { 4 - Ethyl - 5 - [ ( 4 - ﬁuoro - phenylamino ) - methyl ] - 4H - [ 1 , 2 , 4 ] triazol - 3 - ylsulfanyl } - acetic acid cyclohexyl ester ; . N - ( 4 - Chloro - phenyl ) - 2 - [ 4 - ethyl - 5 - ( 4 - hydroxy - phenyl ) - 4H - [ 1 , 2 , 4 ] triazol - 3 - ylsulfanyl ] - acetamide ; . N - ( 4 - Acetyl - phenyl ) - 2 - ( 5 - cyclohexyl - 4 - ethyl - 4H - [ 1 , 2 , 4 ] triazol - 3 - ylsulfanyl ) - acetamide ; . 2 - [ 4 - Ethyl - 5 - ( 4 - hydroxy - phenyl ) - 4H - [ 1 , 2 , 4 ] triazol - 3 - ylsulfanyl ] - N - ( 4 - methyl - 3 - nitro - phenyl ) - acetamide ; . 100 N - cyclohexyl - 2 - ( 4 - phenethyl - 5 - pyridin - 3 - yl - 4H - [ 1 , 2 , 4 ] triazol - 3 - ylsulfanyl ) - acetamide ; N - ( 2 , 4 - Dimethyl - phenyl ) - 2 - [ 4 - furan - 2 - ylmethyl - 5 - ( 4 - hydroxy - pheny1 ) - 4H - [ 1 , 2 , 4 ] triazol - 3 - yl sulfany1 ] - acetamide ; 5 4 - [ 2 - ( 5 - cyclohexyl - 4 - methyl - 4H - [ 1 , 2 , 4 ] triazol - 3 - yfsulfanyl ) - acetylamino ] - benzoic acid ethyl ester ; 2 - [ 4 - Furan - 2 - ylmethyl - 5 - ( 4 - hydroxy - phenyl ) - 4H - [ 1 , 2 , 4 ] triazol - 3 - ylsulfanyl ] - N - ( 4 - methyl - 3 - nitro - phenyl ) - acetamide ; 3 - I sobutylsulfanyl - 4 - methyl - 5 - p - tolyl - 4H - [ 1 , 2 , 4 ] triazole ; 2 - [ 2 - ( 4 - Methyl - 5 - m - tolyl - 4H - [ l , 2 , 4 ] triazol - 3 - ylsulfanyl ) - acetylamino ] - benzoic acid methyl ester ; 2 - { 4 - Ethyl - 5 - [ 4 - ( morpholine - 4 - sulfonyl ) - phenyl ] - 4H - [ 1 , 2 , 4 ] triazol - 3 - ylsulfanyl } - 1 - p - tolyl - ethanone ; 15 4 - Methyl - 3 - phenethylsulfanyl - 5 - p - tolyl - 4H - [ 1 , 2 , 4 ] triazole ; 2 - ( 4 - Benzyl - 5 - pyridin - 3 - yl - 4H - [ 1 , 2 , 4 ] triazol - 3 - ylsulfanyl ) - N - p - tolyl - acetamide ; . lO. 2 - ( 4 - Benzyl - 5 - pyridin - 3 - yl - 4H - [ 1 , 2 , 4 ] t1iazol - 3 - ylsulfanyl ) - N - ( 4 - nitro - phenyl ) - acetamide ; . 2 - ( 4 - Benzyl - 5 - pyridin - 3 - yl - 4H - [ 1 , 2 , 4 ] t1iazol - 3 - ylsulfanyl ) - N - phenyl - acetamide ; . 2 - ( 4 - Benzyl - 5 - pyridin - 3 - yl - 4H - [ 1 , 2 , 4 ] triazol - 3 - ylsulfanyl ) - N - ( 3 - chloro - phenyl ) - acetamide ; . 2 - ( 4 - Benzyl - 5 - pyridin - 3 - yl - 4H - [ 1 , 2 , 4 ] t1iazol - 3 - ylsulfanyl ) - N - ( 4 - nitro - phenyl ) - propionamide ; . 2 - ( 4 - Benzyl - 5 - pyridin - 3 - yl - 4H - [ 1 , 2 , 4 ] triazol - 3 - ylsulfanyl ) - N - ( 2 , 5 - dichloro - phenyl ) - acetamide ; . N - ( 3 - Ch1oro - phenyl ) - 2 - ( 4 - phenethyl - 5 - pyridin - 3 - yl - 4H - [ 1 , 2 , 4 ] triazol - 3 - ylsulfanyl ) - acetamide ; . N - ( 4 - Nitro - phenyl ) - 2 - ( 4 - phenethyl - 5 - pyridin - 3 - yl - 4H - [ 1 , 2 , 4 ] triazol - 3 - ylsulfanyl ) - propionamide ; . N - ( 2 - Bromo - 4 - methyl - phenyl ) - 2 - [ 5 - ( 3 , 4 - dimethoxy - phenyl ) - 4 - methyl - 4H - [ 1 , 2 , 4 ] triazo1 - 3 - ylsulfany1 ] - acetamide ; . 2 - { 4 - Ethy1 - 5 - [ ( 4 - ﬂuoro - phenylamino ) - methy1 ] - 4H - [ 1 , 2 , 4 ] triazol - 3 - ylsulfanyl } - N - ( 4 - nitro - phenyl ) - acetamide ; . 3 - Benzylsulfanyl - 5 - cyclohexyl - 4 - ethyl - 4H - [ 1 , 2 , 4 ] triazole ; . [ 5 - ( 4 - Hydroxy - phenyl ) - 4 - methyl - 4H - [ 1 , 2 , 4 ] triazol - 3 - ylsulfanyl ] - acetic acid cyclohexyl ester ; . 2 - ( 5 - cyclohexyl - 4 - ethyl - 4H - [ 1 , 2 , 4 ] triazol - 3 - ylsulfanyl ) - N - ( 5 - ethyl - [ 1 , 3 , 4 ] thiadiazol - 2 - yl ) - acetamide ; . N - ( 3 - Chloro - 4 - methyl - phenyl ) - 2 - [ 4 - ethyl - 5 - ( 4 - hydroxyphenyl ) - 4H - [ 1 , 2 , 4 ] triazol - 3 - ylsulfanyl ] - acetamide ; . [ 4 - Benzy1 - 5 - ( 4 - methoxy - phenyl ) - 4H - [ 1 , 2 , 4 ] triazol - 3 - ylsulfanyl ] - acetic acid ethy1 ester ; . 3 - Benzylsulfanyl - 4 - methyl - 5 - ( 3 , 4 , 5 - trimethoxy - phenyl ) - 4H - [ 1 , 2 , 4 ] triazole ; . N - ( 2 - Chloro - phenyl ) - 2 - [ 4 - ethyl - 5 - ( 4 - hydroxy - phenyl ) - 4H - [ 1 , 2 , 4 ] triazol - 3 - ylsulfanyl ] - acetamide ; . N - ( 2 , 4 - Dimethoxy - phenyl ) - 2 - ( 4 - methyl - 5 - o - tolyl - 4H - [ 1 , 2 , 4 ] triazol - 3 - ylsulfanyl ) - acetamide ; . 2 - ( 5 - cyclohexyl - 4 - methyl - 4H - [ 1 , 2 , 4 ] triazol - 3 - ylsulfanyl ) - N - ( 2 - methyl - 4 - nitro - phenyl ) - acetamide ; . 2 - ( 5 - cyclohexyl - 4 - methyl - 4H - [ 1 , 2 , 4 ] triazol - 3 - ylsulfany1 ) - 1 - phenyl - ethanone ; . 3 - cyclohexyl - 4 - methyl - 5 - ( 4 - methyl - benzylsulfanyl ) - 4H - [ 1 , 2 , 4 ] triazole ; . N - ( 2 - Bromo - phenyl ) - 2 - ( 5 - cyclohexyl - 4 - methyl - 4H - [ 1 , 2 , 4 ] triazol - 3 - y1sulfany1 ) - acetamide ; . 2 - ( 5 - cyclohexyl - 4 - methyl - 4H - [ 1 , 2 , 4 ] triazol - 3 - ylsulfanyl ) - N - ( 4 - iodo - 2 - methyl - phenyl ) - acetamide ; . N - ( 3 - Cyano - 4 , 5 , 6 , 7 - tetrahydro - benzo [ b ] thiophen - 2 - yl ) - 2 - ( 5 - cyclohexyl - 4 - methyl - 4H - [ 1 , 2 , 4 ] triazol - 3 - ylsulfanyl ) - acetamide ; . N - ( 4 - Acetyl - phenyl ) - 2 - ( 5 - cyclohexyl - 4 - methyl - 4H - [ 1 , 2 , 4 ] triazol - 3 - ylsulfanyl ) - acetamide ; . 2 - ( 5 - cyclohexyl - 4 - methyl - 4H - [ 1 , 2 , 4 ] triazol - 3 - ylsulfanyl ) - N - ( 4 - methoxy - phenyl ) - acetamide ; . 25. 30. 35. 45. 60. 65. US 7 , 50l , 405 B2. 101 N - ( 4 - Chloro - phenyl ) - 2 - ( 5 - cyclohexyl - 4 - methyl - 4H - [ l , 2 , 4 ] triazol - 3 - ylsulfanyl ) - acetamide ; 2 - ( 5 - cyclohexyl - 4 - methyl - 4H - [ 1 , 2 , 4 ] triazol - 3 - ylsulfanyl ) - N - phenyl - acetamide ; . 2 - [ 5 - ( 2 - Bromo - phenyl ) - 4 - ethyl - 4H - [ 1 , 2 , 4 ] triazol - 3 - ylsulfa - . nyl ] - N - ( 2 - methoxy - 4 - nitro - phenyl ) - acetamide ; N - ( 3 - Cyano - 4 , 5 , 6 , 7 - tetrahydro - benzo [ b ] thiophen - 2 - yl ) - 2 - [ 5 - ( 2 - methoxy - phenyl ) - 4 - methyl - 4H - [ 1 , 2 , 4 ] triazol - 3 - ylsulfanyl ] - acetamide ; N - ( 4 - Bromo - phenyl ) - 2 - ( 5 - cyclohexyl - 4 - ethyl - 4H - [ 1 , 2 , 4 ] triazol - 3 - ylsulfanyl ) - acetamide ; . 2 - [ 4 - Ethyl - 5 - ( 4 - hydroxy - phenyl ) - 4H - [ 1 , 2 , 4 ] triazol - 3 - ylsul - . fanyl ] - N - phenyl - acetamide ; N - ( 3 - Chloro - phenyl ) - 2 - [ 4 - ethyl - 5 - ( 4 - hydroxy - phenyl ) - 4H - [ 1 , 2 , 4 ] triazol - 3 - ylsulfanyl ] - acetamide ; N - ( 4 - Acetyl - phenyl ) - 2 - [ 4 - ethyl - 5 - ( 4 - hydroxy - phenyl ) - 4H - [ 1 , 2 , 4 ] triazol - 3 - ylsulfanyl ] - acetamide ; N - ( 4 - Bromo - phenyl ) - 2 - [ 4 - ethyl - 5 - ( 4 - hydroxy - phenyl ) - 4H - [ 1 , 2 , 4 ] triazol - 3 - ylsulfanyl ] - acetamide ; 2 - [ 4 - Ethyl - 5 - ( 4 - hydroxy - phenyl ) - 4H - [ 1 , 2 , 4 ] triazol - 3 - ylsulfanyl ] - N - ( 4 - iodo - 2 - methyl - phenyl ) - acetamide ; . N - ( 2 , 4 - Dimethyl - phenyl ) - 2 - [ 4 - ethyl - 5 - ( 4 - hydroxy - phenyl ) - . 4H - [ 1 , 2 , 4 ] tdazol - 3 - ylsulfanyl ] - acetamide ; . 4 - [ 5 - ( 4 - Chloro - benzylsulfanyl ) - 4 - ethyl - 4H - [ 1 , 2 , 4 ] triazol - 3 - . yl ] - phenol ; [ 4 - Ethyl - 5 - ( 4 - hydroxy - phenyl ) - 4H - [ 1 , 2 , 4 ] triazol - 3 - ylsulfanyl ] - acetic acid cyclohexyl ester ; 2 - [ 5 - ( 2 - Methoxy - phenyl ) - 4 - methyl - 4H - [ 1 , 2 , 4 ] triazol - 3 - ylsulfanyl ] - N - ( 4 - phenyl - thiazol - 2 - yl ) - acetamide ; . N - ( 3 - Chloro - phenyl ) - 2 - [ 4 - ethyl - 5 - ( 2 - methoxy - phenyl ) - 4H - . [ 1 , 2 , 4 ] triazol - 3 - ylsulfanyl ] - acetamide ; . 2 - [ 5 - ( 2 - Bromo - phenyl ) - 4 - methy1 - 4H - [ 1 , 2 , 4 ] triazol - 3 - y1su1 - . fanyl ] - N - ( 2 - nitro - phenyl ) - acetamide ; . 2 - [ 4 - Methy1 - 5 - ( 4 - nitro - pheny1 ) - 4H - [ 1 , 2 , 4 ] triazo1 - 3 - ylsulfa - . nyl ] - 1 - phenyl - ethanone ; N - ( 4 - Bromo - phenyl ) - 2 - { 4 - ethy1 - 5 - [ ( 4 - ﬂuoro - phenylamino ) - methyl ] - 4H - [ 1 , 2 , 4 ] triazo1 - 3 - ylsu1fanyl } - acetamide ; N - ( 4 - Chloro - phenyl ) - 2 - { 4 - ethy1 - 5 - [ ( 4 - ﬂuoro - phenylamino ) - methyl ] - 4H - [ 1 , 2 , 4 ] triazo1 - 3 - ylsu1fanyl } - acetamide ; 2 - { 4 - Ethy1 - 5 - [ ( 4 - ﬂuoro - phenylamino ) - methy1 ] - 4H - [ 1 , 2 , 4 ] triazo1 - 3 - ylsulfany1 } - N - ( 2 - nitro - pheny1 ) - acetamide ; 1 - ( 4 - Methoxy - phenyl ) - 2 - [ 4 - methyl - 5 - ( 4 - nitro - phenyl ) - 4H - [ 1 , 2 , 4 ] triazol - 3 - ylsulfanyl ] - ethanone ; [ 5 - ( 4 - Chloro - benzylsulfanyl ) - 4 - ethyl - 4H - [ 1 , 2 , 4 ] triazol - 3 - ylmethyl ] - ( 4 - ﬂuoro - phenyl ) - amine ; 2 - { 4 - Ethyl - 5 - [ ( 4 - ﬂuoro - phenylamino ) - methyl ] - 4H - [ 1 , 2 , 4 ] triazol - 3 - yl sulfanyl } - 1 - p - tolyl - ethanone ; 2 - { 4 - Ethyl - 5 - [ ( 4 - ﬂuoro - phenylamino ) - methyl ] - 4H - [ 1 , 2 , 4 ] triazol - 3 - yl sulfanyl } - N - ( 4 - methyl - 3 - nitro - phenyl ) - acetamide ; . N - ( 2 - Bromo - 4 - methyl - phenyl ) - 2 - { 4 - ethyl - 5 - [ ( 4 - ﬂuoro - phenylamino ) - methyl ] - 4H - [ 1 , 2 , 4 ] triazol - 3 - ylsulfanyl } - aceta - . mide ; . 4 - Allyl - 5 - ( 3 - bromo - phenyl ) - 4H - [ 1 , 2 , 4 ] triazole - 3 - thiol ; . N - ( 2 - Nitro - phenyl ) - 2 - ( 4 - phenethyl - 5 - pyridin - 3 - yl - 4H - [ 1 , 2 , 4 ] triazol - 3 - ylsulfanyl ) - acetamide ; . 2 - { 4 - Ethyl - 5 - [ 4 - ( piperidine - 1 - sulfonyl ) - phenyl ] - 4H - [ 1 , 2 , 4 ] triazol - 3 - ylsulfanyl } - 1 - p - tolyl - ethanone ; . 2 - { 4 - Ethyl - 5 - [ 4 - ( piperidine - 1 - sulfonyl ) - phenyl ] - 4H - [ 1 , 2 , 4 ] triazol - 3 - ylsulfanyl } - 1 - phenyl - ethanone ; . N - Biphenyl - 2 - yl - 2 - ( 4 - ethyl - 5 - phenyl - 4H - [ 1 , 2 , 4 ] triazol - 3 - ylsulfanyl ) - acetamide ; . 2 - ( 4 - Benzyl - 5 - pyridin - 3 - yl - 4H - [ 1 , 2 , 4 ] triazol - 3 - ylsulfanyl ) - N - ( 3 - chloro - 4 - methyl - phenyl ) - acetamide ; . lO. lS. 20. 25. 30. 35. 40. 45. 50. 55. 60. 65. 102. N - ( 2 - Bromo - phenyl ) - 2 - ( 4 - ethyl - 5 - phenyl - 4H - [ l , 2 , 4 ] riazol - 3 - yl sulfanyl ) - acetamide ; . 4 - Benzyl - 5 - cyclohexyl - 4H - [ 1 , 2 , 4 ] triazole - 3 - thiol ; . 2 - ( 5 - cyclohexyl - 4 - ethyl - 4H - [ 1 , 2 , 4 ] triazol - 3 - ylsulfanyl ) - 1 - phenyl - ethanone ; . 2 - [ 5 - ( 2 - Bromo - phenyl ) - 4 - methyl - 4H - [ l , 2 , 4 ] triazol - 3 - ylsulfanyl ] - 1 - phenyl - ethanone ; . ( 5 - Benzyl - 4 - methyl - 4H - [ 1 , 2 , 4 ] triazol - 3 - ylsulfanyl ) - acetic acid cyclohexyl ester ; . 4 - Methyl - 3 - ( 4 - nitro - benzylsulfanyl ) - 5 - phenyl - 4H - [ 1 , 2 , 4 ] triazole ; . 2 - ( 4 - Methyl - 5 - phenyl - 4H - [ 1 , 2 , 4 ] triazol - 3 - ylsulfanyl ) - 1 - p - tolyl - ethanone ; . 2 - ( 4 - Methyl - 5 - phenyl - 4H - [ 1 , 2 , 4 ] triazol - 3 - ylsulfanyl ) - 1 - phenyl - ethanone ; . 3 - Benzylsulfanyl - 4 - methyl - 5 - ( naphthalen - 2 - yloxymethyl ) - 4H - [ 1 , 2 , 4 ] triazole ; . 2 - ( 5 - cyclohexyl - 4 - methyl - 4H - [ 1 , 2 , 4 ] triazol - 3 - ylsulfanyl ) - N - p - tolyl - acetamide ; . 3 - Benzylsulfanyl - 5 - cyclohexyl - 4 - methyl - 4H - [ 1 , 2 , 4 ] triazole ; . 2 - ( 5 - Benzyl - 4 - ethyl - 4H - [ 1 , 2 , 4 ] triazol - 3 - ylsulfanyl ) - N - ( 4 - chloro - 3 - nitro - phenyl ) - acetamide ; . 2 - ( 5 - Benzyl - 4 - ethyl - 4H - [ 1 , 2 , 4 ] triazol - 3 - ylsulfanyl ) - N - ( 4 - methyl - 3 - nitro - phenyl ) - acetamide ; . 2 - ( 5 - Benzyl - 4 - ethyl - 4H - [ 1 , 2 , 4 ] triazol - 3 - ylsulfanyl ) - N - ( 2 - methoxy - 4 - nitro - phenyl ) - acetamide ; . N - ( 2 - Bromo - 4 - methy1 - phenyl ) - 2 - ( 4 - methyl - 5 - pheny1 - 4H - [ 1 , 2 , 4 ] triazol - 3 - ylsulfanyl ) - acetamide ; . 3 - Benzylsulfanyl - 4 - ethyl - 5 - ( 4 - nitro - phenyl ) - 4H - [ 1 , 2 , 4 ] triazole ; . 4 - Ethyl - 3 - ( 4 - methyl - benzylsulfanyl ) - 5 - ( 4 - nitro - phenyl ) - 4H - [ 1 , 2 , 4 ] triazole ; . 2 - [ 4 - Ethyl - 5 - ( 4 - nitro - phenyl ) - 4H - [ 1 , 2 , 4 ] triazol - 3 - ylsulfanyl ] - 1 - p - tolyl - ethanone ; . 3 - ( 4 - Chloro - benzylsulfanyl ) - 4 - ethyl - 5 - ( 4 - nitro - phenyl ) - 4H - [ 1 , 2 , 4 ] triazole ; . 2 - [ 4 - Ethyl - 5 - ( 4 - nitro - phenyl ) - 4H - [ 1 , 2 , 4 ] triazol - 3 - ylsulfanyl ] - 1 - phenyl - ethanone ; . 2 - [ 5 - ( 2 - Bromo - phenyl ) - 4 - methyl - 4H - [ 1 , 2 , 4 ] triazol - 3 - ylsulfanyl ] - N - ( 3 , 4 - dimethyl - phenyl ) - acetamide ; . ( 2 , 4 - Dimethyl - phenyl ) - [ 4 - ethyl - 5 - ( 4 - nitro - benzylsulfanyl ) - 4H - [ 1 , 2 , 4 ] triazol - 3 - ylmethyl ] - amine. 2 - [ 5 - ( 2 - Bromo - phenyl ) - 4 - methy1 - 4H - [ 1 , 2 , 4 ] triazol - 3 - ylsu1 - fanyl ] - N - ( 4 - methyl - 3 - nitro - phenyl ) - acetamide ; . 2 - ( 4 - Methyl - 5 - o - tolyl - 4H - [ 1 , 2 , 4 ] triazol - 3 - ylsulfanyl ) - N - ( 2 - triﬂuoromethyl - phenyl ) - acetamide ; . 2 - [ 5 - [ ( 2 , 4 - Dimethyl - phenylamino ) - methyl ] - 4 - ( tetrahydrofuran - 2 - ylmethyl ) - 4H - [ 1 , 2 , 4 ] triazol - 3 - ylsulfanyl ] - 1 - p - tolyl - ethanone ; . 4 - [ 5 - ( 2 , 6 - Dichloro - benzylsulfanyl ) - 4 - ( tetrahydro - furan - 2 - ylmethyl ) - 4H - [ 1 , 2 , 4 ] triazol - 3 - yl ] - pyridine ; . 3 - Benzy1sulfanyl - 5 - ( 4 - chloro - phenoxymethyl ) - 4 - ethyl - 4H - [ 1 , 2 , 4 ] triazole ; . 3 - Butylsulfanyl - 4 - methyl - 5 - p - tolyl - 4H - [ 1 , 2 , 4 ] triazole ; . 1 - ( 5 - Chloro - 2 - methoxy - phenyl ) - 2 - ( 4 - methyl - 5 - p - tolyl - 4H - [ 1 , 2 , 4 ] triazol - 3 - ylsulfanyl ) - ethanone ; . 1 - ( 4 - Chioro - pheny1 ) - 2 - ( 4 - methy1 - 5 - p - toly1 - 4H - [ 1 , 2 , 4 ] triazol - 3 - ylsulfanyl ) - ethanone ; . N - ( 2 , 4 - Dimethoxy - phenyl ) - 2 - ( 4 - ethyl - 5 - phenyl - 4H - [ 1 , 2 , 4 ] triazol - 3 - yl sulfanyl ) - acetamide ; . 2 - ( 4 - Ethyl - 5 - phenyl - 4H - [ 1 , 2 , 4 ] triazol - 3 - ylsulfanyl ) - N - ( 2 - methyl - 4 - nitro - phenyl ) - acetamide ; . N - ( 4 - Ethoxy - phenyl ) - 2 - ( 4 - ethyl - 5 - phenyl - 4H - [ 1 , 2 , 4 ] triazol - 3 - ylsulfanyl ) - acetamide ; . N - ( 4 - Ethyl - phenyl ) - 2 - ( 4 - ethyl - 5 - phenyl - 4H - [ 1 , 2 , 4 ] triazol - 3 - yl sulfanyl ) - acetamide ; . US 7 , 50l , 405 B2. 103. 2 - ( 4 - Ethyl - 5 - phenyl - 4H - [ l , 2 , 4 ] triazol - 3 - ylsulfanyl ) - N - thiazol - 2 - yl - acetamide ; . 2 - ( 4 - Ethyl - 5 - phenyl - 4H - [ 1 , 2 , 4 ] triazol - 3 - ylsulfanyl ) - 1 - phenyl - ethanone ; . 2 - ( 4 - Ethyl - 5 - phenyl - 4H - [ 1 , 2 , 4 ] triazol - 3 - ylsulfanyl ) - 1 - p - tolyl - ethanone ; . 2 - ( 4 - Ethyl - 5 - phenyl - 4H - [ 1 , 2 , 4 ] triazol - 3 - ylsulfanyl ) - N - ( 2 - nitro - phenyl ) - acetamide ; . N - ( 3 - Chloro - phenyl ) - 2 - ( 4 - ethyl - 5 - phenyl - 4H - [ 1 , 2 , 4 ] triazol - 3 - ylsulfanyl ) - acetamide ; . N - ( 2 - Chloro - phenyl ) - 2 - ( 4 - ethyl - 5 - phenyl - 4H - [ l , 2 , 4 ] triazol - 3 - ylsulfanyl ) - acetamide ; . 2 - [ 5 - ( 2 - Hydroxy - phenyl ) - 4 - phenethyl - 4H - [ 1 , 2 , 4 ] triazol - 3 - ylsulfanyl ] - 1 - piperidin - 1 - yl - ethanone ; . 2 - [ 5 - ( 2 - Morpholin - 4 - yl - ethylsulfanyl ) - 4 - phenethyl - 4H - [ 1 , 2 , 4 ] triazol - 3 - yl ] - phenol ; . N - ( 2 - Methyl - 4 - nitro - phenyl ) - 2 - ( 4 - phenethyl - 5 - pyridin - 4 - yl - 4H - [ 1 , 2 , 4 ] triazol - 3 - ylsulfanyl ) - acetamide ; . N - ( 2 - Methyl - 5 - nitro - phenyl ) - 2 - ( 4 - phenethyl - 5 - pyridin4 - yl - 4H - [ 1 , 2 , 4 ] triazol - 3 - ylsulfanyl ) - acetamide ; . N - ( 4 - Bromo - phenyl ) - 2 - ( 4 - phenethyl - 5 - pyridin - 4 - yl - 4H - [ 1 , 2 , 4 ] triazol - 3 - ylsulfanyl ) - acetamide ; . N - ( 3 - Nitro - pheny1 ) - 2 - ( 4 - phenethyl - 5 - pyridin - 4 - y1 - 4H - [ 1 , 2 , 4 ] triazol - 3 - ylsulfanyl ) - acetamide ; . 2 - ( 4 - Ethyl - 5 - phenyl - 4H - [ 1 , 2 , 4 ] triazol - 3 - ylsulfanyl ) - N - ( 4 - ﬁuoro - phenyl ) - acetamide ; . 2 - ( 4 - Ethyl - 5 - phenyl - 4H - [ 1 , 2 , 4 ] triazol - 3 - ylsulfanyl ) - N - ( 2 - methoxy - 4 - nitro - phenyl ) - acetamide ; . N - ( 2 , 5 - Dich1oro - pheny1 ) - 2 - [ 4 - ethyl - 5 - ( 2 - methoxy - pheny1 ) - 4H - [ 1 , 2 , 4 ] triazol - 3 - ylsulfanyl ] - acetamide ; . 2 - ( 5 - cyclohexyl - 4 - methyl - 4H - [ 1 , 2 , 4 ] triazo1 - 3 - ylsulfany1 ) - N - ( 3 - nitro - phenyl ) - acetamide ; . 2 - [ 4 - Benzyl - 5 - ( 4 - hydroxy - phenyl ) - 4H - [ 1 , 2 , 4 ] triazol - 3 - yl - su1fanyl ] - N - ( 2 - methyl - 4 - nitro - pheny1 ) - acetamide ; . 2 - ( 4 - Phenethyl - 5 - pyridin - 4 - yl - 4H - [ 1 , 2 , 4 ] triazol - 3 - ylsulfanyl ) - N - ( 3 - trtﬂuoromethy1 - phenyl ) - acetamide ; . [ 4 - Furan - 2 - ylmethyl - 5 - ( 4 - hydroxy - phenyl ) - 4H - [ 1 , 2 , 4 ] triazol - 3 - ylsulfanyl ] - acetic acid cyclohexyl ester ; . 2 - [ 4 - Furan - 2 - ylmethyl - 5 - ( 4 - hydroxy - phenyl ) - 4H - [ 1 , 2 , 4 ] triazol - 3 - yl sulfanyl ] - 1 - phenyl - ethanone ; . 2 - [ 4 - Ethyl - 5 - ( 2 - methoxy - phenyl ) - 4H - [ l , 2 , 4 ] triazol - 3 - ylsul - . fanyl ] - N - ( 2 - ethyl - phenyl ) - acetamide ; . 2 - ( 5 - cyclohexyl - 4 - methyl - 4H - [ 1 , 2 , 4 ] triazo1 - 3 - ylsulfany1 ) - N - ( 3 , 4 - dichloro - phenyl ) - acetamide ; . 2 - ( 5 - cyclohexyl - 4 - methyl - 4H - [ 1 , 2 , 4 ] triazo1 - 3 - ylsulfany1 ) - 1 - ( 4 - methoxy - phenyl ) - ethanone ; . 2 - ( 4 - Benzyl - 5 - phenyl - 4H - [ 1 , 2 , 4 ] triazol - 3 - ylsulfanyl ) - N - ( 4 - methoxy - 2 - nitro - phenyl ) - acetamide ; . 2 - ( 4 - Benzyl - 5 - phenyl - 4H - [ 1 , 2 , 4 ] triazol - 3 - ylsulfanyl ) - N - ( 5 - methyl - thiazo1 - 2 - yl ) - acetamide ; . 2 - ( 4 - Benzyl - 5 - phenyl - 4H - [ 1 , 2 , 4 ] triazol - 3 - ylsulfanyl ) - N - thiazol - 2 - yl - acetamide ; . 2 - ( 4 , 5 - Dibenzyl - 4H - [ 1 , 2 , 4 ] triazol - 3 - ylsulfanyl ) - N - ( 4 - nitrophenyl ) - acetamide ; . 2 - ( 4 - Benzyl - 5 - phenyl - 4H - [ 1 , 2 , 4 ] triazol - 3 - ylsulfanyl ) - N - ( 2 - nitro - phenyl ) - acetamide ; . 3 - Benzylsufanyl - 5 - ( 4 - bromo - phenyl ) - 4 - methyl - 4H - [ 1 , 2 , 4 ] triazole ; . 2 - [ 4 - Ethyl - 5 - ( 4 - methoxy - phenyl ) - 4H - [ 1 , 2 , 4 ] triazol - 3 - ylsul - . fanyl ] - N - ( 4 - methyl - 3 - nitro - phenyl ) - acetamide ; . 2 - [ 4 - Ethyl - 5 - ( 4 - methoxy - phenyl ) - 4H - [ 1 , 2 , 4 ] triazol - 3 - ylsul - . fanyl ] - 1 - phenyl - ethanone ; 2 - ( 4 - Benzyl - 5 - methyl - 4H - [ 1 , 2 , 4 ] triazol - 3 - ylsulfanyl ) - 1 - phenyl - ethanone ; . 2 - ( 5 - Methyl - 4 - phenethyl - 4H - [ 1 , 2 , 4 ] triazol - 3 - ylsulfanyl ) - N - . p - tolyl - acetamide ; . 5. lO. 20. 30. 35. 40. 45. 50. 55. 60. 65. 104. 2 - ( 5 - Methyl - 4 - phenethyl - 4H - [ 1 , 2 , 4 ] triazol - 3 - ylsulfanyl ) - N - ( 3 - triﬁuoromethyl - phenyl ) - acetamide ; . N - ( 3 - Chloro - phenyl ) - 2 - ( 5 - methyl - 4 - phenethyl - 4H - [ 1 , 2 , 4 ] triazol - 3 - y1sulfany1 ) - acetamide ; . N - ( 4 - Chloro - phenyl ) - 2 - ( 5 - methyl - 4 - phenethyl - 4H - [ 1 , 2 , 4 ] triazol - 3 - ylsulfanyl ) - acetamide ; . 2 - [ 5 - ( 2 - Bromo - phenyl ) - 4 - methyl - 4H - [ 1 , 2 , 4 ] triazol - 3 - ylsulfanyl ] - N - ( 2 - methoxy - 4 - nitro - phenyl ) - acetamide ; . 2 - ( 5 - cyclohexyl - 4 - ethyl - 4H - [ 1 , 2 , 4 ] triazol - 3 - ylsulfanyl ) - N - ( 3 - nitro - phenyl ) - acetamide ; . N - ( 2 , 3 - Dichloro - phenyl ) - 2 - [ 4 - ethyl - 5 - ( 2 - methoxy - phenyl ) - 4H - [ 1 , 2 , 4 ] triazol - 3 - ylsulfanyl ] - acetamide ; . N - ( 2 , 3 - Dichloro - phenyl ) - 2 - [ 4 - ethyl - 5 - ( 4 - hydroxy - phenyl ) - 4H - [ 1 , 2 , 4 ] triazol - 3 - ylsulfanyl ] - acetamide ; . 2 - [ 4 - Ethyl - 5 - ( 2 - methoxy - phenyl ) - 4H - [ 1 , 2 , 4 ] triazol - 3 - ylsulfanyl ] - 1 - ( 4 - methoxy - phenyl ) - ethanone ; . 2 - [ 4 - Benzyl - 5 - ( 2 - hydroxy - phenyl ) - 4H - [ 1 , 2 , 4 ] triazol - 3 - ylsulfanyl ] - 1 - piperidin - 1 - yl - ethanone ; . 2 - [ 4 - Benzyl - 5 - ( 2 - hydroxy - phenyl ) - 4H - [ 1 , 2 , 4 ] triazol - 3 - ylsulfanyl ] - N - p - tolyl - acetamide ; . 2 - { 5 - [ ( 2 , 4 - Dimethyl - phenylamino ) - methyl ] - 4 - furan - 2 - ylmethyl - 4H - [ 1 , 2 , 4 ] triazol - 3 - ylsulfanyl } - 1 - phenyl - ethanone ; . 2 - ( 4 - Methy1 - 5 - m - tolyl - 4H - [ 1 , 2 , 4 ] triazol - 3 - ylsulfanyl ) - N - p - tolyl - acetamide ; . 4 - { 4 - Ethyl - 5 - [ 4 - ( piperidine - 1 - sulfonyl ) - phenyl ] - 4H - [ 1 , 2 , 4 ] triazol - 3 - yl sulfanylmethyl } - benzonitrile ; . N - ( 2 - Methoxy - phenyl ) - 2 - ( 4 - methyl - 5 - m - tolyl - 4H - [ 1 , 2 , 4 ] triazol - 3 - y1sulfany1 ) - acetamide ; . N - ( 4 - Acetyl - phenyl ) - 2 - ( 4 - ethyl - 5 - m - tolyl - 4H - [ 1 , 2 , 4 ] triazol - 3 - ylsulfanyl ) - acetamide ; . 2 - ( 4 - Ethyl - 5 - m - tolyl - 4H - [ 1 , 2 , 4 ] triazol - 3 - ylsulfanyl ) - N - ( 4 - methyl - 3 - nitro - phenyl ) - acetamide ; . 2 - [ 5 - ( 4 - Amino - phenyl ) - 4 - methyl - 4H - [ 1 , 2 , 4 ] triazol - 3 - ylsulfanyl ] - 1 - ( 4 - nitro - phenyl ) - ethanone ; . N - { 4 - [ 5 - ( 2 - Chloro - benzylsu1fanyl ) - 4 - methyl - 4H - [ 1 , 2 , 4 ] triazol - 3 - yl ] - phenyl } - 2 - methoxy - benzamide ; . 2 - ( 4 - Ally1 - 5 - pyridin - 4 - yl - 4H - [ 1 , 2 , 4 ] triazo1 - 3 - y1sulfanyl ) - 1 - ( 4 - ﬂuoro - phenyl ) - ethanone ; . 2 - ( 4 - Benzyl - 5 - pyridin - 3 - yl - 4H - [ 1 , 2 , 4 ] t1iazol - 3 - ylsulfanyl ) - N - ( 4 - ﬂuoro - phenyl ) - acetamide ; . 2 - [ 5 - ( 4 - Amino - phenyl ) - 4 - methyl - 4H - [ 1 , 2 , 4 ] triazol - 3 - ylsulfanyl ] - 1 - ( 4 - nitro - phenyl ) - ethanone ; . 2 - ( 4 - Allyl - 5 - thiophen - 2 - yl - 4H - [ 1 , 2 , 4 ] triazol - 3 - ylsulfanyl ) - N - ( 4 - chloro - phenyl ) - acetamide ; . ( 4 - Benzyl - 5 - phenyl - 4H - [ 1 , 2 , 4 ] triazol - 3 - ylsulfanyl ) - acetic acid ethyl ester ; . 4 - [ 5 - ( 4 - tert - Butyl - benzylsulfanyl ) - 4 - methyl - 4H - [ 1 , 2 , 4 ] triazol - 3 - yl ] - pyridine ; . 2 - { 5 - [ ( 3 - Chloro - phenylamino ) - methyl ] - 4 - ethyl - 4H - [ 1 , 2 , 4 ] triazol - 3 - ylsufanyl } 1 - phenyl - ethanone ; . { 5 - [ ( 2 - Chloro - phenylamino ) - methyl ] - 4 - ethyl - 4H - [ 1 , 2 , 4 ] triazol - 3 - ylsulfanyl } - acetic acid isopropyl ester ; . 2 - [ 4 - Ethyl - 5 - ( 4 - methoxy - phenoxymethyl ) - 4H - [ 1 , 2 , 4 ] triazol - 3 - ylsulfanyl ] - 1 - phenyl - ethanone ; . 1 - ( 4 - Chloro - phenyl ) - 2 - { 5 - [ ( 2 - chloro - phenylamino ) - methy1 ] - 4 - ethy1 - 4H - [ 1 , 2 , 4 ] triazol - 3 - y1sulfanyl } - ethanone ; 4 - [ 5 - ( 2 - Chloro - 6 - ﬁuoro - benzylsulfanyl ) - 4 - methyl - 4H - [ 1 , 2 , . 4 ] triazol - 3 - yl ] - pyridine ; 3 - Benzyl - 5 - benzylsulfanyl - 4 - ethyl - 4H - [ 1 , 2 , 4 ] triazole ; 3 - Benzylsulfanyl - 4 - methyl - 5 - o - tolyl - 4H - [ 1 , 2 , 4 ] triazole ; N - ( 4 - Chloro - 3 - nitro - phenyl ) - 2 - ( 4 - methyl - 5 - o - tolyl - 4H - [ 1 , 2 , 4 ] triazol - 3 - ylsulfanyl ) - acetamide ; 2 - ( 4 - Methyl - 5 - o - tolyl - 4H - [ 1 , 2 , 4 ] triazol - 3 - ylsulfanyl ) - 1 - p - tolyl - ethanone ; 1 - ( 4 - Methoxy - phenyl ) - 2 - ( 4 - methyl - 5 - o - tolyl - 4H - [ 1 , 2 , 4 ] triazol - 3 - yl sulfanyl ) - ethanone ; . US 7 , 50l , 405 B2. 105. [ 5 - ( 2 - Bromo - phenyl ) - 4 - methyl - 4H - [ l , 2 , 4 ] triazol - 3 - ylsulfanyl ] - acetonitrile ; . [ 5 - ( 2 - Hydroxy - phenyl ) - 4 - phenethyl - 4H - [ 1 , 2 , 4 ] triazol - 3 - ylsulfanyl ] - acetonitrile ; . 1 - [ 5 - ( 2 - Hydroxy - phenyl ) - 4 - phenethyl - 4H - [ 1 , 2 , 4 ] triazol - 3 - ylsulfanyl ] - propan - 2 - one ; . N - ( 2 , 3 - Dichloro - phenyl ) - 2 - [ 4 - furan - 2 - ylmethyl - 5 - ( 2 - methoxy - phenyl ) - 4H - [ 1 , 2 , 4 ] triazol - 3 - ylsulfanyl ] - acetamide ; . N - ( 3 - Chloro - phenyl ) - 2 - [ 4 - furan - 2 - ylmethyl - 5 - ( 2 - methoxyphenyl ) - 4H - [ 1 , 2 , 4 ] triazol - 3 - ylsulfanyl ] - acetamide ; . N - ( 4 - Chloro - phenyl ) - 2 - [ 4 - furan - 2 - ylmethyl - 5 - ( 2 - methoxyphenyl ) - 4H - [ 1 , 2 , 4 ] triazol - 3 - ylsulfanyl ] - acetamide ; . 2 - [ 5 - ( 4 - Methoxy - phenoxymethyl ) - 4 - methyl - 4H - [ 1 , 2 , 4 ] triazol - 3 - ylsulfanyl ] - 1 - phenyl - ethanone ; . 2 - { 5 - [ ( 2 - Chloro - phenylamino ) - methyl ] - 4 - ethyl - 4H - [ 1 , 2 , 4 ] triazol - 3 - ylsulfanyl } - 1 - piperidin - 1 - yl - ethanone ; . 2 - [ 5 - ( 4 - Methoxy - phenoxymethyl ) - 4 - methyl - 4H - [ 1 , 2 , 4 ] triazol - 3 - ylsulfanyl ] - 1 - ( 4 - methoxy - phenyl ) - ethanone ; . N - ( 2 , 3 - Dichloro - phenyl ) - 2 - [ 4 - furan - 2 - ylmethyl - 5 - ( 4 - hydroxy - phenyl ) - 4H - [ 1 , 2 , 4 ] triazol - 3 - ylsulfanyl ] - acetamide ; . 2 - [ 4 - Furan - 2 - ylmethyl - 5 - ( 4 - hydroxy - phenyl ) - 4H - [ 1 , 2 , 4 ] triazol - 3 - yl sulfanyl ] - 1 - ( 4 - methoxy - phenyl ) - ethanone ; . { 5 - [ ( 2 - Chloro - pheny1amino ) - methyl ] - 4 - ethyl - 4H - [ 1 , 2 , 4 ] triazol - 3 - ylsulfanyl } - acetic acid cyclohexyl ester ; . 2 - ( 4 - Phenethyl - 5 - pyridin - 4 - yl - 4H - [ 1 , 2 , 4 ] trazol - 3 - ylsulfanyl ) - N - thiazol - 2 - y1 - acetamide ; . 2 - ( 4 - Ethyl - 5 - m - tolyl - 4H - [ 1 , 2 , 4 ] triazol - 3 - ylsulfanyl ) - N - ( 4 - nitro - pheny1 ) - acetamide ; . 2 - ( 4 - Ethyl - 5 - phenyl - 4H - [ 1 , 2 , 4 ] triazol - 3 - ylsulfanyl ) - N - ( 2 - methoxy - phenyl ) - acetamide ; . 2 - ( 4 - Ethyl - 5 - phenyl - 4H - [ 1 , 2 , 4 ] triazol - 3 - ylsulfanyl ) - N - ( 2 - triﬂuoromethyl - phenyl ) - acetamide ; . 2 - [ 4 - Furan - 2 - ylmethyl - 5 - ( 2 - methoxy - phenyl ) - 4H - [ 1 , 2 , 4 ] triazol - 3 - ylsulfanyl ] - N - ( 2 - methyl - 4 - nitro - phenyl ) - acetamide ; . N - ( 3 - Chloro - 2 - methyl - phenyl ) - 2 - [ 4 - ﬁiran - 2 - ylmethyl - 5 - ( 2 - methoxy - phenyl ) - 4H - [ 1 , 2 , 4 ] triazol - 3 - ylsulfanyl ] - acetamide ; . 4 - Allyl - 5 - m - tolyl - 4H - [ 1 , 2 , 4 ] triazole - 3 - thiol ; . 4 - ( 2 - Methy1 - a1lyl ) - 5 - m - toly1 - 4H - [ 1 , 2 , 4 ] triazole - 3 - thiol ; . 2 - [ 4 - Allyl - 5 - ( 3 - bromo - phenyl ) - 4H - [ 1 , 2 , 4 ] triazol - 3 - ylsufanyl ] - N - ( 4 - ethyl - pheny1 ) - acetamide ; . 4 - Allyl - 3 - ( 3 - bromo - phenyl ) - 5 - ( 2 - nitro - benzylsulfanyl ) - 4H - [ 1 , 2 , 4 ] triazole ; . 2 - [ 4 - Allyl - 5 - ( 3 - bromo - phenyl ) - 4H - [ 1 , 2 , 4 ] triazol - 3 - ylsulfanyl ] - 1 - biphenyl - 4 - yl - ethanone ; . 4 - ( 2 - Methyl - allyl ) - 5 - ( 3 - nitro - phenyl ) - 4H - [ 1 , 2 , 4 ] triazole - 3 - thiol ; . 4 - Allyl - 5 - ( 2 - carbazol - 9 - yl - ethyl ) - 4H - [ 1 , 2 , 4 ] triazole - 3 - thiol ; . 5 - ( 4 - Bromo - phenyl ) - 4 - ( 2 - methyl - allyl ) - 4H - [ 1 , 2 , 4 ] triazole - 3 - thiol ; . 4 - ( 2 - Methyl - allyl ) - 5 - ( 3 - methyl - 2 - nitro - phenyl ) - 4H - [ 1 , 2 , 4 ] triazo1e - 3 - thio1 ; . 5 - ( 4 - Methoxy - phenyl ) - 4 - ( 2 - methyl - allyl ) - 4H - [ 1 , 2 , 4 ] triazole - 3 - thiol ; . 2 - ( 4 - Allyl - 5 - benzotriazol - 1 - ylmethyl - 4H - [ 1 , 2 , 4 ] triazol - 3 - ylsulfanyl ) - N - ( 4 - bromo - phenyl ) - acetamide ; . 2 - ( 4 - Allyl - 5 - benzotriazol - 1 - ylmethyl - 4H - [ 1 , 2 , 4 ] triazol - 3 - ylsulfanyl ) - N - pyridin - 2 - yl - acetamide ; . { 4 - Allyl - 5 - [ 3 - ( 1 , 3 - dioxo - 1H , 3H - benzo [ de ] isoquinolin - 2 - yl ) - propyl ] - 4H - [ 1 , 2 , 4 ] triazol - 3 - ylsulfanyl } - acetic acid ethyl ester ; and. 4 - Allyl - 5 - ( 4 - phenyl - piperazin - 1 - ylmethyl ) - 4H - [ 1 , 2 , 4 ] triazole - 3 - thiol ; or. lO. lS. 20. m. 5. 40. 45. 50. 55. 60. 65. 106. a salt thereof With a pharmaceutically acceptable acid or base , or any optical isomer or mixture of optical isomers , including a racemic mixture , or any tautomeric forms. In another embodiment of the present inVention said substituted 1 , 2 , 4 - triazole , or a prodrug thereof , as a component of the combination therapy is selected from the group consisting of : 4 - [ 2 - ( 4 - Ethyl - 5 - pyridin - 4 - yl - 4H - [ 1 , 2 , 4 ] triazol - 3 - ylsulfanyl ) . ethyl ] morpholine ; 1 - Benzothiazol - 2 - yl - 2 - ( 4 - ethyl - 5 - phenyl - 4H - [ 1 , 2 , 4 ] triazol - . 3 - ylsulfanyl ) - ethanone ; . N - cyclohexyl - 2 - ( 4 - ethyl - 5 - phenyl - 4H - [ 1 , 2 , 4 ] triazol - 3 - ylsulfanyl ) - N - methyl - acetamide ; . 2 - ( 4 - Ethyl - 5 - phenyl - 4H - [ 1 , 2 , 4 ] triazol - 3 - ylsulfanyl ) - 1 - phenyl - ethanone ; . 2 - ( 4 - Ethyl - 5 - phenyl - 4H - [ 1 , 2 , 4 ] triazol - 3 - ylsulfanyl ) - 1 - ( 4 - methoxy - phenyl ) - ethanone ; . 2 - ( 4 - Ethyl - 5 - phenyl - 4H - [ 1 , 2 , 4 ] triazol - 3 - ylsulfanyl ) - 1 - pyridin - 3 - yl - ethanone ; . 2 - ( 4 - Ethyl - 5 - phenyl - 4H - [ 1 , 2 , 4 ] triazol - 3 - ylsulfanyl ) - 1 - ( 4 - methanesulfonyl - phenyl ) - ethanone ; . 2 - ( 4 - Phenethyl - 5 - phenyl - 4H - [ 1 , 2 , 4 ] triazol - 3 - ylsulfanyl ) - 1 - phenyl - ethanone ; . 1 - ( 4 - Methoxy - phenyl ) - 2 - ( 4 - phenethyl - 5 - phenyl - 4H - [ 1 , 2 , 4 ] triazol - 3 - ylsulfanyl ) - ethanone ; . 2 - ( 4 - Phenethyl - 5 - phenyl - 4H - [ 1 , 2 , 4 ] triazol - 3 - ylsulfanyl ) - 1 - pyridin - 3 - yl - ethanone ; . 1 - ( 4 - Methanesufonyl - phenyl ) - 2 - ( 4 - phenethyl - 5 - phenyl - 4H - [ 1 , 2 , 4 ] triazol - 3 - ylsulfanyl ) - ethanone ; . 2 - ( 4 - Ethyl - 5 - pyridin - 4 - yl - 4H - [ 1 , 2 , 4 ] riazol - 3 - ylsufanyl ) - 1 - phenyl - ethanone ; . 2 - ( 4 - Ethyl - 5 - pyridin - 4 - yl - 4H - [ 1 , 2 , 4 ] triazol - 3 - ylsulfanyl ) - 1 - ( 4 - methoxy - pheny1 ) - ethanone ; . 2 - ( 4 - Ethyl - 5 - pyridin - 4 - yl - 4H - [ 1 , 2 , 4 ] triazol - 3 - ylsulfany1 ) - 1 - pyridin - 3 - yl - ethanone ; . 2 - ( 4 - Ethyl - 5 - pyridin - 4 - yl - 4H - [ 1 , 2 , 4 ] triazol - 3 - ylsulfanyl ) - 1 - ( 4 - methanesulfonyl - phenyl ) - ethanone ; . 2 - ( 4 - Phenethy1 - 5 - pyridin - 4 - yl - 4H - [ 1 , 2 , 4 ] triazo1 - 3 - ylsulfanyl ) - 1 - phenyl - ethanone ; . 1 - ( 4 - Methoxy - phenyl ) - 2 - ( 4 - phenethyl - 5 - pyridin - 4 - yl - 4H - [ 1 , 2 , 4 ] triazol - 3 - ylsulfanyl ) - ethanone ; . 2 - ( 4 - Phenethyl - 5 - pyridin - 4 - yl - 4H - [ 1 , 2 , 4 ] triazol - 3 - ylsulfanyl ) - 1 - pyri din - 3 - yl - ethanone ; . 1 - ( 4 - Methanesufonyl - phenyl ) - 2 - ( 4 - phenethyl - 5 - pyridin - 4 - yl - 4H - [ 1 , 2 , 4 ] triazol - 3 - ylsulfanyl ) - ethanone ; . 2 - ( 4 - Ethyl - 5 - furan - 2 - yl - 4H - [ 1 , 2 , 4 ] triazol - 3 - ylsulfanyl ) - 1 - phenyl - ethanone ; . 2 - ( 4 - Ethyl - 5 - furan - 2 - yl - 4H - [ 1 , 2 , 4 ] triazol - 3 - ylsulfanyl ) - 1 - ( 4 - methoxy - phenyl ) - ethanone ; . 2 - ( 4 - Ethyl - 5 - furan - 2 - yl - 4H - [ 1 , 2 , 4 ] triazol - 3 - ylsulfanyl ) - 1 - pyridin - 3 - yl - ethanone ; . 2 - ( 4 - Ethyl - 5 - furan - 2 - yl - 4H - [ 1 , 2 , 4 ] triazol - 3 - ylsulfanyl ) - 1 - ( 4 - methanesulfonyl - phenyl ) - ethanone ; . 2 - ( 5 - Furan - 2 - yl - 4 - phenethyl - 4H - [ 1 , 2 , 4 ] triazol - 3 - ylsulfanyl ) - 1 - phenyl - ethanone ; . 2 - ( 5 - Furan - 2 - yl - 4 - phenethyl - 4H - [ 1 , 2 , 4 ] triazol - 3 - ylsulfanyl ) - 1 - ( 4 - methoxy - phenyl ) - ethanone ; 2 - ( 5 - Furan - 2 - yl - 4 - phenethyl - 4H - [ 1 , 2 , 4 ] triazol - 3 - ylsulfanyl ) - 1 - pyri din - 3 - yl - ethanone ; 2 - ( 5 - Furan - 2 - yl - 4 - phenethyl - 4H - [ 1 , 2 , 4 ] triazol - 3 - ylsulfanyl ) - 1 - ( 4 - methanesulfonyl - phenyl ) - ethanone ; 1 - Adamantan - 1 - yl - 2 - ( 4 - methyl - 4H - [ 1 , 2 , 4 ] triazol - 3 - ylsulfanyl ) - ethanone ; 3 - [ 5 - ( 2 - Chloro - benzylsulfanyl ) - 4 - ethyl - 4H - [ 1 , 2 , 4 ] triazol - 3 - . yl ] - propan - 1 - ol ; 4 - [ 4 - Ethyl - 5 - ( 3 - hydroxy - propyl ) - 4H - [ 1 , 2 , 4 ] triazol - 3 - ylsul - . fanylmethyl ] - b enzonitrile ; . US 7 , 50l , 405 B2. 107 3 - [ 5 - ( 6 - Chloro - benzo [ l , 3 ] dioxol - 5 - ylmethylsufanyl ) - 4 - ethyl - 4H - [ 1 , 2 , 4 ] triazol - 3 - yl ] - propan - 1 - ol ; 3 - [ 5 - ( 3 , 4 - Dichloro - benzylsufanyl ) - 4 - ethyl - 4H - [ 1 , 2 , 4 ] triazol - 3 - y1 ] - propan - 1 - ol ; . 3 - ( 5 - cyclohexylmethylsulfanyl - 4 - ethyl - 4H - [ 1 , 2 , 4 ] triazol - 3 - . yl ) - propan - l - ol ; . 3 - [ 4 - Ethyl - 5 - ( 4 - triﬁuoromethyl - benzylsulfanyl ) - 4H - [ 1 , 2 , 4 ] triazol - 3 - yl ] - propan - 1 - ol ; . 3 - ( 5 - Benzylsulfanyl - 4 - ethyl - 4H - [ 1 , 2 , 4 ] triazol - 3 - yl ) - propan - 1 - ol ; . 3 - [ 4 - Ethyl - 5 - ( 4 - methanesulfonyl - benzylsulfanyl ) - 4H - [ 1 , 2 , 4 ] triazol - 3 - yl ] - propan - 1 - ol ; . 3 - [ 4 - Ethyl - 5 - ( 3 - nitro - benzylsulfanyl ) - 4H - [ 1 , 2 , 4 ] triazol - 3 - yl ] - propan - 1 - ol ; . 3 - [ 5 - ( 2 , 6 - Dichioro - benzylsulfanyl ) - 4 - ethyl - 4H - [ 1 , 2 , 4 ] triazol - 3 - yl ] - propan - 1 - ol ; . 3 - [ 4 - Ethyl - 5 - ( 3 - triﬁuoromethoxy - benzylsufanyl ) - 4H - [ 1 , 2 , 4 ] triazol - 3 - yl ] - propan - 1 - ol ; . N - { 4 - [ 4 - Ethyl - 5 - ( 3 - hydroxy - propyl ) - 4H - [ 1 , 2 , 4 ] triazol - 3 - ylsulfanylmethyl ] - phenyl } - acetamide ; . 3 - [ 4 - Ethyl - 5 - ( 5 - methyl - 2 - nitro - benzylsulfanyl ) - 4H - [ 1 , 2 , 4 ] triazol - 3 - yl ] - propan - 1 - ol ; . 3 - [ 4 - Ethyl - 5 - ( 2 - nitro - benzy1sulfanyl ) - 4H - [ 1 , 2 , 4 ] triazo1 - 3 - yl ] - propan - 1 - ol ; . 4 - [ 4 - Ethyl - 5 - ( 4 - hydroxy - phenyl ) - 4H - [ 1 , 2 , 4 ] triazol - 3 - ylsul - . fanylmethyl ] - benzonitrile ; 4 - [ 5 - ( 6 - Chloro - benzo [ 1 , 3 ] dioxol - 5 - ylmethylsulfanyl ) - 4 - ethy1 - 4H - [ 1 , 2 , 4 ] triazol - 3 - yl ] - phenol ; . 4 - [ 5 - ( 4 - Bromo - benzylsulfany1 ) - 4 - ethy1 - 4H - [ 1 , 2 , 4 ] triazol - 3 - . yl ] - phenol ; 4 - [ 4 - Ethyl - 5 - ( 4 - triﬁuoromethyl - benzylsulfanyl ) - 4H - [ 1 , 2 , 4 ] triazol - 3 - yl ] - phenol ; . 4 - ( 5 - Benzy1su1fanyl - 4 - ethyl - 4H - [ 1 , 2 , 4 ] triazol - 3 - yl ) - phenol ; . 4 - [ 4 - Ethyl - 5 - ( 4 - methanesulfonyl - benzy1sulfanyl ) - 4H - [ 1 , 2 , 4 ] triazol - 3 - yl ] - phenol ; . 4 - [ 4 - Ethyl - 5 - ( 3 - nitro - benzylsulfanyl ) - 4H - [ 1 , 2 , 4 ] triazol - 3 - yl ] - phenol ; . 4 - [ 4 - Ethyl - 5 - ( 4 - hydroxy - phenyl ) - 4H - [ 1 , 2 , 4 ] triazol - 3 - ylsu1 - . fanylmethy1 ] - benzoic acid methy1 etser ; 4 - [ 5 - ( 4 - Benzyloxy - benzylsulfanyl ) - 4 - ethyl - 4H - [ 1 , 2 , 4 ] triazol - 3 - yl ] - phenol ; N - { 4 - [ 4 - Ethyl - 5 - ( 4 - hydroxy - phenyl ) - 4H - [ 1 , 2 , 4 ] triazol - 3 - ylsulfanylmethy1 ] - phenyl } - acetamide ; . 4 - [ 4 - Ethyl - 5 - ( 4 - methoxy - benzylsu1fanyl ) - 4H - [ 1 , 2 , 4 ] triazol - . 3 - yl ] - phenol ; . 4 - [ 4 - Ethyl - 5 - ( 5 - methyl - 2 - nitro - benzylsulfanyl ) - 4H - [ 1 , 2 , 4 ] triazol - 3 - yl ] - phenol ; . 4 - [ 4 - Ethyl - 5 - ( 2 - nitro - benzy1sulfanyl ) - 4H - [ 1 , 2 , 4 ] triazo1 - 3 - yl ] - phenol ; . 4 - [ 5 - ( 2 , 4 - Dichloro - benzylsulfanyl ) - 4 - ethyl - 4H - [ 1 , 2 , 4 ] triazol - 3 - yl ] - phenol ; . 3 - Benzo [ 1 , 3 ] dioxol - 5 - yl - 5 - ( 2 - chloro - benzylsulfanyl ) - 4 - ethy1 - 4H - [ 1 , 2 , 4 ] t1iazole ; . 4 - ( 5 - Benzo [ 1 , 3 ] dioxol - 5 - yl - 4 - ethyl - 4H - [ 1 , 2 , 4 ] triazol - 3 - ylsulfanylmethyl ) - benzonitrile ; . 3 - Benzo [ 1 , 3 ] dioxol - 5 - yl - 5 - ( 6 - chloro - benzo [ 1 , 3 ] dioxol - 5 - ylmethylsulfanyl ) - 4 - ethyl - 4H - [ 1 , 2 , 4 ] triazole ; . 3 - Benzo [ 1 , 3 ] dioxol - 5 - y1 - 5 - ( 4 - bromo - benzylsu1fanyl ) - 4 - ethyl - 4H - [ 1 , 2 , 4 ] triazole ; . 4 - [ 4 - ( 5 - Benzo [ 1 , 3 ] dioxol - 5 - yl - 4 - ethyl - 4H - [ 1 , 2 , 4 ] triazol - 3 - ylsulfanylmethyl ) - phenyl ] - [ 1 , 2 , 3 ] thiadiazole ; . 3 - Benzo [ 1 , 3 ] dioxol - 5 - yl - 5 - cyclohexylmethylsulfanyl - 4 - ethyl - 4H - [ 1 , 2 , 4 ] triazole ; . 3 - Benzo [ 1 , 3 ] dioxol - 5 - yl - 4 - ethyl - 5 - ( 4 - triﬂuoromethoxybenzylsulfanyl ) - 4H - [ 1 , 2 , 4 ] triazole ; . 3 - Benzo [ 1 , 3 ] dioxol - 5 - yl - 5 - ( 3 , 5 - dimethoxy - benzylsulfanyl ) - 4 - ethyl - 4H - [ 1 , 2 , 4 ] triazole ; . 5. lO. 20. 25. 30. 35. 40. 45. 55. 65. 108 3 - Benzo [ 1 , 3 ] dioxol - 5 - yl - 4 - ethyl - 5 - ( 4 - methanesulfonylbenzylsulfanyl ) - 4H - [ 1 , 2 , 4 ] triazole ; 4 - ( 5 - Benzo [ 1 , 3 ] dioxol - 5 - yl - 4 - ethyl - 4H - [ 1 , 2 , 4 ] triazol - 3 - yl - su1fanylmethyl ) - benzoic acid methyl etser ; 3 - Benzo [ 1 , 3 ] dioxol - 5 - yl - 5 - ( 2 , 6 - dichloro - benzylsulfanyl ) - 4 - ethyl - 4H - [ 1 , 2 , 4 ] triazole ; 3 - Benzo [ 1 , 3 ] dioxol - 5 - yl - 5 - ( 4 - benzyloxy - benzylsulfanyl ) - 4 - ethyl - 4H - [ 1 , 2 , 4 ] triazole ; N - [ 4 - ( 5 - Benzo [ 1 , 3 ] dioxol - 5 - yl - 4 - ethyl - 4H - [ 1 , 2 , 4 ] triazol - 3 - ylsulfanylmethyl ) - phenyl ] - acetamide ; 3 - Benzo [ 1 , 3 ] dioxol - 5 - yl - 4 - ethyl - 5 - ( 4 - methoxy - benzylsulfanyl ) - 4H - [ 1 , 2 , 4 ] triazole ; 3 - Benzo [ 1 , 3 ] dioxol - 5 - yl - 4 - ethyl - 5 - ( 5 - methyl - 2 - nitro - benzylsulfanyl ) - 4H - [ 1 , 2 , 4 ] triazole ; 3 - Benzo [ 1 , 3 ] dioxol - 5 - yl - 4 - ethyl - 5 - ( 2 - nitro - benzylsulfanyl ) - 4H - [ 1 , 2 , 4 ] triazole ; 3 - Benzo [ 1 , 3 ] dioxol - 5 - yl - 5 - ( 2 , 4 - dichloro - benzylsulfanyl ) - 4 - ethyl - 4H - [ 1 , 2 , 4 ] triazole ; 4 - [ 4 - Ethyl - 5 - ( 2 - phenoxy - phenyl ) - 4H - [ 1 , 2 , 4 ] triazol - 3 - ylsulfanylmethyl ] - b enzonitrile ; 3 - ( 6 - Chloro - benzo [ 1 , 3 ] dioxol - 5 - ylmethylsulfanyl ) - 4 - ethyl - 5 - ( 2 - phenoxy - phenyl ) - 4H - [ 1 , 2 , 4 ] triazole ; 3 - ( 3 , 4 - Dichloro - benzy1sufanyl ) - 4 - ethyl - 5 - ( 2 - phenoxy - phenyl ) - 4H - [ 1 , 2 , 4 ] triazole ; 3 - ( 4 - Bromo - benzylsufanyl ) - 4 - ethyl - 5 - ( 2 - phenoxy - phenyl ) - 4H - [ 1 , 2 , 4 ] triazole ; 4 - { 4 - [ 4 - Ethyl - 5 - ( 2 - phenoxy - phenyl ) - 4H - [ 1 , 2 , 4 ] triazol - 3 - ylsulfanylmethyl ] - phenyl } - [ 1 , 2 , 3 ] thiadiazole ; 3 - ( 3 , 5 - Dimethoxy - benzylsulfany1 ) - 4 - ethyl - 5 - ( 2 - phenoxyphenyl ) - 4H - [ 1 , 2 , 4 ] triazole ; 4 - Ethyl - 3 - ( 2 - phenoxy - phenyl ) - 5 - ( 4 - triﬂuoromethy1 - benzy1 - su1fanyl ) - 4H - [ 1 , 2 , 4 ] triazo1e ; 4 - Ethyl - 3 - ( 4 - methanesulfonyl - benzylsulfanyl ) - 5 - ( 2 - phenoxy - pheny1 ) - 4H - [ 1 , 2 , 4 ] triazole ; 4 - [ 4 - Ethyl - 5 - ( 2 - phenoxy - phenyl ) - 4H - [ 1 , 2 , 4 ] triazol - 3 - ylsulfanylmethy1 ] - benzoic acid methy1 etser ; 3 - ( 2 , 6 - Dichloro - benzylsulfanyl ) - 4 - ethyl - 5 - ( 2 - phenoxy - phenyl ) - 4H - [ 1 , 2 , 4 ] triazole ; 3 - ( 4 - Benzyloxy - benzylsulfanyl ) - 4 - ethyl - 5 - ( 2 - phenoxy - phenyl ) - 4H - [ 1 , 2 , 4 ] triazole ; 4 - Ethyl - 3 - ( 4 - methyl - benzylsulfanyl ) - 5 - ( 2 - phenoxy - phenyl ) - 4H - [ 1 , 2 , 4 ] triazole ; 4 - Ethyl - 3 - ( 2 - phenoxy - phenyl ) - 5 - ( 3 - triﬂuoromethoxy - benzylsulfanyl ) - 4H - [ 1 , 2 , 4 ] triazole ; 4 - Ethyl - 3 - ( 4 - methoxy - benzy1sulfanyl ) - 5 - ( 2 - phenoxy - phenyl ) - 4H - [ 1 , 2 , 4 ] triazole ; 4 - Ethyl - 3 - ( 2 - nitro - benzylsulfanyl ) - 5 - ( 2 - phenoxy - phenyl ) - 4H - [ 1 , 2 , 4 ] triazole ; 3 - ( 2 , 4 - Dichloro - benzylsulfanyl ) - 4 - ethyl - 5 - ( 2 - phenoxy - phenyl ) - 4H - [ 1 , 2 , 4 ] triazole ; 3 - cyclohexylmethylsulfanyl - 4 - ethyl - 5 - naphthalen - 1 - yl - 4H - [ 1 , 2 , 4 ] triazole ; 4 - Ethyl - 3 - naphthalen - 1 - yl - 5 - ( 4 - triﬁuoromethyl - benzylsulfanyl ) - 4H - [ 1 , 2 , 4 ] triazole ; 4 - Ethyl - 3 - ( 4 - methanesulfonyl - benzylsulfanyl ) - 5 - naphthalen - 1 - yl - 4H - [ 1 , 2 , 4 ] triazole ; 4 - Ethyl - 3 - naphthalen - 1 - yl - 5 - ( 3 - nitro - benzylsulfanyl ) - 4H - [ 1 , 2 , 4 ] triazole ; 4 - ( 4 - Ethyl - 5 - naphthalen - 1 - yl - 4H - [ 1 , 2 , 4 ] triazol - 3 - ylsulfanylmethyl ) - benzoic acid methyl etser ; 4 - Ethyl - 3 - naphthalen - 1 - yl - 5 - ( 4 - nitro - benzylsulfanyl ) - 4H - [ 1 , 2 , 4 ] triazole ; 3 - ( 2 , 6 - Dichloro - benzylsulfanyl ) - 4 - ethyl - 5 - naphthalen - 1 - yl - 4H - [ 1 , 2 , 4 ] triazole ; 4 - Ethyl - 3 - ( 4 - methyl - benzylsulfanyl ) - 5 - naphthalen - 1 - yl - 4H - [ 1 , 2 , 4 ] triazole ; . US 7 , 50l , 405 B2. 109. 4 - Ethyl - 3 - ( 4 - methoxy - benzylsulfanyl ) - 5 - naphthalen - 1 - yl - 4H - [ 1 , 2 , 4 ] triazole ; . 4 - Ethyl - 3 - ( 5 - methyl - 2 - nitro - benzylsulfanyl ) - 5 - naphthalen - 1 - yl - 4H - [ 1 , 2 , 4 ] t1iazole ; . 3 - ( 2 , 4 - Dichloro - benzylsulfanyl ) - 4 - ethyl - 5 - naphthalen - 1 - yl - 4H - [ 1 , 2 , 4 ] triazole ; . [ 4 - ( 5 - cyclohexylmethylsulfanyl - 4 - ethyl - 4H - [ 1 , 2 , 4 ] triazol - 3 - yl ) - phenyl ] - dimethyl - amine. { 4 - [ 5 - ( 3 , 5 - Dimethoxy - benzylsulfanyl ) - 4 - ethyl - 4H - [ 1 , 2 , 4 ] triazol - 3 - yl ] - phenyl } - dimethyl - amine. { 4 - [ 4 - Ethyl - 5 - ( 4 - triﬁuoromethyl - benzyl sulfanyl ) - 4H - [ l , 2 , 4 ] triazol - 3 - yl ] - phenyl } - dimethyl - amine. 4 - [ 5 - ( 4 - Dimethylamino - phenyl ) - 4 - ethyl - 4H - [ 1 , 2 , 4 ] t1iazol - 3 - ylsulfanylmethyl ] - benzoic acid methyl etser ; . { 4 - [ 4 - Ethyl - 5 - ( 4 - nitro - benzylsulfanyl ) - 4H - [ 1 , 2 , 4 ] triazol - 3 - yl ] - phenyl } - dimethyl - amine ; . { 4 - [ 4 - Ethyl - 5 - ( 4 - methoxy - benzylsulfanyl ) - 4H - [ 1 , 2 , 4 ] triazol - 3 - yl ] - phenyl } - dimethyl - amine ; . { 4 - [ 4 - Ethyl - 5 - ( 5 - methyl - 2 - nitro - benzylsulfanyl ) - 4H - [ 1 , 2 , 4 ] triazol - 3 - yl ] - phenyl } - dimethyl - amine ; . { 4 - [ 5 - ( 2 , 4 - Dichloro - benzylsulfanyl ) - 4 - ethyl - 4H - [ 1 , 2 , 4 ] triazol - 3 - yl ] - phenyl } - dimethyl - amine ; . 4 - ( 4 - Ethyl - 5 - thiophen - 2 - yl - 4H - [ 1 , 2 , 4 ] triazol - 3 - ylsulfanylmethyl ) - benzonitrile ; . 3 - ( 6 - Chloro - benzo [ 1 , 3 ] dioxol - 5 - ylmethylsulfanyl ) - 4 - ethyl - 5 - thiophen - 2 - yl - 4H - [ 1 , 2 , 4 ] triazole ; . 3 - ( 3 , 4 - Dichloro - benzylsulfanyl ) - 4 - ethyl - 5 - thiophen - 2 - yl - 4H - [ 1 , 2 , 4 ] triazole ; . 3 - ( 4 - Bromo - benzylsulfanyl ) - 4 - ethy1 - 5 - thiophen - 2 - yl - 4H - [ 1 , 2 , 4 ] triazole ; . 4 - [ 4 - ( 4 - Ethyl - 5 - thiophen - 2 - yl - 4H - [ 1 , 2 , 4 ] triazo1 - 3 - ylsu1fanylmethyl ) - phenyl ] - [ 1 , 2 , 3 ] thiadiazole ; . 4 - Ethyl - 3 - thiophen - 2 - yl - 5 - ( 4 - triﬁuoromethoxy - benzylsulfanyl ) - 4H - [ 1 , 2 , 4 ] triazole ; . 3 - ( 3 , 5 - Dimethoxy - benzylsulfanyl ) - 4 - ethyl - 5 - thiophen - 2 - yl - 4H - [ 1 , 2 , 4 ] triazole ; . 4 - Ethyl - 3 - thiophen - 2 - yl - 5 - ( 4 - triﬁuoromethyl - benzylsulfanyl ) - 4H - [ 1 , 2 , 4 ] triazole ; . 3 - Benzylsulfanyl - 4 - ethyl - 5 - thiophen - 2 - yl - 4H - [ 1 , 2 , 4 ] triazole ; . 4 - Ethyl - 3 - ( 4 - methanesulfonyl - benzylsulfanyl ) - 5 - thiophen - 2 - yl - 4H - [ 1 , 2 , 4 ] t1iazole ; . 4 - ( 4 - Ethyl - 5 - thiophen - 2 - yl - 4H - [ 1 , 2 , 4 ] triazol - 3 - ylsulfanylmethyl ) - benzoic acid methyl etser ; . 4 - Ethy1 - 3 - ( 4 - nitro - benzylsu1fanyl ) - 5 - thiophen - 2 - y1 - 4H - [ 1 , 2 , 4 ] triazole ; . 3 - ( 2 , 6 - Dichloro - benzylsulfanyl ) - 4 - ethyl - 5 - thiophen - 2 - yl - 4H - [ 1 , 2 , 4 ] triazole ; . 4 - Ethyl - 3 - ( 4 - methyl - benzylsulfanyl ) - 5 - thiophen - 2 - yl - 4H - [ 1 , 2 , 4 ] triazole ; . 4 - Ethyl - 3 - ( 4 - methoxy - benzylsulfanyl ) - 5 - thiophen - 2 - yl - 4H - [ 1 , 2 , 4 ] triazole ; . 4 - Ethyl - 3 - ( 5 - methyl - 2 - nitro - benzylsulfanyl ) - 5 - thiophen - 2 - yl - 4H - [ 1 , 2 , 4 ] triazole ; . 3 - ( 2 - Chloro - benzylsulfanyl ) - 4 - ethyl - 5 - ( 2 - methoxy - phenyl ) - 4H - [ 1 , 2 , 4 ] triazole ; . 3 - ( 6 - Chloro - benzo [ 1 , 3 ] dioxol - 5 - ylmethylsulfanyl ) - 4 - ethyl - 5 - ( 2 - methoxy - phenyl ) - 4H - [ 1 , 2 , 4 ] triazole ; . 4 - Ethyl - 3 - ( 2 - methoxy - phenyl ) - 5 - ( 4 - triﬁuoromethoxy - benzylsulfanyl ) - 4H - [ 1 , 2 , 4 ] triazole ; . 3 - ( 3 , 5 - Dimethoxy - benzylsulfanyl ) - 4 - ethyl - 5 - ( 2 - methoxyphenyl ) - 4H - [ 1 , 2 , 4 ] triazole ; . 4 - Ethyl - 3 - ( 2 - methoxy - phenyl ) - 5 - ( 4 - triﬁuoromethyl - benzylsulfanyl ) - 4H - [ 1 , 2 , 4 ] triazole ; . 3 - Benzylsulfanyl - 4 - ethyl - 5 - ( 2 - methoxy - phenyl ) - 4H - [ 1 , 2 , 4 ] triazole ; . N. 5. lO. 20. 5. 30. 40. 45. 55. 65. 110 4 - Ethyl - 3 - ( 4 - methanesulfonyl - benzylsulfanyl ) - 5 - ( 2 - methoxy - phenyl ) - 4H - [ 1 , 2 , 4 ] triazole ; 4 - [ 4 - Ethyl - 5 - ( 2 - methoxy - phenyl ) - 4H - [ 1 , 2 , 4 ] triazol - 3 - ylsulfanylmethy1 ] - benzoic acid methy1 etser ; 4 - Ethyl - 3 - ( 2 - methoxy - phenyl ) - 5 - ( 4 - nitro - benzylsulfanyl ) - 4H - [ l , 2 , 4 ] triazole ; 3 - ( 2 , 6 - Dichloro - benzylsulfanyl ) - 4 - ethyl - 5 - ( 2 - methoxy - phenyl ) - 4H - [ 1 , 2 , 4 ] triazole ; 3 - ( 4 - Benzyloxy - benzylsulfanyl ) - 4 - ethyl - 5 - ( 2 - methoxy - phenyl ) - 4H - [ 1 , 2 , 4 ] triazole ; 4 - Ethyl - 3 - ( 2 - methoxy - phenyl ) - 5 - ( 4 - methyl - benzylsulfanyl ) - 4H - [ 1 , 2 , 4 ] triazole ; 4 - Ethyl - 3 - ( 2 - methoxy - phenyl ) - 5 - ( 3 - triﬂuoromethoxy - benzylsulfanyl ) - 4H - [ 1 , 2 , 4 ] triazole ; 4 - Ethyl - 3 - ( 2 - methoxy - phenyl ) - 5 - ( 5 - methyl - 2 - nitro - benzylsulfanyl ) - 4H - [ 1 , 2 , 4 ] triazole ; 4 - Ethyl - 3 - ( 2 - methoxy - phenyl ) - 5 - ( 2 - nitro - benzylsulfanyl ) - 4H - [ 1 , 2 , 4 ] triazole ; 3 - ( 2 - Chioro - benzylsulfanyl ) - 4 - ethyl - 5 - ( 4 - methoxy - phenyl ) - 4H - [ 1 , 2 , 4 ] triazole ; 4 - [ 4 - Ethyl - 5 - ( 4 - methoxy - phenyl ) - 4H - [ 1 , 2 , 4 ] triazol - 3 - ylsulfanylmethyl ] - b enzonitrile ; 3 - ( 6 - Chloro - benzo [ 1 , 3 ] dioxol - 5 - ylmethylsulfany1 ) - 4 - ethyl - 5 - ( 4 - methoxy - phenyl ) - 4H - [ 1 , 2 , 4 ] triazole ; 3 - ( 3 , 4 - Dichloro - benzylsulfanyl ) - 4 - ethyl - 5 - ( 4 - methoxy - phenyl ) - 4H - [ 1 , 2 , 4 ] triazole ; 3 - ( 4 - Bromo - benzylsulfanyl ) - 4 - ethyl - 5 - ( 4 - methoxy - phenyl ) - 4H - [ 1 , 2 , 4 ] triazole ; 4 - { 4 - [ 4 - Ethyl - 5 - ( 4 - methoxy - pheny1 ) - 4H - [ 1 , 2 , 4 ] triazol - 3 - ylsulfanylmethyl ] - phenyl } - [ 1 , 2 , 3 ] thiadiazole ; 3 - cyclohexylmethylsu1fanyl - 4 - ethyl - 5 - ( 4 - methoxy - phenyl ) - 4H - [ 1 , 2 , 4 ] triazole ; 4 - Ethyl - 3 - ( 4 - methoxy - phenyl ) - 5 - ( 4 - triﬂuoromethyl - benzyl - su1fanyl ) - 4H - [ 1 , 2 , 4 ] triazo1e ; 4 - Ethyl - 3 - ( 4 - methanesulfonyl - benzylsulfanyl ) - 5 - ( 4 - methoxy - phenyl ) - 4H - [ 1 , 2 , 4 ] triazole ; 4 - [ 4 - Ethyl - 5 - ( 4 - methoxy - phenyl ) - 4H - [ 1 , 2 , 4 ] triazol - 3 - ylsulfanylmethyl ] - benzoic acid methyl etser ; 3 - ( 2 , 6 - Dichloro - benzylsulfanyl ) - 4 - ethyl - 5 - ( 4 - methoxy - phenyl ) - 4H - [ 1 , 2 , 4 ] triazole ; 3 - ( 4 - Benzyloxy - benzylsulfanyl ) - 4 - ethyl - 5 - ( 4 - methoxy - phenyl ) - 4H - [ 1 , 2 , 4 ] triazole ; 4 - Ethyl - 3 - ( 4 - methoxy - pheny1 ) - 5 - ( 3 - triﬂuoromethoxy - benzylsulfanyl ) - 4H - [ 1 , 2 , 4 ] triazole ; N - { 4 - [ 4 - Ethyl - 5 - ( 4 - methoxy - pheny1 ) - 4H - [ 1 , 2 , 4 ] triazol - 3 - ylsulfanylmethyl ] - phenyl } - acetamide ; 4 - Ethyl - 3 - ( 4 - methoxy - benzylsulfanyl ) - 5 - ( 4 - methoxy - phenyl ) - 4H - [ 1 , 2 , 4 ] triazole ; 4 - Ethyl - 3 - ( 4 - methoxy - phenyl ) - 5 - ( 2 - nitro - benzylsulfanyl ) - 4H - [ 1 , 2 , 4 ] triazole ; 4 - ( 4 - Ethyl - 5 - pyridin - 4 - yl - 4H - [ 1 , 2 , 4 ] triazol - 3 - ylsulfanylmethyl ) - benzonitrile ; 4 - [ 5 - ( 4 - Bromo - benzylsulfanyl ) - 4 - ethyl - 4H - [ 1 , 2 , 4 ] triazol - 3 - yl ] - pyridine ; 4 - [ 5 - ( 3 , 5 - Dimethoxy - benzylsulfanyl ) - 4 - ethyl - 4H - [ 1 , 2 , 4 ] triazol - 3 - yl ] - pyridine ; 4 - [ 4 - Ethyl - 5 - ( 4 - methanesulfonyl - benzylsulfanyl ) - 4H - [ 1 , 2 , 4 ] triazol - 3 - yl ] - pyridine ; 4 - ( 4 - Ethyl - 5 - pyridin - 4 - yl - 4H - [ 1 , 2 , 4 ] triazol - 3 - ylsulfanylmethyl ) - benzoic acid methyl etser ; 4 - [ 4 - Ethyl - 5 - ( 4 - methyl - benzylsulfanyl ) - 4H - [ 1 , 2 , 4 ] triazol - 3 - yl ] - pyridine ; 4 - [ 4 - Ethyl - 5 - ( 3 - triﬁuoromethoxy - benzyl sulfanyl ) - 4H - [ 1 , 2 , 4 ] triazol - 3 - yl ] - pyridine ; 4 - [ 5 - ( 2 , 4 - Dichloro - benzylsulanyl ) - 4 - ethyl - 4H - [ 1 , 2 , 4 ] triazol - 3 - yl ] - pyridine ; . US 7 , 50l , 405 B2. 1 1 1. 3 - [ 5 - ( 2 - Chloro - benzylsulfanyl ) - 4 - ethyl - 4H - [ l , 2 , 4 ] triazol - 3 - yl ] - pyridine ; . 4 - ( 4 - Ethyl - 5 - pyridin - 3 - yl - 4H - [ 1 , 2 , 4 ] triazol - 3 - ylsulfanylmethy1 ) - benzonitri1e ; . 3 - [ 5 - ( 6 - Chloro - benzo [ 1 , 3 ] dioxol - 5 - ylmethylsulfanyl ) - 4 - ethyl - 4H - [ l , 2 , 4 ] triazol - 3 - yl ] - pyridine ; . 3 - [ 5 - ( 3 , 4 - Dichloro - benzylsulfanyl ) - 4 - ethyl - 4H - [ 1 , 2 , 4 ] triazol - 3 - yl ] - pyridine ; . 3 - [ 5 - ( 4 - Bromo - benzylsulfanyl ) - 4 - ethyl - 4H - [ 1 , 2 , 4 ] triazol - 3 - yl ] - pyridine ; . 3 - [ 4 - Ethyl - 5 - ( 4 - [ 1 , 2 , 3 ] thiadiazol - 4 - yl - benzylsulfanyl ) - 4H - [ 1 , 2 , 4 ] triazol - 3 - yl ] - pyridine ; . 3 - [ 4 - Ethyl - 5 - ( 4 - triﬁuoromethoxy - benzylsulfanyl ) - 4H - [ 1 , 2 , 4 ] triazol - 3 - yl ] - pyridine ; . 3 - [ 5 - ( 3 , 5 - Dimethoxy - benzylsulfanyl ) - 4 - ethyl - 4H - [ 1 , 2 , 4 ] triazol - 3 - yl ] - pyridine ; . 3 - [ 4 - Ethyl - 5 - ( 4 - triﬁuoromethyl - benzylsulfanyl ) - 4H - [ 1 , 2 , 4 ] triazol - 3 - yl ] - py1idine ; . 3 - ( 5 - Benzylsulfanyl - 4 - ethyl - 4H - [ 1 , 2 , 4 ] triazol - 3 - yl ) - pyridine ; . 3 - [ 4 - Ethyl - 5 - ( 4 - methanesulfonyl - benzylsulfanyl ) - 4H - [ 1 , 2 , 4 ] triazol - 3 - yl ] - pyridine ; . 3 - [ 4 - Ethyl - 5 - ( 3 - nitro - benzy1sulfanyl ) - 4H - [ 1 , 2 , 4 ] triazo1 - 3 - yl ] - pyridine ; . 4 - ( 4 - Ethyl - 5 - pyridin - 3 - yl - 4H - [ 1 , 2 , 4 ] triazol - 3 - ylsulfanylmethyl ) - benzoic acid methyl etser ; . 3 - [ 5 - ( 2 , 6 - Dichioro - benzylsulfanyl ) - 4 - ethyl - 4H - [ 1 , 2 , 4 ] triazol - 3 - yl ] - pyridine ; . 3 - [ 5 - ( 4 - Benzy1oxy - benzylsulfanyl ) - 4 - ethyl - 4H - [ 1 , 2 , 4 ] triazol - 3 - yl ] - pyridine ; . 3 - [ 4 - Ethyl - 5 - ( 4 - methy1 - benzylsulfany1 ) - 4H - [ 1 , 2 , 4 ] triazo1 - 3 - yl ] - pyridine ; . 3 - [ 4 - Ethyl - 5 - ( 3 - triﬁuoromethoxy - benzylsulfanyl ) - 4H - [ 1 , 2 , 4 ] triazol - 3 - yl ] - pyridine ; . N - [ 4 - ( 4 - Ethyl - 5 - pyridin - 3 - yl - 4H - [ 1 , 2 , 4 ] triazol - 3 - ylsulfanylmethyl ) - phenyl ] - acetamide ; . 3 - [ 4 - Ethyl - 5 - ( 4 - methoxy - benzylsulfanyl ) - 4H - [ 1 , 2 , 4 ] triazol - 3 - yl ] - pyridine ; . 3 - [ 4 - Ethyl - 5 - ( 5 - methyl - 2 - nitro - benzylsulfanyl ) - 4H - [ 1 , 2 , 4 ] triazol - 3 - yl ] - pyridine ; . 3 - [ 4 - Ethyl - 5 - ( 2 - nitro - benzylsulfanyl ) - 4H - [ 1 , 2 , 4 ] triazol - 3 - yl ] - pyridine ; . 3 - [ 5 - ( 2 , 4 - Dichioro - benzy1su1fanyl ) - 4 - ethyl - 4H - [ 1 , 2 , 4 ] triazol - 3 - yl ] - pyridine ; . 3 - ( 2 - Chloro - benzylsulfanyl ) - 5 - ( 4 - chloro - pheny1 ) - 4 - ethy1 - 4H - [ 1 , 2 , 4 ] triazole ; . 4 - [ 5 - ( 4 - Chloro - phenyl ) - 4 - ethyl - 4H - [ 1 , 2 , 4 ] triazol - 3 - ylsulfanylmethyl ] - benzonitrile ; . 3 - ( 4 - Chloro - phenyl ) - 5 - ( 3 , 4 - dichloro - benzylsulfanyl ) - 4 - ethy1 - 4H - [ 1 , 2 , 4 ] t1iazole ; . 4 - { 4 - [ 5 - ( 4 - Chloro - phenyl ) - 4 - ethyl - 4H - [ 1 , 2 , 4 ] triazol - 3 - ylsulfanylmethyl ] - phenyl } - [ 1 , 2 , 3 ] thiadiazole ; . 3 - ( 4 - Chloro - phenyl ) - 4 - ethyl - 5 - ( 4 - methanesulfonyl - benzylsulfanyl ) - 4H - [ 1 , 2 , 4 ] triazole ; . 3 - ( 4 - Chloro - phenyl ) - 4 - ethyl - 5 - ( 3 - nitro - benzylsulfanyl ) - 4H - [ 1 , 2 , 4 ] triazole ; . 4 - [ 5 - ( 4 - Chloro - phenyl ) - 4 - ethyl - 4H - [ 1 , 2 , 4 ] triazol - 3 - ylsulfanylmethyl ] - benzoic acid methyl etser ; . 3 - ( 4 - Chloro - phenyl ) - 5 - ( 2 , 6 - dichloro - benzylsulfanyl ) - 4 - ethyl - 4H - [ 1 , 2 , 4 ] triazole ; . 3 - ( 4 - Benzyloxy - benzylsulfanyl ) - 5 - ( 4 - chloro - phenyl ) - 4 - ethyl - 4H - [ 1 , 2 , 4 ] triazole ; . 3 - ( 4 - Chloro - phenyl ) - 4 - ethyl - 5 - ( 4 - methyl - benzylsulfanyl ) - 4H - [ 1 , 2 , 4 ] triazole ; . 3 - ( 4 - Chloro - phenyl ) - 4 - ethyl - 5 - ( 3 - triﬁuoromethoxy - benzylsulfanyl ) - 4H - [ 1 , 2 , 4 ] triazole ; . 112 N - { 4 - [ 5 - ( 4 - Chloro - phenyl ) - 4 - ethyl - 4H - [ l , 2 , 4 ] triazol - 3 - ylsulfanylmethyl ] - phenyl } - acetamide ; 3 - ( 4 - Chloro - phenyl ) - 4 - ethyl - 5 - ( 5 - methyl - 2 - nitro - benzylsulfanyl ) - 4H - [ 1 , 2 , 4 ] triazole ; 5 3 - ( 4 - Chioro - phenyl ) - 5 - ( 2 , 4 - dichloro - benzylsulfanyl ) - 4 - ethyl - 4H - [ 1 , 2 , 4 ] triazole ; 5 - [ 5 - ( 2 - Chloro - benzylsulfanyl ) - 4 - ethyl - 4H - [ 1 , 2 , 4 ] triazol - 3 - yl ] - 4 - phenyl - [ 1 , 2 , 3 ] thiadiazole ; 4 - [ 4 - Ethyl - 5 - ( 4 - phenyl - [ 1 , 2 , 3 ] thiadiazol - 5 - yl ) - 4H - [ 1 , 2 , 4 ] triazol - 3 - yl sulfanylmethyl ] - benzonitrile ; . 5 - [ 5 - ( 3 , 4 - Dichloro - benzylsulfanyl ) - 4 - ethyl - 4H - [ 1 , 2 , 4 ] tria - . zol - 3 - yl ] - 4 - phenyl - [ 1 , 2 , 3 ] thiadiazole ; . 5 - [ 4 - Ethyl - 5 - ( 4 - triﬁuoromethoxy - benzyl sulfanyl ) - 4H - [ 1 , 2 , . 4 ] triazol - 3 - yl ] - 4 - phenyl - [ 1 , 2 , 3 ] thiadiazole ; . 15 5 - [ 5 - ( 3 , 5 - Dimethoxy - benzylsulfanyl ) - 4 - ethyl - 4H - [ 1 , 2 , 4 ] . triazol - 3 - yl ] - 4 - phenyl - [ 1 , 2 , 3 ] thiadiazole ; . 5 - [ 4 - Ethyl - 5 - ( 4 - triﬁuoromethyl - benzylsulfanyl ) - 4H - [ 1 , 2 , 4 ] . triazol - 3 - yl ] - 4 - phenyl - [ 1 , 2 , 3 ] thiadiazole ; 5 - ( 5 - Benzylsulfanyl - 4 - ethyl - 4H - [ 1 , 2 , 4 ] triazol - 3 - yl ) - 4 - phenyl - [ 1 , 2 , 3 ] thiadiazole ; . 5 - [ 4 - Ethyl - 5 - ( 4 - methanesulfonyl - benzylsulfanyl ) - 4H - [ 1 , 2 , . 4 ] riazol - 3 - yl ] - 4 - phenyl - [ 1 , 2 , 3 ] thiadiazole ; . 5 - [ 4 - Ethyl - 5 - ( 4 - nitro - benzylsulfany1 ) - 4H - [ 1 , 2 , 4 ] triazol - 3 - . yl ] - 4 - phenyl - [ 1 , 2 , 3 ] thiadiazole ; . 25 5 - [ 5 - ( 2 , 6 - Dichloro - benzylsulfanyl ) - 4 - ethyl - 4H - [ 1 , 2 , 4 ] tria - . zol - 3 - yl ] - 4 - pheny1 - [ 1 , 2 , 3 ] thiadiazo1e ; . 5 - [ 4 - Ethyl - 5 - ( 3 - triﬁuoromethoxy - benzyl sulfanyl ) - 4H - [ 1 , 2 , . 4 ] triazol - 3 - y1 ] - 4 - phenyl - [ 1 , 2 , 3 ] thiadiazole ; . 5 - [ 4 - Ethyl - 5 - ( 4 - methoxy - benzylsulfanyl ) - 4H - [ 1 , 2 , 4 ] triazol - . 3 - yl ] - 4 - phenyl - [ 1 , 2 , 3 ] thiadiazole ; . 5 - [ 4 - Ethyl - 5 - ( 2 - nitro - benzylsulfanyl ) - 4H - [ 1 , 2 , 4 ] triazol - 3 - . yl ] - 4 - phenyl - [ 1 , 2 , 3 ] thiadiazole ; . 4 - { 5 - [ 4 - ( 2 , 5 - Dimethyl - pyrrol - 1 - yl ) - phenyl ] - 4 - ethyl - 4H - [ 1 , . 2 , 4 ] triazol - 3 - ylsulfanylmethyl } > - benzonitrile ; . 35 3 - ( 6 - Chloro - benzo [ 1 , 3 ] dioxol - 5 - ylmethylsulfany1 ) - 5 - [ 4 - ( 2 , 5 - dimethyl - pyrrol - 1 - yl ) - phenyl ] - 4 - ethyl - 4H - [ 1 , 2 , 4 ] triazole ; . 3 - ( 3 , 4 - Dichloro - benzy1sulfanyl ) - 5 - [ 4 - ( 2 , 5 - dimethyl - pyrrol - 1 - yl ) - phenyl ] - 4 - ethyl - 4H - [ 1 , 2 , 4 ] triazole ; 40 3 - [ 4 - ( 2 , 5 - Dimethy1 - pyrrol - 1 - y1 ) - phenyl ] - 4 - ethyl - 5 - ( 4 - trifluoromethoxy - benzylsulfanyl ) - 4H - [ 1 , 2 , 4 ] triazole ; 3 - ( 3 , 5 - Dimethoxy - benzylsulfany1 ) - 5 - [ 4 - ( 2 , 5 - dimethyl - pyrrol - 1 - y1 ) - phenyl ] - 4 - ethyl - 4H - [ 1 , 2 , 4 ] triazo1e ; 3 - [ 4 - ( 2 , 5 - Dimethyl - pyrrol - 1 - yl ) - phenyl ] - 4 - ethyl - 5 - ( 4 - trifluoromethyl - benzy1su1fanyl ) - 4H - [ 1 , 2 , 4 ] triazo1e ; . 3 - Benzylsulfanyl - 5 - [ 4 - ( 2 , 5 - dimethyl - pyrrol - 1 - yl ) - phenyl ] - . 4 - ethyl - 4H - [ 1 , 2 , 4 ] triazole ; . 3 - [ 4 - ( 2 , 5 - Dimethyl - pyrrol - 1 - yl ) - phenyl ] - 4 - ethyl - 5 - ( 4 - meth - . anesulfonyl - benzylsulfanyl ) - 4H - [ 1 , 2 , 4 ] triazole ; 3 - [ 4 - ( 2 , 5 - Dimethyl - pyrrol - 1 - yl ) - phenyl ] - 4 - ethyl - 5 - ( 3 - nitrobenzylsulfanyl ) - 4H - [ 1 , 2 , 4 ] triazole ; . 4 - { 5 - [ 4 - ( 2 , 5 - Dimethyl - pyrrol - 1 - yl ) - phenyl ] - 4 - ethyl - 4H - [ 1 , . 2 , 4 ] triazol - 3 - ylsulfanylmethyl } - benzoic acid methyl etser ; 3 - [ 4 - ( 2 , 5 - Dimethyl - pyrrol - 1 - yl ) - phenyl ] - 4 - ethyl - 5 - ( 4 - nitrobenzylsulfanyl ) - 4H - [ 1 , 2 , 4 ] triazole ; 3 - ( 4 - Benzyloxy - benzylsulfanyl ) - 5 - [ 4 - ( 2 , 5 - dimethyl - pyrrol - l - yl ) - phenyl ] - 4 - ethyl - 4H - [ l , 2 , 4 ] triazole ; 60 N - ( 4 - { 5 - [ 4 - ( 2 , 5 - Dimethyl - pyrrol - 1 - yl ) - phenyl ] - 4 - ethyl - 4H - [ 1 , 2 , 4 ] triazol - 3 - ylsulfanylmethyl } - phenyl ) - acetamide ; 3 - [ 4 - ( 2 , 5 - Dimethyl - pyrrol - 1 - yl ) - phenyl ] - 4 - ethyl - 5 - ( 4 - methoxy - benzylsulfanyl ) - 4H - [ 1 , 2 , 4 ] triazole ; 3 - [ 4 - ( 2 , 5 - Dimethyl - pyrrol - 1 - yl ) - phenyl ] - 4 - ethyl - 5 - ( 5 - methyl - 2 - nitro - benzylsulfanyl ) - 4H - [ 1 , 2 , 4 ] triazole ; . 3 - [ 4 - ( 2 , 5 - Dimethyl - pyrrol - 1 - yl ) - phenyl ] - 4 - ethyl - 5 - ( 2 - nitro - . benzylsulfanyl ) - 4H - [ 1 , 2 , 4 ] triazole ; . lO. 20. 30. 55. 65. US 7 , 50l , 405 B2. 1 13. 3 - ( 2 , 4 - Dichloro - benzylsulfanyl ) - 5 - [ 4 - ( 2 , 5 - dimethyl - pyrrol - 1 - yl ) - phenyl ] - 4 - ethyl - 4H - [ 1 , 2 , 4 ] triazole ; . 3 - Benzo [ b ] thiophen - 2 - yl - 5 - ( 2 - chloro - benzylsulfanyl ) - 4 - ethy1 - 4H - [ 1 , 2 , 4 ] t1iazole ; . 4 - ( 5 - Benzo [ b ] thiophen - 2 - yl - 4 - ethyl - 4H - [ 1 , 2 , 4 ] triazol - 3 - ylsulfanylmethyl ) - benzonitrile ; . 3 - Benzo [ b ] thiophen - 2 - yl - 5 - ( 6 - chloro - benzo [ 1 , 3 ] dioxol - 5 - ylmethylsulfanyl ) - 4 - ethyl - 4H - [ 1 , 2 , 4 ] triazole ; . 3 - Benzo [ b ] thiophen - 2 - yl - 5 - ( 4 - bromo - benzylsulfanyl ) - 4 - ethyl - 4H - [ 1 , 2 , 4 ] triazole ; . 4 - [ 4 - ( 5 - Benzo [ b ] thiophen - 2 - yl - 4 - ethyl - 4H - [ l , 2 , 4 ] triazol - 3 - ylsulfanylmethyl ) - phenyl ] - [ 1 , 2 , 3 ] thiadiazole ; . 3 - Benzo [ b ] thiophen - 2 - yl - 4 - ethyl - 5 - ( 3 - nitro - benzylsulfanyl ) - 4H - [ 1 , 2 , 4 ] triazole ; . 4 - ( 5 - Benzo [ b ] thiophen - 2 - yl - 4 - ethyl - 4H - [ 1 , 2 , 4 ] triazol - 3 - ylsufanylmethyl ) - benzoic acid methyl etser ; . 3 - Benzo [ b ] thiophen - 2 - yl - 4 - ethyl - 5 - ( 4 - nitro - benzylsufanyl ) - 4H - [ 1 , 2 , 4 ] triazole ; . 3 - Benzo [ b ] thiophen - 2 - yl - 5 - ( 4 - benzyloxy - benzylsulfanyl ) - 4 - ethyl - 4H - [ 1 , 2 , 4 ] triazole ; . 3 - Benzo [ b ] thiophen - 2 - yl - 4 - ethyl - 5 - ( 3 - triﬁuoromethoxybenzylsulfanyl ) - 4H - [ 1 , 2 , 4 ] triazole ; . N - [ 4 - ( 5 - Benzo [ b ] thiophen - 2 - yl - 4 - ethyl - 4H - [ 1 , 2 , 4 ] triazol - 3 - ylsulfanylmethyl ) - phenyl ] - acetamide ; . 3 - Bezo [ b ] thiophen - 2 - yl - 4 - ethyl - 5 - ( 4 - methoxy - benzylsulfanyl ) - 4H - [ 1 , 2 , 4 ] triazole ; . 3 - Benzo [ b ] thiophen - 2 - y1 - 4 - ethyl - 5 - ( 2 - nitro - benzylsulfanyl ) - 4H - [ 1 , 2 , 4 ] triazole ; . 3 - ( 2 - Chloro - benzylsulany1 ) - 4 - ethy1 - 5 - ( 1 - phenyl - 5 - triﬂuoromethyl - 1 H - pyrazol - 4 - yl ) - 4H - [ 1 , 2 , 4 ] triazole ; . 3 - ( 6 - Chloro - benzo [ 1 , 3 ] dioxol - 5 - ylmethylsulfanyl ) - 4 - ethyl - 5 - ( 1 - phenyl - 5 - triﬂuoromethyl - 1H - pyrazol - 4 - yl ) - 4H - [ 1 , 2 , 4 ] triazole ; . 4 - { 4 - [ 4 - Ethyl - 5 - ( 1 - pheny1 - 5 - triﬂuoromethyl - 1H - pyrazol - 4 - yl ) - 4H - [ 1 , 2 , 4 ] triazol - 3 - ylsu1fanylmethyl ] - phenyl } - [ 1 , 2 , 3 ] thiadiazole ; . 4 - Ethy1 - 3 - ( 1 - phenyl - 5 - triﬂuoromethyl - 1H - pyrazol - 4 - yl ) - 5 - ( 4 - triﬂuoromethoxy - benzy1sulfanyl ) - 4H - [ 1 , 2 , 4 ] triazole ; . 3 - ( 3 , 5 - Dimethoxy - benzylsulfany1 ) - 4 - ethyl - 5 - ( 1 - pheny1 - 5 - triﬂuoromethy1 - 1H - pyrazol - 4 - yl ) - 4H - [ 1 , 2 , 4 ] triazole ; . 3 - Benzylsulfanyl - 4 - ethyl - 5 - ( 1 - phenyl - 5 - triﬁuoromethyl - 1H - pyrazol - 4 - yl ) - 4H - [ 1 , 2 , 4 ] triazole ; . 4 - Ethyl - 3 - ( 4 - methanesulfonyl - benzylsulfanyl ) - 5 - ( 1 - phenyl - 5 - triﬂuoromethyl - 1H - pyrazol - 4 - yl ) - 4H - [ 1 , 2 , 4 ] triazole ; . 4 - Ethyl - 3 - ( 3 - nitro - benzylsulfanyl ) - 5 - ( 1 - phenyl - 5 - triﬂuoromethyl - 1H - pyrazol4 - yl ) - 4H - [ 1 , 2 , 4 ] triazole ; . 4 - [ 4 - Ethyl - 5 - ( 1 - phenyl - 5 - triﬁuoromethyl - 1H - pyrazol4 - yl ) - 4H - [ 1 , 2 , 4 ] triazol - 3 - ylsulfanylmethyl ] - benzoic methyl etser ; . 3 - ( 2 , 6 - Dichloro - benzylsulfanyl ) - 4 - ethyl - 5 - ( 1 - phenyl - 5 - trifluoromethyl - 1H - pyrazol4 - yl ) - 4H - [ 1 , 2 , 4 ] triazole ; . 3 - ( 4 - Benzyloxy - benzylsulfanyl ) - 4 - ethyl - 5 - ( 1 - phenyl - 5 - trifluoromethyl - 1H - pyrazol4 - yl ) - 4H - [ 1 , 2 , 4 ] triazole ; . 4 - Ethyl - 3 - ( 4 - methyl - benzylsulfanyl ) - 5 - ( 1 - phenyl - 5 - triﬂuoromethyl - 1H - pyrazol - 4 - yl ) - 4H - [ 1 , 2 , 4 ] triazole ; . N - { 4 - [ 4 - Ethyl - 5 - ( 1 - phenyl - 5 - triﬂuoromethyl - 1H - pyrazol4 - yl ) - 4H - [ 1 , 2 , 4 ] triazol - 3 - ylsulfanylmethyl ] - phenyl } - acetamide ; . 4 - Ethyl - 3 - ( 5 - methyl - 2 - nitro - benzylsulfanyl ) - 5 - ( 1 - phenyl - 5 - triﬂuoromethyl - 1H - pyrazol - 4 - yl ) - 4H - [ 1 , 2 , 4 ] triazole ; . 4 - Ethyl - 3 - ( 2 - nitro - benzylsulfanyl ) - 5 - ( 1 - phenyl - 5 - triﬁuoromethyl - 1H - pyrazol - 4 - yl ) - 4H - [ 1 , 2 , 4 ] triazole ; . 3 - ( 2 , 4 - Dichloro - benzylsulfanyl ) - 4 - ethyl - 5 - ( 1 - phenyl - 5 - trifluoromethyl - 1H - pyrazol4 - yl ) - 4H - [ 1 , 2 , 4 ] triazole ; . 3 - ( 2 - Chloro - benzylsulfanyl ) - 5 - ( 3 - chloro - 4 - methylthiophen - 2 - yl ) - 4 - ethyl - 4H - [ 1 , 2 , 4 ] triazole ; . acid. 114 4 - [ 5 - ( 3 - Chloro - 4 - methyl - thiophen - 2 - yl ) - 4 - ethyl - 4H - [ 1 , 2 , 4 ] triazol - 3 - yl sulfanylmethyl ] - benzonitrile ; 3 - ( 3 - Chloro - 4 - methyl - thiophen - 2 - yl ) - 5 - ( 3 , 4 - dichloro - benzylsulfanyl ) - 4 - ethyl - 4H - [ 1 , 2 , 4 ] triazo1e ; . 5 4 - { 4 - [ 5 - ( 3 - Chloro - 4 - methyl - thiophen - 2 - yl ) - 4 - ethyl - 4H - [ 1 , 2 , 4 ] triazol - 3 - ylsulfanylmethyl ] - phenyl } > - [ 1 , 2 , 3 ] thiadiazole ; . 3 - ( 3 - Chloro - 4 - methyl - thiophen - 2 - yl ) - 5 - cyclohexylmethylsulfanyl - 4 - ethyl - 4H - [ 1 , 2 , 4 ] triazole ; . 10 3 - ( 3 - Chioro - 4 - methyl - thiophen - 2 - yl ) - 4 - ethyl - 5 - ( 4 - triﬂuoromethoxy - benzylsulfanyl ) - 4H - [ l , 2 , 4 ] triazole ; . 3 - ( 3 - Chloro - 4 - methyl - thiophen - 2 - yl ) - 4 - ethyl - 5 - ( 4 - triﬁuoromethyl - benzylsufanyl ) - 4H - [ 1 , 2 , 4 ] triazole ; 3 - ( 3 - Chioro - 4 - methyl - thiophen - 2 - yl ) - 4 - ethyl - 5 - ( 3 - nitro - . 15 benzylsulfanyl ) - 4H - [ 1 , 2 , 4 ] triazole ; . 4 - [ 5 - ( 3 - Chloro - 4 - methyl - thiophen - 2 - yl ) - 4 - ethyl - 4H - [ 1 , 2 , 4 ] . triazol - 3 - ylsulfanylmethyl ] - benzoic acid methyl etser ; 3 - ( 3 - Chloro - 4 - methyl - thiophen - 2 - yl ) - 5 - ( 2 , 6 - dichloro - benzylsulfanyl ) - 4 - ethyl - 4H - [ 1 , 2 , 4 ] triazole ; 3 - ( 3 - Chioro - 4 - methyl - thiophen - 2 - yl ) - 4 - ethyl - 5 - ( 4 - methylbenzylsulfanyl ) - 4H - [ 1 , 2 , 4 ] triazole ; 3 - ( 3 - Chloro - 4 - methyl - thiophen - 2 - yl ) - 4 - ethyl - 5 - ( 3 - triﬁuoromethoxy - benzy1su1fanyl ) - 4H - [ 1 , 2 , 4 ] triazo1e ; 3 - ( 3 - Chioro - 4 - methyl - thiophen - 2 - yl ) - 4 - ethyl - 5 - ( 5 - methyl - . 5 2 - nitro - benzylsulfanyl ) - 4H - [ 1 , 2 , 4 ] triazole ; . 3 - ( 3 - Chloro - 4 - methyl - thiophen - 2 - yl ) - 4 - ethyl - 5 - ( 2 - nitro - . benzylsulfanyl ) - 4H - [ 1 , 2 , 4 ] triazole ; . 4 - ( 4 - Ethyl - 5 - pyridin - 2 - yl - 4H - [ 1 , 2 , 4 ] triazol - 3 - ylsulfany1m - . ethyl ) - benzonitri1e ; 2 - [ 5 - ( 6 - Chloro - benzo [ 1 , 3 ] dioxol - 5 - ylmethylsulfanyl ) - 4 - ethyl - 4H - [ 1 , 2 , 4 ] triazol - 3 - yl ] - pyridine. 2 - [ 5 - ( 3 , 4 - Dichloro - benzylsulfanyl ) - 4 - ethyl - 4H - [ 1 , 2 , 4 ] tria - . zol - 3 - yl ] - pyridine ; 2 - [ 5 - ( 4 - Bromo - benzy1sulfanyl ) - 4 - ethy1 - 4H - [ 1 , 2 , 4 ] triazol - 3 - . 5 yl ] - pyridine ; . 2 - [ 4 - Ethyl - 5 - ( 4 - [ 1 , 2 , 3 ] thiadiazol - 4 - yl - benzylsulfanyl ) - 4H - [ 1 , 2 , 4 ] triazol - 3 - yl ] - pyridine ; . 2 - [ 5 - ( 3 , 5 - Dimethoxy - benzylsu1fanyl ) - 4 - ethyl - 4H - [ 1 , 2 , 4 ] triazol - 3 - y1 ] - pyridine ; . 40 2 - [ 4 - Ethyl - 5 - ( 4 - triﬂuoromethyl - benzylsulfanyl ) - 4H - [ 1 , 2 , 4 ] triazol - 3 - yl ] - pyridine ; . 2 - [ 4 - Ethyl - 5 - ( 4 - methanesulfonyl - benzylsulfanyl ) - 4H - [ 1 , 2 , 4 ] triazol - 3 - y1 ] - pyridine ; . 20. N. m. 2 - [ 4 - Ethyl - 5 - ( 3 - nitro - benzylsulfany1 ) - 4H - [ 1 , 2 , 4 ] triazol - 3 - 45 yl ] - pyridine ; 4 - ( 4 - Ethyl - 5 - pyridin - 2 - yl - 4H - [ 1 , 2 , 4 ] triazol - 3 - ylsulfanylmethyl ) - benzoic acid methyl etser ; 2 - [ 4 - Ethyl - 5 - ( 4 - nitro - benzylsulfany1 ) - 4H - [ 1 , 2 , 4 ] triazol - 3 - yl ] - pyridine ; 50 2 - [ 5 - ( 4 - Benzyloxy - benzylsulfanyl ) - 4 - ethyl - 4H - [ 1 , 2 , 4 ] triazol - 3 - yl ] - pyridine ; 2 - [ 4 - Ethyl - 5 - ( 4 - methyl - benzylsulfanyl ) - 4H - [ 1 , 2 , 4 ] triazol - 3 - yl ] - pyridine ; 2 - [ 4 - Ethyl - 5 - ( 3 - triﬂuoromethoxy - benzyl sulfanyl ) - 4H - [ 1 , 2 , 5 4 ] triazol - 3 - yl ] - pyridine ; 2 - [ 4 - Ethyl - 5 - ( 5 - methyl - 2 - nitro - benzylsulfanyl ) - 4H - [ 1 , 2 , 4 ] triazol - 3 - yl ] - pyridine ; 2 - [ 4 - Ethyl - 5 - ( 2 - nitro - benzylsulfany1 ) - 4H - [ 1 , 2 , 4 ] triazol - 3 - yl ] - pyridine ; 0 3 - [ 5 - ( 3 , 4 - Dichloro - benzylsulfanyl ) - 4 - ethyl - 4H - [ 1 , 2 , 4 ] triazol - 3 - yl ] - 2 - methylsulfanyl - pyridine ; 3 - [ 4 - Ethyl - 5 - ( 4 - [ 1 , 2 , 3 ] thiadiazol - 4 - yl - benzylsulfanyl ) - 4H - [ 1 , 2 , 4 ] triazol - 3 - yl ] - 2 - methylsulfanyl - pyridine ; . m. O‘. 3 - ( 5 - cyclohexylmethylsulfanyl - 4 - ethyl - 4H - [ 1 , 2 , 4 ] triazol - 3 - 65 yl ) - 2 - methylsulfanyl - pyridine ; 3 - [ 4 - Ethyl - 5 - ( 4 - triﬁuoromethoxy - benzyl sulfanyl ) - 4H - [ 1 , 2 , 4 ] triazol - 3 - yl ] - 2 - methylsulfanyl - pyridine ; . US 7 , 50l , 405 B2. 115. 3 - [ 5 - ( 3 , 5 - Dimethoxy - benzylsulfanyl ) - 4 - ethyl - 4H - [ l , 2 , 4 ] triazol - 3 - yl ] - 2 - methylsulfanyl - pyridine ; . 3 - [ 4 - Ethyl - 5 - ( 4 - triﬁuoromethyl - benzylsulfanyl ) - 4H - [ 1 , 2 , 4 ] triazo1 - 3 - yl ] - 2 - methy1sulfanyl - pyridine ; . 3 - ( 5 - Benzylsulfanyl - 4 - ethyl - 4H - [ 1 , 2 , 4 ] triazol - 3 - yl ) - 2 - methylsulfanyl - pyridine ; . 3 - [ 4 - Ethyl - 5 - ( 4 - methanesulfonyl - benzylsulfanyl ) - 4H - [ 1 , 2 , 4 ] triazol - 3 - yl ] - 2 - methylsulfanyl - pyridine ; . 4 - [ 4 - Ethyl - 5 - ( 2 - methylsulfanyl - pyridin - 3 - yl ) - 4H - [ 1 , 2 , 4 ] triazol - 3 - ylsulfanylmethyl ] - benzoic acid methyl etser ; . 3 - [ 5 - ( 2 , 6 - Dichloro - benzylsufanyl ) - 4 - ethyl - 4H - [ 1 , 2 , 4 ] triazol - 3 - yl ] - 2 - methylsulfanyl - pyridine ; . 3 - [ 5 - ( 4 - Benzyloxy - benzylsulfanyl ) - 4 - ethyl - 4H - [ 1 , 2 , 4 ] triazol - 3 - yl ] - 2 - methylsulfanyl - pyridine ; . 3 - [ 4 - Ethyl - 5 - ( 4 - methyl - benzylsulfanyl ) - 4H - [ 1 , 2 , 4 ] triazol - 3 - yl ] - 2 - methylsulfanyl - pyridine ; . 3 - [ 4 - Ethyl - 5 - ( 3 - triﬁuoromethoxy - benzylsulfanyl ) - 4H - [ 1 , 2 , 4 ] triazol - 3 - yl ] - 2 - methylsulfanyl - pyridine ; . N - { 4 - [ 4 - Ethyl - 5 - ( 2 - methylsufanyl - pyridin - 3 - yl ) - 4H - [ 1 , 2 , 4 ] triazol - 3 - ylsulfanylmethyl ] - phenyl } - acetamide ; . 3 - [ 4 - Ethyl - 5 - ( 5 - methyl - 2 - nitro - benzylsulfanyl ) - 4H - [ 1 , 2 , 4 ] triazol - 3 - yl ] - 2 - methylsulfanyl - pyridine ; . 3 - [ 4 - Ethyl - 5 - ( 2 - nitro - benzy1sulfanyl ) - 4H - [ 1 , 2 , 4 ] triazo1 - 3 - yl ] - 2 - methylsulfanyl - pyridine ; . 3 - ( 2 - Chloro - benzylsulfanyl ) - 4 - ethyl - 5 - ( 5 - methyl - thiophen - . 2 - yl ) - 4H - [ 1 , 2 , 4 ] triazole ; 4 - [ 4 - Ethyl - 5 - ( 5 - methyl - thiophen - 2 - yl ) - 4H - [ 1 , 2 , 4 ] triazol - 3 - ylsulfanylmethyl ] - benzonitrile ; 3 - ( 6 - Chloro - benzo [ 1 , 3 ] dioxol - 5 - ylmethylsulfanyl ) - 4 - ethyl - 5 - ( 5 - methyl - thiophen - 2 - yl ) - 4H - [ 1 , 2 , 4 ] triazole ; 3 - ( 3 , 4 - Dichloro - benzylsu1fanyl ) - 4 - ethyl - 5 - ( 5 - methy1 - thiophen - 2 - y1 ) - 4H - [ 1 , 2 , 4 ] triazole ; 4 - { 4 - [ 4 - Methyl - 5 - ( 5 - methyl - thiophen - 2 - yl ) - 4H - [ 1 , 2 , 4 ] triazol - 3 - y1sulfanylmethy1 ] - phenyl } - [ 1 , 2 , 3 ] thiadiazole ; 3 - cyclohexylmethylsulfanyl - 4 - ethyl - 5 - ( 5 - methyl - thiophen - 2 - yl ) - 4H - [ 1 , 2 , 4 ] triazole ; 4 - Ethyl - 3 - ( 5 - methyl - thiophen - 2 - yl ) - 5 - ( 4 - triﬁuoromethoxybenzylsulfanyl ) - 4H - [ 1 , 2 , 4 ] triazole ; 3 - ( 3 , 5 - Dimethoxy - benzylsulfanyl ) - 4 - ethyl - 5 - ( 5 - methylthiophen - 2 - yl ) - 4H - [ 1 , 2 , 4 ] triazole ; 4 - Ethyl - 3 - ( 5 - methyl - thiophen - 2 - yl ) - 5 - ( 4 - triﬁuoromethylbenzylsulfanyl ) - 4H - [ 1 , 2 , 4 ] triazole ; 3 - Benzylsulfany1 - 4 - ethyl - 5 - ( 5 - methyl - thiophen - 2 - y1 ) - 4H - [ 1 , 2 , 4 ] triazole ; . 4 - Ethy1 - 3 - ( 4 - methanesulfonyl - benzylsu1fanyl ) - 5 - ( 5 - methy1 - . thiophen - 2 - yl ) - 4H - [ 1 , 2 , 4 ] triazole ; 4 - Ethyl - 3 - ( 5 - methyl - thiophen - 2 - yl ) - 5 - ( 3 - nitro - benzylsulfanyl ) - 4H - [ 1 , 2 , 4 ] triazole ; 4 - [ 4 - Ethyl - 5 - ( 5 - methyl - thiophen - 2 - yl ) - 4H - [ 1 , 2 , 4 ] triazol - 3 - ylsulfanylmethy1 ] - benzoic acid methy1 etser ; 4 - Ethyl - 3 - ( 5 - methyl - thiophen - 2 - yl ) - 5 - ( 4 - nitro - benzylsulfanyl ) - 4H - [ 1 , 2 , 4 ] triazole ; 3 - ( 2 , 6 - Dichloro - benzylsulfanyl ) - 4 - ethyl - 5 - ( 5 - methylthiophen - 2 - yl ) - 4H - [ 1 , 2 , 4 ] triazole ; . 4 - Ethyl - 3 - ( 4 - methyl - benzylsulfanyl ) - 5 - ( 5 - methyl - thiophen - . 2 - yl ) - 4H - [ 1 , 2 , 4 ] triazole ; . N - { 4 - [ 4 - Ethyl - 5 - ( 5 - methyl - thiophen - 2 - yl ) - 4H - [ 1 , 2 , 4 ] triazol - 3 - ylsulfanylmethyl ] - phenyl } - acetamide ; . 4 - Ethyl - 3 - ( 4 - methoxy - benzylsulfanyl ) - 5 - ( 5 - methylthiophen - 2 - yl ) - 4H - [ 1 , 2 , 4 ] triazole ; . 4 - Ethyl - 3 - ( 5 - methyl - thiophen - 2 - yl ) - 5 - ( 2 - nitro - benzylsulfanyl ) - 4H - [ 1 , 2 , 4 ] triazole ; . 3 - ( 2 , 4 - Dichloro - benzylsulfanyl ) - 4 - ethyl - 5 - ( 5 - methylthiophen - 2 - yl ) - 4H - [ 1 , 2 , 4 ] triazole ; . 4 - [ 5 - ( 5 - Chloro - thiophen - 2 - yl ) - 4 - ethyl - 4H - [ 1 , 2 , 4 ] triazol - 3 - ylsulfanylmethyl ] - benzonitrile ; . 5. 20. 25. 30. 35. 40. 55. 65. 11 6. 3 - ( 5 - Chloro - thiophen - 2 - yl ) - 5 - ( 3 , 4 - dichloro - benzylsulfanyl ) - 4 - ethyl - 4H - [ 1 , 2 , 4 ] triazole ; . 3 - ( 4 - Bromo - benzylsulfanyl ) - 5 - ( 5 - chloro - thiophen - 2 - yl ) - 4 - ethyl - 4H - [ 1 , 2 , 4 ] t1iazole ; . 4 - { 4 - [ 5 - ( 5 - Chloro - thiophen - 2 - yl ) - 4 - ethyl - 4H - [ 1 , 2 , 4 ] triazol - 3 - yl sufanylmethyl ] - phenyl } - [ l , 2 , 3 ] thiadiazole ; . 3 - ( 5 - Chloro - thiophen - 2 - yl ) - 5 - cyclohexylmethylsulfanyl - 4 - ethyl - 4H - [ 1 , 2 , 4 ] triazole ; . 3 - ( 5 - Chioro - thiophen - 2 - y ) - 4 - ethyl - 5 - ( 4 - triﬂuoromethoxybenzylsulfanyl ) - 4H - [ 1 , 2 , 4 ] triazole ; . 3 - ( 5 - Chloro - thiophen - 2 - yl ) - 5 - ( 3 , 5 - dimethoxy - benzylsulfanyl ) - 4 - ethyl - 4H - [ 1 , 2 , 4 ] triazole ; . 3 - ( 5 - Chloro - thiophen - 2 - yl ) - 4 - ethyl - 5 - ( 4 - triﬁuoromethylbenzylsufanyl ) - 4H - [ 1 , 2 , 4 ] triazole ; . 3 - ( 5 - Chioro - thiophen - 2 - yl ) - 4 - ethyl - 5 - ( 3 - nitro - benzylsulfanyl ) - 4H - [ 1 , 2 , 4 ] triazole ; . 4 - [ 5 - ( 5 - Chloro - thiophen - 2 - yl ) - 4 - ethyl - 4H - [ 1 , 2 , 4 ] triazol - 3 - ylsulfanylmethyl ] - benzoic acid methyl etser ; . 3 - ( 5 - Chioro - thiophen - 2 - yl ) - 5 - ( 2 , 6 - dichloro - benzylsulfanyl ) - 4 - ethyl - 4H - [ 1 , 2 , 4 ] triazole ; . 3 - ( 5 - Chloro - thiophen - 2 - yl ) - 4 - ethyl - 5 - ( 4 - methyl - benzylsulfanyl ) - 4H - [ 1 , 2 , 4 ] triazole ; . 3 - ( 5 - Chioro - thiophen - 2 - yl ) - 4 - ethyl - 5 - ( 3 - tr1uoromethoxybenzylsulfanyl ) - 4H - [ 1 , 2 , 4 ] triazole ; . N - { 4 - [ 5 - ( 5 - Chloro - thiophen - 2 - yl ) - 4 - ethyl - 4H - [ 1 , 2 , 4 ] triazol - 3 - ylsulfanylmethyl ] - phenyl } - acetamide ; . 3 - ( 5 - Chioro - thiophen - 2 - yl ) - 4 - ethyl - 5 - ( 4 - methoxy - benzylsulfanyl ) - 4H - [ 1 , 2 , 4 ] triazole ; . 3 - ( 5 - Chioro - thiophen - 2 - yl ) - 4 - ethyl - 5 - ( 5 - methy1 - 2 - nitrobenzysulfanyl ) - 4H - [ 1 , 2 , 4 ] triazole ; . 3 - ( 5 - Chioro - thiophen - 2 - yl ) - 4 - ethyl - 5 - ( 2 - nitro - benzylsulfanyl ) - 4H - [ 1 , 2 , 4 ] triazole ; . 3 - ( 5 - Chloro - thiophen - 2 - yl ) - 5 - ( 2 , 4 - dichloro - benzylsulfanyl ) - 4 - ethyl - 4H - [ 1 , 2 , 4 ] triazole ; . 4 - [ 4 - Ethyl - 5 - ( 1H - indol - 3 - ylmethyl ) - 4H - [ 1 , 2 , 4 ] triazol - 3 - yl - su1fanylmethyl ] - benzonitrile ; . 3 - [ 5 - ( 3 , 4 - Dichloro - benzylsulfanyl ) - 4 - ethyl - 4H - [ 1 , 2 , 4 ] triazol - 3 - ylmethyl ] - 1H - indole ; . 3 - [ 5 - ( 3 , 5 - Dimethoxy - benzylsulfanyl ) - 4 - ethyl - 4H - [ 1 , 2 , 4 ] triazol - 3 - ylmethyl ] - 1H - indole ; . 3 - [ 4 - Ethyl - 5 - ( 4 - methanesulfonyl - benzylsulfanyl ) - 4H - [ 1 , 2 , 4 ] triazol - 3 - ylmethyl ] - 1H - indole ; . 3 - [ 4 - Ethyl - 5 - ( 3 - nitro - benzylsulfany1 ) - 4H - [ 1 , 2 , 4 ] triazol - 3 - ylmethyl ] - 1H - indole ; . 3 - [ 4 - Ethyl - 5 - ( 4 - nitro - benzylsulfany1 ) - 4H - [ 1 , 2 , 4 ] triazol - 3 - ylmethyl ] - 1H - indole ; . 3 - [ 5 - ( 2 , 6 - Dichloro - benzylsulfanyl ) - 4 - ethyl - 4H - [ 1 , 2 , 4 ] triazol - 3 - ylmethy1 ] - 1H - indole ; . 3 - [ 5 - ( 4 - Benzyloxy - benzylsulfanyl ) - 4 - ethyl - 4H - [ 1 , 2 , 4 ] triazol - 3 - ylmethy1 ] - 1H - indole ; . 3 - [ 4 - Ethyl - 5 - ( 3 - triﬁuoromethoxy - benzyl sulfanyl ) - 4H - [ 1 , 2 , 4 ] triazol - 3 - ylmethyl ] - 1H - indole ; . N - { 4 - [ 4 - Ethyl - 5 - ( 1 H - indol - 3 - ylmethyl ) - 4H - [ 1 , 2 , 4 ] triazol - 3 - yl sulfanylmethyl ] - phenyl } - ac etamide ; . 3 - [ 4 - Ethyl - 5 - ( 4 - methoxy - benzylsulfanyl ) - 4H - [ 1 , 2 , 4 ] triazol - 3 - ylmethyl ] - 1H - indole ; . 3 - [ 4 - Ethyl - 5 - ( 5 - methyl - 2 - nitro - benzylsulfanyl ) - 4H - [ 1 , 2 , 4 ] triazol - 3 - ylmethyl ] - l H - indole ; . 3 - [ 4 - Ethyl - 5 - ( 2 - nitro - benzylsulfanyl ) - 4H - [ 1 , 2 , 4 ] triazol - 3 - ylmethyl ] - 1H - indole ; . 3 - [ 5 - ( 2 , 4 - Dichloro - benzylsulfanyl ) - 4 - ethyl - 4H - [ 1 , 2 , 4 ] triazol - 3 - ylmethyl ] - 1H - indole ; . 2 - [ 5 - ( 6 - Chloro - benzo [ 1 , 3 ] dioxol - 5 - ylmethylsulfanyl ) - 4 - ethyl - 4H - [ 1 , 2 , 4 ] t1iazol - 3 - yl ] - phenol ; . 2 - [ 4 - Ethyl - 5 - ( 4 - [ 1 , 2 , 3 ] thiadiazol - 4 - yl - benzylsulfanyl ) - 4H - [ 1 , 2 , 4 ] triazol - 3 - yl ] - phenol ; . US 7 , 50l , 405 B2. 117. 2 - ( 5 - cyclohexylmethylsulfanyl - 4 - ethyl - 4H - [ l , 2 , 4 ] triazol - 3 - yl ) - phenol ; . 2 - [ 5 - ( 3 , 5 - Dimethoxy - benzylsulfanyl ) - 4 - ethyl - 4H - [ 1 , 2 , 4 ] triazo1 - 3 - yl ] - pheno1 ; . 2 - [ 4 - Ethyl - 5 - ( 4 - triﬂuoromethyl - benzylsulfanyl ) - 4H - [ 1 , 2 , 4 ] triazol - 3 - yl ] - phenol ; . 2 - ( 5 - Benzylsulfanyl - 4 - ethyl - 4H - [ 1 , 2 , 4 ] triazol - 3 - yl ) - phenol ; . 2 - [ 4 - Ethyl - 5 - ( 4 - methanesulfonyl - benzylsulfanyl ) - 4H - [ 1 , 2 , 4 ] triazol - 3 - yl ] - phenol ; . 2 - [ 4 - Ethyl - 5 - ( 3 - nitro - benzylsulfanyl ) - 4H - [ 1 , 2 , 4 ] triazol - 3 - yl ] - phenol ; . 4 - [ 4 - Ethyl - 5 - ( 2 - hydroxy - phenyl ) - 4H - [ 1 , 2 , 4 ] triazol - 3 - ylsulfanylmethyl ] - benzoic acid methyl etser ; . 2 - [ 4 - Ethyl - 5 - ( 4 - nitro - benzylsulfanyl ) - 4H - [ 1 , 2 , 4 ] triazol - 3 - yl ] - phenol ; . 2 - [ 5 - ( 2 , 6 - Dichloro - benzylsulfanyl ) - 4 - ethyl - 4H - [ 1 , 2 , 4 ] triazol - 3 - yl ] - phenol ; . 2 - [ 4 - Ethyl - 5 - ( 4 - methyl - benzylsulfanyl ) - 4H - [ 1 , 2 , 4 ] triazol - 3 - yl ] - phenol ; . 2 - [ 4 - Ethyl - 5 - ( 3 - triﬂuoromethoxy - benzylsulfanyl ) - 4H - [ 1 , 2 , 4 ] triazol - 3 - yl ] - phenol ; . N - { 4 - [ 4 - Ethyl - 5 - ( 2 - hydroxy - phenyl ) - 4H - [ 1 , 2 , 4 ] triazol - 3 - ylsulfanylmethy1 ] - phenyl } - acetamide ; . 2 - [ 4 - Ethyl - 5 - ( 5 - methyl - 2 - nitro - benzylsulfanyl ) - 4H - [ 1 , 2 , 4 ] triazol - 3 - yl ] - phenol ; . 2 - [ 4 - Ethyl - 5 - ( 2 - nitro - benzylsulfanyl ) - 4H - [ 1 , 2 , 4 ] triazol - 3 - yl ] - phenol ; . 2 - [ 5 - ( 2 , 4 - Dichloro - benzylsulfanyl ) - 4 - ethyl - 4H - [ 1 , 2 , 4 ] triazol - 3 - yl ] - phenol ; . 5 - [ 5 - ( 3 , 4 - Dichioro - benzylsulfanyl ) - 4 - ethyl - 4H - [ 1 , 2 , 4 ] triazol - 3 - yl ] - 4 - methyl - [ 1 , 2 , 3 ] thiadiazole ; . 5 - [ 5 - ( 4 - Bromo - benzylsulfany1 ) - 4 - ethy1 - 4H - [ 1 , 2 , 4 ] triazol - 3 - yl ] - 4 - methyl - [ 1 , 2 , 3 ] thiadiazole ; . 5 - ( 5 - cyclohexylmethylsulfany1 - 4 - ethyl - 4H - [ 1 , 2 , 4 ] triazol - 3 - yl ) - 4 - methyl - [ 1 , 2 , 3 ] thiadiazole ; . 5 - [ 5 - ( 3 , 5 - Dimethoxy - benzylsulfanyl ) - 4 - ethyl - 4H - [ 1 , 2 , 4 ] triazo1 - 3 - yl ] - 4 - methy1 - [ 1 , 2 , 3 ] thiadiazo1e ; . 5 - ( 5 - Benzylsulfanyl - 4 - ethyl - 4H - [ 1 , 2 , 4 ] triazol - 3 - yl ) - 4 - methyl - [ 1 , 2 , 3 ] thiadiazole ; . 5 - [ 4 - Ethyl - 5 - ( 3 - nitro - benzylsulfanyl ) - 4H - [ 1 , 2 , 4 ] triazol - 3 - yl ] - 4 - methyl - [ 1 , 2 , 3 ] thiadiazole ; . 4 - [ 4 - Ethyl - 5 - ( 4 - methyl - [ 1 , 2 , 3 ] thiadiazol - 5 - yl ) - 4H - [ 1 , 2 , 4 ] triazol - 3 - ylsulfanylmethyl ] - benzoic acid methyl etser ; . 5 - [ 4 - Ethyl - 5 - ( 4 - nitro - benzylsulfanyl ) - 4H - [ 1 , 2 , 4 ] triazol - 3 - yl ] - 4 - methyl - [ 1 , 2 , 3 ] thiadiazole ; . 5 - [ 5 - ( 4 - Benzyloxy - benzylsulfanyl ) - 4 - ethyl - 4H - [ 1 , 2 , 4 ] triazol - 3 - yl ] - 4 - methyl - [ 1 , 2 , 3 ] thiadiazole ; . 5 - [ 4 - Ethyl - 5 - ( 4 - methy1 - benzylsulfany1 ) - 4H - [ 1 , 2 , 4 ] triazo1 - 3 - yl ] - 4 - methyl - [ 1 , 2 , 3 ] thiadiazole ; . 5 - [ 4 - Ethyl - 5 - ( 3 - triﬂuoromethoxy - benzylsulfany1 ) - 4H - [ 1 , 2 , 4 ] triazol - 3 - yl ] - 4 - methyl - [ 1 , 2 , 3 ] thiadiazole ; . 5 - [ 4 - Ethyl - 5 - ( 5 - methyl - 2 - nitro - benzylsulfanyl ) - 4H - [ 1 , 2 , 4 ] triazo1 - 3 - yl ] - 4 - methy1 - [ 1 , 2 , 3 ] thiadiazo1e ; . 5 - [ 5 - ( 2 , 4 - Dichloro - benzylsulfanyl ) - 4 - ethyl - 4H - [ 1 , 2 , 4 ] triazol - 3 - yl ] - 4 - methyl - [ 1 , 2 , 3 ] thiadiazole ; . 4 - ( 5 - Benzyl - 4 - ethyl - 4H - [ 1 , 2 , 4 ] triazol - 3 - ylsulfanylmethyl ) - benzonitrile ; . 3 - Benzyl - 5 - ( 3 , 4 - dichloro - benzylsulfanyl ) - 4 - ethyl - 4H - [ l , 2 , 4 ] triazole ; . 4 - [ 4 - ( 5 - Benzyl - 4 - ethyl - 4H - [ 1 , 2 , 4 ] triazol - 3 - ylsulfanylmethyl ) - phenyl ] - [ 1 , 2 , 3 ] thiadiazole ; . 3 - Benzyl - 5 - ( 3 , 5 - dimethoxy - benzyl sulfanyl ) - 4 - ethyl - 4H - [ 1 , 2 , 4 ] triazole ; . 3 - Benzyl - 4 - ethyl - 5 - ( 4 - triﬂuoromethyl - benzylsulfanyl ) - 4H - [ 1 , 2 , 4 ] triazole ; . 3 - Benzyl - 5 - benzylsulfanyl - 4 - ethyl - 4H - [ 1 , 2 , 4 ] triazole ; . 5. lS. 25. 35. 40. 45. 50. 55. 60. 65. 118. 3 - Benzyl - 5 - ( 2 , 6 - dichloro - benzylsulfanyl ) - 4 - ethyl - 4H - [ 1 , 2 , 4 ] triazole ; . 3 - Benzyl - 4 - ethyl - 5 - ( 4 - methyl - benzylsulfanyl ) - 4H - [ 1 , 2 , 4 ] triazole ; . 3 - Benzyl - 4 - ethyl - 5 - ( 4 - methoxy - benzylsulfanyl ) - 4H - [ 1 , 2 , 4 ] triazole ; . 3 - Benzyl - 4 - ethyl - 5 - ( 5 - methyl - 2 - nitro - benzylsulfanyl ) - 4H - [ 1 , 2 , 4 ] triazole ; . 3 - Benzyl - 4 - ethyl - 5 - ( 2 - nitro - benzylsulfanyl ) - 4H - [ 1 , 2 , 4 ] triazole ; . 3 - Benzyl - 5 - ( 2 , 4 - dichloro - benzylsulfanyl ) - 4 - ethyl - 4H - [ 1 , 2 , 4 ] triazole ; . 3 - ( 2 - Bromo - phenyl ) - 5 - ( 2 - chloro - benzylsulfanyl ) - 4 - ethyl - 4H - [ 1 , 2 , 4 ] triazole ; . 4 - [ 5 - ( 2 - Bromo - phenyl ) - 4 - ethyl - 4H - [ 1 , 2 , 4 ] triazol - 3 - ylsulfanylmethyl ] - benzonitrile ; . 3 - ( 2 - Bromo - phenyl ) - 5 - ( 6 - chloro - benzo [ 1 , 3 ] dioxol - 5 - ylmethylsufanyl ) - 4 - ethyl - 4H - [ 1 , 2 , 4 ] triazole ; . 3 - ( 2 - Bromophenyl ) - 5 - ( 3 , 4 - dichloro - benzylsulfanyl ) - 4 - ethyl - 4H - [ 1 , 2 , 4 ] triazole ; . 3 - ( 2 - Bromo - phenyl ) - 5 - cyclohexylmethylsulfanyl - 4 - ethyl - 4H - [ 1 , 2 , 4 ] triazole ; . 3 - ( 2 - Bromo - pheny1 ) - 4 - ethy1 - 5 - ( 4 - triﬂuoromethoxy - benzylsulfanyl ) - 4H - [ 1 , 2 , 4 ] triazole ; . 3 - ( 2 - Bromo - phenyl ) - 5 - ( 3 , 5 - dimethoxy - benzylsulfanyl ) - 4 - ethyl - 4H - [ 1 , 2 , 4 ] t1iazole ; . 3 - ( 2 - Bromo - phenyl ) - 4 - ethyl - 5 - ( 4 - t1iﬂuoromethyl - benzylsulfanyl ) - 4H - [ 1 , 2 , 4 ] triazole ; . 3 - ( 2 - Bromo - pheny1 ) - 4 - ethy1 - 5 - ( 3 - nitro - benzy1su1fanyl ) - 4H - [ 1 , 2 , 4 ] triazole ; . 3 - ( 4 - Benzyloxy - benzylsulfany1 ) - 5 - ( 2 - bromo - phenyl ) - 4 - ethyl - 4H - [ 1 , 2 , 4 ] triazole ; . 3 - ( 2 - Bromo - phenyl ) - 4 - ethyl - 5 - ( 4 - methoxy - benzylsufanyl ) - 4H - [ 1 , 2 , 4 ] triazole ; . 3 - ( 2 - Bromo - phenyl ) - 4 - ethyl - 5 - ( 5 - methyl - 2 - nitro - benzyl sulfanyl ) - 4H - [ 1 , 2 , 4 ] triazole ; . 3 - ( 2 - Bromo - phenyl ) - 5 - ( 2 , 4 - dichloro - benzylsulfanyl ) - 4 - ethyl - 4H - [ 1 , 2 , 4 ] t1iazole ; . 2 - [ 4 - ( 3 - Methoxy - propyl ) - 5 - ( 1 - methyl - piperidin - 2 - yl ) - 4H - [ 1 , 2 , 4 ] triazol - 3 - ylsulfanylmethyl ] - benzonitrile ; . 2 - [ 4 - ( 3 - Methoxy - propyl ) - 5 - ( 1 - methyl - piperidin - 2 - yl ) - 4H - [ 1 , 2 , 4 ] triazol - 3 - ylsulfanylmethyl ] - pyridine ; . 2 - [ 5 - ( 2 - Methoxy - ethylsulfanyl ) - 4 - ( 3 - methoxy - propyl ) - 4H - [ 1 , 2 , 4 ] triazol - 3 - yl ] - 1 - methyl - piperidine ; . 2 - [ 4 - ( 2 - Methoxy - ethyl ) - 5 - ( 1 - methyl - piperidin - 2 - yl ) - 4H - [ 1 , 2 , 4 ] triazol - 3 - ylsulfanylmethyl ] - benzonitrile ; . 2 - [ 4 - ( 2 - Methoxy - ethyl ) - 5 - ( 1 - methyl - piperidin - 2 - yl ) - 4H - [ 1 , 2 , 4 ] triazol - 3 - ylsulfanylmethyl ] - pyridine ; . 2 - [ 4 - ( 2 - Methoxy - ethyl ) - 5 - ( 2 - methoxy - ethylsulfanyl ) - 4H - [ 1 , 2 , 4 ] triazol - 3 - yl ] - 1 - methyl - piperidine ; . 2 - [ 4 - cyclopropyl - 5 - ( 1 - methyl - piperidin - 2 - yl ) - 4H - [ 1 , 2 , 4 ] triazol - 3 - yl sulfanylmethyl ] - benzonitrile ; . 2 - [ 4 - cyclopropyl - 5 - ( 1 - methyl - piperidin - 2 - yl ) - 4H - [ 1 , 2 , 4 ] tri azol - 3 - yl sulfanylmethyl ] - pyridine ; . 2 - [ 4 - cyclopropyl - 5 - ( 2 - methoxy - ethylsulfanyl ) - 4H - [ 1 , 2 , 4 ] triazol - 3 - yl ] - 1 - methyl - piperidine ; . 2 - [ 5 - ( 1 - Methyl - piperidin - 2 - yl ) - 4 - ( 2 - piperidin - 1 - yl - ethyl ) - 4H - [ l , 2 , 4 ] triazol - 3 - ylsulfanylmethyl ] - benzonitrile ; . 2 - [ 5 - ( 1 - Methyl - piperidin - 2 - yl ) - 4 - ( 2 - piperidin - 1 - yl - ethyl ) - 4H - [ 1 , 2 , 4 ] triazol - 3 - ylsulfanylmethyl ] - pyridine ; . 2 - [ 4 - cyclopropylmethyl - 5 - ( 1 - methyl - piperidin - 2 - yl ) - 4H - [ 1 , 2 , 4 ] triazol - 3 - ylsulfanylmethyl ] - benzonitrile ; . 2 - [ 4 - cyclopropylmethyl - 5 - ( 1 - methyl - piperidin - 2 - yl ) - 4H - [ 1 , 2 , 4 ] triazol - 3 - ylsulfanylmethyl ] - pyridine ; . 2 - [ 4 - cyclopropylmethyl - 5 - ( 2 - methoxy - ethylsulfanyl ) - 4H - [ 1 , 2 , 4 ] triazol - 3 - yl ] - 1 - methyl - piperidine ; . US 7 , 50l , 405 B2. 1 19 2 - [ 5 - ( 2 - Hydroxy - phenyl ) - 4 - ( 3 - methoxy - propyl ) - 4H - [ l , 2 , 4 ] triazol - 3 - ylsulfanylmethyl ] - benzonitrile ; 2 - [ 4 - ( 3 - Methoxy - propyl ) - 5 - ( pyridin - 2 - ylmethylsulfanyl ) - 4H - [ 1 , 2 , 4 ] triazol - 3 - yl ] - phenol ; 2 - [ 5 - ( 2 - Methoxy - ethylsulfanyl ) - 4 - ( 3 - methoxy - propyl ) - 4H - [ 1 , 2 , 4 ] triazol - 3 - yl ] - phenol ; 2 - [ 5 - ( 2 - Hydroxy - phenyl ) - 4 - ( 2 - methoxy - ethyl ) - 4H - [ 1 , 2 , 4 ] triazol - 3 - ylsulfanylmethyl ] - benzonitrile ; . 2 - [ 4 - ( 2 - Methoxy - ethyl ) - 5 - ( pyridin - 2 - ylmethylsulfanyl ) - 4H - . [ 1 , 2 , 4 ] triazol - 3 - yl ] - phenol ; . 2 - [ 4 - ( 2 - Methoxy - ethyl ) - 5 - ( 2 - methoxy - ethylsulfanyl ) - 4H - [ 1 , 2 , 4 ] triazol - 3 - yl ] - phenol ; . 2 - [ 4 - Cyclopropyl - 5 - ( 2 - hydroxy - phenyl ) - 4H - [ 1 , 2 , 4 ] triazol - 3 - ylsulfanylmethyl ] - benzonitrile ; . 2 - [ 4 - Cyclopropyl - 5 - ( pyridin - 2 - ylmethylsulfanyl ) - 4H - [ 1 , 2 , 4 ] triazol - 3 - yl ] - phenol ; . 2 - [ 4 - Cyclopropyl - 5 - ( 2 - methoxy - ethylsulfanyl ) - 4H - [ 1 , 2 , 4 ] triazol - 3 - yl ] - phenol ; . 2 - [ 5 - ( 2 - Hydroxy - phenyl ) - 4 - ( 2 - piperidin - 1 - yl - ethyl ) - 4H - [ 1 , 2 , 4 ] triazol - 3 - ylsulfanylmethyl ] - benzonitrile ; . 2 - [ 4 - ( 2 - Piperidin - 1 - yl - ethyl ) - 5 - ( pyridin - 2 - ylmethylsulfanyl ) - 4H - [ 1 , 2 , 4 ] triazol - 3 - yl ] - phenol ; . 2 - [ 5 - ( 2 - Methoxy - ethylsulfanyl ) - 4 - ( 2 - piperidin - 1 - y1 - ethy1 ) - 4H - [ 1 , 2 , 4 ] triazol - 3 - yl ] - phenol ; . 2 - [ 4 - Cyclopropylmethyl - 5 - ( 2 - hydroxy - phenyl ) - 4H - [ 1 , 2 , 4 ] triazol - 3 - ylsulfanylmethyl ] - benzonitrile ; . 2 - [ 4 - Cyclopropylmethyl - 5 - ( pyridin - 2 - ylmethylsulfanyl ) - 4H - [ 1 , 2 , 4 ] triazol - 3 - yl ] - phenol ; . 2 - [ 4 - Cyclopropylmethy1 - 5 - ( 2 - methoxy - ethylsu1fanyl ) - 4H - [ 1 , 2 , 4 ] triazol - 3 - yl ] - phenol ; . 2 - [ 5 - ( 2 - Methoxy - pheny1 ) - 4 - ( 3 - methoxy - propy1 ) - 4H - [ 1 , 2 , 4 ] . triazo1 - 3 - ylsulfany1methyl ] - benzonitri1e ; . 2 - [ 5 - ( 2 - Methoxy - phenyl ) - 4 - ( 3 - methoxy - propyl ) - 4H - [ 1 , 2 , 4 ] . triazo1 - 3 - ylsulfany1methyl ] - pyridine ; . 3 - ( 2 - Methoxy - ethylsulfanyl ) - 5 - ( 2 - methoxy - phenyl ) - 4 - ( 3 - methoxy - propy1 ) - 4H - [ 1 , 2 , 4 ] triazole ; . 2 - [ 4 - ( 2 - Methoxy - ethyl ) - 5 - ( 2 - methoxy - phenyl ) - 4H - [ 1 , 2 , 4 ] triazol - 3 - ylsulfanylmethyl ] - benzonitrile ; . 2 - [ 4 - ( 2 - Methoxy - ethyl ) - 5 - ( 2 - methoxy - phenyl ) - 4H - [ 1 , 2 , 4 ] triazol - 3 - yl sulfanylmethyl ] - pyridine ; . 4 - ( 2 - Methoxy - ethyl ) - 3 - ( 2 - methoxy - ethylsulfanyl ) - 5 - ( 2 - methoxy - phenyl ) - 4H - [ 1 , 2 , 4 ] triazole ; . 2 - [ 4 - Cyclopropyl - 5 - ( 2 - methoxy - phenyl ) - 4H - [ 1 , 2 , 4 ] triazol - 3 - ylsulfanylmethyl ] - benzonitrile ; . 2 - [ 4 - Cyclopropyl - 5 - ( 2 - methoxy - phenyl ) - 4H - [ 1 , 2 , 4 ] triazol - 3 - yl sulfanylmethyl ] - pyridine ; . 4 - Cyclopropyl - 3 - ( 2 - methoxy - ethylsulfanyl ) - 5 - ( 2 - methoxyphenyl ) - 4H - [ 1 , 2 , 4 ] triazole ; . 2 - [ 5 - ( 2 - Methoxy - phenyl ) - 4 - ( 2 - piperidin - 1 - yl - ethyl ) - 4H - [ 1 , 2 , 4 ] triazol - 3 - ylsulfanylmethyl ] - benzonitrile ; . 2 - [ 5 - ( 2 - Methoxy - phenyl ) - 4 - ( 2 - piperidin - 1 - yl - ethyl ) - 4H - [ 1 , 2 , 4 ] triazol - 3 - ylsulfanylmethyl ] - pyridine ; . 1 - { 2 - [ 3 - ( 2 - Methoxy - ethylsulfanyl ) - 5 - ( 2 - methoxy - phenyl ) - [ 1 , 2 , 4 ] triazol - 4 - yl ] - ethyl } - piperidine ; . 2 - [ 4 - Cyclopropylmethyl - 5 - ( 2 - methoxy - phenyl ) - 4H - [ 1 , 2 , 4 ] triazol - 3 - ylsulfanylmethyl ] - benzonitrile ; . 2 - [ 4 - Cyclopropylmethyl - 5 - ( 2 - methoxy - phenyl ) - 4H - [ 1 , 2 , 4 ] triazol - 3 - ylsulfanylmethyl ] - pyridine ; . 4 - Cyclopropylmethyl - 3 - ( 2 - methoxy - ethylsulfanyl ) - 5 - ( 2 - methoxy - phenyl ) - 4H - [ 1 , 2 , 4 ] triazole ; . 2 - [ 4 - ( 3 - Methoxy - propyl ) - 5 - thiophen - 2 - yl - 4H - [ 1 , 2 , 4 ] triazol - 3 - ylsulfanylmethyl ] - benzonitrile ; . 2 - [ 4 - ( 3 - Methoxy - propyl ) - 5 - thiophen - 2 - yl - 4H - [ 1 , 2 , 4 ] triazol - 3 - ylsulfanylmethyl ] - pyridine ; . 3 - ( 2 - Methoxy - ethylsulfanyl ) - 4 - ( 3 - methoxy - propyl ) - 5 - thiophen - 2 - yl - 4H - [ 1 , 2 , 4 ] triazole ; . 1_. O‘. 12 0. 2 - [ 4 - ( 2 - Methoxy - ethyl ) - 5 - thiophen - 2 - yl - 4H - [ 1 , 2 , 4 ] triazol - 3 - yl sulfanylmethyl ] - b enzonitrile ; . 2 - [ 4 - ( 2 - Methoxy - ethyl ) - 5 - thiophen - 2 - yl - 4H - [ 1 , 2 , 4 ] triazol - 3 - yl sulfanylmethyl ] - pyri dine ; . 4 - ( 2 - Methoxy - ethyl ) - 3 - ( 2 - methoxy - ethylsulfanyl ) - 5 - thiophen - 2 - yl - 4H - [ 1 , 2 , 4 ] triazole ; . 2 - ( 4 - Cyclopropyl - 5 - thiophen - 2 - yl - 4H - [ 1 , 2 , 4 ] triazol - 3 - ylsulfanylmethyl ) - benzonitrile ; . 2 - ( 4 - Cyclopropyl - 5 - thiophen - 2 - yl - 4H - [ 1 , 2 , 4 ] triazol - 3 - ylsulfanylmethyl ) - pyridine ; . 4 - Cyclopropyl - 3 - ( 2 - methoxy - ethylsulfanyl ) - 5 - thiophen - 2 - yl - 4H - [ 1 , 2 , 4 ] triazole ; . 2 - [ 4 - ( 2 - Piperidin - 1 - yl - ethyl ) - 5 - thiophen - 2 - yl - 4H - [ 1 , 2 , 4 ] triazol - 3 - yl sulfanylmethyl ] - benzonitrile ; . 2 - [ 4 - ( 2 - Piperidin - 1 - yl - ethyl ) - 5 - thiophen - 2 - yl - 4H - [ 1 , 2 , 4 ] tri azol - 3 - yl sulfanylmethyl ] - pyridine ; . 1 - { 2 - [ 3 - ( 2 - Methoxy - ethylsulfanyl ) - 5 - thiophen - 2 - yl - [ 1 , 2 , 4 ] triazol - 4 - y1 ] - ethyl } - piperidine ; . 2 - ( 4 - Cyclopropylmethyl - 5 - thiophen - 2 - yl - 4H - [ 1 , 2 , 4 ] triazol - 3 - yl sulfanylmethyl ) - b enzonitrile ; . 2 - ( 4 - Cyclopropylmethyl - 5 - thiophen - 2 - yl - 4H - [ 1 , 2 , 4 ] triazol - 3 - yl sulfanylmethyl ) - pyri dine ; . 4 - Cyclopropylmethyl - 3 - ( 2 - methoxy - ethylsulfanyl ) - 5 - thiophen - 2 - yl - 4H - [ 1 , 2 , 4 ] triazole ; or. a salt thereof With a pharmaceutica1ly acceptab1e acid or base , . or any optical isomer or mixture of optical isomers , including a racemic mixture , or any tautomeric forms. The compounds of the present inVention haVe asymmetric centers and may occur as racemates , racemic mixtures , and as indiVidual enantiomers or diastereoisomers , With all isomeric forms being included in the present inVention as Well as mixtures thereof. The present inVention also encompasses pharmaceutically acceptable salts of the present compounds. Such salts include pharmaceutically acceptable acid addition salts , pharmaceutical1y acceptab1e base addition salts , pharmaceutically acceptable metal sa1ts , ammonium and alkylated ammonium salts. Acid addition salts include salts of inorganic acids as Well as organic acids. RepresentatiVe examples of suitable inorganic acids include hydrochloric , hydrobromic , hydroiodic , phosphoric , su1furic , nitric acids and the 1ike. RepresentatiVe examples of suitable organic acids include formic , acetic , trichloroacetic , triﬂuoroacetic , propionic , benzoic , cinnamic , citric , fumaric , glycolic , lactic , maleic , malic , malonic , mandelic , oxalic , picric , pyruVic , salicylic , succinic , methanesu1fonic , ethanesu1fonic , tartaric , ascorbic , pamoic , bismethylene salicylic , ethanedisulfonic , gluconic , citraconic , aspartic , stearic , palmitic , EDTA , glycolic , p - aminobenzoic , glutamic , benzenesulfonic , p - toluenesulfonic acids , sulphates , nitrates , phosphates , perchlorates , borates , acetates , benzoates , hydroxynaphthoates , glycerophosphates , ketoglutarates and the like. Further examples of pharmaceutically acceptable inorganic or organic acid addition salts include the pharmaceutically acceptable salts listed in J. Pharm. Sci. , 66 , 2 ( 1977 ) , Which is incorporated herein by reference. Examples of meta1 salts include lithium , sodium , potassium , barium , calcium , magnesium , zinc , calcium salts and the like. Examples of amines and organic amines include ammonium , methylamine , dimethylamine , trimethylamine , ethylamine , diethylamine , propylamine , butylamine , tetramethylamine , ethanolamine , diethanolamine , triethanolamine , meglumine , ethylenediamine , choline , N , N ' - dibenzylethyl - . 65 enediamine , N - benzylphenylethylamine , N - methyl - D - glu - . camine , guanidine and the like. Examples of cationic amino acids include lysine , arginine , histidine and the like. US 7 , 50l , 405 B2. 121. Further , some of the compounds of the present inVention may form solVates With Water or common organic solVents. Such solVates are encompassed Within the scope of the inVention. The pharmaceutically acceptable salts are prepared by reacting a compound of the present inVention With 1 to 4 equiValents of a base such as sodium hydroxide , sodium methoxide , sodium hydride , potassium tert - butoxide , calcium hydroxide , magnesium hydroxide and the like , in solVents like ether , THF , methanol , tert - butanol , dioxane , isopropanol , ethanol etc. Mixtures of solVents may be used. Organic bases like lysine , arginine , diethanolamine , choline , guandine and their deriVatiVes etc. may also be used. AlternatiVely , acid addition salts WhereVer applicable are prepared by treatment With acids such as hydrochloric acid , hydrobromic acid , nitric acid , sulfuric acid , phosphoric acid , p - toluenesulphonic acid , methanesulfonic acid , acetic acid , citric acid , maleic acid salicylic acid , hydroxynaphthoic acid , ascorbic acid , palmitic acid , succinic acid , benzoic acid , benzenesulfonic acid , tartaric acid and the like in solVents like ethyl acetate , ether , alcohols , acetone , THF , dioxane etc. Mixture of solVents may also be used. The stereoisomers of the compounds forming part of this inVention may be prepared by using reactants in their single enantiomeric form in the process WhereVer possible or by conducting the reaction in the presence of reagents or catalysts in their single enantiomer form or by resolVing the mixture of stereoisomers by conVentiona1 methods. Some of the preferred methods include use of microbial resolution , enzymatic resolution , resolVing the diastereomeric salts formed With chiral acids such as mandelic acid , camphorsulfonic acid , tartaric acid , lactic acid , and the like WhereVer applicable or chiral bases such as brucine , ( R ) — or ( S ) - phenylethylamine , cinchona a1kaloids and their deriVatiVes and the like. Commonly used methods are compiled by Jaques et al. in “Enantiomers , Racemates and Resolution” ( Wiley Interscience , 1981 ) . More speciﬁcally the compound of the present inVention may be conVerted to a 1 : 1 mixture of diastereomeric amides by treating With chiral amines , aminoacids , aminoalcohols deriVed from aminoacids ; conVentional reaction conditions may be employed to conVert acid into an amide ; the diastereomers may be separated either by fractional crystal1ization or chromatography and the stereoisomers of compound of fonnula I may be prepared by hydro1 - ysing the pure diastereomeric amide. Various polymorphs of the compounds forming part of this inVention may be prepared by crystallization of said compounds under different conditions. For example , using different solVents commoniy used or their mixtures for recrystallization ; crystallizations at different temperatures ; and Various modes of cooling , ranging from Very fast to Very sloW cooling during crystallizations. Polymorphs may also be obtained by heating or melting the compound fo1loWed by gradual or fast cooling. The presence of polymorphs may be detennined by solid probe NMR spectroscopy , IR spectroscopy , differential scanning calorimetry , poWder X - ray diffraction or such other techniques. The inVention also encompasses prodrugs of the present compounds , Which on administration undergo chemical conVersion by metabolic processes before becoming actiVe pharmacological substances. In general , such prodrugs Will be functional deriVatiVes of the present compounds , Which are readily conVertible in ViVo into the required compound of the present inVention. ConVentional procedures for the selection and preparation of suitable prodrug deriVatiVes are described , for example , in “Design of Prodrugs” , ed. H. Bundgaard , ElseVier , 1985. 5. lO. lS. 20. 25. 30. 35. 40. 45. 50. 55. 60. 65. 122. lt is a Well knoWn problem in drug discoVery that compounds , such as enzyme inhibitors , may be Very potent and selectiVe in biochemical assays , yet be inactiVe in ViVo. This lack of so - ca1led bioaVailability may be ascribed to a number of different factors such as lack of or poor absorption in the gut , ﬁrst pass metabolism in the liVer and / or poor uptake in cells. Although the factors determining bioaVailability are not completely understood , there are many examples in the scientiﬁc literature , Well knoWn to those skilled in the art , of hoW to modify compounds , Which are potent and selectiVe in biochemical assays but shoW loW or no actiVity in ViVo , into drugs that are biologically actiVe. It is Within the scope of the inVention to modify the compounds of the present inVention , termed the “original compound” , by attaching chemical groups that Will improVe the bioaVailability of said compounds in such a Way that the uptake in cells or mammals is facilitated. Examples of said modiﬁcations , Which are not intended in any Way to limit the scope of the inVention , include changing of one or more carboxy groups to esters ( for instance methyl esters , ethyl esters , tert - butyl , acetoxymethyl , inaloyloxymethyl esters or other acyloxymethyl esters ) . Compounds of the inVention , original compounds , such modiﬁed by attaching chemical groups are termed “modiﬁed compounds”. The inVention also encompasses actiVe metabolites of the present compounds. The compounds according to the inVention alters , and more speciﬁcal1y , reduces the leVe1 of actiVe intracellular g1ucocorticoid and are according1y useful for the treatment , preVention and / or prophylaxis of disorders and diseases in Which such a modulation or reduction is beneﬁcial. Accordingly , the present compounds may be applicable for the treatment , preVention and / or prophylaxis of the metabo1ic syndrome , insulin resistance , dys1ipidemia , hypertension , obesity , type 2 diabetes , impaired glucose tolerance ( IGT ) , impaired fasting glucose ( IFG ) , Latent Autoimmune Diabetes in the Adult ( LADA ) , type 1 diabetes , diabetic late complications including cardioVascular diseases , cardioVascular disorders , disorders of lipid metabolism , neurodegeneratiVe and psychiatric disorders , dysregulation of intraocular pressure including glaucoma , immune disorders , inappropriate immune responses , musculo - skeletal disorders , gastrointestinal disorders , polycystic oVary syndrome ( PCOS ) , reduced hair grthh or other diseases , disorders or conditions that are inﬂuenced by intracellular glucocorticoid leVels , adVerse effects of increased blood leVels of actiVe endogenous or exogenous glucocorticoid , and any combination thereof , adVerse effects of increased p1asma leVe1s of endogenous actiVe glucocorticoid , Cushings disease , Cushings syndrome , adVerse effects of glucocorticoid receptor agonist treatment of autoimmune diseases , adVerse effects of glucocorticoid receptor agonist treatment of inﬂammatory diseases , adVerse effects of glucocorticoid receptor agonist treatment of diseases With an inﬂammatory component , adVerse effects of glucocorticoid receptor agonist treatment as a part of cancer chemotherapy , adVerse effects of glucocorticoid receptor agoni st treatment for surgical / post - surgical or other trauma , adVerse effects of g1ucocorticoid receptor agonist therapy in the context of organ or tissue transplantation or adVerse effects of glucocorticoid receptor agonist treatment in other diseases , disorders or conditions Where glucocorticoid receptor agonists proVide clinically beneﬁcial effects. More speciﬁcally the present compounds may be applicable for the treatment , preVention and / or prophylaxis of the metabolic syndrome , type 2 diabetes , diabetes as a consequence of obesity , insulin resistance , hyperglycemia , prandial hyperglycemia , hyperinsulinemia , inappropriately loW insu - . US 7 , 50l , 405 B2. 123. lin secretion , impaired glucose tolerance ( IGT ) , impaired fasting glucose ( IFG ) , increased hepatic glucose production , type 1 diabetes , LADA , pediatric diabetes , dyslipidemia , diabetic dys1ipidemia , hyperlipidemia , hypertriglyceridemia , hyperlipoproteinemia , hypercholesterolemia , decreased HDL cholesterol , impaired LDL / HDL ratio , other disorders of lipid metabolism , obesity , Visceral obesity , obesity as a consequence of diabetes , increased food intake , hypertension , diabetic late complications , micro - / macroalbuminuria , nephropathy , retinopathy , neuropathy , diabetic ulcers , cardioVascular diseases , arteriosclerosis , atherosclerosis , coronary artery disease , cardiac hypertrophy , myocardial ischemia , heart insufﬁciency , congestional heart failure , stroke , myocardial infarction , arrythmia , decreased blood ﬂoW , erectile dysfunction ( male or female ) , myopathy , loss of muscle tissue , muscle Wasting , muscle catabolism , osteoporosis , decreased linear grthh , neurodegeneratiVe and psychiatric disorders , Alzheimers disease , neuronal death , impaired co g - nitiVe function , depression , anxiety , eating disorders , appetite regulation , migraine , epilepsia , addiction to chemical substances , disorders of intraocular pressure , glaucoma , polycystic oVary syndrome ( PCOS ) , inappropriate immune responses , inappropriate T helper - 1 / T he1per - 2 polarisation , bacterial infections , mycobacterial infections , fungal infections , Viral infections , parasitic infestations , suboptimal responses to immunizations , immune dysﬁinction , partial or complete baldness , or other diseases , disorders or conditions that are inﬂuenced by intracellular glucocorticoid leVels and any combination thereof , adVerse effects of glucocorticoid receptor agonist treatment of allergic - inﬂammatory diseases such as asthma and atopic dermatitis , adVerse effects of glucocorticoid receptor agonist treatment of disorders of the respiratory system e. g. asthma , cystic ﬁbrosis , emphysema , bronchitis , hypersensitiVity , pneumonitis , eosinophilic pneumonias , pulmonary ﬁbrosis , adVerse effects of glucocorticoid receptor agonist treatment of inﬂammatory boWel disease such as Crohn s disease and ulceratiVe colitis ; adVerse effects of glucocorticoid receptor agonist treatment of disorders of the immune system , connectiVe tissue and joints e. g. reactiVe arthritis , rheumatoid arthritis , Sjogrens syndrome , systemic lupus erythemato sus , lupus nephritis , Henoch - Schonlein purpura , Wegener s granulomatosis , temporal arteritis , systemic sclerosis , Vasculitis , sarcoidosis , dermatomyositis - polymyositis , pemphigus Vu1garis ; adVerse effects of glucocorticoid receptor agonist treatment of endocrinological diseases such as hyperthyroidism , hypoaldosteronism , hypopituitarism ; adVerse effects of glucocorticoid receptor agonist treatment of hematological diseases e. g. hemolytic anemia , thrombocytopenia , paroxysmal nocturnal hemoglobinuria ; adVerse effects of glucocorticoid receptor agonist treatment of cancer such as spinal cord diseases , neoplastic compression of the spinal cord , brain tumours , acute lymphoblastic leukemia , Hodgkins disease , chemotherapy - induced nausea , adVerse effects of glucocorticoid receptor agonist treatment of diseases of muscle and at the neuro - muscular joint e. g. myasthenia graVis and heriditary myopathies ( e. g. Duchenne muscular dystrophy ) , adVerse effects of glucocorticoid receptor agonist treatment in the context of surgery & transplantation e. g. trauma , post - surgical stress , surgical stress , renal transplantation , liVer transplantation , lung transplantation , pancreatic islet transplantation , blood stem cell transplantation , bone marroW transplantation , heart transplantation , adrenal gland transplantation , tracheal transplantation , intestinal transplantation , corneal transplantation , skin grafting , keratoplasty , lens implantation and other procedures Where immunosuppression With glucocorticoid receptor agonists is ben - eﬁcial ; adVerse effects of glucocorticoid receptor agonist. 5. lO. lS. 20. 25. 30. 35. 40. 45. 50. 55. 60. 65. 124. treatment of brain ab sess , nausea / Vomiting , infections , hypercalcemia , adrenal hyperplasia , autoimmune hepatitis , spinal cord diseases , saccular aneurysms ; or adVerse effects to glucocorticoid receptor agonist treatment in other diseases , disorders and conditions Where glucocorticoid receptor agonists proVide clinically beneﬁcial effects. Accordingly , in a further aspect the inVention relates to a compound according to the inVention for use as a pharmaceutical composition. The inVention also relates to pharmaceutical compositions comprising , as an actiVe ingredient , at least one compound according to the inVention together With one or more pharmaceutically acceptable carriers or diluents. The pharmaceutical composition is preferably in unit dosage form , comprising from about 0.05 mg / day to about 2000 mg / day , preferably from about 1 mg / day to about 500 mg / day of a compound according to the inVention. In another embodiment , the patient is treated With a compound according to the inVention for at least about 1 Week , for at least about 2 Weeks , for at least about 4 Weeks , for at least about 2 months or for at least about 4 months. In yet another embodiment , the pharmaceutical composition is for ora1 , nasal , transdermal , pulmonal or parenteral administration. Furthermore , the inVention relates to the use of a compound according to the inVention for the preparation of a pharmaceutical composition for the treatment , preVention and / or prophylaxis of disorders and diseases Wherein a modulation or an inhibition of the actiVity of 118 - HSD1 is beneﬁcial. The inVention also relates to a method for the treatment , preVention and / or prophylaxis of disorders and diseases Wherein a modulation or an inhibition of the actiVity of 118 - HSD1 is beneﬁcial , the method comprising administering to a subj ect in need thereof an effectiVe amount of a compound according to the inVention. In a preferred embodiment of the inVention the present compounds are used for the preparation of a medicament for the treatment , preVention and / or prophylaxis of any diseases and conditions that are inﬂuenced by intracellu1ar g1ucocorticoid leVels as mentioned aboVe. Thus , in a preferred embodiment of the inVention the present compounds are used for the preparation of a medicament for the treatment , preVention and / or prophylaxis of conditions and disorders Where a decreased 1eVel of actiVe intracellular glucocorticoid is desirable , such as the conditions and diseases mentioned aboVe. In yet a preferred embodiment of the inVention the present compounds are used for the preparation of a medicament for the treatment , preVention and / or prophylaxis of the metabolic syndrome including insulin resistance , dyslipidemia , hypertension and obesity. In yet another preferred embodiment of the inVention the present compounds are used for the preparation of a medicament for the treatment , preVention and / or prophylaxis of type 2 diabetes , impaired glucose tolerance ( IGT ) , impaired fasting glucose ( IFG ) . In yet another preferred embodiment of the inVention the present compounds are used for the preparation of a pharmaceutical composition for the delaying or preVention of the progression from IGT to type 2 diabetes. In yet another preferred embodiment of the inVention the present compounds are used for the preparation of a pharmaceutical composition for the delaying or preVention of the progression of the metabolic syndrome into type 2 diabetes. ln still another preferred embodiment of the inVention the present compounds are used for the preparation of a pharmaceutical composition for the treatment , preVention and / or pro - . US 7 , 50l , 405 B2. 125. phylaxis of diabetic late complications including cardioVascular diseases ; arteriosclerosis ; atherosclerosis. In a further preferred embodiment of the inVention the present compounds are used for the preparation of a pharmaceutical composition for the treatment , preVention and / or pro - phylaxis of neurodegeneratiVe and psychiatric disorders. In yet a further preferred embodiment of the inVention the present compounds are used for the preparation of a pharmaceutical composition for the treatment , preVention and / or pro - phylaxis of adVerse effects of glucocorticoid receptor agonist therapy. In another embodiment of the present inVention , the route of administration may be any route Which effectiVely transports a compound according to the inVention to the appropriate or desired site of action , such as oral , nasal , buccal , transdermal , pulmonal , or parenteral. In still a further aspect of the inVention the present compounds are administered in combination With one or more further actiVe substances in any suitable ratios. Such further actiVe substances may e. g. be selected from antiobesity agents , antidiabetics , agents modifying the lipid metabolism , antihypertensiVe agents , glucocorticoid receptor agonists , agents for the treatment and / or preVention of complications resulting from or associated With diabetes and agents for the treatment and / or preVention of complications and disorders resulting from or associated With obesity. Thus , in a further aspect of the inVention the present compounds may be administered in combination With one or more antiobesity agents or appetite regulating agents. Such agents may be selected from the group consisting of CART ( cocaine amphetamine regu1ated transcript ) agonists , NPY ( neuropeptide Y ) antagonists , MC4 ( melanocortin 4 ) agonists , orexin antagonists , TNF ( tumor necrosis factor ) agonists , CRF ( corticotropin releasing factor ) agonists , CRF BP ( corticotropin releasing factor binding protein ) antagonists , urocortin agonists , B3 agonists , MSH ( melanocytestimu1ating honnone ) agonists , MCH ( me1anocyte - concentrating hormone ) antagonists , CCK ( cholecystokinin ) agonists , serotonin re - uptake inhibitors , serotonin and noradrena1ine re - uptake inhibitors , mixed serotonin and noradrenergic compounds , 5HT ( serotonin ) agonists , bombesin agonists , galanin antagonists , grthh hormone , grthh hormone releasing compounds , TRH ( thyreotropin releasing hormone ) agonists , UCP 2 or 3 ( uncoupling protein 2 or 3 ) modulators , leptin agonists , DA agonists ( bromocriptin , doprexin ) , lipase / amylase inhibitors , PPAR ( peroxisome proliferator - actiVated receptor ) modulators , R><R ( retinoidxreceptor ) modulators , TR 8 agonists , AGRP ( Agouti related protein ) inhibitors , H3 histamine antagonists , opioid antagonists ( such as naltrexone ) , exendin - 4 , GLP - 1 and ciliary neurotrophic factor. In one embodiment of the inVention the antiobesity agent is leptin ; dexamphetamine or amphetamine ; fenﬂuramine or dexfenﬂuramine ; sibutramine ; orlistat ; mazindol or phenter - m1ne. Suitable antidiabetic agents include insulin , insulin analogues and deriVatiVes such as those disc1osed in EP 792 290 ( NoVo Nordisk A / S ) , eg N”29 - tetradecanoyl des ( B30 ) human insulin , EP 214 826 and EP 705 275 ( NoVo Nordisk A / S ) , eg AspB” human insulin , U. S. Pat. No. 5 , 504 , 188 ( Eli Lilly ) , eg LysB” ProB29 human insulin , EP 368 187 ( AVentis ) , eg Lantus , Which are all incorporated herein by reference , GLP - 1 ( glucagon like peptide - 1 ) and GLP - 1 deriVatiVes such. lO. lS. 20. 25. 30. 35. 40. 45. 50. 55. 60. 126. The orally actiVe hypoglycaemic agents preferably comprise sulphonylureas , biguanides , meglitinides , glucosidase inhibitors , glucagon antagonists such as those disclosed in WO 99 / 01423 to NoVo Nordisk A / S and Agouron Pharmaceuticals , Inc. , GLP - 1 agonists , potassium channel openers such as those disclosed in WO 97 / 26265 and WO 99 / 03861 to NoVo Nordisk A / S Which are incorporated herein by reference , DPP - IV ( dipeptidyl peptidase - IV ) inhibitors , inhibitors of hepatic enzymes inVolVed in stimulation of gluconeogenesis and / or glycogenolysis , glucose uptake modulators , compounds modifying the lipid metabolism such as antihyperlipidemic agents and antilipidemic agents as PPARo. modulators , PPARE ) modulators , cholesterol absorption inhibitors , HSL ( hormone - sensitiVe lipase ) inhibitors and HMG CoA inhibitors ( statins ) , nicotinic acid , ﬁbrates , anion exchangers , compounds loWering food intake , bile acid resins , R><R agonists and agents acting on the ATP - dependent potassium channel of the [ 3 - cells. In one embodiment , the present compounds are administered in combination With insulin or an insulin analogue or deriVatiVe , such as N”29 - tetradecanoyl des ( B30 ) human insulin , AspB28 human insulin , LysB” Prom” human insulin , Lantus® , or a mix - preparation comprising one or more of these. In a further embodiment the present compounds are administered in combination With a sulphonylurea e. g. tolbutamide , glibenclamide , glipizide or glicazide. In another embodiment the present compounds are administered in combination With a biguanide e. g. metformin. In yet another embodiment the present compounds are administered in combination With a meglitinide e. g. repaglinide or senaglinide. In still another embodiment the present compounds are administered in combination With a thiazolidinedione e. g. troglitazone , cig1itazone , pioglitazone , rosiglitazone or compounds disclosed in WO 97 / 41097 such as 5 - [ [ 4 - [ 3 - Methyl - 4 - oxo - 3 , 4 - dihydro - 2 - quinazolinyl ] methoxy ] phenyl - methyl ] thiazolidine - 2 , 4 - dione or a pharmaceutically acceptable salt thereof , preferab1y the potassium sa1t. In yet another embodiment the present compounds may be administered in combination With the insu1in sensitizers disclosed in WO 99 / 19313 such as ( — ) 3 - [ 4 - [ 2 - Phenoxazin - 10 - yl ) ethoxy ] phenyl ] - 2 - ethoxypropanoic acid or a pharmaceutically acceptable salts thereof , preferably the arginine salt. In a further embodiment the present compounds are administered in combination With an o. - g1ucosidase inhibitor e. g. miglitol or acarbose. In another embodiment the present compounds are administered in combination With an agent acting on the ATPdependent potassium channel of the [ 3 - cells e. g. tolbutamide , glibenclamide , g1ipizide , g1icazide or repaglinide. Furthermore , the present compounds may be administered in combination With nateglinide. In still another embodiment the present compounds are administered in combination With an antihyperlipidemic agent or antilipidemic agent e. g. cholestyramine , colestipol , cloﬁbrate , gemﬂbrozil , fenoﬂbrate , bezaﬁbrate , tesaglitazar , EML - 4156 , LY - 818 , MK - 767 , atorVastatin , ﬂuVastatin , loVastatin , praVastatin , simVastatin , acipimox , probucol , ezetimibe or dextrothyroxine. In a further embodiment the present compounds are administered in combination With more than one of the aboVementioned compounds e. g. in combination With a sulphony - . as those disclosed in WO 98 / 0887l to NoVo Nordisk A / S , 65 lurea and metformin , a sulphonylurea and acarbose , . Which is incorporated herein by reference as Well as orally actiVe hypoglycaemic agents. repaglinide and metformin , insulin and a sulphonylurea , insulin and metformin , insulin , insulin and loVastatin , etc. US 7 , 50l , 405 B2. 127. Further , the present compounds may be administered in combination With one or more antihypertensiVe agents. Examples of antihypertensiVe agents are B - blockers such as alprenolol , atenolol , timolol , pindolol , propranolol , metoprolol , bisoprololfumerate , esmolol , acebutelol , metoprolol , acebutolol , betaxolol , celiprolol , nebiVolol , tertatolol , oxprenolol , amusolalul , carVedilol , labetalol , B2 - receptor blockers e. g. S - atenolol , OPC - 1085 , ACE ( angiotensin conVerting enzyme ) inhibitors such as quinapril , lisinopril , enalapril , captopril , benazepril , perindopril , trandolapril , fosinopril , ramipril , cilazapril , delapril , imidapril , moexipril , spirapril , temocapril , zofenopril , S - 5590 , fasidotril , Hoechst - Marion Roussel : 100240 ( EP 00481522 ) , omapatrilat , gemopatrilat and GW - 660511 , calcium channel blockers such as nifedipine , felodipine , nicardipine , isradipine , nimodipine , diltiazem , amlodipine , nitrendipine , Verapamil , lacidipine , lercanidipine , aranidipine , cilnidipine , cleVidipine , azelnidipine , barnidipine , efonodipine , iasidipine , iemildipine , iercanidipine , manidipine , nilVadipine , pranidipine , furnidipine , a - blockers such as doxazosin , urapidil , prazosin , terazosin , bunazosin and OPC - 28326 , diuretics such as thiazides / sulphonamides ( e. g. bendroﬂumetazide , chlorothalidone , hydrochiorothiazide and clopamide ) , 10op - diuretics ( e. g. bumetanide , furosemide and torasemide ) and potassium sparing diuretics ( e. g. amiloride , spironolactone ) , endothelin ET - A antagonists such as ABT - 546 , ambrisetan , atrasentan , SB - 234551 , CI - 1034 , S - 0139 and YM - 598 , endothelin antagonists e. g. bosentan and J - 104133 , renin inhibitors such as aliskiren , Vasopressin V1 antagonists e. g. OPC - 21268 , Vasopressin V2 antagonists such as tolVaptan , SR - 121463 and OPC - 31260 , B - type natriuretic peptide agonists e. g. Nesiritide , angiotensin II antagonists such as irbesartan , candesartanci1exeti1 , losartan , Valsartan , te1misartan , eprosartan , candesartan , CL - 329167 , eprosartan , iosartan , olmesartan , pratosartan , TA - 606 , and YM - 358 , 5 - HT2 agonists e. g. fenoldopam and ketanserin , adeno sine A1 antagonists such as naftopidil , N - O861 and FK - 3 52 , thromboxane A2 antagonists such as KT2 - 962 , endopeptidase inhibitors e. g. ecadotril , nitric oxide agonists such as LP - 805 , dopamine D1 antagonists e. g. MYD - 37 , dopamine D2 agonists such as nolomirole , n - 3 fatty acids e. g. omacor , prostacyclin agonists such as treprostinil , beraprost , PGE1 agonists e. g. ecraprost , Na + / K + ATPase modulators e. g. PST - 2238 , Potassium channel actiVators e. g. KR - 30450 , Vaccines such as PMD - 3117 , Indapamides , CGRP - unigene , guanylate cyclase stimulators , . hydralazines , methyldopa , docarpamine , moxonidine , CoAproVel , MondoBiotech - 81 1 . Further reference can be made to Remington : The Science and Practice of Pharmacy , 19” Edition , Gennaro , Ed. , Mack Publishing Co. , Easton , Pa. , 1995. Furthermore , the present compounds may be administered in combination With one or more glucocorticoid receptor agonists. Examples of such glucocorticoid receptor agonists are betametasone , dexamethasone , hydrocortisone , methylprednisolone , predniso1one , prednisone , beclomethasone , butixicort , clobetasol , ﬂunisolide , ﬂucatisone ( and analogues ) , momethasone , triamcinolonacetonide , triamcinolonhexacetonide GW - 685698 , NXC - 1015 , NXC - 1020 , NXC - 1021 , NS - 126 , P - 4112 , P - 4114 , RU - 24858 and T - 25 ser1es. It should be understood that any suitable combination of the compounds according to the inVention With one or more of. lO. lS. 20. 25. 30. 35. 40. 45. 50. 55. 60. 128. Pharmaceutical Compositions. The compounds of the present inVention may be administered alone or in combination With pharmaceutically acceptable carriers or excipients , in either single or multiple doses as part of combination therapy comprising antihypertensiVe agents. The pharmaceutical compositions according to the inVention may be formulated With pharmaceutically acceptable carriers or diluents as Well as any other knoWn adjuVants and excipients in accordance With conVentional techniques such as those disclosed in Remington : The Science and Practice of Pharmacy , l9” Edition , Gennaro , Ed. , Mack Publishing Co. , Easton , Pa. , 1995. The pharmaceutical compositions may be speciﬁcally formulated for administration by any suitable route such as the oral , rectal , nasal , pulmonary , topical ( including buccal and sublingual ) , transdermal , intracisternal , intraperitoneal , Vaginal and parenteral ( including subcutaneous , intramuscular , intrathecal , intraVenous and intradermal ) route , the oral route being preferred. It Will be appreciated that the preferred route Will depend on the general condition and age of the subject to be treated , the nature of the condition to be treated and the actiVe ingredient chosen. Pharmaceutical compositions for ora1 administration include solid dosage forms such as hard or soft capsules , tablets , troches , dragees , pills , lozenges , poWders and granules. Where appropriate , they can be prepared With coatings such as enteric coatings or they can be formulated so as to proVide controlled release of the actiVe ingredient such as sustained or pro1onged release according to methods Wel1 - knoWn in the art. Liquid dosage forms for oral administration include solutions , emulsions , suspensions , syrups and elixirs. Pharmaceutical compositions for parenteral administration inc1ude steri1e aqueous and non - aqueous injectable solutions , dispersions , suspensions or emulsions as Well as sterile poWders to be reconstituted in sterile injectable solutions or dispersions prior to use. Depot injectable formulations are a1so contemplated as being Within the scope of the present inVention. Other suitable administration forms include suppositories , sprays , ointments , cremes , gels , inhalants , dermal patches , implants etc. A typical ora1 dosage is in the range of from about 0.001 to about 100 mg / kg body Weight per day , preferably from about 0.01 to about 50 mg / kg body Weight per day , and more preferred from about 0.05 to about 10 mg / kg body Weight per day administered in one or more dosages such as 1 to 3 dosages. The exact dosage Will depend upon the frequency and mode of administration , the sex , age , Weight and general condition of the subject treated , the nature and seVerity of the condition treated and any concomitant diseases to be treated and other factors eVident to those skilled in the art. The formu1ations may conVeniently be presented in unit dosage form by methods knoWn to those skilled in the art. A typical unit dosage form for oral administration one or more times per day such as 1 to 3 times per day may contain from 0.05 to about 2000 mg , e. g. from about 0.1 to about 1000 mg , from about 0.5 mg to about 500 mg. , from about 1 mg to about 200 mg , e. g. about 100 mg. For parenteral routes , such as intraVenous , intrathecal , intramuscular and similar administration , typically doses are in the order of about half the dose employed for oral administration. The compounds of this inVention are generally utilized as. the aboVe - mentioned compounds and optionally one or more 65 the free substance or as a pharmaceutically acceptable salt. further pharmacologically actiVe substances are considered to be Within the scope of the present inVention. thereof. Examples are an acid addition salt of a compound haVing the utility of a free base and a base addition salt of a. US 7 , 50l , 405 B2. 129. compound haVing the utility of a free acid. The term “pharmaceutically acceptable salts” refers to non - toxic salts of the compounds for use according to the present inVention Which are genera1ly prepared by reacting the free base With a suitable organic or inorganic acid or by reacting the acid With a suitable organic or inorganic base. When a compound for use according to the present inVention , contains a free base such salts are prepared in a conVentional manner by treating a solution or suspension of the compound With a chemical equiValent of a phannaceutically acceptable acid. When a compounds for use according to the present inVention , contains a free acid such salts are prepared in a conVentional manner by treating a solution or suspension of the compound With a chemical equiValent of a phannaceutically acceptable base. Physiologically acceptable salts of a compound With a hydroxy group include the anion of said compound in combination With a suitable cation such as sodium or ammonium ion. Other salts Which are not pharmaceutically acceptable may be useful in the preparation of compounds for use according to the present inVention and these form a further aspect of the present inVention. For parenteral administration , solutions of the present compounds in sterile aqueous solution , aqueous propylene glycol or sesame or peanut oil may be employed. Such aqueous solutions should be suitable buffered if necessary and the liquid diluent ﬁrst rendered isotonic With sufﬁcient saline or glucose. The aqueous solutions are particularly suitable for intraVenous , intramuscular , subcutaneous and intraperitoneal administration. The sterile aqueous media employed are all readily aVailable by standard techniques knoWn to those skilled in the art. Suitable pharmaceutical carriers include inert solid diluents or ﬁllers , steri1e aqueous so1ution and Various organic solVents. Examples of suitable carriers are Water , sa1t solutions , alcohols , polyethylene glycols , polyhydroxyethoxylated castor oil , peanut oil , oliVe oil , syrup , phospholipids , gelatine , lactose , terra alba , sucrose , cyclodextrin , amylose , magnesium stearate , talc , ge1atin , agar , pectin , acacia , stearic acid or loWer alkyl ethers of cellu1ose , si1icic acid , fatty acids , fatty acid amines , fatty acid monoglycerides and diglycerides , pentaerythritol fatty acid esters , polyoxyethylene , hydroxymethylcellulose and polyVinylpyrrolidone. Similarly , the carrier or diluent may include any sustained re1ease material knoWn in the art , such as glyceryl monostearate or glyceryl distearate , alone or mixed With a Wax. The formulations may also include Wetting agents , emulsifying and suspending agents , preserVing agents , sWeetening agents or ﬂa - Vouring agents. The pharmaceutical compositions formed by combining the compounds of the inVention and the pharmaceutically acceptable carriers are then readily administered in a Variety of dosage fonns suitable for the disclosed routes of administration. The formulations may conVeniently be presented in unit dosage form by methods knoWn in the art of pharmacy. Formulations of the present inVention suitable for oral administration may be presented as discrete units such as capsules or tablets , each containing a predetermined amount of the actiVe ingredient , and Which may include a suitable excipient. These formulations may be in the form of poWder or granules , as a solution or suspension in an aqueous or non - aqueous liquid , or as an oil - in - Water or Water - in - oil liquid emulsion. Compositions intended for oral use may be prepared according to any knoWn method , and such compositions may contain one or more agents selected from the group consisting of sWeetening agents , ﬂaVouring agents , colouring agents , and preserVing agents in order to proVide pharmaceutically. lO. lS. 20. 25. 30. 35. 40. 45. 50. 55. 60. 65. 130. elegant and palatable preparations. Tablets may contain the actiVe ingredient in admixture With non - toxic pharmaceutically - acceptable excipients Which are suitable for the manufacture of tablets. These excipients may be for examp1e , inert diluents , such as calcium carbonate , sodium carbonate , lactose , calcium phosphate or sodium phosphate ; granulating and disintegrating agents , for example corn starch or alginic acid ; binding agents , for example , starch , gelatine or acacia ; and lubricating agents , for example magnesium stearate , stearic acid or talc. The tablets may be uncoated or they may be coated by knoWn techniques to delay disintegration and absorption in the gastrointestinal tract and thereby proVide a sustained action oVer a longer period. For example , a time delay material such as glyceryl monostearate or glyceryl distearate may be employed. They may also be coated by the techniques described in U. S. Pat. Nos. 4 , 356 , 108 ; 4 , 166 , 452 ; and 4 , 265 , 874 , incorporated herein by reference , to form osmotic therapeutic tablets for controlled release. Formulations for oral use may also be presented as hard gelatine capsules Where the actiVe ingredient is mixed With an inert solid diluent , for example , calcium carbonate , calcium phosphate or kaolin , or a soft gelatine capsule Wherein the actiVe ingredient is mixed With Water or an oi1 medium , for example peanut oil , liquid parafﬁn , or oliVe oil. Aqueous suspensions may contain the actiVe compounds in admixture With excipients suitable for the manufacture of aqueous suspensions. Such excipients are suspending agents , for examp1e sodium carboxymethylce1lu1ose , methylcellulose , hydroxypropylmethylce1lu1ose , sodium a1ginate , polyVinylpyrrolidone , gum tragacanth and gum acacia ; dispersing or Wetting agents may be a naturally - occurring phosphatide such as lecithin , or condensation products of an alkylene oxide With fatty acids , for example polyoxyethylene stearate , or condensation products of ethylene oxide With long chain aliphatic alcohols , for example , heptadecaethyl - eneoxycetanol , or condensation products of ethylene oxide With partial esters deriVed from fatty acids and a hexitol such as polyoxyethy1ene sorbitol monooleate , or condensation products of ethy1ene oxide With partial esters deriVed from fatty acids and hexitol anhydrides , for example polyethylene sorbitan monooleate. The aqueous suspensions may also contain one or more colouring agents , one or more ﬂaVouring agents , and one or more sWeetening agents , such as sucrose or saccharin. Oily suspensions may be formulated by suspending the actiVe ingredient in a Vegetable oil , for example arachis oil , oliVe oil , sesame oil or coconut oil , or in a mineral oil such as a liquid parafﬁn. The oily suspensions may contain a thickening agent , for examp1e beesWax , hard parafﬁn or cetyl alcohol. SWeetening agents such as those set forth aboVe , and ﬂaVouring agents may be added to proVide a palatable oral preparation. These compositions may be preserVed by the addition of an anti - oxidant such as ascorbic acid. Dispersib1e poWders and granu1es suitable for preparation of an aqueous suspension by the addition of Water proVide the actiVe compound in admixture With a dispersing or Wetting agent , suspending agent and one or more preserVatiVes. Suitable dispersing or Wetting agents and suspending agents are exemp1iﬁed by those a1ready mentioned aboVe. Additional excipients , for example , sWeetening , ﬂaVouring , and colouring agents may also be present. The pharmaceutical compositions comprising a compound for use according to the present inVention may also be in the form of oil - in - Water emulsions. The oily phase may be a Vegetable oil , for example , oliVe oil or arachis oil , or a mineral oil , for example a liquid parafﬁn , or a mixture thereof. Suitable emulsifying agents may be naturally - occurring gums , for example gum acacia or gum tragacanth , naturally - occur - . US 7 , 50l , 405 B2. 131. ring phosphatides , for example soy bean , lecithin , and esters or partial esters deriVed from fatty acids and hexitol anhydrides , for example sorbitan monooleate , and condensation products of said partial esters With ethylene oxide , for example polyoxyethylene sorbitan monooleate. The emulsions may also contain sWeetening and ﬂaVouring agents. Syrups and elixirs may be formulated With sWeetening agents , for example glycerol , propylene glycol , sorbitol or sucrose. Such formulations may also contain a demulcent , preserVatiVe , ﬂaVouring and colouring agents. The phannaceutical compositions may be in the form of a sterile injectable aqueous or oleaginous suspension. This suspension may be formulated according to the knoWn methods using suitable dispersing or Wetting agents and suspending agents described aboVe. The sterile injectab1e preparation may also be a sterile inj ectable solution or suspension in a non - toxic parenterallyacceptable diluent or solVent , for example as a solution in 1 , 3 - butanediol. Among the acceptable Vehicles and solVents that may be employed are Water , Ringers solution , and isotonic sodium chloride solution. In addition , sterile , ﬁxed oils are conVeniently employed as solVent or suspending medium. For this purpose , any bland ﬁxed oil may be employed using synthetic mono - or dig1ycerides. In addition , fatty acids such as oleic acid ﬁnd use in the preparation of inj ectables. The compositions may also be in the form of suppositories for rectal administration of the compounds of the present inVention. These compositions can be prepared by mixing the drug With a suitable non - irritating excipient Which is solid at ordinary temperatures but liquid at the rectal temperature and Will thus melt in the rectum to release the drug. Such materials include cocoa butter and polyethylene glycols , for example. For topical use , creams , ointments , je1lies , solutions of suspensions , etc. , containing the compounds of the present inVention are contemp1ated. For the purpose of this application , topical applications shal1 include mouth Washes and gargles. The compounds for use according to the present inVention may also be administered in the form of liposome deliVery systems , such as small unilamellar Vesicles , large unilamellar Vesicles , and multilamellar Vesicles. Liposomes may be formed from a Variety of phospholipids , such as cholesterol , stearylamine , or phosphatidylcho1ines. In addition , some of the compounds for use according to the present inVention may form so1Vates With Water or common organic solVents. Such solVates are also encompassed Within the scope of the present inVention. Thus , in a further embodiment , there is proVided a pharmaceutical composition comprising a compound and antihypertensiVe agent ( s ) for use according to the present inVention , or a pharmaceutically acceptable salt , solVate , or prodrug thereof , and one or more pharmaceutically acceptable carriers , excipients , or diluents. If a solid carrier is used for oral administration , the preparation may be tabletted , placed in a hard gelatine capsule in poWder or pellet form or it can be in the form of a troche or lozenge. The amount of solid carrier Will Vary Widely but Will usually be from about 25 mg to about 1 g. If a liquid carrier is. lO. lS. 20. 25. 30. 35. 40. 45. 50. 55. 60. 132. A typical tablet Which may be prepared by conVentional tabletting techniques may contain : . . Core : . . . ActiVe comp0und ( as free 5.0 mg compound or salt thereof ) . Lactosum Ph. Eur. 67.8 mg Cellulose , microcryst. ( AVicel ) 31.4 mg Amberlite ® IRP88 * 1.0 mg Magnesii stearas Ph. Eur. q. s. Coating : . Hydroxypropyl methylcellulose approx. 9 mg. MyWacett 9 - 40 T * * approx. 0.9 mg. . * Polacrillin potassium NF , tablet disintegrant , R0hm and Haas. * * Acylated monoglyceride used as plasticizer for ﬁlm coating. The compounds of the inVention may be administered to a patient Which is a mamma1 , especial1y a human. Such mammals include animals , both domestic animals , e. g. household pets , and non - domestic animals such as Wildlife. Pharmacological Methods. Materials : . 3 H - cortisone , 3H - cortisol and scintillation proximity assay ( SPA ) beads Were purchased from Amersham Pharmacia Biotech , [ 3 - NADPH and [ 3 - NAD Were from Sigma Chemical Co , rabbit anti - cortisol antibodies Were from Fitzgerald and sheep - anti - 11 - dehydrocorticosterone antibodies Were from Chemicon International INC. Hepes and pho sphate - buffered saline Were purchased from Life Technologies. The test compounds Were dissolVed in DMSO ( 10 mM ) . All dilutions Were performed in a buffer containing 50 mM TRIS - HCl ( Sigma Chemical Co ) , 4 mM EDTA ( Sigma Chemical Co ) , 0.1% BSA ( Sigma Chemical Co ) , 0.01% TWeen - 20 ( Sigma Chemical Co ) and 0.005% bacitracin moVo Nordisk A / S ) , pH=7.4. Optiplate 96 Wells plates Were supplied by Packard. The amount of radioligand bound to the SPA beads Was measured on TopCount NXT , Packard. Experimental Procedures in Vitro : . l lB - HSDl Enzymatic ActiVity Assay : . An extract of yeast transformed With h - 1 1 [ 3 HSD1 ( Hult et al. , FEBS Lett. , 441 , 25 ( 1998 ) ) Was used as the source of enzyme. Enzyme preparation , 120 nM 3H - cortisone , 4 mM B - NADPH , rabbit - anti cortisol antibody ( 1 : 200 ) , seria1 dilutions of test compound and anti - rabbit Ig coated SPA particles ( 2 mg / Well ) Were added to the Wells. The reaction Was initiated by mixing the different components and Was alloWed to proceed under shaking for 60 min at 300 C. The reaction Was stopped be the addition of 10 fold excess of a stopping buffer containing 500 11M carbenoxolone and 1.0 11M cortisone. Data Was analysed using GraphPad Prism softWare. SelectiVity Vs. h - 11BHSD2 : . Baby hamster kidney ( BHK ) cel1s Were transfected With full - length h - 11BHSD2. The cells Were sonicated in phosphate - buffered saline containing 10 mM HEPES ( Life Technologies ) . The cell lysate Was used as the source of enzyme. Enzyme preparation , 50 nM 3H - cortisol , 4 mM B - NAD , antibody ( 1 : 40 ) , serial dilutions of test compound and anti - sheep Ig coated SPA particles ( 1 mg / Well ) Were added to the Wells of. used , the preparation may be th the t01h1 ofa Syrup , emulsion , 65 96 - Well plates. The reaction Was initiated by mixing the dif - . soft gelatine capsule or sterile injectable liquid such as an aqueous or non - aqueous liquid suspension or solution. ferent components and Was alloWed to proceed under shaking for 30 min at 300 C. The reaction Was stopped be the addition. US 7 , 50l , 405 B2. 133. of lO fold excess of a stopping buffer containing 5 11M carbenoxolone. Data Was analysed using GraphPad Prism softWare. Animal Studies Pharmacological actiVity may be determined in an in ViVo. test procedure in rats as folloWs : . Spontaneously hypertensiVe rats ( SHR ) are alloWed to acclimatise for at least 2 Weeks after Which a telemetry - transducer is surgically implanted in the aorta according to the manufacturers instructions. The rats are alloWed to restitute for at least 4 Weeks , and acclimatise to the test facility. Throughout the experiment , the rats are kept in their home cages at a standard 12 hour light712 hour dark cycle at 20 : 2O C. With free access to standard laboratory rat choW and drinking Water. The combination according to the present inVention or the actiVe ingredients alone are dissolVed in a Vehicle appropriate for the chosen route of administration and administered in ﬁxed amounts alone or in combination to the test animals. At predetermined timepoints blood pressure is determined. Synergy Versus additiVity is tested at each of the doses used in combination , using a contrast betWeen the mean from the combination group and the sum of the means from each monotherapy group. 25 Whi1e the inVention has been described and 111ustrated With. reference to certain particular embodiments thereof , those. skilled in the art Will appreciate that Various adaptations , changes , modiﬁcations , substitutions , deletions , or additions of procedures and protocols may be made Without departing from the spirit and scope of the inVention. Al1 references cited herein are hereby incorporated by reference in their entirety. The inVention claimed is : . 1. A combination therapy Which comprises an 1 1 B - hydroxysteroid dehydrogenase type 1 ( 11B - HSD1 ) inhibitor and an 35 antihypertensiVe agent , Wherein the 1 1 [ 3 - HSD1 inhibitor is of the Formula ( IIa ) : . R2 0 40 3 R1—N | \ / R4 N. 45. Wherein. R1 is aryl , arle1 - C6a1kyl , hetaryl or hetarle1 - C6alkyl optionally substituted With one or more of R6 independently ; 50. R2 is halo , C1 - C6alkyl , C2 - C6alkenyl , C2 - C6alkynyl , C3 - C1Ocycloalkyl , C3 - C10cycloalkle1 - C6 - alkyl , trihalomethyl , aryl , arle1 - C6alkyl , C1 - C6alkyloxyC1 - C6alkyl , arle1 - C6alkyloxyC1 - C6 - alkyl , C1 - C6alkleR5C1 - C6alky1 , arle1 - C6alkleR5C1 - 55 C6alkyl , hetaryl or hetarle 1 - C6alkyl Wherein the alkyl , alkenyl , alkynyl , cycloalkyl and aryl groups independently are optionally substituted With one or more R7 ; . R3 and R4 together With the nitrogen to Which they are attached , are forming a saturated or partially saturated 60 bicyclic / bridge ring system containing from 7 to 12 carbon atoms and from 0 to 2 additional heteroatoms selected from nitrogen , oxygen or sulphur , the ring system optionally being substituted With at least one of C1 - C6alkyl , aryl , hetaryl , arle1 - C6alkyl , hetarle1 - 65 C6alkyl , hydroxy , oxo , C1 - C6alkyloxy , arle1 - C6alkyloxy or hetarle1 - C6alkyloxy , . 134. Wherein the alkyl and aryl groups independently are optionally substituted With one ore more of R9 ; . R5 is C1 - C6alkyl , C2 - C6alkenyl , C2 - C6alkynyl , C3 - C10cycloalkyl , C3 - C10hetcyc1oalkyl , C3 - C10 - cycloalkle1 - C6alkyl , C3 - C10hetcycloalkle1 - alkyl , aryl , hetaryl , arle1 - C6alkyl or hetarle1 - C6alkyl Wherein the alkyl , alkenyl , alkynyl , aryl , hetaryl , cycloalkyl and hetcycloalkyl groups independently are optionally substituted With one or more of R9 ; . R6 and R7 independently are hydrogen , hydroxy , oxo , halo , nitro , cyano , C1 - C6alkyl , C1 - C6alkyloxy , trihalomethyl , trihalomethoxy , NRl OR1 1 , arle 1 - C6alkyloxy , hetarle1 - C6alkyloxy , C1 - C6alkylcarbonyl , arylcarbonyl , hetarylcarbonyl , arle1 - C6alkylcarbonyl , C1 - C6alkyloxycarbonyl , aryloxycarbonyl , arle1 - C6alkyloxycarbonyl , C1 - C6alkylcarboxy , arylcarboxy or arle1 - C5alkylcarboxy ; . R9 independently is hydrogen , C1 - C6alkyl , aryl , hetaryl , arle1 - C6alkyl , hetarle1 - C6alkyl , hydroxy , oxo , cyano , NR”R” , C1 - C6alkyloxy , aryloxy , arle1 - C6alkyloxy , hetaryloxy , hetarle1 - C6alkyloxy , C1 - C6alkyloxyC1 - C6alkyl , C1 - C6alkylcarbonyl , arylcarbony1 , hetarylcarbonyl , ary1C1 - C6alkylcarbonyl , hetarle1 - C6alkylcarbonyl , C1 - C6alkylcarboxy , arylcarboxy or arle1 - C6alkylcarboxy ; . R” and R” independently are hydrogen , C1 - C8alkyl , aryl , hetaryl , arle1 - C6alkyl , C3 - C10cycloalkyl , C3 - C1Ohetcycloa1ky1 , C3 - C1Ocycloalky1C1 - C6alkyl , C1 - C6alkylcarbonyl , C1 - C6alkylcarboxyC1 - C6alkyl ; or. R” and R” together With the nitrogen to Which they are attached , are forming a saturated or partially saturated cyclic , bicyclic or tricyclic ring system containing from 4 to 10 carbon atoms and from 0 to 2 additiona1 heteroatoms se1ected from nitrogen , oxygen or sulphur , the ring system optionally being substituted With at least one of C1 - C8alkyl , aryl , hetaryl , arle1 - C6alkyl , hetarle1 - C6alkyl , hydroxy , oxo , cyano , C1 - C6alkyloxy , arle1 - C6alkyloxy , hetarle 1 - C6alkyloxy , C 1 - C6a1kyloxyC 1 - C6alkyl , C1 - C6a1kylcarbony1 , arylcarbonyl , hetarylcarbonyl , arle1 - C6alkylcarbonyl , hetarle1 - C6alkylcarbonyl , C1 - C6alkylcarboxy , arylcarboxy or arle 1 - 6alkylcarboxy ; or. a sa1t thereof With a phannaceutical1y acceptable acid or base , or optical isomer or mixture of optical isomers , racemic mixture , or tautomeric form thereof. 2. The combination according to claim 1 , Wherein the. 118 - HSD1 inhibitor is of the Formula ( IIa ) Wherein : . R1 is aryl or hetaryl optionally substituted With one or more R6 independently ; . R2 is halo , C1 - C6alkyl , C2 - C6alkenyl , C2 - C6alkynyl , C3 - C10cycloalkyl , C3 - C1Ocycloalkle1 - C6 - alkyl , aryl , arle1 - C6alkyl , C1 - C6alkyloxyC 1 - C6alkyl , arle1 - C6alkyloxyC1 - C6alkyl , C1 - C6 - alkleR5C1 - C6alkyl , arle1 - C6alkleR5C1 - C6alkyl , hetaryl or hetarle1 - C6alkyl Where the alkyl , alkenyl , alkynyl , cycloalkyl and aryl groups independently are optionally substituted With one or more R7 ; . R5 is C1 - C6alky1 , C2 - C6alkeny1 , C2 - C6alkynyl , C3 - C1Ocycloalkyl , C3 - C10hetcycloalkyl , C3 - C10 - cycloalkle1 - C6alkyl , C3 - C10hetcycloalkle1 - C6alkyl , aryl , hetaryl , arle1 - C6alkyl or hetarle1 - C6alkyl Wherein the alkyl , alkenyl , alkynyl , aryl , hetaryl , cycloalkyl and hetcycloalkyl groups independently are optionally substituted With one or more of R9 ; . R6 and R7 independently are hydrogen , hydroxy , oxo , halo , nitro , cyano , C1 - C6alkyl , C1 - C6 - alkyloxy , trihalomethyl , trihalomethoxy , NR”R” , arle1 - C6alkyloxy , . US 7 , 50l , 405 B2. 135 hetarle1 - C6alkyloxy , C1 - C6alkylcarbonyl , arylcarbonyl , hetarylcarbonyl , arle1 - C6alkylcarbonyl , C1 - C6alkyloxycarbonyl , aryloxycarbonyl , arle1 - C6alkyloxycarbonyl , C1 - C6a1ky1carboxy , arylcarboxy or arle1 - C6alkylcarboxy ; 5. R9 independently is hydrogen , C1 - C6alkyl , aryl , hetaryl , arle1 - C6alkyl , hetarle1 - C6 - alkyl , hydroxy , oxo , cyano , NR”R” , C1 - C6alkyloxy , aryloxy , arle1 - C6alkyloxy , hetaryloxy , hetarle1 - C6alkyloxy , C1 - C6alkyloxyC1 - C6alkyl , C1 - C6alkyl - carbonyl , aryl - 10 carbonyl , hetarylcarbonyl , arle1 - C6alkylcarbonyl , hetarle1 - C6alkyl - carbonyl , C1 - C6alkylcarboxy , arylcarboxy or arle1 - C6alkylcarboxy ; . R” and R1 1 independently are hydrogen , C1 - C8alkyl , aryl , hetaryl , arle1 - C6alkyl , C3 - C10 - cycloalkyl , 15 C3 - C1Oheteycloalkyl , C3 - C10cycloalkle1 - C6alkyl , C1 - C6alkylcarboxyC1 - C6alkyl ; or. R” and R” together With the nitrogen to Which they are attached , are forming a saturated or partially saturated cyclic , bicyclic or tricyclic ring system containing from 20 4 to 10 carbon atoms and from 0 to 2 additional heteroatoms selected from nitrogen , oxygen or sulphur , the ring system optiona1ly being substituted With at least one of C1 - C8alkyl , aryl , hetaryl , arle 1 - C6alkyl , hetarle1 - . 136 C6alkyl , hydroxy , oxo , cyano , C1 - C6alkyloxy , arle1 - C6alkyloxy , hetaryl C1 - C6alkyloxy , C1 - C6alkyloxyC1 - C6alkyl , C1 - C6alkylcarbonyl , arylcarbonyl , hetarylcarbonyl , arle1 - C6alkylcarbony1 , hetarle1 - C6alkylcarbonyl , C1 - C6alkylcarboxy , arylcarboxy or arle 1_6alkylcarboxy ; or. a salt thereof With a pharmaceutically acceptable acid or. base , or optical isomer or mixture of optical isomers , racemic mixture , a prodrug thereof , or tautomeric form thereof. 3. The combination according to claim 1 , Wherein the 118 - HSD1 inhibitor is selected from : [ 1 - ( 4 - Methoxy - phenyl ) - 5 - methyl - 1H - pyrazol - 4 - yl ] - ( 1 , 3 , . 3 - trimethyl - 6 - aza - bicyclo [ 3 .2. 1 ] oct - 6 - yl ) - methanone ; . 1 - [ 1 - ( 4 - Chioro - phenyl ) - 5 - propyl - 1H - pyrazol - 4 - yl ] - ( 1 , 3 , . 3 - trimethyl - 6 - aza - bicyclo [ 3 .2. 1 ] oct - 6 - yl ) - methanone ; or [ 1 - ( 3 , 5 - Dichloro - phenyl ) - 5 - propyl - 1H - pyrazol - 4 - yl ] - ( 1 , 3 , 3 - trimethyl - 6 - aza - bicyclo [ 3.2.1 ] oct - 6 - yl ) - methanone ; . a salt thereof With a phannaceutically acceptable acid or. base , or optical isomer or mixture of optical isomers , racemic mixture , or tautomeric form thereof. 55 * $ $ $